{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "name": "NER_bert_bilstm_crf.ipynb",
      "provenance": [],
      "collapsed_sections": [],
      "authorship_tag": "ABX9TyOoEvqOUh7NH8CNHUynw2tS",
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "widgets": {
      "application/vnd.jupyter.widget-state+json": {
        "8c52910c46264f02881cb99e2b09f194": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "state": {
            "_view_name": "HBoxView",
            "_dom_classes": [],
            "_model_name": "HBoxModel",
            "_view_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_view_count": null,
            "_view_module_version": "1.5.0",
            "box_style": "",
            "layout": "IPY_MODEL_f42a5d1f9065477f800e737894ba34a6",
            "_model_module": "@jupyter-widgets/controls",
            "children": [
              "IPY_MODEL_ee12caae1eaf41619baa86de1ba78122",
              "IPY_MODEL_aac430dbfe9d4975b3d2e1504927bd12"
            ]
          }
        },
        "f42a5d1f9065477f800e737894ba34a6": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "state": {
            "_view_name": "LayoutView",
            "grid_template_rows": null,
            "right": null,
            "justify_content": null,
            "_view_module": "@jupyter-widgets/base",
            "overflow": null,
            "_model_module_version": "1.2.0",
            "_view_count": null,
            "flex_flow": null,
            "width": null,
            "min_width": null,
            "border": null,
            "align_items": null,
            "bottom": null,
            "_model_module": "@jupyter-widgets/base",
            "top": null,
            "grid_column": null,
            "overflow_y": null,
            "overflow_x": null,
            "grid_auto_flow": null,
            "grid_area": null,
            "grid_template_columns": null,
            "flex": null,
            "_model_name": "LayoutModel",
            "justify_items": null,
            "grid_row": null,
            "max_height": null,
            "align_content": null,
            "visibility": null,
            "align_self": null,
            "height": null,
            "min_height": null,
            "padding": null,
            "grid_auto_rows": null,
            "grid_gap": null,
            "max_width": null,
            "order": null,
            "_view_module_version": "1.2.0",
            "grid_template_areas": null,
            "object_position": null,
            "object_fit": null,
            "grid_auto_columns": null,
            "margin": null,
            "display": null,
            "left": null
          }
        },
        "ee12caae1eaf41619baa86de1ba78122": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "state": {
            "_view_name": "ProgressView",
            "style": "IPY_MODEL_37aee5698d0249878ea5841c0a1fb587",
            "_dom_classes": [],
            "description": "Downloading: 100%",
            "_model_name": "FloatProgressModel",
            "bar_style": "success",
            "max": 433,
            "_view_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "value": 433,
            "_view_count": null,
            "_view_module_version": "1.5.0",
            "orientation": "horizontal",
            "min": 0,
            "description_tooltip": null,
            "_model_module": "@jupyter-widgets/controls",
            "layout": "IPY_MODEL_21f73ff5483d44be847624235d3bc48d"
          }
        },
        "aac430dbfe9d4975b3d2e1504927bd12": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "state": {
            "_view_name": "HTMLView",
            "style": "IPY_MODEL_2e17a9c5d5d74242a87e7834c99323de",
            "_dom_classes": [],
            "description": "",
            "_model_name": "HTMLModel",
            "placeholder": "​",
            "_view_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "value": " 433/433 [00:00&lt;00:00, 3.89kB/s]",
            "_view_count": null,
            "_view_module_version": "1.5.0",
            "description_tooltip": null,
            "_model_module": "@jupyter-widgets/controls",
            "layout": "IPY_MODEL_5e0ae6ad70bf4391ae83dd7d32d91a7f"
          }
        },
        "37aee5698d0249878ea5841c0a1fb587": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "state": {
            "_view_name": "StyleView",
            "_model_name": "ProgressStyleModel",
            "description_width": "initial",
            "_view_module": "@jupyter-widgets/base",
            "_model_module_version": "1.5.0",
            "_view_count": null,
            "_view_module_version": "1.2.0",
            "bar_color": null,
            "_model_module": "@jupyter-widgets/controls"
          }
        },
        "21f73ff5483d44be847624235d3bc48d": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "state": {
            "_view_name": "LayoutView",
            "grid_template_rows": null,
            "right": null,
            "justify_content": null,
            "_view_module": "@jupyter-widgets/base",
            "overflow": null,
            "_model_module_version": "1.2.0",
            "_view_count": null,
            "flex_flow": null,
            "width": null,
            "min_width": null,
            "border": null,
            "align_items": null,
            "bottom": null,
            "_model_module": "@jupyter-widgets/base",
            "top": null,
            "grid_column": null,
            "overflow_y": null,
            "overflow_x": null,
            "grid_auto_flow": null,
            "grid_area": null,
            "grid_template_columns": null,
            "flex": null,
            "_model_name": "LayoutModel",
            "justify_items": null,
            "grid_row": null,
            "max_height": null,
            "align_content": null,
            "visibility": null,
            "align_self": null,
            "height": null,
            "min_height": null,
            "padding": null,
            "grid_auto_rows": null,
            "grid_gap": null,
            "max_width": null,
            "order": null,
            "_view_module_version": "1.2.0",
            "grid_template_areas": null,
            "object_position": null,
            "object_fit": null,
            "grid_auto_columns": null,
            "margin": null,
            "display": null,
            "left": null
          }
        },
        "2e17a9c5d5d74242a87e7834c99323de": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "state": {
            "_view_name": "StyleView",
            "_model_name": "DescriptionStyleModel",
            "description_width": "",
            "_view_module": "@jupyter-widgets/base",
            "_model_module_version": "1.5.0",
            "_view_count": null,
            "_view_module_version": "1.2.0",
            "_model_module": "@jupyter-widgets/controls"
          }
        },
        "5e0ae6ad70bf4391ae83dd7d32d91a7f": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "state": {
            "_view_name": "LayoutView",
            "grid_template_rows": null,
            "right": null,
            "justify_content": null,
            "_view_module": "@jupyter-widgets/base",
            "overflow": null,
            "_model_module_version": "1.2.0",
            "_view_count": null,
            "flex_flow": null,
            "width": null,
            "min_width": null,
            "border": null,
            "align_items": null,
            "bottom": null,
            "_model_module": "@jupyter-widgets/base",
            "top": null,
            "grid_column": null,
            "overflow_y": null,
            "overflow_x": null,
            "grid_auto_flow": null,
            "grid_area": null,
            "grid_template_columns": null,
            "flex": null,
            "_model_name": "LayoutModel",
            "justify_items": null,
            "grid_row": null,
            "max_height": null,
            "align_content": null,
            "visibility": null,
            "align_self": null,
            "height": null,
            "min_height": null,
            "padding": null,
            "grid_auto_rows": null,
            "grid_gap": null,
            "max_width": null,
            "order": null,
            "_view_module_version": "1.2.0",
            "grid_template_areas": null,
            "object_position": null,
            "object_fit": null,
            "grid_auto_columns": null,
            "margin": null,
            "display": null,
            "left": null
          }
        },
        "dadac6ae4663473596c47df55c10d628": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "state": {
            "_view_name": "HBoxView",
            "_dom_classes": [],
            "_model_name": "HBoxModel",
            "_view_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_view_count": null,
            "_view_module_version": "1.5.0",
            "box_style": "",
            "layout": "IPY_MODEL_c214207f1b5646ce839b828d0711f1fa",
            "_model_module": "@jupyter-widgets/controls",
            "children": [
              "IPY_MODEL_5610c6b4f5974aba8033cbf6e575b104",
              "IPY_MODEL_2ab572f1e228487ca99ef57a36b54e95"
            ]
          }
        },
        "c214207f1b5646ce839b828d0711f1fa": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "state": {
            "_view_name": "LayoutView",
            "grid_template_rows": null,
            "right": null,
            "justify_content": null,
            "_view_module": "@jupyter-widgets/base",
            "overflow": null,
            "_model_module_version": "1.2.0",
            "_view_count": null,
            "flex_flow": null,
            "width": null,
            "min_width": null,
            "border": null,
            "align_items": null,
            "bottom": null,
            "_model_module": "@jupyter-widgets/base",
            "top": null,
            "grid_column": null,
            "overflow_y": null,
            "overflow_x": null,
            "grid_auto_flow": null,
            "grid_area": null,
            "grid_template_columns": null,
            "flex": null,
            "_model_name": "LayoutModel",
            "justify_items": null,
            "grid_row": null,
            "max_height": null,
            "align_content": null,
            "visibility": null,
            "align_self": null,
            "height": null,
            "min_height": null,
            "padding": null,
            "grid_auto_rows": null,
            "grid_gap": null,
            "max_width": null,
            "order": null,
            "_view_module_version": "1.2.0",
            "grid_template_areas": null,
            "object_position": null,
            "object_fit": null,
            "grid_auto_columns": null,
            "margin": null,
            "display": null,
            "left": null
          }
        },
        "5610c6b4f5974aba8033cbf6e575b104": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "state": {
            "_view_name": "ProgressView",
            "style": "IPY_MODEL_c50b69727ffd4e268d65fbfc35fcef6c",
            "_dom_classes": [],
            "description": "Downloading: 100%",
            "_model_name": "FloatProgressModel",
            "bar_style": "success",
            "max": 526681800,
            "_view_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "value": 526681800,
            "_view_count": null,
            "_view_module_version": "1.5.0",
            "orientation": "horizontal",
            "min": 0,
            "description_tooltip": null,
            "_model_module": "@jupyter-widgets/controls",
            "layout": "IPY_MODEL_89791d4f2bbf423093982cf8206d8d71"
          }
        },
        "2ab572f1e228487ca99ef57a36b54e95": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "state": {
            "_view_name": "HTMLView",
            "style": "IPY_MODEL_4923abd553514bd98156f1f3d4c0f071",
            "_dom_classes": [],
            "description": "",
            "_model_name": "HTMLModel",
            "placeholder": "​",
            "_view_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "value": " 527M/527M [00:09&lt;00:00, 57.8MB/s]",
            "_view_count": null,
            "_view_module_version": "1.5.0",
            "description_tooltip": null,
            "_model_module": "@jupyter-widgets/controls",
            "layout": "IPY_MODEL_d8c68d1701b74f6ab82580c84783f882"
          }
        },
        "c50b69727ffd4e268d65fbfc35fcef6c": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "state": {
            "_view_name": "StyleView",
            "_model_name": "ProgressStyleModel",
            "description_width": "initial",
            "_view_module": "@jupyter-widgets/base",
            "_model_module_version": "1.5.0",
            "_view_count": null,
            "_view_module_version": "1.2.0",
            "bar_color": null,
            "_model_module": "@jupyter-widgets/controls"
          }
        },
        "89791d4f2bbf423093982cf8206d8d71": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "state": {
            "_view_name": "LayoutView",
            "grid_template_rows": null,
            "right": null,
            "justify_content": null,
            "_view_module": "@jupyter-widgets/base",
            "overflow": null,
            "_model_module_version": "1.2.0",
            "_view_count": null,
            "flex_flow": null,
            "width": null,
            "min_width": null,
            "border": null,
            "align_items": null,
            "bottom": null,
            "_model_module": "@jupyter-widgets/base",
            "top": null,
            "grid_column": null,
            "overflow_y": null,
            "overflow_x": null,
            "grid_auto_flow": null,
            "grid_area": null,
            "grid_template_columns": null,
            "flex": null,
            "_model_name": "LayoutModel",
            "justify_items": null,
            "grid_row": null,
            "max_height": null,
            "align_content": null,
            "visibility": null,
            "align_self": null,
            "height": null,
            "min_height": null,
            "padding": null,
            "grid_auto_rows": null,
            "grid_gap": null,
            "max_width": null,
            "order": null,
            "_view_module_version": "1.2.0",
            "grid_template_areas": null,
            "object_position": null,
            "object_fit": null,
            "grid_auto_columns": null,
            "margin": null,
            "display": null,
            "left": null
          }
        },
        "4923abd553514bd98156f1f3d4c0f071": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "state": {
            "_view_name": "StyleView",
            "_model_name": "DescriptionStyleModel",
            "description_width": "",
            "_view_module": "@jupyter-widgets/base",
            "_model_module_version": "1.5.0",
            "_view_count": null,
            "_view_module_version": "1.2.0",
            "_model_module": "@jupyter-widgets/controls"
          }
        },
        "d8c68d1701b74f6ab82580c84783f882": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "state": {
            "_view_name": "LayoutView",
            "grid_template_rows": null,
            "right": null,
            "justify_content": null,
            "_view_module": "@jupyter-widgets/base",
            "overflow": null,
            "_model_module_version": "1.2.0",
            "_view_count": null,
            "flex_flow": null,
            "width": null,
            "min_width": null,
            "border": null,
            "align_items": null,
            "bottom": null,
            "_model_module": "@jupyter-widgets/base",
            "top": null,
            "grid_column": null,
            "overflow_y": null,
            "overflow_x": null,
            "grid_auto_flow": null,
            "grid_area": null,
            "grid_template_columns": null,
            "flex": null,
            "_model_name": "LayoutModel",
            "justify_items": null,
            "grid_row": null,
            "max_height": null,
            "align_content": null,
            "visibility": null,
            "align_self": null,
            "height": null,
            "min_height": null,
            "padding": null,
            "grid_auto_rows": null,
            "grid_gap": null,
            "max_width": null,
            "order": null,
            "_view_module_version": "1.2.0",
            "grid_template_areas": null,
            "object_position": null,
            "object_fit": null,
            "grid_auto_columns": null,
            "margin": null,
            "display": null,
            "left": null
          }
        },
        "ba727c1c9d014082b4cb27208c79ccf5": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "state": {
            "_view_name": "HBoxView",
            "_dom_classes": [],
            "_model_name": "HBoxModel",
            "_view_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_view_count": null,
            "_view_module_version": "1.5.0",
            "box_style": "",
            "layout": "IPY_MODEL_cfae1dbeaa444781bfc9aa8141141bed",
            "_model_module": "@jupyter-widgets/controls",
            "children": [
              "IPY_MODEL_e94175a824a742b29ac96c957c8512cd",
              "IPY_MODEL_72aaef4c05e7413480e1713fa29378f2"
            ]
          }
        },
        "cfae1dbeaa444781bfc9aa8141141bed": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "state": {
            "_view_name": "LayoutView",
            "grid_template_rows": null,
            "right": null,
            "justify_content": null,
            "_view_module": "@jupyter-widgets/base",
            "overflow": null,
            "_model_module_version": "1.2.0",
            "_view_count": null,
            "flex_flow": null,
            "width": null,
            "min_width": null,
            "border": null,
            "align_items": null,
            "bottom": null,
            "_model_module": "@jupyter-widgets/base",
            "top": null,
            "grid_column": null,
            "overflow_y": null,
            "overflow_x": null,
            "grid_auto_flow": null,
            "grid_area": null,
            "grid_template_columns": null,
            "flex": null,
            "_model_name": "LayoutModel",
            "justify_items": null,
            "grid_row": null,
            "max_height": null,
            "align_content": null,
            "visibility": null,
            "align_self": null,
            "height": null,
            "min_height": null,
            "padding": null,
            "grid_auto_rows": null,
            "grid_gap": null,
            "max_width": null,
            "order": null,
            "_view_module_version": "1.2.0",
            "grid_template_areas": null,
            "object_position": null,
            "object_fit": null,
            "grid_auto_columns": null,
            "margin": null,
            "display": null,
            "left": null
          }
        },
        "e94175a824a742b29ac96c957c8512cd": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "state": {
            "_view_name": "ProgressView",
            "style": "IPY_MODEL_4512b37a54ad48558dfeaee8beda1f5a",
            "_dom_classes": [],
            "description": "Downloading: 100%",
            "_model_name": "FloatProgressModel",
            "bar_style": "success",
            "max": 213450,
            "_view_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "value": 213450,
            "_view_count": null,
            "_view_module_version": "1.5.0",
            "orientation": "horizontal",
            "min": 0,
            "description_tooltip": null,
            "_model_module": "@jupyter-widgets/controls",
            "layout": "IPY_MODEL_e041f389bb9b4adeac5a6372a68b6138"
          }
        },
        "72aaef4c05e7413480e1713fa29378f2": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "state": {
            "_view_name": "HTMLView",
            "style": "IPY_MODEL_37189a4da7d24164adb597a717d7bc4d",
            "_dom_classes": [],
            "description": "",
            "_model_name": "HTMLModel",
            "placeholder": "​",
            "_view_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "value": " 213k/213k [00:00&lt;00:00, 819kB/s]",
            "_view_count": null,
            "_view_module_version": "1.5.0",
            "description_tooltip": null,
            "_model_module": "@jupyter-widgets/controls",
            "layout": "IPY_MODEL_41e56946285145afbba8294371268b7e"
          }
        },
        "4512b37a54ad48558dfeaee8beda1f5a": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "state": {
            "_view_name": "StyleView",
            "_model_name": "ProgressStyleModel",
            "description_width": "initial",
            "_view_module": "@jupyter-widgets/base",
            "_model_module_version": "1.5.0",
            "_view_count": null,
            "_view_module_version": "1.2.0",
            "bar_color": null,
            "_model_module": "@jupyter-widgets/controls"
          }
        },
        "e041f389bb9b4adeac5a6372a68b6138": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "state": {
            "_view_name": "LayoutView",
            "grid_template_rows": null,
            "right": null,
            "justify_content": null,
            "_view_module": "@jupyter-widgets/base",
            "overflow": null,
            "_model_module_version": "1.2.0",
            "_view_count": null,
            "flex_flow": null,
            "width": null,
            "min_width": null,
            "border": null,
            "align_items": null,
            "bottom": null,
            "_model_module": "@jupyter-widgets/base",
            "top": null,
            "grid_column": null,
            "overflow_y": null,
            "overflow_x": null,
            "grid_auto_flow": null,
            "grid_area": null,
            "grid_template_columns": null,
            "flex": null,
            "_model_name": "LayoutModel",
            "justify_items": null,
            "grid_row": null,
            "max_height": null,
            "align_content": null,
            "visibility": null,
            "align_self": null,
            "height": null,
            "min_height": null,
            "padding": null,
            "grid_auto_rows": null,
            "grid_gap": null,
            "max_width": null,
            "order": null,
            "_view_module_version": "1.2.0",
            "grid_template_areas": null,
            "object_position": null,
            "object_fit": null,
            "grid_auto_columns": null,
            "margin": null,
            "display": null,
            "left": null
          }
        },
        "37189a4da7d24164adb597a717d7bc4d": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "state": {
            "_view_name": "StyleView",
            "_model_name": "DescriptionStyleModel",
            "description_width": "",
            "_view_module": "@jupyter-widgets/base",
            "_model_module_version": "1.5.0",
            "_view_count": null,
            "_view_module_version": "1.2.0",
            "_model_module": "@jupyter-widgets/controls"
          }
        },
        "41e56946285145afbba8294371268b7e": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "state": {
            "_view_name": "LayoutView",
            "grid_template_rows": null,
            "right": null,
            "justify_content": null,
            "_view_module": "@jupyter-widgets/base",
            "overflow": null,
            "_model_module_version": "1.2.0",
            "_view_count": null,
            "flex_flow": null,
            "width": null,
            "min_width": null,
            "border": null,
            "align_items": null,
            "bottom": null,
            "_model_module": "@jupyter-widgets/base",
            "top": null,
            "grid_column": null,
            "overflow_y": null,
            "overflow_x": null,
            "grid_auto_flow": null,
            "grid_area": null,
            "grid_template_columns": null,
            "flex": null,
            "_model_name": "LayoutModel",
            "justify_items": null,
            "grid_row": null,
            "max_height": null,
            "align_content": null,
            "visibility": null,
            "align_self": null,
            "height": null,
            "min_height": null,
            "padding": null,
            "grid_auto_rows": null,
            "grid_gap": null,
            "max_width": null,
            "order": null,
            "_view_module_version": "1.2.0",
            "grid_template_areas": null,
            "object_position": null,
            "object_fit": null,
            "grid_auto_columns": null,
            "margin": null,
            "display": null,
            "left": null
          }
        }
      }
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/debugk/NER_Covid19/blob/AddEval/NER_bert_bilstm_crf.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "NUZ7Zxv0zr1r",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 165
        },
        "outputId": "4a320ee1-ceb5-45fb-e33a-d833f158cacb"
      },
      "source": [
        "import numpy as np\n",
        "import seaborn as sns\n",
        "import matplotlib.pyplot as plt\n",
        "\n",
        "from google.colab import drive\n",
        "drive.mount('/content/gdrive')"
      ],
      "execution_count": 1,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/statsmodels/tools/_testing.py:19: FutureWarning: pandas.util.testing is deprecated. Use the functions in the public API at pandas.testing instead.\n",
            "  import pandas.util.testing as tm\n"
          ],
          "name": "stderr"
        },
        {
          "output_type": "stream",
          "text": [
            "Go to this URL in a browser: https://accounts.google.com/o/oauth2/auth?client_id=947318989803-6bn6qk8qdgf4n4g3pfee6491hc0brc4i.apps.googleusercontent.com&redirect_uri=urn%3aietf%3awg%3aoauth%3a2.0%3aoob&response_type=code&scope=email%20https%3a%2f%2fwww.googleapis.com%2fauth%2fdocs.test%20https%3a%2f%2fwww.googleapis.com%2fauth%2fdrive%20https%3a%2f%2fwww.googleapis.com%2fauth%2fdrive.photos.readonly%20https%3a%2f%2fwww.googleapis.com%2fauth%2fpeopleapi.readonly\n",
            "\n",
            "Enter your authorization code:\n",
            "··········\n",
            "Mounted at /content/gdrive\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "hkLnG3wY0ytz",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 655
        },
        "outputId": "fb732752-8382-4f45-d16c-b0c799076a1c"
      },
      "source": [
        "#install the amazing transformers package by huggingface\n",
        "!pip install transformers\n",
        "import transformers\n",
        "from transformers import BertTokenizer, BertConfig"
      ],
      "execution_count": 2,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "Collecting transformers\n",
            "\u001b[?25l  Downloading https://files.pythonhosted.org/packages/27/3c/91ed8f5c4e7ef3227b4119200fc0ed4b4fd965b1f0172021c25701087825/transformers-3.0.2-py3-none-any.whl (769kB)\n",
            "\r\u001b[K     |▍                               | 10kB 16.8MB/s eta 0:00:01\r\u001b[K     |▉                               | 20kB 2.9MB/s eta 0:00:01\r\u001b[K     |█▎                              | 30kB 3.6MB/s eta 0:00:01\r\u001b[K     |█▊                              | 40kB 4.3MB/s eta 0:00:01\r\u001b[K     |██▏                             | 51kB 3.3MB/s eta 0:00:01\r\u001b[K     |██▋                             | 61kB 3.8MB/s eta 0:00:01\r\u001b[K     |███                             | 71kB 4.0MB/s eta 0:00:01\r\u001b[K     |███▍                            | 81kB 4.3MB/s eta 0:00:01\r\u001b[K     |███▉                            | 92kB 4.4MB/s eta 0:00:01\r\u001b[K     |████▎                           | 102kB 4.5MB/s eta 0:00:01\r\u001b[K     |████▊                           | 112kB 4.5MB/s eta 0:00:01\r\u001b[K     |█████▏                          | 122kB 4.5MB/s eta 0:00:01\r\u001b[K     |█████▌                          | 133kB 4.5MB/s eta 0:00:01\r\u001b[K     |██████                          | 143kB 4.5MB/s eta 0:00:01\r\u001b[K     |██████▍                         | 153kB 4.5MB/s eta 0:00:01\r\u001b[K     |██████▉                         | 163kB 4.5MB/s eta 0:00:01\r\u001b[K     |███████▎                        | 174kB 4.5MB/s eta 0:00:01\r\u001b[K     |███████▊                        | 184kB 4.5MB/s eta 0:00:01\r\u001b[K     |████████                        | 194kB 4.5MB/s eta 0:00:01\r\u001b[K     |████████▌                       | 204kB 4.5MB/s eta 0:00:01\r\u001b[K     |█████████                       | 215kB 4.5MB/s eta 0:00:01\r\u001b[K     |█████████▍                      | 225kB 4.5MB/s eta 0:00:01\r\u001b[K     |█████████▉                      | 235kB 4.5MB/s eta 0:00:01\r\u001b[K     |██████████▎                     | 245kB 4.5MB/s eta 0:00:01\r\u001b[K     |██████████▋                     | 256kB 4.5MB/s eta 0:00:01\r\u001b[K     |███████████                     | 266kB 4.5MB/s eta 0:00:01\r\u001b[K     |███████████▌                    | 276kB 4.5MB/s eta 0:00:01\r\u001b[K     |████████████                    | 286kB 4.5MB/s eta 0:00:01\r\u001b[K     |████████████▍                   | 296kB 4.5MB/s eta 0:00:01\r\u001b[K     |████████████▉                   | 307kB 4.5MB/s eta 0:00:01\r\u001b[K     |█████████████▏                  | 317kB 4.5MB/s eta 0:00:01\r\u001b[K     |█████████████▋                  | 327kB 4.5MB/s eta 0:00:01\r\u001b[K     |██████████████                  | 337kB 4.5MB/s eta 0:00:01\r\u001b[K     |██████████████▌                 | 348kB 4.5MB/s eta 0:00:01\r\u001b[K     |███████████████                 | 358kB 4.5MB/s eta 0:00:01\r\u001b[K     |███████████████▍                | 368kB 4.5MB/s eta 0:00:01\r\u001b[K     |███████████████▊                | 378kB 4.5MB/s eta 0:00:01\r\u001b[K     |████████████████▏               | 389kB 4.5MB/s eta 0:00:01\r\u001b[K     |████████████████▋               | 399kB 4.5MB/s eta 0:00:01\r\u001b[K     |█████████████████               | 409kB 4.5MB/s eta 0:00:01\r\u001b[K     |█████████████████▌              | 419kB 4.5MB/s eta 0:00:01\r\u001b[K     |██████████████████              | 430kB 4.5MB/s eta 0:00:01\r\u001b[K     |██████████████████▎             | 440kB 4.5MB/s eta 0:00:01\r\u001b[K     |██████████████████▊             | 450kB 4.5MB/s eta 0:00:01\r\u001b[K     |███████████████████▏            | 460kB 4.5MB/s eta 0:00:01\r\u001b[K     |███████████████████▋            | 471kB 4.5MB/s eta 0:00:01\r\u001b[K     |████████████████████            | 481kB 4.5MB/s eta 0:00:01\r\u001b[K     |████████████████████▌           | 491kB 4.5MB/s eta 0:00:01\r\u001b[K     |████████████████████▉           | 501kB 4.5MB/s eta 0:00:01\r\u001b[K     |█████████████████████▎          | 512kB 4.5MB/s eta 0:00:01\r\u001b[K     |█████████████████████▊          | 522kB 4.5MB/s eta 0:00:01\r\u001b[K     |██████████████████████▏         | 532kB 4.5MB/s eta 0:00:01\r\u001b[K     |██████████████████████▋         | 542kB 4.5MB/s eta 0:00:01\r\u001b[K     |███████████████████████         | 552kB 4.5MB/s eta 0:00:01\r\u001b[K     |███████████████████████▍        | 563kB 4.5MB/s eta 0:00:01\r\u001b[K     |███████████████████████▉        | 573kB 4.5MB/s eta 0:00:01\r\u001b[K     |████████████████████████▎       | 583kB 4.5MB/s eta 0:00:01\r\u001b[K     |████████████████████████▊       | 593kB 4.5MB/s eta 0:00:01\r\u001b[K     |█████████████████████████▏      | 604kB 4.5MB/s eta 0:00:01\r\u001b[K     |█████████████████████████▋      | 614kB 4.5MB/s eta 0:00:01\r\u001b[K     |██████████████████████████      | 624kB 4.5MB/s eta 0:00:01\r\u001b[K     |██████████████████████████▍     | 634kB 4.5MB/s eta 0:00:01\r\u001b[K     |██████████████████████████▉     | 645kB 4.5MB/s eta 0:00:01\r\u001b[K     |███████████████████████████▎    | 655kB 4.5MB/s eta 0:00:01\r\u001b[K     |███████████████████████████▊    | 665kB 4.5MB/s eta 0:00:01\r\u001b[K     |████████████████████████████▏   | 675kB 4.5MB/s eta 0:00:01\r\u001b[K     |████████████████████████████▌   | 686kB 4.5MB/s eta 0:00:01\r\u001b[K     |█████████████████████████████   | 696kB 4.5MB/s eta 0:00:01\r\u001b[K     |█████████████████████████████▍  | 706kB 4.5MB/s eta 0:00:01\r\u001b[K     |█████████████████████████████▉  | 716kB 4.5MB/s eta 0:00:01\r\u001b[K     |██████████████████████████████▎ | 727kB 4.5MB/s eta 0:00:01\r\u001b[K     |██████████████████████████████▊ | 737kB 4.5MB/s eta 0:00:01\r\u001b[K     |███████████████████████████████ | 747kB 4.5MB/s eta 0:00:01\r\u001b[K     |███████████████████████████████▌| 757kB 4.5MB/s eta 0:00:01\r\u001b[K     |████████████████████████████████| 768kB 4.5MB/s eta 0:00:01\r\u001b[K     |████████████████████████████████| 778kB 4.5MB/s \n",
            "\u001b[?25hRequirement already satisfied: numpy in /usr/local/lib/python3.6/dist-packages (from transformers) (1.18.5)\n",
            "Requirement already satisfied: regex!=2019.12.17 in /usr/local/lib/python3.6/dist-packages (from transformers) (2019.12.20)\n",
            "Collecting sentencepiece!=0.1.92\n",
            "\u001b[?25l  Downloading https://files.pythonhosted.org/packages/d4/a4/d0a884c4300004a78cca907a6ff9a5e9fe4f090f5d95ab341c53d28cbc58/sentencepiece-0.1.91-cp36-cp36m-manylinux1_x86_64.whl (1.1MB)\n",
            "\u001b[K     |████████████████████████████████| 1.1MB 21.9MB/s \n",
            "\u001b[?25hRequirement already satisfied: requests in /usr/local/lib/python3.6/dist-packages (from transformers) (2.23.0)\n",
            "Requirement already satisfied: dataclasses; python_version < \"3.7\" in /usr/local/lib/python3.6/dist-packages (from transformers) (0.7)\n",
            "Collecting tokenizers==0.8.1.rc1\n",
            "\u001b[?25l  Downloading https://files.pythonhosted.org/packages/40/d0/30d5f8d221a0ed981a186c8eb986ce1c94e3a6e87f994eae9f4aa5250217/tokenizers-0.8.1rc1-cp36-cp36m-manylinux1_x86_64.whl (3.0MB)\n",
            "\u001b[K     |████████████████████████████████| 3.0MB 31.3MB/s \n",
            "\u001b[?25hRequirement already satisfied: packaging in /usr/local/lib/python3.6/dist-packages (from transformers) (20.4)\n",
            "Collecting sacremoses\n",
            "\u001b[?25l  Downloading https://files.pythonhosted.org/packages/7d/34/09d19aff26edcc8eb2a01bed8e98f13a1537005d31e95233fd48216eed10/sacremoses-0.0.43.tar.gz (883kB)\n",
            "\u001b[K     |████████████████████████████████| 890kB 39.7MB/s \n",
            "\u001b[?25hRequirement already satisfied: tqdm>=4.27 in /usr/local/lib/python3.6/dist-packages (from transformers) (4.41.1)\n",
            "Requirement already satisfied: filelock in /usr/local/lib/python3.6/dist-packages (from transformers) (3.0.12)\n",
            "Requirement already satisfied: chardet<4,>=3.0.2 in /usr/local/lib/python3.6/dist-packages (from requests->transformers) (3.0.4)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.6/dist-packages (from requests->transformers) (2020.6.20)\n",
            "Requirement already satisfied: urllib3!=1.25.0,!=1.25.1,<1.26,>=1.21.1 in /usr/local/lib/python3.6/dist-packages (from requests->transformers) (1.24.3)\n",
            "Requirement already satisfied: idna<3,>=2.5 in /usr/local/lib/python3.6/dist-packages (from requests->transformers) (2.10)\n",
            "Requirement already satisfied: pyparsing>=2.0.2 in /usr/local/lib/python3.6/dist-packages (from packaging->transformers) (2.4.7)\n",
            "Requirement already satisfied: six in /usr/local/lib/python3.6/dist-packages (from packaging->transformers) (1.15.0)\n",
            "Requirement already satisfied: click in /usr/local/lib/python3.6/dist-packages (from sacremoses->transformers) (7.1.2)\n",
            "Requirement already satisfied: joblib in /usr/local/lib/python3.6/dist-packages (from sacremoses->transformers) (0.16.0)\n",
            "Building wheels for collected packages: sacremoses\n",
            "  Building wheel for sacremoses (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
            "  Created wheel for sacremoses: filename=sacremoses-0.0.43-cp36-none-any.whl size=893260 sha256=a47bc2175f4dca635a6f79dc662f2db272af81b9b45a4de0c424f9db5f89aa2f\n",
            "  Stored in directory: /root/.cache/pip/wheels/29/3c/fd/7ce5c3f0666dab31a50123635e6fb5e19ceb42ce38d4e58f45\n",
            "Successfully built sacremoses\n",
            "Installing collected packages: sentencepiece, tokenizers, sacremoses, transformers\n",
            "Successfully installed sacremoses-0.0.43 sentencepiece-0.1.91 tokenizers-0.8.1rc1 transformers-3.0.2\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "DGOzKE851TCt",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 278,
          "referenced_widgets": [
            "8c52910c46264f02881cb99e2b09f194",
            "f42a5d1f9065477f800e737894ba34a6",
            "ee12caae1eaf41619baa86de1ba78122",
            "aac430dbfe9d4975b3d2e1504927bd12",
            "37aee5698d0249878ea5841c0a1fb587",
            "21f73ff5483d44be847624235d3bc48d",
            "2e17a9c5d5d74242a87e7834c99323de",
            "5e0ae6ad70bf4391ae83dd7d32d91a7f",
            "dadac6ae4663473596c47df55c10d628",
            "c214207f1b5646ce839b828d0711f1fa",
            "5610c6b4f5974aba8033cbf6e575b104",
            "2ab572f1e228487ca99ef57a36b54e95",
            "c50b69727ffd4e268d65fbfc35fcef6c",
            "89791d4f2bbf423093982cf8206d8d71",
            "4923abd553514bd98156f1f3d4c0f071",
            "d8c68d1701b74f6ab82580c84783f882",
            "ba727c1c9d014082b4cb27208c79ccf5",
            "cfae1dbeaa444781bfc9aa8141141bed",
            "e94175a824a742b29ac96c957c8512cd",
            "72aaef4c05e7413480e1713fa29378f2",
            "4512b37a54ad48558dfeaee8beda1f5a",
            "e041f389bb9b4adeac5a6372a68b6138",
            "37189a4da7d24164adb597a717d7bc4d",
            "41e56946285145afbba8294371268b7e"
          ]
        },
        "outputId": "1590b809-6ffa-4c74-efc7-ae4276abef43"
      },
      "source": [
        "from transformers import BertTokenizer, TFBertModel\n",
        "import tensorflow as tf\n",
        "\n",
        "tf_model = TFBertModel.from_pretrained('bert-base-cased')\n",
        "tokenizer = BertTokenizer.from_pretrained('bert-base-cased')"
      ],
      "execution_count": 3,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "application/vnd.jupyter.widget-view+json": {
              "model_id": "8c52910c46264f02881cb99e2b09f194",
              "version_minor": 0,
              "version_major": 2
            },
            "text/plain": [
              "HBox(children=(FloatProgress(value=0.0, description='Downloading', max=433.0, style=ProgressStyle(description_…"
            ]
          },
          "metadata": {
            "tags": []
          }
        },
        {
          "output_type": "stream",
          "text": [
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "display_data",
          "data": {
            "application/vnd.jupyter.widget-view+json": {
              "model_id": "dadac6ae4663473596c47df55c10d628",
              "version_minor": 0,
              "version_major": 2
            },
            "text/plain": [
              "HBox(children=(FloatProgress(value=0.0, description='Downloading', max=526681800.0, style=ProgressStyle(descri…"
            ]
          },
          "metadata": {
            "tags": []
          }
        },
        {
          "output_type": "stream",
          "text": [
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "Some weights of the model checkpoint at bert-base-cased were not used when initializing TFBertModel: ['nsp___cls', 'mlm___cls']\n",
            "- This IS expected if you are initializing TFBertModel from the checkpoint of a model trained on another task or with another architecture (e.g. initializing a BertForSequenceClassification model from a BertForPretraining model).\n",
            "- This IS NOT expected if you are initializing TFBertModel from the checkpoint of a model that you expect to be exactly identical (initializing a BertForSequenceClassification model from a BertForSequenceClassification model).\n",
            "All the weights of TFBertModel were initialized from the model checkpoint at bert-base-cased.\n",
            "If your task is similar to the task the model of the ckeckpoint was trained on, you can already use TFBertModel for predictions without further training.\n"
          ],
          "name": "stderr"
        },
        {
          "output_type": "display_data",
          "data": {
            "application/vnd.jupyter.widget-view+json": {
              "model_id": "ba727c1c9d014082b4cb27208c79ccf5",
              "version_minor": 0,
              "version_major": 2
            },
            "text/plain": [
              "HBox(children=(FloatProgress(value=0.0, description='Downloading', max=213450.0, style=ProgressStyle(descripti…"
            ]
          },
          "metadata": {
            "tags": []
          }
        },
        {
          "output_type": "stream",
          "text": [
            "\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "z9qqiHio_Z0j",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 72
        },
        "outputId": "2c4b03b9-a619-4c59-a2bd-b4fd887a518d"
      },
      "source": [
        "import nltk\n",
        "nltk.download('punkt')"
      ],
      "execution_count": 4,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "[nltk_data] Downloading package punkt to /root/nltk_data...\n",
            "[nltk_data]   Unzipping tokenizers/punkt.zip.\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "True"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 4
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "HlMYjDbqK8iK",
        "colab_type": "text"
      },
      "source": [
        "# Word embedding"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "XYqfE68zlZiz",
        "colab_type": "code",
        "colab": {}
      },
      "source": [
        "\n",
        "#==========================================================================================\n",
        "def prepare_tokentags(data, max_length = 150, fdebug=False):\n",
        "    data_tags   = []\n",
        "    data_tokens = []\n",
        "\n",
        "    sentences = nltk.tokenize.sent_tokenize(data['text'])\n",
        "    entities  = sorted(data['entities'], key=lambda entity: entity['start'], reverse=True) # sort by the entity start point, reverse\n",
        "\n",
        "    # The target is the group of the words in top entity, i.e. papillomavirus -> \n",
        "    entity = entities.pop()\n",
        "    target_tokens = tokenizer.tokenize(entity['entity'])\n",
        "    target_token  = '_'.join(target_tokens)  \n",
        "    len_targets   = len(target_tokens)\n",
        "    entity_end    = entity['end'] # help to aviod duplicated tag\n",
        "    \n",
        "    is_never_match = True    \n",
        "\n",
        "    for sentence in sentences:\n",
        "        # init the sentence tags\n",
        "        sentence_tags = ['O']*max_length\n",
        "        # Add the special tokens.\n",
        "        sentence = \"[CLS] \" + sentence + \"[SEP]\" \n",
        "\n",
        "        tokens = tokenizer.tokenize(sentence)\n",
        "\n",
        "        if len(tokens) < max_length:\n",
        "            tokens += [\"[PAD]\"]*(max_length - len(tokens))\n",
        "        \n",
        "        i = 0\n",
        "\n",
        "        while i < min(len(tokens), max_length): # some len(tokens) > 150 \n",
        "            end_point = i+len_targets if (i+len_targets) < len(tokens) else len(tokens)\n",
        "            match_token = '_'.join(tokens[i:end_point])\n",
        "\n",
        "            if match_token ==  target_token:\n",
        "                is_never_match = False\n",
        "\n",
        "                sentence_tags[i] = 'B-' + entity['type']\n",
        "\n",
        "                for j in range(1, len_targets):\n",
        "                    if i+j >= max_length: continue \n",
        "\n",
        "                    sentence_tags[i+j] = 'I-' + entity['type']\n",
        "\n",
        "                # update the position\n",
        "                i += len_targets \n",
        "\n",
        "                if entities:\n",
        "                    # remove the top entity, move to next entity\n",
        "                    entity = entities.pop()\n",
        "\n",
        "                    # check whether the new entity is inside the privious entity\n",
        "                    while entity['end'] <= entity_end:\n",
        "                        print(\"Current entity is inside the privious entity, skip it: \", entity)\n",
        "\n",
        "                        if entities:\n",
        "                            entity = entities.pop()\n",
        "                        else:\n",
        "                            # entities is empty, stop loop\n",
        "                            i = len(tokens)\n",
        "                            break\n",
        "\n",
        "                    # update \n",
        "                    target_tokens = tokenizer.tokenize(entity['entity'])  \n",
        "                    target_token  = '_'.join(target_tokens)  \n",
        "                    len_targets   = len(target_tokens)\n",
        "                    entity_end    = entity['end']\n",
        "                else:\n",
        "                    # entities is empty, stop loop\n",
        "                    i = len(tokens)\n",
        "            else:\n",
        "                  i += 1\n",
        "\n",
        "        if fdebug:\n",
        "            for token, tag in zip(tokens, sentence_tags):\n",
        "                print(\"{}\\t{}\".format(tag, token))\n",
        "        \n",
        "        data_tokens += [tokens]\n",
        "        data_tags   += [sentence_tags]           \n",
        "\n",
        "    if entities: \n",
        "        print(sentences)\n",
        "        print(\"unmatched tags: \", entities)\n",
        "    elif is_never_match:\n",
        "        print(sentences)\n",
        "        print(\"Only one tag and it is not matched: \", entity)\n",
        "\n",
        "    return (data_tokens, data_tags)\n",
        "\n",
        "\n",
        "#==========================================================================================\n",
        "def prepare_embedding(datas, max_length = 150, fdebug=False):\n",
        "    sentences = []\n",
        "    \n",
        "    for data in datas:\n",
        "        sentences += nltk.tokenize.sent_tokenize(data['text'])\n",
        "    \n",
        "    # it will extrat the same token as \"tokenizer.encode(sentence)\" or \"tokenizer.tokenize(sentence); tokenizer.convert_tokens_to_ids()\"\n",
        "    tf_inputs = tokenizer(sentences, padding=True, pad_to_multiple_of=max_length, return_attention_mask=True, return_tensors=\"tf\") \n",
        "\n",
        "    if fdebug:\n",
        "        print(tf_inputs)\n",
        "\n",
        "    tf_outputs = tf_model(tf_inputs)\n",
        "\n",
        "    # use the second-to-last layer for embedding.   \n",
        "    last_hidden_states = tf_outputs[0]\n",
        "\n",
        "    return last_hidden_states # tensorflow tensor"
      ],
      "execution_count": 18,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "CUT3c4jDzUA_",
        "colab_type": "text"
      },
      "source": [
        "# Word embedding test"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "z9KQnZaQzcyP",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "9a05e191-99c7-4ce1-fa52-8bba1084de94"
      },
      "source": [
        "test_data = {\"text\": \"Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference\\tThe search for an HIV/AIDS vaccine is steadily moving ahead, generating and validating new concepts in terms of novel vectors for antigen delivery and presentation, new vaccine and adjuvant strategies, alternative approaches to design HIV-1 antigens for eliciting protective cross-neutralising antibodies, and identification of key mechanisms in HIV infection and modulation of the immune system. All these different perspectives are contributing to the unprecedented challenge of developing a protective HIV-1 vaccine.\", \n",
        "             \"entities\": [\n",
        "                          #{\"entity\": \"HIV vaccine\", \"type\": \"Drug\", \"start\": 35, \"end\": 46}, \n",
        "                          #{\"entity\": \"AIDS\", \"type\": \"Disease\", \"start\": 62, \"end\": 66}, \n",
        "                          {\"entity\": \"HIV/AIDS vaccine\", \"type\": \"Drug\", \"start\": 109, \"end\": 125}, \n",
        "                          {\"entity\": \"vaccine\", \"type\": \"Drug\", \"start\": 118, \"end\": 125}, \n",
        "                          {\"entity\": \"vaccine\", \"type\": \"Drug\", \"start\": 260, \"end\": 267}, \n",
        "                          {\"entity\": \"HIV-1 antigens\", \"type\": \"Virus\", \"start\": 326, \"end\": 340}, \n",
        "                          {\"entity\": \"cross-neutralising antibodies\", \"type\": \"Chemical\", \"start\": 366, \"end\": 395}, \n",
        "                          {\"entity\": \"HIV infection\", \"type\": \"Phenotype\", \"start\": 437, \"end\": 450}, \n",
        "                          {\"entity\": \"HIV-1 vaccine\", \"type\": \"Drug\", \"start\": 596, \"end\": 609}]}\n",
        "\n",
        "\n",
        "test_tokens, test_tags = prepare_tokentags(test_data, fdebug=True) "
      ],
      "execution_count": 14,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 118, 'end': 125}\n",
            "O\t[CLS]\n",
            "O\tProgress\n",
            "O\ttowards\n",
            "O\tdevelopment\n",
            "O\tof\n",
            "O\tan\n",
            "O\tHIV\n",
            "O\tvaccine\n",
            "O\t:\n",
            "O\treport\n",
            "O\tof\n",
            "O\tthe\n",
            "O\tAIDS\n",
            "O\tV\n",
            "O\t##ac\n",
            "O\t##cine\n",
            "O\t2009\n",
            "O\tConference\n",
            "O\tThe\n",
            "O\tsearch\n",
            "O\tfor\n",
            "O\tan\n",
            "B-Drug\tHIV\n",
            "I-Drug\t/\n",
            "I-Drug\tAIDS\n",
            "I-Drug\tvaccine\n",
            "O\tis\n",
            "O\tsteadily\n",
            "O\tmoving\n",
            "O\tahead\n",
            "O\t,\n",
            "O\tgenerating\n",
            "O\tand\n",
            "O\tvalid\n",
            "O\t##ating\n",
            "O\tnew\n",
            "O\tconcepts\n",
            "O\tin\n",
            "O\tterms\n",
            "O\tof\n",
            "O\tnovel\n",
            "O\tvectors\n",
            "O\tfor\n",
            "O\tanti\n",
            "O\t##gen\n",
            "O\tdelivery\n",
            "O\tand\n",
            "O\tpresentation\n",
            "O\t,\n",
            "O\tnew\n",
            "B-Drug\tvaccine\n",
            "O\tand\n",
            "O\tad\n",
            "O\t##ju\n",
            "O\t##vant\n",
            "O\tstrategies\n",
            "O\t,\n",
            "O\talternative\n",
            "O\tapproaches\n",
            "O\tto\n",
            "O\tdesign\n",
            "B-Virus\tHIV\n",
            "I-Virus\t-\n",
            "I-Virus\t1\n",
            "I-Virus\tanti\n",
            "I-Virus\t##gens\n",
            "O\tfor\n",
            "O\tel\n",
            "O\t##icit\n",
            "O\t##ing\n",
            "O\tprotective\n",
            "B-Chemical\tcross\n",
            "I-Chemical\t-\n",
            "I-Chemical\tneutral\n",
            "I-Chemical\t##ising\n",
            "I-Chemical\tantibodies\n",
            "O\t,\n",
            "O\tand\n",
            "O\tidentification\n",
            "O\tof\n",
            "O\tkey\n",
            "O\tmechanisms\n",
            "O\tin\n",
            "B-Phenotype\tHIV\n",
            "I-Phenotype\tinfection\n",
            "O\tand\n",
            "O\tm\n",
            "O\t##od\n",
            "O\t##ulation\n",
            "O\tof\n",
            "O\tthe\n",
            "O\timmune\n",
            "O\tsystem\n",
            "O\t.\n",
            "O\t[SEP]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[CLS]\n",
            "O\tAll\n",
            "O\tthese\n",
            "O\tdifferent\n",
            "O\tperspectives\n",
            "O\tare\n",
            "O\tcontributing\n",
            "O\tto\n",
            "O\tthe\n",
            "O\tunprecedented\n",
            "O\tchallenge\n",
            "O\tof\n",
            "O\tdeveloping\n",
            "O\ta\n",
            "O\tprotective\n",
            "B-Drug\tHIV\n",
            "I-Drug\t-\n",
            "I-Drug\t1\n",
            "I-Drug\tvaccine\n",
            "O\t.\n",
            "O\t[SEP]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "4U5mgVj4-rQJ",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "outputId": "0008a4af-ec23-422e-9731-ba86b3f4fa13"
      },
      "source": [
        "tokenizer.tokenize('HIV-1 antigens')"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['HIV', '-', '1', 'anti', '##gens']"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 23
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "YR_A8rBfz7Ar",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "94ffc723-b2a8-48bd-b5ee-b73f0494df9e"
      },
      "source": [
        "test_embedding = prepare_embedding([test_data], fdebug=True)"
      ],
      "execution_count": 15,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "{'input_ids': <tf.Tensor: shape=(2, 150), dtype=int32, numpy=\n",
            "array([[  101, 12798,  2019,  1718,  1104,  1126,  9622, 20034,   131,\n",
            "         2592,  1104,  1103,  9837,   159,  7409, 15459,  1371,  3047,\n",
            "         1109,  3403,  1111,  1126,  9622,   120,  9837, 20034,  1110,\n",
            "        11383,  2232,  3075,   117, 12713,  1105,  9221,  3798,  1207,\n",
            "         8550,  1107,  2538,  1104,  2281, 21118,  1111,  2848,  4915,\n",
            "         6779,  1105,  8685,   117,  1207, 20034,  1105,  8050,  9380,\n",
            "        14194, 10700,   117,  4174,  8015,  1106,  1902,  9622,   118,\n",
            "          122,  2848, 21144,  1111,  8468, 22308,  1158,  9760,  2771,\n",
            "          118,  8795,  7131, 26491,   117,  1105,  9117,  1104,  2501,\n",
            "        10748,  1107,  9622,  8974,  1105,   182,  5412,  6856,  1104,\n",
            "         1103, 11650,  1449,   119,   102,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0],\n",
            "       [  101,  1398,  1292,  1472, 22168,  1132,  7773,  1106,  1103,\n",
            "        16789,  4506,  1104,  4297,   170,  9760,  9622,   118,   122,\n",
            "        20034,   119,   102,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0]], dtype=int32)>, 'token_type_ids': <tf.Tensor: shape=(2, 150), dtype=int32, numpy=\n",
            "array([[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0],\n",
            "       [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]],\n",
            "      dtype=int32)>, 'attention_mask': <tf.Tensor: shape=(2, 150), dtype=int32, numpy=\n",
            "array([[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,\n",
            "        1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,\n",
            "        1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,\n",
            "        1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,\n",
            "        1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0],\n",
            "       [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]],\n",
            "      dtype=int32)>}\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "YclHEqEuE8VC",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 526
        },
        "outputId": "c2888bb7-7a99-489c-c22d-a68b0b49778a"
      },
      "source": [
        "test_embedding"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "<tf.Tensor: shape=(2, 150, 768), dtype=float32, numpy=\n",
              "array([[[ 0.4363854 , -0.1632477 , -0.11115196, ..., -0.25759783,\n",
              "          0.26675612, -0.04911983],\n",
              "        [ 0.53498375, -0.37613547,  0.6197574 , ..., -0.48218685,\n",
              "          0.4739411 ,  0.03731754],\n",
              "        [ 0.06586276, -0.01871911,  0.1025427 , ..., -0.3968396 ,\n",
              "          0.37530273, -0.19556184],\n",
              "        ...,\n",
              "        [ 0.15870129, -0.274877  ,  0.29720005, ...,  0.10504033,\n",
              "          0.21371704,  0.000665  ],\n",
              "        [ 0.48579338, -0.08223107,  0.11456744, ..., -0.33001724,\n",
              "          0.41771904, -0.01777348],\n",
              "        [ 0.51903564, -0.03776171,  0.10572539, ..., -0.38374949,\n",
              "          0.44076625, -0.04853794]],\n",
              "\n",
              "       [[ 0.2896441 , -0.18142474, -0.11874117, ..., -0.18844052,\n",
              "          0.42566782, -0.04289698],\n",
              "        [ 0.5129229 , -0.5060614 ,  0.58507246, ..., -0.15320691,\n",
              "          0.08374327, -0.07635534],\n",
              "        [ 0.12277415, -0.3039294 ,  0.26171896, ...,  0.5650633 ,\n",
              "          0.47797385,  0.26285738],\n",
              "        ...,\n",
              "        [ 0.07941712, -0.19985408,  0.00152268, ..., -0.04625719,\n",
              "          0.2203204 , -0.07603956],\n",
              "        [ 0.04922026, -0.10260182,  0.09288636, ...,  0.07104383,\n",
              "          0.14390855, -0.08832169],\n",
              "        [-0.10810792, -0.04483195,  0.11805558, ...,  0.23810817,\n",
              "          0.3263795 ,  0.15852752]]], dtype=float32)>"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 26
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "cGDgMMyy0h71",
        "colab_type": "text"
      },
      "source": [
        "# Read training file"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "zFG16Iw2fjnU",
        "colab_type": "code",
        "colab": {}
      },
      "source": [
        "import json\n",
        "input_dir = \"/content/gdrive/My Drive/Covid19_data/\"\n",
        "\n",
        "f = open(input_dir+'new_train.json','r')\n",
        "datas = []\n",
        "for line in f:\n",
        "  datas.append(json.loads(line))"
      ],
      "execution_count": 16,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "3TwEFuZku0Hm",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "0ec73f9b-de93-4ee0-c105-4558fb215147"
      },
      "source": [
        "train_tags = []\n",
        "\n",
        "for data in datas:\n",
        "    _, cur_tags = prepare_tokentags(data)\n",
        "    \n",
        "    train_tags += cur_tags"
      ],
      "execution_count": 19,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "['Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial\\tBimagrumab showed a good safety profile, relative to placebo, in individuals with inclusion body myositis but did not improve 6MWD.', 'The strengths of our study are that, to the best of our knowledge, it is the largest randomised controlled trial done in people with inclusion body myositis, and it provides important natural history data over 12 months.']\n",
            "unmatched tags:  [{'entity': 'inclusion body myositis', 'type': 'Disease', 'start': 413, 'end': 436}, {'entity': '6MWD', 'type': 'Gene', 'start': 274, 'end': 278}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 118, 'end': 125}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'infliximab', 'type': 'Gene', 'start': 109, 'end': 119}\n",
            "['Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial\\tIrinotecan–temozolomide–dinutuximab met protocol-defined criteria for selection as the combination meriting further study whereas irinotecan–temozolomide–temsirolimus did not.', 'Irinotecan–temozolomide–dinutuximab shows notable anti-tumour activity in patients with relapsed or refractory neuroblastoma.', 'Further evaluation of biomarkers in a larger cohort of patients might identify those most likely to respond to this chemoimmunotherapeutic regimen.']\n",
            "unmatched tags:  [{'entity': 'neuroblastoma', 'type': 'Disease', 'start': 455, 'end': 468}, {'entity': 'Irinotecan–temozolomide-dinutuximab', 'type': 'Drug', 'start': 344, 'end': 379}, {'entity': 'irinotecan-temozolomide-temsirolimus', 'type': 'Drug', 'start': 298, 'end': 334}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 93, 'end': 101}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'DDT', 'type': 'ChemicalCompound', 'start': 449, 'end': 452}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'psoriatic arthritis', 'type': 'Disease', 'start': 349, 'end': 368}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'epilepsy', 'type': 'Disease', 'start': 224, 'end': 232}\n",
            "['Dose recommendations for anticancer drugs in patients with renal or hepatic impairment\\tRenal or hepatic impairment is a common comorbidity for patients with cancer either because of the disease itself, toxicity of previous anticancer treatments, or because of other factors affecting organ function, such as increased age.', 'Because renal and hepatic function are among the main determinants of drug exposure, the pharmacokinetic profile might be altered for patients with cancer who have renal or hepatic impairment, necessitating dose adjustments.', 'Most anticancer drugs are dosed near their maximum tolerated dose and are characterised by a narrow therapeutic index.']\n",
            "unmatched tags:  [{'entity': 'cancer', 'type': 'Disease', 'start': 557, 'end': 563}, {'entity': 'hepatic impairment', 'type': 'Disease', 'start': 496, 'end': 514}, {'entity': 'cancer', 'type': 'Disease', 'start': 471, 'end': 477}, {'entity': 'cancer', 'type': 'Disease', 'start': 227, 'end': 233}, {'entity': 'cancer', 'type': 'Disease', 'start': 157, 'end': 163}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 1011, 'end': 1018}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'symptom', 'type': 'Phenotype', 'start': 136, 'end': 143}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'polytetrafluoroethylene', 'type': 'Drug', 'start': 543, 'end': 566}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNA', 'type': 'Gene', 'start': 1014, 'end': 1017}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNA', 'type': 'Gene', 'start': 1297, 'end': 1300}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNA', 'type': 'Gene', 'start': 1407, 'end': 1410}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNA', 'type': 'Gene', 'start': 2093, 'end': 2096}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'nucleocapsid', 'type': 'Gene', 'start': 1152, 'end': 1164}\n",
            "['Site-specific analysis of the SARS-CoV-2 glycan shield\\tThe emergence of the betacoronavirus, SARS-CoV-2 that causes COVID-19, represents a significant threat to global human health.', 'Vaccine development is focused on the principal target of the humoral immune response, the spike (S) glycoprotein, that mediates cell entry and membrane fusion.', 'SARS-CoV-2 S gene encodes 22 N-linked glycan sequons per protomer, which likely play a role in immune evasion and occluding immunogenic protein epitopes.', 'Here, using a site-specific mass spectrometric approach, we reveal the glycan structures on a recombinant SARS-CoV-2 S immunogen.', 'This analysis enables mapping of the glycan-processing states across the trimeric viral spike.', 'We show how SARS-CoV-2 S glycans differ from typical host glycan processing, which may have implications in viral pathobiology and vaccine design.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 853, 'end': 860}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'undernutrition', 'type': 'Disease', 'start': 108, 'end': 122}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'proalbumin', 'type': 'Gene', 'start': 2516, 'end': 2526}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'psoriatic arthritis', 'type': 'Disease', 'start': 246, 'end': 265}\n",
            "['Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors\\tAfter binding to the target cell, the transmembrane spike protein might change conformation by association between the HR1 and HR2 regions to form an oligomeric structure, leading to fusion between the viral and target-cell membranes.', 'At the prefusion intermediate state, CP-1 could bind to the HR1 region and interfere with the conformational changes, resulting in inhibition of SARS-CoV fusion with the target cells.', 'CP-1 might be modifiable to increase its anti-SARS-CoV activity and could be further developed as an antiviral agent for treatment or prophylaxis of SARS-CoV infection.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV', 'type': 'Virus', 'start': 750, 'end': 758}, {'entity': 'antiviral agent', 'type': 'Drug', 'start': 702, 'end': 717}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 647, 'end': 655}, {'entity': 'CP-1', 'type': 'Gene', 'start': 601, 'end': 605}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 163, 'end': 171}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 392, 'end': 398}\n",
            "['Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approaches\\tHereditary spastic paraplegia (HSP) describes a heterogeneous group of genetic neurodegenerative diseases characterised by progressive spasticity of the lower limbs.', 'The pathogenic mechanism, associated clinical features, and imaging abnormalities vary substantially according to the affected gene and differentiating HSP from other genetic diseases associated with spasticity can be challenging.', 'Next generation sequencing-based gene panels are now widely available but have limitations and a molecular diagnosis is not made in most suspected cases.']\n",
            "unmatched tags:  [{'entity': 'gene', 'type': 'Gene', 'start': 511, 'end': 515}, {'entity': 'gene', 'type': 'Gene', 'start': 483, 'end': 487}, {'entity': 'spasticity', 'type': 'Phenotype', 'start': 447, 'end': 457}, {'entity': 'gene', 'type': 'Gene', 'start': 414, 'end': 418}, {'entity': 'HSP', 'type': 'Gene', 'start': 399, 'end': 402}, {'entity': 'gene', 'type': 'Gene', 'start': 374, 'end': 378}, {'entity': 'clinical features', 'type': 'Gene', 'start': 284, 'end': 301}, {'entity': 'spasticity', 'type': 'Phenotype', 'start': 216, 'end': 226}]\n",
            "['Global efforts toward the cure of childhood acute lymphoblastic leukaemia\\tImprovements in risk-directed treatment and supportive care, together with increased reliance on both national and international collaborative studies, have made childhood acute lymphoblastic leukaemia (ALL) one of the most curable human cancers.', 'Next-generation sequencing studies of leukaemia cells and the host germline provide new opportunities for precision medicine and thus potential improvements in the cure rate and quality of life of patients.', 'Efforts are underway to assess the global impact of childhood ALL and develop initiatives that can meet the long-term challenge of providing quality care to children with this disease worldwide and improving cure rates globally.']\n",
            "unmatched tags:  [{'entity': 'leukaemia cells', 'type': 'Disease', 'start': 359, 'end': 374}, {'entity': 'cancers', 'type': 'Disease', 'start': 312, 'end': 319}, {'entity': 'acute lymphoblastic leukaemia', 'type': 'Disease', 'start': 246, 'end': 275}, {'entity': 'childhood acute lymphoblastic leukaemia', 'type': 'Disease', 'start': 236, 'end': 275}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 301, 'end': 307}\n",
            "['Evolution and variation of 2019-novel coronavirus\\tBackground The current outbreak caused by novel coronavirus (2019-nCoV) in China has become a worldwide concern.', 'As of 28 January 2020, there were 4631 confirmed cases and 106 deaths, and 11 countries or regions were affected.', 'Methods We downloaded the genomes of 2019-nCoVs and similar isolates from the Global Initiative on Sharing Avian Influenza Database (GISAID and nucleotide database of the National Center for Biotechnology Information (NCBI).', 'Lasergene 7.0 and MEGA 6.0 softwares were used to calculate genetic distances of the sequences, to construct phylogenetic trees, and to align amino acid sequences.', 'Bayesian coalescent phylogenetic analysis, implemented in the BEAST software package, was used to calculate the molecular clock related characteristics such as the nucleotide substitution rate and the most recent common ancestor (tMRCA) of 2019-nCoVs.', 'Results An isolate numbered EPI_ISL_403928 showed different phylogenetic trees and genetic distances of the whole length genome, the coding sequences (CDS) of ployprotein (P), spike protein (S), and nucleoprotein (N) from other 2019-nCoVs.', 'There are 22, 4, 2 variations in P, S, and N at the level of amino acid residues.', 'The nucleotide substitution rates from high to low are 1·05 × 10 −2 (nucleotide substitutions/site/year, with 95% HPD interval being 6.27 × 10 −4 to 2.72 × 10 −2 ) for N, 5.34 × 10 −3 (5.10 × 10 −4 , 1.28 × 10 −2 ) for S, 1.69 × 10 −3 (3.94 × 10 −4 , 3.60 × 10 −3 ) for P, 1.65 × 10 −3 (4.47 × 10 −4 , 3.24 × 10 −3 ) for the whole genome, respectively.', 'At this nucleotide substitution rate, the most recent common ancestor (tMRCA) of 2019-nCoVs appeared about 0.253-0.594 year before the epidemic.', 'Conclusion Our analysis suggests that at least two different viral strains of 2019-nCoV are involved in this outbreak that might occur a few months earlier before it was officially reported.']\n",
            "unmatched tags:  [{'entity': '2019-nCoV', 'type': 'Virus', 'start': 1816, 'end': 1825}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 1674, 'end': 1683}, {'entity': 'tMRCA', 'type': 'Chemical', 'start': 1664, 'end': 1669}, {'entity': 'nucleotide substitution', 'type': 'Gene', 'start': 1601, 'end': 1624}, {'entity': 'HPD', 'type': 'Drug', 'start': 1354, 'end': 1357}, {'entity': 'nucleotide substitution', 'type': 'Gene', 'start': 1309, 'end': 1332}, {'entity': 'nucleotide substitution', 'type': 'Gene', 'start': 1244, 'end': 1267}, {'entity': 'amino acid residues', 'type': 'Chemical', 'start': 1219, 'end': 1238}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 1146, 'end': 1155}, {'entity': 'nucleoprotein (N)', 'type': 'Gene', 'start': 1117, 'end': 1134}, {'entity': 'spike protein', 'type': 'Gene', 'start': 1094, 'end': 1107}, {'entity': 'coding sequences', 'type': 'Gene', 'start': 1051, 'end': 1067}, {'entity': 'EPI_ISL_403928', 'type': 'Chemical', 'start': 946, 'end': 960}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 906, 'end': 915}, {'entity': 'tMRCA', 'type': 'Chemical', 'start': 896, 'end': 901}, {'entity': 'nucleotide substitution', 'type': 'Gene', 'start': 830, 'end': 853}, {'entity': 'construct', 'type': 'Gene', 'start': 601, 'end': 610}, {'entity': 'NCBI', 'type': 'Organization', 'start': 495, 'end': 499}, {'entity': 'National Center for Biotechnology Information', 'type': 'Organization', 'start': 448, 'end': 493}, {'entity': 'nucleotide database', 'type': 'Gene', 'start': 421, 'end': 440}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'migraine', 'type': 'Disease', 'start': 164, 'end': 172}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'breast cancer', 'type': 'Disease', 'start': 581, 'end': 594}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'SARS-CoV protein', 'type': 'Virus', 'start': 70, 'end': 86}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 70, 'end': 78}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cirrhosis', 'type': 'Disease', 'start': 42, 'end': 51}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'overdose', 'type': 'Disease', 'start': 266, 'end': 274}\n",
            "['Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia\\tAim: The new coronavirus pneumonia (COVID-19) outbreaking at the end of 2019 is highly contagious.', 'Crude mortality rate reached 49% in critical patients.', 'Inflammation matters on disease progression.', 'This study analyzed blood inflammation indicators among mild, severe and critical patients, helping to identify severe or critical patients early.', 'Methods: In this cross-sectional study, 100 patients were included and divided to mild, severe or critical groups.', 'Correlation of peripheral blood inflammation-related indicators with disease criticality was analyzed.', 'Cut-off values for critically ill patients were speculated through the ROC curve.', 'Results：Significantly, disease severity were associated with age (R=-0.564, P<0.001), interleukin-2 receptor (IL2R) (R=-0.534, P<0.001), interleukin-6 (IL-6) (R=-0.535, P<0.001), interleukin-8 (IL-8) (R=-0.308, P<0.001), interleukin-10 (IL-10) (R=-0.422, P<0.001), tumor necrosis factor α (TNFα) (R=-0.322, P<0.001), C-reactive protein (CRP) (R=-0.604, P<0.001), ferroprotein (R=-0.508, P<0.001), procalcitonin (R=-0.650, P<0.001), white cell counts (WBC) (R=-0.54, P<0.001), lymphocyte counts (LC) (R=-0.56, P<0.001), neutrophil count (NC) (R=-0.585, P<0.001) and eosinophil counts (EC) (R=-0.299, P=0.01).', 'Conclusion：With following parameters such as age >67.5 years, IL2R >793.5U/mL, CRP >30.7ng/mL, ferroprotein >2252μg/L, WBC>9.5*10^9/L or NC >7.305*10^9/L, the progress of COVID-19 to critical stage should be closely observed and possibly prevented.', 'Inflammation is closely related to severity of COVID-19, and IL-6, TNFα and IL-8 might be promising therapeutic targets.']\n",
            "unmatched tags:  [{'entity': 'IL-8', 'type': 'Gene', 'start': 1697, 'end': 1701}, {'entity': 'TNFα', 'type': 'Gene', 'start': 1688, 'end': 1692}, {'entity': 'IL-6', 'type': 'Gene', 'start': 1682, 'end': 1686}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1668, 'end': 1676}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1543, 'end': 1551}, {'entity': 'NC', 'type': 'Gene', 'start': 1509, 'end': 1511}, {'entity': 'ferroprotein', 'type': 'Chemical', 'start': 1467, 'end': 1479}, {'entity': 'IL2R', 'type': 'Gene', 'start': 1434, 'end': 1438}, {'entity': 'NC', 'type': 'Gene', 'start': 1301, 'end': 1303}, {'entity': 'procalcitonin', 'type': 'Gene', 'start': 1161, 'end': 1174}, {'entity': 'ferroprotein', 'type': 'Chemical', 'start': 1127, 'end': 1139}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'lipofuscinosis', 'type': 'Disease', 'start': 449, 'end': 463}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 327, 'end': 334}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronavirus', 'type': 'Virus', 'start': 1311, 'end': 1322}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'obesity', 'type': 'Phenotype', 'start': 314, 'end': 321}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNA-Seq', 'type': 'Gene', 'start': 478, 'end': 48}\n",
            "['A mechanistic population balance model to evaluate the impact of interventions on infectious disease outbreaks: Case for COVID19\\tInfectious diseases, especially when new and highly contagious, could be devastating producing epidemic outbreaks and pandemics.', 'Predicting the outcomes of such events in relation to possible interventions is crucial for societal and healthcare planning and forecasting of resource needs.', 'Deterministic and mechanistic models can capture the main known phenomena of epidemics while also allowing for a meaningful interpretation of results.', 'In this work a deterministic mechanistic population balance model was developed.', 'The model describes individuals in a population by infection stage and age group.', 'The population is treated as in a close well mixed community with no migrations.', 'Infection rates and clinical and epidemiological information govern the transitions between stages of the disease.', 'The present model provides a steppingstone to build upon and its current low complexity retains accessibility to non experts and policy makers to comprehend the variables and phenomena at play.', 'The impact of specific interventions on the outbreak time course, number of cases and outcome of fatalities were evaluated including that of available critical care.', 'Data available from the COVID19 outbreak as of early April 2020 was used.', 'Key findings in our results indicate that (i) universal social isolation measures appear effective in reducing total fatalities only if they are strict and the number of daily social interactions is reduced to very low numbers; (ii) selective isolation of only the elderly (at higher fatality risk) appears almost as effective in reducing total fatalities but at a much lower economic damage; (iii) an increase in the number of critical care beds could save up to eight lives per extra bed in a million population with the current parameters used; (iv) the use of protective equipment (PPE) appears effective to dramatically reduce total fatalities when implemented extensively and in a high degree; (v) infection recognition through random testing of the population, accompanied by subsequent (self) isolation of infected aware individuals, can dramatically reduce the total fatalities but only if conducted extensively to almost the entire population and sustained over time; (vi) ending isolation measures while R0 values remain above 1.0 (with a safety factor) renders the isolation measures useless and total fatality numbers return to values as if nothing was ever done; (vii) ending the isolation measures for only the population under 60 y/o at R0 values still above 1.0 increases total fatalities but only around half as much as if isolation ends for everyone; (viii) a threshold value, equivalent to that for R0, appears to exist for the daily fatality rate at which to end isolation measures, this is significant as the fatality rate is (unlike R0) very accurately known.', 'Any interpretation of these results for the COVID19 outbreak predictions and interventions should be considered only qualitatively at this stage due to the low confidence (lack of complete and valid data) on the parameter values available at the time of writing.', 'Any quantitative interpretation of the results must be accompanied with a critical discussion in terms of the model limitations and its frame of application.']\n",
            "unmatched tags:  [{'entity': 'COVID19', 'type': 'Chemical', 'start': 2992, 'end': 2999}, {'entity': 'R0', 'type': 'Organization', 'start': 2919, 'end': 2921}, {'entity': 'R0', 'type': 'Organization', 'start': 2782, 'end': 2784}, {'entity': 'fatalities', 'type': 'Disease', 'start': 2658, 'end': 2668}, {'entity': 'R0', 'type': 'Organization', 'start': 2616, 'end': 2618}, {'entity': 'R0', 'type': 'Organization', 'start': 2378, 'end': 2380}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'lung cancer', 'type': 'Disease', 'start': 499, 'end': 510}\n",
            "['Direct Measurement of Rates of Asymptomatic Infection and Clinical Care-Seeking for Seasonal Coronavirus\\tThe pandemic potential of the novel coronavirus (nCoV) that emerged in Wuhan, China, during December 2019 is strongly tied to the number and contagiousness of undocumented human infections.', 'Here we present findings from a proactive longitudinal sampling study of acute viral respiratory infections that documents rates of asymptomatic infection and clinical care seeking for seasonal coronavirus.', 'We find that the majority of infections are asymptomatic by most symptom definitions and that only 4% of individuals experiencing a seasonal coronavirus infection episode sought medical care for their symptoms.', 'These numbers indicate that a very high percentage of seasonal coronavirus infections are undocumented and provide a reference for understanding the spread of the emergent nCoV.']\n",
            "unmatched tags:  [{'entity': 'nCoV', 'type': 'Virus', 'start': 887, 'end': 891}, {'entity': 'coronavirus infections', 'type': 'Disease', 'start': 778, 'end': 800}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 644, 'end': 655}, {'entity': 'coronavirus infection', 'type': 'Disease', 'start': 644, 'end': 665}, {'entity': 'seasonal coronavirus', 'type': 'Virus', 'start': 635, 'end': 655}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 568, 'end': 575}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 548, 'end': 555}, {'entity': 'seasonal coronavirus', 'type': 'Virus', 'start': 480, 'end': 500}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 428, 'end': 435}, {'entity': 'viral respiratory infections', 'type': 'Disease', 'start': 374, 'end': 402}, {'entity': 'nCoV', 'type': 'Virus', 'start': 154, 'end': 158}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 141, 'end': 152}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccines', 'type': 'Drug', 'start': 320, 'end': 328}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNA', 'type': 'Gene', 'start': 771, 'end': 774}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'DNA', 'type': 'Gene', 'start': 799, 'end': 802}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'DNA', 'type': 'Gene', 'start': 1203, 'end': 1206}\n",
            "['Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial\\tPatients with NSCLC of PS2 are a group of patients of unmet therapeutic need.', 'The PePS2 trial shows that pembrolizumab can be safely administered to these patients, with no increase in the risk of immune-related or other toxicities.', 'Efficacy outcomes are at least as good as those in patients with PS0–1 and the data provides clinicians with the confidence to incorporate pembrolizumab into the treatment pathway of patients with NSCLC of PS2.']\n",
            "unmatched tags:  [{'entity': 'PS2', 'type': 'Gene', 'start': 558, 'end': 561}, {'entity': 'NSCLC', 'type': 'Disease', 'start': 549, 'end': 554}, {'entity': 'pembrolizumab', 'type': 'Drug', 'start': 491, 'end': 504}, {'entity': 'toxicities', 'type': 'Disease', 'start': 340, 'end': 350}, {'entity': 'immune-related', 'type': 'Organization', 'start': 316, 'end': 330}, {'entity': 'pembrolizumab', 'type': 'Drug', 'start': 224, 'end': 237}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'injury', 'type': 'Disease', 'start': 179, 'end': 185}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 215, 'end': 224}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 359, 'end': 368}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 605, 'end': 613}\n",
            "['Comparative analyses of SAR-CoV2 genomes from different geographical locations and other coronavirus family genomes reveals unique features potentially consequential to host-virus interaction and pathogenesis\\tThe ongoing pandemic of the coronavirus disease 2019 (COVID - 19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2).', 'We have performed an integrated sequence-based analysis of SARS-CoV2 genomes from different geographical locations in order to identify its unique features absent in SARS-CoV and other related coronavirus family genomes, conferring unique infection, facilitation of transmission, virulence and immunogenic features to the virus.', 'The phylogeny of the genomes yields some interesting results.', 'Systematic gene level mutational analysis of the genomes has enabled us to identify several unique features of the SARS-CoV2 genome, which includes a unique mutation in the spike surface glycoprotein (A930V (24351C>T)) in the Indian SARS-CoV2, absent in other strains studied here.', 'We have also predicted the impact of the mutations in the spike glycoprotein function and stability, using computational approach.', 'To gain further insights into host responses to viral infection, we predict that antiviral host-miRNAs may be controlling the viral pathogenesis.', 'Our analysis reveals nine host miRNAs which can potentially target SARS-CoV2 genes.', 'Interestingly, the nine miRNAs do not have targets in SARS and MERS genomes.', 'Also, hsa-miR-27b is the only unique miRNA which has a target gene in the Indian SARS-CoV2 genome.', 'We also predicted immune epitopes in the genomes']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1563, 'end': 1571}, {'entity': 'gene', 'type': 'Gene', 'start': 1544, 'end': 1548}, {'entity': 'miRNA', 'type': 'Gene', 'start': 1519, 'end': 1524}, {'entity': 'genomes', 'type': 'Gene', 'start': 1473, 'end': 1480}, {'entity': 'MERS', 'type': 'Disease', 'start': 1468, 'end': 1472}, {'entity': 'SARS', 'type': 'Disease', 'start': 1459, 'end': 1463}, {'entity': 'miRNAs', 'type': 'Gene', 'start': 1429, 'end': 1435}, {'entity': 'gene', 'type': 'Gene', 'start': 1398, 'end': 1402}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1388, 'end': 1396}, {'entity': 'miRNAs', 'type': 'Gene', 'start': 1352, 'end': 1358}, {'entity': 'gene', 'type': 'Gene', 'start': 1312, 'end': 1316}, {'entity': 'host-miRNAs', 'type': 'Organization', 'start': 1266, 'end': 1277}, {'entity': 'antiviral', 'type': 'Virus', 'start': 1256, 'end': 1265}, {'entity': 'viral infection', 'type': 'Virus', 'start': 1223, 'end': 1238}, {'entity': 'strains', 'type': 'Disease', 'start': 1022, 'end': 1029}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 995, 'end': 1003}, {'entity': 'spike surface glycoprotein', 'type': 'Gene', 'start': 935, 'end': 961}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 877, 'end': 885}, {'entity': 'genomes', 'type': 'Gene', 'start': 811, 'end': 818}, {'entity': 'gene', 'type': 'Gene', 'start': 773, 'end': 777}, {'entity': 'genomes', 'type': 'Gene', 'start': 721, 'end': 728}, {'entity': 'genomes', 'type': 'Gene', 'start': 583, 'end': 590}, {'entity': 'coronavirus family', 'type': 'Virus', 'start': 564, 'end': 582}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 537, 'end': 545}, {'entity': 'genomes', 'type': 'Gene', 'start': 440, 'end': 447}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 430, 'end': 438}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 359, 'end': 367}, {'entity': 'acute respiratory syndrome coronavirus 2', 'type': 'Virus', 'start': 317, 'end': 357}, {'entity': 'infectious disease', 'type': 'Disease', 'start': 281, 'end': 299}]\n",
            "[\"Dementia associated with Parkinson's disease\\tDementia affects about 40% of patients with Parkinson's disease; the incidence of dementia in these patients is up to six times that in healthy people.\", 'Clinically, the prototype of dementia in PD is a dysexecutive syndrome.', 'Loss of cholinergic, dopaminergic, and noradrenergic innervation has been suggested to be the underlying neurochemical deficits.', 'Nigral pathology alone is probably not sufficient for the development of dementia.', 'Although there is some controversy with regard to the site and type of pathology involved, dementia is likely to be associated with the spread of pathology to other subcortical nuclei, the limbic system, and the cerebral cortex.']\n",
            "unmatched tags:  [{'entity': 'dementia', 'type': 'Disease', 'start': 572, 'end': 580}, {'entity': 'type', 'type': 'Gene', 'start': 544, 'end': 548}, {'entity': 'dementia', 'type': 'Disease', 'start': 471, 'end': 479}, {'entity': 'dopaminergic', 'type': 'Drug', 'start': 290, 'end': 302}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 166, 'end': 174}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'lymphoma', 'type': 'Disease', 'start': 57, 'end': 65}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'lymphoma', 'type': 'Disease', 'start': 505, 'end': 513}\n",
            "['Adverse health consequences of the Iraq War\\tThe adverse health consequences of the Iraq War (2003–11) were profound.', 'We conclude that at least 116\\u2008903 Iraqi non-combatants and more than 4800 coalition military personnel died over the 8-year course.', 'Many Iraqi civilians were injured or became ill because of damage to the health-supporting infrastructure of the country, and about 5 million were displaced.', 'More than 31\\u2008000 US military personnel were injured and a substantial percentage of those deployed suffered post-traumatic stress disorder, traumatic brain injury, and other neuropsychological disorders and their concomitant psychosocial problems.']\n",
            "unmatched tags:  [{'entity': 'psychosocial problems', 'type': 'Disease', 'start': 632, 'end': 653}, {'entity': 'neuropsychological disorders', 'type': 'Disease', 'start': 581, 'end': 609}, {'entity': 'traumatic brain injury', 'type': 'Disease', 'start': 547, 'end': 569}, {'entity': 'post-traumatic stress disorder', 'type': 'Disease', 'start': 515, 'end': 545}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'rotavirus vaccine', 'type': 'Drug', 'start': 206, 'end': 223}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 270, 'end': 279}\n",
            "['Experiences of hearing voices: analysis of a novel phenomenological survey\\tThis study is, to our knowledge, the largest mixed-methods investigation of auditory hallucination phenomenology so far.', 'Our survey was completed by a diverse sample of people who hear voices with various diagnoses and clinical histories.', 'Our findings both overlap with past large-sample investigations of auditory hallucination and suggest potentially important new findings about the association between acoustic perception and thought, somatic and multisensorial features of auditory hallucinations, and the link between auditory hallucinations and characterological entities.']\n",
            "unmatched tags:  [{'entity': 'auditory hallucinations', 'type': 'Phenotype', 'start': 599, 'end': 622}, {'entity': 'auditory hallucinations', 'type': 'Phenotype', 'start': 553, 'end': 576}, {'entity': 'auditory hallucination', 'type': 'Phenotype', 'start': 381, 'end': 403}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'pleural mesothelioma', 'type': 'Disease', 'start': 302, 'end': 322}\n",
            "['Single-cell analysis of human lung epithelia reveals concomitant expression of the SARS-CoV-2 receptor ACE2 with multiple virus receptors and scavengers in alveolar type II cells\\tThe novel coronavirus SARS-CoV-2 was identified as the causative agent of the ongoing pandemic COVID 19.', 'COVID-19-associated deaths are mainly attributed to severe pneumonia and respiratory failure.', 'Recent work demonstrated that SARS-CoV-2 binds to angiotensin converting enzyme 2 (ACE2) in the lung.', 'To better understand ACE2 abundance and expression patterns in the lung we interrogated our in-house single-cell RNA-sequencing dataset containing 70,085 EPCAM+ lung epithelial cells from paired normal and lung adenocarcinoma tissues.', 'Transcriptomic analysis revealed a diverse repertoire of airway lineages that included alveolar type I and II, bronchioalveolar, club/secretory, quiescent and proliferating basal, ciliated and malignant cells as well as rare populations such as ionocytes.', 'While the fraction of lung epithelial cells expressing ACE2 was low (1.7% overall), alveolar type II (AT2, 2.2% ACE2 +) cells exhibited highest levels of ACE2 expression among all cell subsets.', 'Further analysis of the AT2 compartment (n = 27,235 cells) revealed a number of genes co-expressed with ACE2 that are important for lung pathobiology including those associated with chronic obstructive pulmonary disease (COPD; HHIP ), pneumonia and infection ( FGG and C4BPA ) as well as malarial/bacterial ( CD36 ) and viral ( DMBT1 ) scavenging which, for the most part, were increased in smoker versus light or non-smoker cells.', 'Notably, DMBT1 was highly expressed in AT2 cells relative to other lung epithelial subsets and its expression positively correlated with ACE2 .', 'We describe a population of ACE2 -positive AT2 cells that co-express pathogen (including viral) receptors (e.g.', 'DMBT1 ) with crucial roles in host defense thus comprising plausible phenotypic targets for treatment of COVID-19.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1958, 'end': 1966}, {'entity': 'DMBT1', 'type': 'Gene', 'start': 1853, 'end': 1858}, {'entity': 'receptors', 'type': 'Gene', 'start': 1837, 'end': 1846}, {'entity': 'co-express', 'type': 'Organization', 'start': 1799, 'end': 1809}, {'entity': 'AT2 cells', 'type': 'Gene', 'start': 1784, 'end': 1793}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1769, 'end': 1773}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1734, 'end': 1738}, {'entity': 'AT2 cells', 'type': 'Gene', 'start': 1636, 'end': 1645}, {'entity': 'DMBT1', 'type': 'Gene', 'start': 1606, 'end': 1611}, {'entity': 'light', 'type': 'Gene', 'start': 1570, 'end': 1575}, {'entity': 'DMBT1', 'type': 'Gene', 'start': 1493, 'end': 1498}, {'entity': 'CD36', 'type': 'Gene', 'start': 1474, 'end': 1478}, {'entity': 'C4BPA', 'type': 'Gene', 'start': 1434, 'end': 1439}, {'entity': 'FGG', 'type': 'Gene', 'start': 1426, 'end': 1429}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 1400, 'end': 1409}, {'entity': 'HHIP', 'type': 'Gene', 'start': 1392, 'end': 1396}, {'entity': 'chronic obstructive pulmonary disease', 'type': 'Disease', 'start': 1347, 'end': 1384}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'oesophageal cancer', 'type': 'Disease', 'start': 256, 'end': 274}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 62, 'end': 71}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 427, 'end': 436}\n",
            "['Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs\\tAngiogenesis is essential for tumour growth, invasion, and metastasis.', 'Tumour blood vessels show many differences from normal vessels and are not genetically unstable, so they form a potentially key area for therapy of all types of cancer including leukaemias.', 'Here we review current knowledge on the multiple pathways controlling tumour angiogenesis and assess which are the most clinically relevant.', 'We also review the clinical evidence that angiogenesis affects the behaviour of cancer.', 'Retrospective studies on intratumoral vascularisation suggest that it is an independent prognostic factor that merits prospective validation.']\n",
            "unmatched tags:  [{'entity': 'cancer', 'type': 'Disease', 'start': 601, 'end': 607}, {'entity': 'tumour angiogenesis', 'type': 'Disease', 'start': 450, 'end': 469}, {'entity': 'leukaemias', 'type': 'Disease', 'start': 368, 'end': 378}, {'entity': 'cancer', 'type': 'Disease', 'start': 351, 'end': 357}, {'entity': 'genetically', 'type': 'Gene', 'start': 265, 'end': 276}, {'entity': 'Tumour blood vessels', 'type': 'Disease', 'start': 190, 'end': 210}]\n",
            "['The bat influenza H17N10 can be neutralized by broadly-neutralizing monoclonal antibodies and its neuraminidase can facilitate viral egress\\tThe diversity of subtypes within the Influenza A virus genus has recently expanded with the identification of H17N10 and H18N11 from bats.', 'In order to further study the tropism and zoonotic potential of these viruses, we have successfully produced lentiviral pseudotypes bearing both haemagglutinin H17 and neuraminidase N10.', 'These pseudotypes were shown to be efficiently neutralized by the broadly-neutralizing monoclonal antibodies CR9114 and FI6.', 'Our studies also confirm previous reports that H17 does not use sialic acid as its cellular receptor, as pseudotypes bearing the H17 envelope glycoprotein are released into the cell supernatant in the absence of NA.', 'However, we demonstrate that N10 facilitates heterosubtypic (H5 and H7) influenza HA-bearing pseudotype release in the absence of another source of NA, significantly increasing luciferase pseudotype production titres.', 'Despite this, N10 shows no activity in the enzyme-linked lectin assay used for traditional sialidases.', 'These findings suggest that this protein plays an important role in viral egress, but is perhaps involved in further accessory roles in the bat influenza lifecycle that are yet to be discovered.', 'Thus we show the lentiviral pseudotype system is a useful research tool, and amenable for investigation of bat influenza tropism, restriction and sero-epidemiology, without the constraints or safety issues with producing a replication-competent virus, to which the human population is naïve.', 'Significance statement Influenza virus is responsible for mortality and morbidity across the globe; human populations are constantly at risk of newly emerging strains from the aquatic bird reservoir which harbors most of the subtypes of influenza A (H1-H16).', 'Recently identified subtypes (H17N10, H18N11) from bats have broadened the reservoir from which potential pandemic strains of influenza can emerge.', 'To evaluate the potential for these novel subtypes to cross over into human populations, their ability to establish an infection, in addition to the extent of cross-reactive immunity established by human seasonal strains needs to be investigated.', 'This study highlights a novel platform for the study of the bat H17 and N10 envelope glycoproteins, using a lentiviral pseudotype system.', 'Following the generation of this pseudotype it was employed in cell entry and microneutralization assays.', 'These showed that two well-characterised monoclonal antibodies (mAb) which target avian and human influenza subtypes will also neutralize H17.', 'Furthermore the data presented in this study show a novel aspect of the N10 glycoprotein in its ability to facilitate the budding of pseudotypes bearing different influenza HAs.']\n",
            "unmatched tags:  [{'entity': 'influenza', 'type': 'Disease', 'start': 2819, 'end': 2828}, {'entity': 'N10 glycoprotein', 'type': 'Gene', 'start': 2728, 'end': 2744}, {'entity': 'H17', 'type': 'Gene', 'start': 2651, 'end': 2654}, {'entity': 'influenza', 'type': 'Disease', 'start': 2611, 'end': 2620}, {'entity': 'mAb', 'type': 'Gene', 'start': 2577, 'end': 2580}, {'entity': 'monoclonal antibodies', 'type': 'Drug', 'start': 2554, 'end': 2575}, {'entity': 'lentiviral', 'type': 'Drug', 'start': 2377, 'end': 2387}, {'entity': 'protein', 'type': 'Gene', 'start': 2359, 'end': 2366}, {'entity': 'H17', 'type': 'Gene', 'start': 2333, 'end': 2336}, {'entity': 'seasonal strains', 'type': 'Organization', 'start': 2226, 'end': 2242}, {'entity': 'influenza', 'type': 'Disease', 'start': 2000, 'end': 2009}, {'entity': 'strains', 'type': 'Disease', 'start': 1989, 'end': 1996}, {'entity': 'H17N10', 'type': 'Gene', 'start': 1904, 'end': 1910}, {'entity': 'H1-H16', 'type': 'Gene', 'start': 1865, 'end': 1871}, {'entity': 'influenza A', 'type': 'Drug', 'start': 1852, 'end': 1863}, {'entity': 'strains', 'type': 'Disease', 'start': 1774, 'end': 1781}, {'entity': 'Influenza virus', 'type': 'Virus', 'start': 1638, 'end': 1653}, {'entity': 'replication-competent virus', 'type': 'Gene', 'start': 1546, 'end': 1573}, {'entity': 'influenza', 'type': 'Disease', 'start': 1434, 'end': 1443}, {'entity': 'bat influenza tropism', 'type': 'Drug', 'start': 1430, 'end': 1451}, {'entity': 'lentiviral', 'type': 'Drug', 'start': 1340, 'end': 1350}, {'entity': 'bat influenza', 'type': 'Drug', 'start': 1268, 'end': 1281}, {'entity': 'protein', 'type': 'Gene', 'start': 1161, 'end': 1168}, {'entity': 'sialidases', 'type': 'Gene', 'start': 1116, 'end': 1126}, {'entity': 'luciferase', 'type': 'Gene', 'start': 984, 'end': 994}, {'entity': 'influenza', 'type': 'Disease', 'start': 879, 'end': 888}]\n",
            "['A prospect on the use of antiviral drugs to control local outbreaks of COVID-19\\tBackground: Current outbreaks of COVID-19 are threatening the health care systems of several countries around the world.', 'Control measures, based on isolation and quarantine, have been shown to decrease and delay the burden of the ongoing epidemic.', 'With respect to the ongoing COVID-19 epidemic, recent modelling work shows that this intervention technique may be inadequate to control local outbreaks, even when perfect isolation is assumed.', 'Furthermore, the effect of  infectiousness prior to symptom onset combined with a significant proportion of asymptomatic infectees further complicates the use of contact tracing.', 'Antivirals, which decrease the viral load and reduce the infectiousness, could be integrated in the control measures in order to augment the feasibility of controlling the epidemic.', 'Methods: Using a simulation-based model of viral transmission we tested the efficacy of different intervention measures for the control of COVID-19.', 'For individuals that were identified through contact tracing, we evaluate two procedures: monitoring individuals for symptoms onset and testing of individuals.', 'Moreover, we investigate the effect of a potent antiviral compound on the contact tracing process.', 'Findings: The use of an antiviral drug, in combination with contact tracing, quarantine and isolation, results in a significant decrease of the final size, the peak incidence, and increases the probability that the outbreak will fade out.', 'Interpretation: For an infectious disease in which presymptomatic infections are plausible, an intervention measure based on contact tracing performs better when realized together with testing instead of monitoring, provided that the test is able to detect infections during the incubation period.', 'In addition, in all tested scenarios, the model highlights the benefits of the administration of an antiviral drug in addition to quarantine, isolation and contact tracing.', 'The resulting control measure, could be an effective strategy to control local and re-emerging outbreaks of COVID-19.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2110, 'end': 2118}, {'entity': 'antiviral drug', 'type': 'Drug', 'start': 1929, 'end': 1943}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 1585, 'end': 1592}, {'entity': 'presymptomatic infections', 'type': 'Disease', 'start': 1582, 'end': 1607}, {'entity': 'infectious disease', 'type': 'Disease', 'start': 1554, 'end': 1572}, {'entity': 'antiviral drug', 'type': 'Drug', 'start': 1316, 'end': 1330}, {'entity': 'antiviral compound', 'type': 'Chemical', 'start': 1240, 'end': 1258}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1022, 'end': 1030}, {'entity': 'Antivirals', 'type': 'Drug', 'start': 701, 'end': 711}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 269, 'end': 277}\n",
            "['Cleft lip and palate\\tClefts of the lip and palate are generally divided into two groups, isolated cleft palate and cleft lip with or without cleft palate, representing a heterogeneous group of disorders affecting the lips and oral cavity.', 'These defects arise in about 1·7 per 1000 liveborn babies, with ethnic and geographic variation.', 'Effects on speech, hearing, appearance, and psychology can lead to longlasting adverse outcomes for health and social integration.', 'Typically, children with these disorders need multidisciplinary care from birth to adulthood and have higher morbidity and mortality throughout life than do unaffected individuals.']\n",
            "unmatched tags:  [{'entity': 'disorders', 'type': 'Disease', 'start': 498, 'end': 507}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 96, 'end': 102}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'ankylosing spondylitis', 'type': 'Disease', 'start': 269, 'end': 291}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'monkeypox', 'type': 'Disease', 'start': 44, 'end': 53}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'thyroid cancers', 'type': 'Disease', 'start': 594, 'end': 609}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'injury', 'type': 'Disease', 'start': 69, 'end': 75}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'pneumonia', 'type': 'Disease', 'start': 144, 'end': 153}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'protein', 'type': 'Gene', 'start': 834, 'end': 841}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'protein', 'type': 'Gene', 'start': 878, 'end': 885}\n",
            "['Genome based Evolutionary study of SARS-CoV-2 towards the Prediction of Epitope Based Chimeric Vaccine\\tSARS-CoV-2 is known to infect the neurological, respiratory, enteric, and hepatic systems of human and has already become an unprecedented threat to global healthcare system.', 'COVID-19, the most serious public condition caused by SARS-CoV-2 leads the world to an uncertainty alongside thousands of regular death scenes.', 'Unavailability of specific therapeutics or approved vaccine has made the recovery of COVI-19 more troublesome and challenging.', 'The present in silico study aimed to predict a novel chimeric vaccines by simultaneously targeting four major structural proteins via the establishment of ancestral relationship among different strains of coronaviruses.', 'Conserved regions from the homologous protein sets of spike glycoprotein (S), membrane protein (M), envelope protein and nucleocapsid protein (N) were identified through multiple sequence alignment.', 'The phylogeny analyses of whole genome stated that four proteins (S, E, M and N) reflected the close ancestral relation of SARS-CoV-2 to SARS-COV-1 and bat coronavirus.', 'Numerous immunogenic epitopes (both T cell and B cell) were generated from the common fragments which were further ranked on the basis of antigenicity, transmembrane topology, conservancy level, toxicity and allergenicity pattern and population coverage analysis.', 'Top putative epitopes were combined with appropriate adjuvants and linkers to construct a novel multiepitope subunit vaccine against COVID-19.', 'The designed constructs were characterized based on physicochemical properties, allergenicity, antigenicity and solubility which revealed the superiority of construct V3 in terms safety and efficacy.', 'Essential molecular dynamics and Normal Mode analysis confirmed minimal deformability of the refined model at molecular level.', 'In addition, disulfide engineering was investigated to accelerate the stability of the protein.', 'Molecular docking study ensured high binding affinity between construct V3 and HLA cells, as well as with different host receptors.', 'Microbial expression and translational efficacy of the constructs were checked using pET28a(+) vector of E. coli strain K12.', 'The development of preventive measures to combat COVID-19 infections might be aided the present study.', 'However, the in vivo and in vitro validation might be ensured with wet lab trials using model animals for the implementation of the presented data.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2273, 'end': 2281}, {'entity': 'combat', 'type': 'Disease', 'start': 2266, 'end': 2272}, {'entity': 'constructs', 'type': 'Gene', 'start': 2154, 'end': 2164}, {'entity': 'host receptors', 'type': 'Gene', 'start': 2083, 'end': 2097}, {'entity': 'construct V3', 'type': 'Gene', 'start': 2029, 'end': 2041}, {'entity': 'protein', 'type': 'Gene', 'start': 1958, 'end': 1965}, {'entity': 'construct V3', 'type': 'Gene', 'start': 1701, 'end': 1713}, {'entity': 'constructs', 'type': 'Gene', 'start': 1557, 'end': 1567}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1534, 'end': 1542}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1518, 'end': 1525}, {'entity': 'bat coronavirus', 'type': 'Virus', 'start': 1120, 'end': 1135}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1091, 'end': 1101}]\n",
            "['Inhibition of SARS-CoV-2 (previously 2019-nCoV)Â\\xa0infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion\\tThe recent outbreak of coronavirus disease (COVID-19) caused by SARS-CoV-2 infection in Wuhan, China has posed a serious threat to global public health.', 'To develop specific anti-coronavirus therapeutics and prophylactics, the molecular mechanism that underlies viral infection must first be defined.', 'Therefore, we herein established a SARS-CoV-2 spike (S) protein-mediated cellâ\\x80\\x93cell fusion assay and found that SARS-CoV-2 showed a superior plasma membrane fusion capacity compared to that of SARS-CoV.', 'We solved the X-ray crystal structure of six-helical bundle (6-HB) core of the HR1 and HR2 domains in the SARS-CoV-2 S protein S2 subunit, revealing that several mutated amino acid residues in the HR1 domain may be associated with enhanced interactions with the HR2 domain.', 'We previously developed a pan-coronavirus fusion inhibitor, EK1, which targeted the HR1 domain and could inhibit infection by divergent human coronaviruses tested, including SARS-CoV and MERS-CoV.', 'Here we generated a series of lipopeptides derived from EK1 and found that EK1C4 was the most potent fusion inhibitor against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection with IC50s of 1.3 and 15.8â\\x80\\x89nM, about 241- and 149-fold more potent than the original EK1 peptide, respectively.', 'EK1C4 was also highly effective against membrane fusion and infection of other human coronavirus pseudoviruses tested, including SARS-CoV and MERS-CoV, as well as SARSr-CoVs, and potently inhibited the replication of 5 live human coronaviruses examined, including SARS-CoV-2.', 'Intranasal application of EK1C4 before or after challenge with HCoV-OC43 protected mice from infection, suggesting that EK1C4 could be used for prevention and treatment of infection by the currently circulating SARS-CoV-2 and other emerging SARSr-CoVs.']\n",
            "unmatched tags:  [{'entity': 'SARSr-CoVs', 'type': 'Virus', 'start': 1999, 'end': 2009}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1969, 'end': 1979}, {'entity': 'EK1', 'type': 'Disease', 'start': 1878, 'end': 1881}, {'entity': 'mice', 'type': 'Gene', 'start': 1841, 'end': 1845}, {'entity': 'HCoV-OC43', 'type': 'Virus', 'start': 1821, 'end': 1830}, {'entity': 'EK1', 'type': 'Disease', 'start': 1784, 'end': 1787}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1746, 'end': 1756}, {'entity': 'coronaviruses', 'type': 'Virus', 'start': 1712, 'end': 1725}, {'entity': 'SARSr-CoVs', 'type': 'Virus', 'start': 1645, 'end': 1655}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 1624, 'end': 1632}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1611, 'end': 1619}, {'entity': 'coronavirus pseudoviruses', 'type': 'Virus', 'start': 1567, 'end': 1592}, {'entity': 'EK1', 'type': 'Disease', 'start': 1482, 'end': 1485}, {'entity': 'EK1 peptide', 'type': 'Chemical', 'start': 1455, 'end': 1466}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1296, 'end': 1306}, {'entity': 'fusion inhibitor', 'type': 'Drug', 'start': 1271, 'end': 1287}, {'entity': 'EK1', 'type': 'Disease', 'start': 1245, 'end': 1248}, {'entity': 'EK1', 'type': 'Disease', 'start': 1226, 'end': 1229}, {'entity': 'lipopeptides', 'type': 'Gene', 'start': 1200, 'end': 1212}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 1160, 'end': 1168}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1147, 'end': 1155}, {'entity': 'coronaviruses', 'type': 'Virus', 'start': 1115, 'end': 1128}, {'entity': 'HR1', 'type': 'Gene', 'start': 1057, 'end': 1060}, {'entity': 'EK1', 'type': 'Disease', 'start': 1033, 'end': 1036}, {'entity': 'fusion inhibitor', 'type': 'Drug', 'start': 1015, 'end': 1031}, {'entity': 'pan-coronavirus', 'type': 'Virus', 'start': 999, 'end': 1014}, {'entity': 'HR2 domain', 'type': 'Disease', 'start': 961, 'end': 971}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CoV', 'type': 'Virus', 'start': 201, 'end': 204}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CoV', 'type': 'Virus', 'start': 1290, 'end': 1293}\n",
            "['Reperfusion therapy for STEMI: is there still a role for thrombolysis in the era of primary percutaneous coronary intervention?', 'In the past ten years, primary percutaneous coronary intervention (PCI) has replaced thrombolysis as the revascularisation strategy for many patients presenting with ST-segment elevation myocardial infarction (STEMI).', 'However, delivery of primary PCI within evidence-based timeframes is challenging, and health-care provision varies substantially worldwide.', 'Consequently, even with the ideal circumstances of rapid initial diagnosis, long transfer delays to the catheter laboratory can occur.', \"These delays are detrimental to outcomes for patients and can be exaggerated by variations in timing of patients' presentation and diagnosis.\"]\n",
            "unmatched tags:  [{'entity': 'era', 'type': 'Gene', 'start': 691, 'end': 694}, {'entity': 'STEMI', 'type': 'Disease', 'start': 338, 'end': 343}, {'entity': 'ST-segment elevation myocardial infarction', 'type': 'Disease', 'start': 294, 'end': 336}]\n",
            "['Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study\\tGlobally spreading lineages expressing invasive serotypes have an important role in serotype replacement, and emerging non-vaccine serotypes associated with different pneumococcal lineages in different countries might be explained by local antibiotic-selective pressures.', 'Continued genomic surveillance of the dynamics of the pneumococcal population with increased geographical representation in the post-vaccine period will generate further knowledge for optimising future vaccine design.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 672, 'end': 679}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'mastocytosis', 'type': 'Disease', 'start': 289, 'end': 301}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'Sf6', 'type': 'Organization', 'start': 34, 'end': 37}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'Sf6', 'type': 'Organization', 'start': 292, 'end': 295}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'encephalopathies', 'type': 'Disease', 'start': 91, 'end': 107}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 80, 'end': 89}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'leukaemia', 'type': 'Disease', 'start': 424, 'end': 433}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'neuropathy', 'type': 'Disease', 'start': 33, 'end': 43}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CoV', 'type': 'Virus', 'start': 358, 'end': 361}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CoV', 'type': 'Virus', 'start': 894, 'end': 897}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'SARS', 'type': 'Disease', 'start': 1135, 'end': 1139}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CoV', 'type': 'Virus', 'start': 1141, 'end': 1144}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 473, 'end': 479}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 578, 'end': 584}\n",
            "['Will COVID-19 pandemic diminish by summer-monsoon in India?', 'Lesson from the first lockdown\\tThe novel Coronavirus (2019-nCoV) was identified in Wuhan, Hubei Province, China, in December 2019 and has created a medical emergency worldwide.', 'It has spread rapidly to multiple countries and has been declared a pandemic by the World Health Organization.', 'In India, it is already reported more than 18 thousand cases and more than 600 deaths due to Coronavirus disease 2019 (COVID-19) till April 20, 2020.', 'Previous studies on various viral infections like influenza have supported an epidemiological hypothesis that the cold and dry (low absolute humidity) environments favor the survival and spread of droplet-mediated viral diseases.', 'These viral transmissions found attenuated in warm and humid (high absolute humidity) environments.', 'However, the role of temperature, humidity, and absolute humidity in the transmission of COVID-19 has not yet been well established.', 'Therefore the study to investigate the meteorological condition for incidence and spread of COVID-19 infection, to predict the epidemiology of the infectious disease, and to provide a scientific basis for prevention and control measures against the new disease is required for India.', 'In this work, we analyze the local weather patterns of the Indian region affected by the COVID-19 virus for March and April months, 2020.', 'We have investigated the effect of meteorological parameters like Temperature, relative humidity, and absolute humidity on the rate of spread of COVID-19 using daily confirm cases in India.', 'We have used daily averaged meteorological data for the last three years (2017-2019) for March and April month and the same for the year 2020 for March 1 to April 15.', 'We found a positive association (Pearsons r=0.56) between temperature and daily COVID-19 cases over India.', 'We found a negative association of humidity (RH and AH) with daily COVID-19 Cases (Persons r=-0.62, -0.37).', 'We have also investigated the role of aerosol in spreading the pandemic across India because its possible airborne nature.', 'For this, we have investigated the association of aerosols (AOD) and other pollutions (NO2) with COVID-19 cases during the study period and also during the first lockdown period (25 March-15 April) in India.', 'We found a negative association in March when there were few cases, but in April, it shows positive association when the number of cases is more (for AOD it was r=-0.41 and r=0.28 respectively).', 'During the lockdown period, aerosols (AOD) and other pollutants (NO2; an indicator of PM2.5) reduced sharply with a percentage drop of about 36 and 37, respectively.', 'This reduction may have reduced the risk for COVID-19 through air transmission due to the unavailability of aerosol particles as a base.', 'HYSPLIT forward trajectory model also shows that surface aerosols may travel up to 4 km according to wind and direction within three h of its generation.', 'If coronavirus becomes airborne as suggested by many studies, then it may have a higher risk of transmission by aerosols particles.', 'So relaxing in the lockdown and environmental rules in terms of pollutant emissions from power plants, factories, and other facilities would be a wrong choice and could result in more COVID-19 incidences and deaths in India.', 'Therefore the current study, although limited, suggests that it is doubtful that the spread of COVID-19 would slow down in India due to meteorological factors, like high temperature and high humidity.', 'Because a large number of cases have already been reported in the range of high Tem, high Relative, and high absolute humidity regions of India.', 'Thus our results in no way suggest that COVID-19 would not spread in warm, humid regions or during summer/monsoon.', 'So effective public health interventions should be implemented across India to slow down the transmission of COVID-19.', 'If COVID-19 is indeed sensitive to environmental factors, it could be tested in the coming summer-monsoon for India.', 'So the only summer is not going to help India until monsoon is coming.', 'Only government mitigations strategies would be helpful, whether its lockdown, aggressive and strategic testing, medical facilities, imposing social distancing, encouraging to use face mask or monitoring by a mobile application (Aarogya Setu).']\n",
            "unmatched tags:  [{'entity': 'government', 'type': 'Organization', 'start': 4068, 'end': 4078}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 3878, 'end': 3886}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 3865, 'end': 3873}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 3681, 'end': 3689}, {'entity': 'Tem', 'type': 'Disease', 'start': 3576, 'end': 3579}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 3390, 'end': 3398}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 3254, 'end': 3262}, {'entity': 'pollutant', 'type': 'Chemical', 'start': 3134, 'end': 3143}, {'entity': 'airborne', 'type': 'Drug', 'start': 2961, 'end': 2969}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 2941, 'end': 2952}, {'entity': 'wind', 'type': 'Phenotype', 'start': 2885, 'end': 2889}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2692, 'end': 2700}, {'entity': 'NO2', 'type': 'Gene', 'start': 2546, 'end': 2549}, {'entity': 'pollutants', 'type': 'Chemical', 'start': 2534, 'end': 2544}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2175, 'end': 2183}, {'entity': 'NO2', 'type': 'Gene', 'start': 2165, 'end': 2168}, {'entity': 'airborne', 'type': 'Drug', 'start': 2061, 'end': 2069}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1914, 'end': 1922}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'rupture', 'type': 'Disease', 'start': 320, 'end': 327}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes mellitus', 'type': 'Disease', 'start': 845, 'end': 862}\n",
            "['Crystal structure of the giant panda MHC class I complex: first insights into the viral peptide presentation profile in the bear family\\tThe viral cytotoxic T lymphocyte (CTL) epitope peptides presented by classical MHC-I molecules require the assembly of a peptide-MHC-I- β 2m (aka pMHC-I) trimolecular complex for TCR recognition, which is the critical activation link for triggering antiviral T cell immunity.', 'Ursidae includes 5 genera and 8 species; however, research on T cell immunology in this family, especially structural immunology, is lacking.', 'In this study, the structure of the key trimolecular complex pMHC-1 (aka pAime-128), which binds a peptide from canine distemper virus, was solved for the first time using giant panda as a representative species of Ursidae.', 'The structural characteristics of the giant panda pMHC-I complex, including the unique pockets in the peptide-binding groove (PBG), were analyzed in detail.', 'Comparing the panda pMHC-I to others in the bear family and extending the comparison to other mammals revealed distinct features.', 'The interaction between MHC-I and β 2m, the features of pAime-128 involved in TCR docking and CD8 binding, the anchor sites in the PBG, and the CTL epitopes of potential viruses that infect pandas were concretely clarified.', 'Unique features of pMHC-I viral antigen presentation in the panda were revealed by solving the three-dimensional structure of pAime-128.', 'The distinct characteristics of pAime-128 indicate an unusual event that emerged during the evolution of the MHC system in the bear family.', 'These results provide a new platform for research on panda CTL immunity and the design of vaccines for application in the bear family.', 'IMPORTANCE Ursidae includes 5 genera and 8 species; however, the study of its immunology, especially structural immunology, is extremely rare to date.', 'In this paper, we first crystallized the key complex pMHC-I, taking the giant panda as its representative species.', 'Structural characteristics of the giant panda pMHC-I complexes, contains the unique pockets of PBG were analyzed in detail.', 'Comparison of the panda pMHC-I in the bear family and other mammals, almost definite features was displayed.', 'Meanwhile, the interaction between HC and LV, the unique features of pMHC-I in the CD8 binding and TCR docking, validation of anchor site in the PBG, and epitopes of potential viruses infected with the pandas, were concretely clarified.', 'These unique characteristics of pMHC-I clearly indicate an unusual situation during the evolution of MHC molecules in the endangered pandas.', 'These results also provide a novel platform for further study of panda T cell immunology and vaccines.']\n",
            "unmatched tags:  [{'entity': 'vaccines', 'type': 'Drug', 'start': 2671, 'end': 2679}, {'entity': 'panda', 'type': 'Gene', 'start': 2643, 'end': 2648}, {'entity': 'pandas', 'type': 'Disease', 'start': 2570, 'end': 2576}, {'entity': 'MHC molecules', 'type': 'Gene', 'start': 2538, 'end': 2551}, {'entity': 'MHC-I', 'type': 'Gene', 'start': 2470, 'end': 2475}, {'entity': 'pMHC-I', 'type': 'Gene', 'start': 2469, 'end': 2475}, {'entity': 'pandas', 'type': 'Disease', 'start': 2402, 'end': 2408}, {'entity': 'PBG', 'type': 'Drug', 'start': 2345, 'end': 2348}, {'entity': 'pMHC-I', 'type': 'Gene', 'start': 2269, 'end': 2275}, {'entity': 'HC', 'type': 'Gene', 'start': 2235, 'end': 2237}, {'entity': 'MHC-I', 'type': 'Gene', 'start': 2116, 'end': 2121}, {'entity': 'pMHC-I', 'type': 'Gene', 'start': 2115, 'end': 2121}, {'entity': 'panda', 'type': 'Gene', 'start': 2109, 'end': 2114}, {'entity': 'PBG', 'type': 'Drug', 'start': 2062, 'end': 2065}, {'entity': 'pMHC-I', 'type': 'Gene', 'start': 2013, 'end': 2019}, {'entity': 'panda', 'type': 'Gene', 'start': 2007, 'end': 2012}, {'entity': 'giant', 'type': 'Disease', 'start': 2001, 'end': 2006}, {'entity': 'panda', 'type': 'Gene', 'start': 1930, 'end': 1935}, {'entity': 'giant', 'type': 'Disease', 'start': 1924, 'end': 1929}, {'entity': 'MHC-I', 'type': 'Gene', 'start': 1906, 'end': 1911}, {'entity': 'pMHC-I', 'type': 'Gene', 'start': 1905, 'end': 1911}, {'entity': 'vaccines', 'type': 'Drug', 'start': 1656, 'end': 1664}, {'entity': 'panda', 'type': 'Gene', 'start': 1619, 'end': 1624}, {'entity': 'HC', 'type': 'Gene', 'start': 1536, 'end': 1538}, {'entity': 'pAime-128', 'type': 'Chemical', 'start': 1458, 'end': 1467}, {'entity': 'pAime-128', 'type': 'Chemical', 'start': 1415, 'end': 1424}, {'entity': 'panda', 'type': 'Gene', 'start': 1349, 'end': 1354}, {'entity': 'pMHC-I', 'type': 'Gene', 'start': 1308, 'end': 1314}, {'entity': 'pandas', 'type': 'Disease', 'start': 1255, 'end': 1261}, {'entity': 'PBG', 'type': 'Drug', 'start': 1196, 'end': 1199}, {'entity': 'pAime-128', 'type': 'Chemical', 'start': 1121, 'end': 1130}, {'entity': 'MHC-I', 'type': 'Gene', 'start': 1089, 'end': 1094}, {'entity': 'pMHC-I', 'type': 'Gene', 'start': 955, 'end': 961}, {'entity': 'panda', 'type': 'Gene', 'start': 949, 'end': 954}, {'entity': 'PBG', 'type': 'Drug', 'start': 904, 'end': 907}, {'entity': 'MHC-I', 'type': 'Gene', 'start': 829, 'end': 834}, {'entity': 'pMHC-I', 'type': 'Gene', 'start': 828, 'end': 834}, {'entity': 'panda', 'type': 'Gene', 'start': 822, 'end': 827}, {'entity': 'giant', 'type': 'Disease', 'start': 816, 'end': 821}, {'entity': 'panda', 'type': 'Gene', 'start': 732, 'end': 737}, {'entity': 'giant', 'type': 'Disease', 'start': 726, 'end': 731}, {'entity': 'distemper virus', 'type': 'Virus', 'start': 673, 'end': 688}, {'entity': 'peptide', 'type': 'Gene', 'start': 653, 'end': 660}, {'entity': 'pAime-128', 'type': 'Chemical', 'start': 627, 'end': 636}, {'entity': 'pMHC-I', 'type': 'Gene', 'start': 282, 'end': 288}, {'entity': 'MHC-I', 'type': 'Gene', 'start': 215, 'end': 220}, {'entity': 'peptides', 'type': 'Gene', 'start': 183, 'end': 191}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNA', 'type': 'Gene', 'start': 304, 'end': 307}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNA', 'type': 'Gene', 'start': 547, 'end': 550}\n",
            "['“Identification and enrichment of SECReTE\\tcis -acting RNA motifs play a major role in regulating many aspects of RNA biology including posttranscriptional processing, nuclear export, RNA localization, translation and degradation.', 'Here we analyzed the genomes of SARS-CoV-2 and other single-strand RNA (ssRNA) viruses for the presence of a unique cis RNA element called SECReTE.', 'This motif consists of 10 or more consecutive triplet nucleotide repeats where a pyrimidine nucleotide (C or U) in present every third base, and which we identified in mRNAs encoding secreted proteins in bacteria, yeast, and humans.', 'This motif facilitates mRNA localization to the endoplasmic reticulum (ER), along with the enhanced translation and secretion of translated protein.', 'We now examined for SECReTE presence in Group IV and V RNA viruses, the former including the Coronaviridae , like SARS-CoV-2 and other positive (+)ssRNA viruses, and the latter consisting of negative (-) ssRNA viruses.', 'Interestingly, the SARS-CoV-2 genome contains 40 SECReTE motifs at an abundance of ~1.3 SECReTEs/kilobase (kb).', 'Moreover, all ssRNA viruses we examined contain multiple copies of this motif and appears in (+)ssRNA viruses as non-random in occurrence and independent of genome length.', 'Importantly, (+)ssRNA viruses ( e.g.', 'Coronaviruses and Hepaciviruses), which utilize ER membranes to create double membrane vesicles to serve as viral replication centers (VRCs), contain more SECReTE motifs per kb as compared to (−)ssRNA viruses ( e.g .', 'Rabies, Mumps, and Influenza), that replicate in the nucleus or the cytoplasm, or other (+)ssRNA viruses ( e.g .', 'Enteroviruses and Flaviviruses) which employ different organellar membranes.', 'As predicted by our earlier work, SECReTE sequences are mostly found in membranal or ER-associated/secreted proteins.', 'Thus, we propose that SECReTE motifs could be important for the efficient translation and secretion of secreted viral proteins, as well as for VRC formation.', 'Future studies of SECReTE function and identification of SECReTE-binding proteins could provide new drug targets to treat COVID-19 and other (+)ssRNA related diseases.']\n",
            "unmatched tags:  [{'entity': 'diseases', 'type': 'Disease', 'start': 2141, 'end': 2149}, {'entity': 'RNA', 'type': 'Gene', 'start': 2129, 'end': 2132}, {'entity': 'ssRNA', 'type': 'Gene', 'start': 2127, 'end': 2132}, {'entity': '(+)ssRNA', 'type': 'Gene', 'start': 2124, 'end': 2132}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2105, 'end': 2113}, {'entity': 'protein', 'type': 'Gene', 'start': 2056, 'end': 2063}, {'entity': 'SECReTE-binding proteins', 'type': 'Gene', 'start': 2040, 'end': 2064}, {'entity': 'VRC', 'type': 'Organization', 'start': 1968, 'end': 1971}, {'entity': 'viral proteins', 'type': 'Gene', 'start': 1937, 'end': 1951}, {'entity': 'protein', 'type': 'Gene', 'start': 1815, 'end': 1822}, {'entity': 'Flaviviruses', 'type': 'Virus', 'start': 1648, 'end': 1660}, {'entity': 'Enteroviruses', 'type': 'Virus', 'start': 1630, 'end': 1643}, {'entity': '(+)ssRNA viruses', 'type': 'Virus', 'start': 1605, 'end': 1621}, {'entity': 'Influenza', 'type': 'Disease', 'start': 1536, 'end': 1545}, {'entity': 'Mumps', 'type': 'Disease', 'start': 1525, 'end': 1530}, {'entity': 'Rabies', 'type': 'Disease', 'start': 1517, 'end': 1523}, {'entity': 'RNA', 'type': 'Gene', 'start': 1497, 'end': 1500}, {'entity': 'ssRNA', 'type': 'Gene', 'start': 1495, 'end': 1500}, {'entity': 'ssRNA viruses', 'type': 'Virus', 'start': 1495, 'end': 1508}, {'entity': '(−)ssRNA viruses', 'type': 'Virus', 'start': 1492, 'end': 1508}, {'entity': 'VRC', 'type': 'Organization', 'start': 1435, 'end': 1438}, {'entity': 'ER', 'type': 'Gene', 'start': 1348, 'end': 1350}, {'entity': 'Hepaciviruses', 'type': 'Virus', 'start': 1318, 'end': 1331}, {'entity': 'Coronaviruses', 'type': 'Virus', 'start': 1300, 'end': 1313}, {'entity': 'ssRNA viruses', 'type': 'Virus', 'start': 1279, 'end': 1292}, {'entity': '(+)ssRNA viruses', 'type': 'Virus', 'start': 1276, 'end': 1292}, {'entity': 'RNA', 'type': 'Gene', 'start': 1189, 'end': 1192}, {'entity': '(+)ssRNA viruses', 'type': 'Virus', 'start': 1184, 'end': 1200}, {'entity': 'ssRNA viruses', 'type': 'Virus', 'start': 1105, 'end': 1118}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 998, 'end': 1008}, {'entity': 'RNA', 'type': 'Gene', 'start': 966, 'end': 969}, {'entity': 'ssRNA', 'type': 'Gene', 'start': 964, 'end': 969}, {'entity': 'ssRNA viruses', 'type': 'Virus', 'start': 964, 'end': 977}, {'entity': '(+)ssRNA viruses', 'type': 'Virus', 'start': 904, 'end': 920}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 874, 'end': 884}, {'entity': 'Coronaviridae', 'type': 'Virus', 'start': 853, 'end': 866}, {'entity': 'RNA', 'type': 'Gene', 'start': 815, 'end': 818}, {'entity': 'V RNA viruses', 'type': 'Virus', 'start': 813, 'end': 826}, {'entity': 'protein', 'type': 'Gene', 'start': 751, 'end': 758}, {'entity': 'ER', 'type': 'Gene', 'start': 682, 'end': 684}]\n",
            "['Incubation periods of acute respiratory viral infections: a systematic review\\tKnowledge of the incubation period is essential in the investigation and control of infectious disease, but statements of incubation period are often poorly referenced, inconsistent, or based on limited data.', 'In a systematic review of the literature on nine respiratory viral infections of public-health importance, we identified 436 articles with statements of incubation period and 38 with data for pooled analysis.', 'We fitted a log-normal distribution to pooled data and found the median incubation period to be 5·6 days (95% CI 4·8–6·3) for adenovirus, 3·2 days (95% CI 2·8–3·7) for human coronavirus, 4·0 days (95% CI 3·6–4·4) for severe acute respiratory syndrome coronavirus, 1·4 days (95% CI 1·3–1·5) for influenza A, 0·6 days (95% CI 0·5–0·6) for influenza B, 12·5 days (95% CI 11·8–13·3) for measles, 2·6 days (95% CI 2·1–3·1) for parainfluenza, 4·4 days (95% CI 3·9–4·9) for respiratory syncytial virus, and 1·9 days (95% CI 1·4–2·4) for rhinovirus.']\n",
            "unmatched tags:  [{'entity': 'rhinovirus', 'type': 'Virus', 'start': 1026, 'end': 1036}, {'entity': 'respiratory syncytial virus', 'type': 'Virus', 'start': 963, 'end': 990}, {'entity': 'parainfluenza', 'type': 'Disease', 'start': 918, 'end': 931}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNAs', 'type': 'Gene', 'start': 152, 'end': 156}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNAs', 'type': 'Gene', 'start': 209, 'end': 213}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'miRNA', 'type': 'Gene', 'start': 380, 'end': 385}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'miRNAs', 'type': 'Gene', 'start': 380, 'end': 386}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNAs', 'type': 'Gene', 'start': 382, 'end': 386}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'miRNAs', 'type': 'Gene', 'start': 561, 'end': 567}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNAs', 'type': 'Gene', 'start': 563, 'end': 567}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNAs', 'type': 'Gene', 'start': 843, 'end': 847}\n",
            "['Isolation and sequencing of AGO-bound RNAs reveals characteristics of mammalian stem-loop processing\\tMicroRNA precursors (pre-miRNAs) are short hairpin RNAs that are rapidly processed into mature microRNAs (miRNAs) in the cytoplasm.', 'Due to their low abundance in cells, sequencing-based studies of pre-miRNAs have been limited.', 'We successfully enriched for and deep sequenced pre-miRNAs in human cells by capturing these RNAs during their interaction with Argonaute (AGO) proteins.', 'Using this approach, we detected > 350 pre-miRNAs in human cells and > 250 pre-miRNAs in a reanalysis of a similar study in mouse cells.', 'We uncovered widespread trimming and non-templated additions to the 3’ ends of pre- and mature miRNAs.', 'Additionally, we created an index for microRNA precursor processing efficiency.', 'This analysis revealed a subset of pre-miRNAs that produce low levels of mature miRNAs despite abundant precursors, including an annotated miRNA in the 5’ UTR of the DiGeorge syndrome critical region 8 mRNA transcript.', 'This led us to search for AGO-associated stem-loops originating from other mRNA species, which identified hundreds of putative pre-miRNAs derived from human and mouse mRNAs.', 'In summary, we provide a wealth of information on mammalian pre-miRNAs, and identify novel microRNA and microRNA-like elements localized in mRNAs.']\n",
            "unmatched tags:  [{'entity': 'mRNAs', 'type': 'Gene', 'start': 1335, 'end': 1340}, {'entity': 'microRNA', 'type': 'Gene', 'start': 1286, 'end': 1294}, {'entity': 'RNAs', 'type': 'Gene', 'start': 1261, 'end': 1265}, {'entity': 'miRNAs', 'type': 'Gene', 'start': 1259, 'end': 1265}, {'entity': 'pre-miRNAs', 'type': 'Gene', 'start': 1255, 'end': 1265}, {'entity': 'mRNAs', 'type': 'Gene', 'start': 1188, 'end': 1193}, {'entity': 'RNAs', 'type': 'Gene', 'start': 1154, 'end': 1158}, {'entity': 'pre-miRNAs', 'type': 'Gene', 'start': 1148, 'end': 1158}, {'entity': 'mRNA', 'type': 'Gene', 'start': 1096, 'end': 1100}, {'entity': 'transcript', 'type': 'Gene', 'start': 1009, 'end': 1019}, {'entity': 'mRNA', 'type': 'Gene', 'start': 1004, 'end': 1008}, {'entity': 'DiGeorge syndrome', 'type': 'Disease', 'start': 968, 'end': 985}, {'entity': 'UTR', 'type': 'Gene', 'start': 957, 'end': 960}, {'entity': 'miRNA', 'type': 'Gene', 'start': 941, 'end': 946}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 135, 'end': 141}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 355, 'end': 361}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 592, 'end': 598}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'hypertension', 'type': 'Disease', 'start': 183, 'end': 195}\n",
            "['Molecular Docking Reveals the Potential of Aliskiren, Dipyridamole, Mopidamol, Rosuvastatin, Rolitetracycline and Metamizole to Inhibit COVID-19 Virus Main Protease\\tDrug repurposing is a fast way to rapidly discover a drug for clinical use.', 'In such circumstances of the spreading of the highly contagious COVID-19, searching for already known drugs is a worldwide demand.', 'In this study, many drugs were evaluated by molecular docking.', 'Among the test compounds, aliskiren (the best), dipyridamole, mopidamol and rosuvastatin showed higher energies of binding than that of the co-crystallized ligand N3 with COVID-19 main protease M']\n",
            "unmatched tags:  [{'entity': 'rosuvastatin', 'type': 'Drug', 'start': 512, 'end': 524}, {'entity': 'mopidamol', 'type': 'Drug', 'start': 498, 'end': 507}, {'entity': 'dipyridamole', 'type': 'Drug', 'start': 484, 'end': 496}, {'entity': 'aliskiren', 'type': 'Drug', 'start': 462, 'end': 471}, {'entity': 'test compounds', 'type': 'Drug', 'start': 446, 'end': 460}, {'entity': 'drug', 'type': 'Drug', 'start': 393, 'end': 397}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 124, 'end': 133}\n",
            "['Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study\\tOver the 10 years studied, there is evidence of a sustained positive change in diagnosis rates of dementia and in the quality of drug treatment provided to those diagnosed.', 'The prescription of antidementia drugs more than doubled and the prescription of potentially hazardous antipsychotics halved after the introduction of national dementia strategies.', 'These data support the formulation and delivery of national policy to improve the quality of care for people with dementia.']\n",
            "unmatched tags:  [{'entity': 'dementia', 'type': 'Disease', 'start': 598, 'end': 606}, {'entity': 'national dementia', 'type': 'Disease', 'start': 454, 'end': 471}, {'entity': 'antipsychotics', 'type': 'Drug', 'start': 406, 'end': 420}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'dyskinesia', 'type': 'Disease', 'start': 63, 'end': 73}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'aspergillosis', 'type': 'Disease', 'start': 363, 'end': 376}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'ischaemic stroke', 'type': 'Disease', 'start': 119, 'end': 135}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'stroke', 'type': 'Disease', 'start': 129, 'end': 135}\n",
            "['Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis\\tTreatment of the neuronal ceroid lipofuscinoses, also known as Batten disease, is at the start of a new era because of diagnostic and therapeutic advances relevant to this group of inherited neurodegenerative and life-limiting disorders that affect children.', 'Diagnosis has improved with the use of comprehensive DNA-based tests that simultaneously screen for many genes.', 'The identification of disease-causing mutations in 13 genes provides a basis for understanding the molecular mechanisms underlying neuronal ceroid lipofuscinoses, and for the development of targeted therapies.']\n",
            "unmatched tags:  [{'entity': 'era', 'type': 'Gene', 'start': 661, 'end': 664}, {'entity': 'lipofuscinoses', 'type': 'Drug', 'start': 607, 'end': 621}, {'entity': 'era', 'type': 'Gene', 'start': 290, 'end': 293}, {'entity': 'era', 'type': 'Gene', 'start': 225, 'end': 228}, {'entity': 'diagnostic', 'type': 'Chemical', 'start': 208, 'end': 218}, {'entity': 'era', 'type': 'Gene', 'start': 193, 'end': 196}, {'entity': 'Batten disease', 'type': 'Disease', 'start': 152, 'end': 166}, {'entity': 'lipofuscinoses', 'type': 'Drug', 'start': 122, 'end': 136}]\n",
            "['New Epidemiological Model Suggestions Revealing Size of Epidemics Based on the COVID-19 Pandemic Example: Wavelength Models\\tThe main purpose of the study is to introduce the wavelength models developed to measure the size of outbreaks based on the COVID-19 example.', 'In this way, the wavelengths of the outbreaks can be calculated, ensuring that the outbreaks are valid, reliable and easy to follow at the national and international level.', 'Wavelength models consist of approved case, death, recovered case and net wavelength models.', 'Thus, the size of the outbreak can be measured both individually and as a whole.', 'COVID-19 cases of 181 countries were used to demonstrate the application of the models.', 'The prominent findings in the applied wavelength models are as follows: the countries with the highest case wavelength are USA, Italy, Spain and Germany, respectively.', 'However, Italy ranks first in the death wavelength, followed by Spain, the USA and France.', 'On the other hand, China has taken the first place in the recovered case wavelength.', 'This country was followed by Spain and Germany and Italy, respectively.', 'Based on all these wavelength models mentioned, net wavelength lengths are calculated.', 'According to the findings of net wavelengths obtained, Canada ranked first, followed by United Kingdom, USA and Italy, respectively.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 613, 'end': 621}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tuberculosis', 'type': 'Disease', 'start': 619, 'end': 631}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'irinotecan', 'type': 'Drug', 'start': 207, 'end': 217}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'pneumonia', 'type': 'Disease', 'start': 1578, 'end': 1587}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'trauma', 'type': 'Phenotype', 'start': 353, 'end': 359}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'fever', 'type': 'Phenotype', 'start': 31, 'end': 36}\n",
            "['Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries\\tThese time trends show a compelling need for more effective lifestyle management of patients with coronary heart disease.', 'Despite a substantial increase in antihypertensive and lipid-lowering drugs, blood pressure management remained unchanged, and almost half of all patients remain above the recommended lipid targets.', 'To salvage the acutely ischaemic myocardium without addressing the underlying causes of the disease is futile; we need to invest in prevention.']\n",
            "unmatched tags:  [{'entity': 'lipid-lowering drugs', 'type': 'Drug', 'start': 311, 'end': 331}, {'entity': 'antihypertensive', 'type': 'Drug', 'start': 290, 'end': 306}, {'entity': 'coronary heart disease', 'type': 'Disease', 'start': 232, 'end': 254}, {'entity': 'II', 'type': 'Gene', 'start': 95, 'end': 97}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 385, 'end': 391}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tuberculosis', 'type': 'Disease', 'start': 498, 'end': 510}\n",
            "[\"Measuring Iran's success in achieving Millennium Development Goal 4: a systematic analysis of under-5 mortality at national and subnational levels from 1990 to 2015\\tIran and most of its provinces achieved MDG 4 and SDG 3 (target 2) goals by 2015.\", 'However, at the subnational level in some provinces, there is substantial inequity.', 'Local policy makers should use effective strategies to accelerate the reduction of child mortality for these provinces by 2030.', 'Possible recommendations for such strategies include enhancing the level of education and health literacy among women, tackling sex discrimination, and improving incomes for families.']\n",
            "unmatched tags:  [{'entity': 'national', 'type': 'Organization', 'start': 266, 'end': 274}, {'entity': 'SDG 3', 'type': 'Drug', 'start': 215, 'end': 220}, {'entity': 'MDG', 'type': 'Gene', 'start': 205, 'end': 208}]\n",
            "['Dangers of vaccine refusal near the herd immunity threshold: a modelling study\\tAs vaccination makes preventable illness rarer, for some diseases, it also increases the expected severity of each case.', 'Because estimates of case risks rely on data for severity generated during a pre-vaccine era they underestimate negative outcomes in the modern post-vaccine epidemiological landscape.', \"Physicians and parents should understand when making decisions about their children's health and safety that remaining unvaccinated in a predominantly vaccine-protected community exposes their children to the most severe possible outcomes for many preventable diseases.\"]\n",
            "unmatched tags:  [{'entity': 'preventable diseases', 'type': 'Disease', 'start': 632, 'end': 652}, {'entity': 'vaccine', 'type': 'Drug', 'start': 349, 'end': 356}]\n",
            "[\"Predictions, role of interventions and effects of a historic national lockdown in India's response to the COVID-19 pandemic: data science call to arms\\tImportance: India has taken strong and early public health measures for arresting the spread of the COVID-19 epidemic.\", 'With only 536 COVID-19 cases and 11 fatalities, India - a democracy of 1.34 billion people - took the historic decision of a 21-day national lockdown on March 25.', 'The lockdown was further extended to May 3, soon after the analysis of this paper was completed.', 'Objective: To study the short- and long-term impact of an initial 21-day lockdown on the total number of COVID-19 cases in India compared to other less severe non-pharmaceutical interventions using epidemiological forecasting models and Bayesian estimation algorithms; to compare effects of hypothetical durations of lockdown from an epidemiological perspective; to study alternative explanations for slower growth rate of the virus outbreak in India, including exploring the association of the number of cases and average monthly temperature; and finally, to outline the pivotal role of reliable and transparent data, reproducible data science methods, tools and products as we reopen the country and prepare for a post lock-down phase of the pandemic.', 'Design, Setting, and Participants: We use the daily data on the number of COVID-19 cases, of recovered and of deaths from March 1 until April 7, 2020 from the 2019 Novel Coronavirus Visual Dashboard operated by the Johns Hopkins University Center for Systems Science and Engineering (JHU CSSE).', 'Additionally, we use COVID-19 incidence counts data from Kaggle and the monthly average temperature of major cities across the world from Wikipedia.', 'Main Outcome and Measures: The current time-series data on daily proportions of cases and removed (recovered and death combined) from India are analyzed using an extended version of the standard SIR (susceptible, infected, and removed) model.', 'The eSIR model incorporates time-varying transmission rates that help us predict the effect of lockdown compared to other hypothetical interventions on the number of cases at future time points.', 'A Markov Chain Monte Carlo implementation of this model provided predicted proportions of the cases at future time points along with credible intervals (CI).', \"Results: Our predicted cumulative number of COVID-19 cases in India on April 30 assuming a 1-week delay in people's adherence to a 21-day lockdown (March 25 - April 14) and a gradual, moderate resumption of daily activities after April 14 is 9,181 with upper 95% CI of 72,245.\", 'In comparison, the predicted cumulative number of cases under \"no intervention\" and \"social distancing and travel bans without lockdown\" are 358 thousand and 46 thousand (upper 95% CI of nearly 2.3 million and 0.3 million) respectively.', 'An effective lockdown can prevent roughly 343 thousand (upper 95% CI 1.8 million) and 2.4 million (upper 95% CI 38.4 million) COVID-19 cases nationwide compared to social distancing alone by May 15 and June 15, respectively.', 'When comparing a 21-day lockdown with a hypothetical lockdown of longer duration, we find that 28-, 42-, and 56-day lockdowns can approximately prevent 238 thousand (upper 95% CI 2.3 million), 622 thousand (upper 95% CI 4.3 million), 781 thousand (upper 95% CI 4.6 million) cases by June 15, respectively.', 'We find some suggestive evidence that the COVID-19 incidence rates worldwide are negatively associated with temperature in a crude unadjusted analysis with Pearson correlation estimates [95% confidence interval] between average monthly temperature and total monthly incidence around the world being -0.185 [-0.548, 0.236] for January, -0.110 [-0.362, 0.157] for February, and -0.173 [-0.314, -0.026] for March.', 'Conclusions and Relevance: The lockdown, if implemented correctly in the end, has a high chance of reducing the total number of COVID-19 cases in the short term, and buy India invaluable time to prepare its healthcare and disease monitoring system.', 'Our analysis shows we need to have some measures of suppression in place after the lockdown for the best outcome.', 'We cannot heavily rely on the hypothetical prevention governed by meteorological factors such as temperature based on current evidence.', 'From an epidemiological perspective, a longer lockdown between 42-56 days is preferable.', 'However, the lockdown comes at a tremendous price to social and economic health through a contagion process not dissimilar to that of the coronavirus itself.', 'Data can play a defining role as we design post-lockdown testing, reopening and resource allocation strategies.', 'Software: Our contribution to data science includes an interactive and dynamic app (covind19.org) with short- and long-term projections updated daily that can help inform policy and practice related to COVID-19 in India.', 'Anyone can visualize the observed data for India and create predictions under hypothetical scenarios with quantification of uncertainties.', 'We make our prediction codes freely available (https://github.com/umich-cphds/cov-ind-19) for reproducible science and for other COVID-19 affected countries to use them for their prediction and data visualization work.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 5135, 'end': 5143}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 4848, 'end': 4856}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 4513, 'end': 4524}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 3915, 'end': 3923}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 3416, 'end': 3424}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2969, 'end': 2977}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2373, 'end': 2381}, {'entity': 'credible intervals', 'type': 'Gene', 'start': 2303, 'end': 2321}, {'entity': 'Wikipedia', 'type': 'Chemical', 'start': 1719, 'end': 1728}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1602, 'end': 1610}, {'entity': 'CSSE', 'type': 'Disease', 'start': 1574, 'end': 1578}, {'entity': 'JHU', 'type': 'Organization', 'start': 1570, 'end': 1573}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'influenza', 'type': 'Disease', 'start': 225, 'end': 234}\n",
            "['Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications\\tBackground The COVID-19 pandemic caused by SARS-CoV-2 coronavirus threatens global public health.', 'Currently, neutralizing antibodies (NAbs) versus this virus are expected to correlate with recovery and protection of this disease.', 'However, the characteristics of these antibodies have not been well studied in association with the clinical manifestations in patients.', 'Methods  Plasma collected from 175 COVID-19 recovered patients with mild symptoms were screened using a safe and sensitive pseudotyped-lentiviral-vector-based neutralization assay.', 'Spike-binding antibody in plasma were determined by ELISA using RBD, S1, and S2 proteins of SARS-CoV-2.', 'The levels and the time course of SARS-CoV-2-specific NAbs and the spike-binding antibodies were monitored at the same time.', 'Findings  SARS-CoV-2 NAbs were unable to cross-reactive with SARS-CoV virus.', 'SARS-CoV-2-specific NAbs were detected in patients from day 10-15 after the onset of the disease and remained thereafter.', 'The titers of NAb among these patients correlated with the spike-binding antibodies targeting S1, RBD, and S2 regions.', 'The titers of NAbs were variable in different patients.', 'Elderly and middle-age patients had significantly higher plasma NAb titers (P<0.0001) and spike-binding antibodies (P=0.0003) than young patients.', 'Notably, among these patients, there were ten patients whose NAb titers were under the detectable level of our assay (ID50: < 40); while in contrast, two patients, showed very high titers of NAb, with ID50 :15989 and 21567 respectively.', 'The NAb titers were positive correlated with plasma CRP levels but negative correlated with the lymphocyte counts of patients at the time of admission, indicating an association between humoral response and cellular immune response.', 'Interpretation The variations of SARS-CoV-2 specific NAbs in recovered COVID-19 patients may raise the concern about the role of NAbs on disease progression.', 'The correlation of NAb titers with age, lymphocyte counts, and blood CRP levels suggested that the interplay between virus and host immune response in coronavirus infections should be further explored for the development of effective vaccine against SARS-CoV-2 virus.', 'Furthermore, titration of NAb is helpful prior to the use of convalescent plasma for prevention or treatment.', 'Funding Ministry of Science and Technology of China, National Natural Science Foundation of China, Shanghai Municipal Health Commission, and Chinese Academy of Medical Sciences']\n",
            "unmatched tags:  [{'entity': 'NAb', 'type': 'Chemical', 'start': 2331, 'end': 2334}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2287, 'end': 2297}, {'entity': 'vaccine', 'type': 'Drug', 'start': 2271, 'end': 2278}, {'entity': 'coronavirus infections', 'type': 'Disease', 'start': 2188, 'end': 2210}, {'entity': 'NAb', 'type': 'Chemical', 'start': 2056, 'end': 2059}, {'entity': 'NAb', 'type': 'Chemical', 'start': 2008, 'end': 2011}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1950, 'end': 1958}, {'entity': 'NAb', 'type': 'Chemical', 'start': 1932, 'end': 1935}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1912, 'end': 1922}, {'entity': 'NAb', 'type': 'Chemical', 'start': 1649, 'end': 1652}, {'entity': 'NAb', 'type': 'Chemical', 'start': 1599, 'end': 1602}, {'entity': 'NAb', 'type': 'Chemical', 'start': 1469, 'end': 1472}, {'entity': 'NAb', 'type': 'Chemical', 'start': 1325, 'end': 1328}, {'entity': 'NAb', 'type': 'Chemical', 'start': 1219, 'end': 1222}, {'entity': 'RBD', 'type': 'Gene', 'start': 1184, 'end': 1187}, {'entity': 'S1', 'type': 'Gene', 'start': 1180, 'end': 1182}, {'entity': 'NAb', 'type': 'Chemical', 'start': 1100, 'end': 1103}, {'entity': 'NAb', 'type': 'Chemical', 'start': 984, 'end': 987}, {'entity': 'SARS-CoV virus', 'type': 'Virus', 'start': 948, 'end': 962}, {'entity': 'NAb', 'type': 'Chemical', 'start': 908, 'end': 911}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 897, 'end': 907}, {'entity': 'NAb', 'type': 'Chemical', 'start': 815, 'end': 818}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 749, 'end': 759}, {'entity': 'S2 proteins', 'type': 'Gene', 'start': 734, 'end': 745}, {'entity': 'S1', 'type': 'Gene', 'start': 726, 'end': 728}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'virus receptor', 'type': 'Gene', 'start': 413, 'end': 427}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'receptor', 'type': 'Gene', 'start': 653, 'end': 661}\n",
            "['TIM-1 Serves as a Nonredundant Receptor for Ebola Virus, Enhancing Viremia and Pathogenesis\\tBackground.', 'T cell immunoglobulin mucin domain-1 (TIM-1) is a phosphatidylserine (PS) receptor, mediating filovirus entry into cells through interactions with PS on virions.', 'TIM-1 expression has been implicated in Ebola virus (EBOV) pathogenesis; however, it remains unclear whether this is due to TIM-1 serving as a filovirus receptor in vivo or, as others have suggested, TIM-1 induces a cytokine storm elicited by T cell/virion interactions.', 'Here, we use a BSL2 model virus that expresses EBOV glycoprotein and demonstrate the importance of TIM-1 as a virus receptor late during in vivo infection.', 'Methodology/Principal findings.', 'We used an infectious, recombinant vesicular stomatitis virus expressing EBOV glycoprotein (EBOV GP/rVSV) to assess the role of TIM-1 during in vivo infection.', 'TIM-1-sufficient or TIM-1-deficient BALB/c interferon α/β receptor -/- mice were challenged with EBOV GP/rVSV-GFP or G/rVSV-GFP.', 'While G/rVSV caused profound morbidity and mortality in both mouse strains, TIM-1-deficient mice had significantly better survival than TIM-1-expressing mice following EBOV GP/rVSV challenge.', 'EBOV GP/rVSV load in spleen was high and unaffected by expression of TIM-1.', 'However, infectious virus in serum, liver, kidney and adrenal gland was reduced late in infection in the TIM-1-deficient mice, suggesting that virus entry via this receptor contributes to virus load.', 'Consistent with higher virus loads, proinflammatory chemokines trended higher in organs from infected TIM-1-sufficient mice compared to the TIM-1-deficient mice, but proinflammatory cytokines were more modestly affected.', 'To assess the role of T cells in EBOV GP/rVSV pathogenesis, T cells were depleted in TIM-1-sufficient and -deficient mice and the mice were challenged with virus.', 'Depletion of T cells did not alter the pathogenic consequences of virus infection.', 'Conclusions.', 'Our studies provide evidence that at late times during EBOV GP/rVSV infection, TIM-1 increased virus load and associated mortality, consistent with an important role of this receptor in virus entry.', 'This work suggests that inhibitors which block TIM-1/virus interaction may serve as effective antivirals, reducing virus load at late times during EBOV infection.', 'Author summary T cell immunoglobulin mucin domain-1 (TIM-1) is one of a number of phosphatidylserine (PS) receptors that mediate clearance of apoptotic bodies by binding PS on the surface of dead or dying cells.', 'Enveloped viruses mimic apoptotic bodies by exposing PS on the outer leaflet of the viral membrane.', 'While TIM-1 has been shown to serve as an adherence factor/receptor for filoviruses in tissue culture, limited studies have investigated the role of TIM-1 as a receptor in vivo.', 'Here, we sought to determine if TIM-1 was critical for Ebola virus glycoprotein-mediated infection using a BSL2 model virus.', 'We demonstrate that loss of TIM-1 expression results in decreased virus load late during infection and significantly reduced virus-elicited mortality.', 'These findings provide evidence that TIM-1 serves as an important receptor for Ebola virus in vivo.', 'Blocking TIM-1/EBOV interactions may be effective antiviral strategy to reduce viral load and pathogenicity at late times of EBOV infection.']\n",
            "unmatched tags:  [{'entity': 'EBOV infection', 'type': 'Disease', 'start': 3315, 'end': 3329}, {'entity': 'EBOV', 'type': 'Virus', 'start': 3205, 'end': 3209}, {'entity': 'TIM-1', 'type': 'Gene', 'start': 3199, 'end': 3204}, {'entity': 'Ebola virus', 'type': 'Virus', 'start': 3169, 'end': 3180}, {'entity': 'receptor', 'type': 'Gene', 'start': 3156, 'end': 3164}, {'entity': 'TIM-1', 'type': 'Gene', 'start': 3127, 'end': 3132}, {'entity': 'TIM-1', 'type': 'Gene', 'start': 2967, 'end': 2972}, {'entity': 'Ebola virus', 'type': 'Virus', 'start': 2869, 'end': 2880}, {'entity': 'TIM-1', 'type': 'Gene', 'start': 2846, 'end': 2851}, {'entity': 'receptor', 'type': 'Gene', 'start': 2796, 'end': 2804}, {'entity': 'TIM-1', 'type': 'Gene', 'start': 2785, 'end': 2790}, {'entity': 'filoviruses', 'type': 'Virus', 'start': 2708, 'end': 2719}, {'entity': 'receptor', 'type': 'Gene', 'start': 2695, 'end': 2703}, {'entity': 'TIM-1', 'type': 'Gene', 'start': 2642, 'end': 2647}, {'entity': 'PS', 'type': 'Gene', 'start': 2589, 'end': 2591}, {'entity': 'Enveloped viruses', 'type': 'Virus', 'start': 2536, 'end': 2553}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'interleukin 5 receptor', 'type': 'Gene', 'start': 22, 'end': 44}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'pembrolizumab', 'type': 'Drug', 'start': 196, 'end': 209}\n",
            "['On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2\\tA new betacoronavirus named SARS-CoV-2 has emerged as a new threat to global health and economy.', 'A promising target for both diagnosis and therapeutics treatments of the new disease named COVID-19 is the coronavirus (CoV) spike (S) glycoprotein.', 'By constant-pH Monte Carlo simulations and the PROCEEDpKa method, we have mapped the electrostatic epitopes for four monoclonal antibodies and the angiotensin-converting enzyme 2 (ACE2) on both SARS-CoV-1 and the new SARS-CoV-2 S receptor binding domain (RBD) proteins.', 'We also calculated free energy of interactions and shown that the S RBD proteins from both SARS viruses binds to ACE2 with similar affinities.', 'However, the affinity between the S RBD protein from the new SARS-CoV-2 and ACE2 is higher than for any studied antibody previously found complexed with SARS-CoV-1.', 'Based on physical chemical analysis and free energies estimates, we can shed some light on the involved molecular recognition processes, their clinical aspects, the implications for drug developments, and suggest structural modifications on the CR3022 antibody that would improve its binding affinities for SARS-CoV-2 and contribute to address the ongoing international health crisis.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1275, 'end': 1285}, {'entity': 'CR3022 antibody', 'type': 'Gene', 'start': 1213, 'end': 1228}, {'entity': 'ACE2', 'type': 'Gene', 'start': 879, 'end': 883}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 864, 'end': 874}]\n",
            "['Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—\\tInspired by unprecedented improvements in human health and development in recent decades, our world has embarked on a quest that only a generation ago would have been considered unreachable—achieving sustainable health and development for all.', \"Improving the health and wellbeing of the world's people is at the core of the Sustainable Development Goals (SDGs), reflected in targets that call for ending the epidemics of AIDS, tuberculosis, and malaria; achieving enormous improvements in maternal and child health; and tackling the growing burden of non-communicable diseases (NCDs).\"]\n",
            "unmatched tags:  [{'entity': 'non-communicable diseases', 'type': 'Disease', 'start': 690, 'end': 715}, {'entity': 'malaria', 'type': 'Disease', 'start': 584, 'end': 591}, {'entity': 'tuberculosis', 'type': 'Disease', 'start': 566, 'end': 578}, {'entity': 'AIDS', 'type': 'Disease', 'start': 560, 'end': 564}, {'entity': 'SDGs', 'type': 'Gene', 'start': 494, 'end': 498}]\n",
            "['The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis\\tABSTRACT IMPORTANCE Coronavirus disease 2019 (COVID-19) is a global pandemic associated with high mortality and effective treatment to prevent clinical deterioration to severe pneumonia has not yet been well clarified.', 'OBJECTIVE To investigate the role of several adjuvant treatments in preventing severe pneumonia in patients with COVID-19.', \"DESIGN, SETTING, AND PARTICIPANTS Multicenter, retrospective cohort study of 564 consecutively hospitalized patients with confirmed COVID-19 at Third Xiangya Hospital of Central South University, Changsha Public Health Treatment Center, First Hospital of Yueyang, Junshan People's Hospital of Yueyang, Central Hospital of Shaoyang, Central Hospital of Xiangtan, Second Hospital of Changde, Central Hospital of Loudi, and First Affiliated Hospital of University of South China in Hunan province from January 17, 2020 to February 28, 2020; The final date of follow-up was March 15, 2020.\", 'EXPOSURES Nonspecific antivirals (arbidol, lopinavir/ritonavir, and interferon α), antihypertensives, and chloroquine.', 'MAIN OUTCOMES AND MEASURES The development of severe COVID-19 pneumonia; Demographic, epidemiological, clinical, laboratory, radiological, and treatment data were collected and analyzed.', 'RESULTS Of 564 patients, the median age was 47 years (interquartile range, 36-58 years), and 284 (50.4%) patients were men.', 'Sixty-nine patients (12.2%) developed severe pneumonia.', 'Patients who developed severe pneumonia were older (median age of 59 and 45 years, respectively), and more patients had comorbidities including hypertension (30.4% and 12.3%, respectively), diabetes (17.4% and 6.7%, respectively), and cardiovascular disease (8.7% and 3.2%, respectively) and presented with fever (84.1% and 60.4%, respectively) and shortness of breath (10.1% and 3.8%, respectively) compared with those who did not.', 'Nonspecific antiviral therapy did not prevent clinical progression to severe pneumonia, although fewer hypertensive patients on angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers (ACEI/ARB) therapy developed severe pneumonia in contrast with those on non-ACEI/ARB antihypertensive therapy (1 of 16 [6.3%] patients and 16 of 49 [32.7%] patients, respectively [difference, 26.4%; 95% CI, 1.5% to 41.3%]).', 'Multivariate logistic regression analysis showed that hypertension without receiving ACEI/ARB therapy was an independent risk factor (odds ratio [OR], 2.07; 95% CI, 1.07 to 4.00) for developing severe pneumonia irrespective of age.', 'Besides, none of patients treated with chloroquine developed severe pneumonia, though without significance (difference, 12.0%; 95% CI, -3.5% to 30.0%) by propensity score matching.', 'CONCLUSIONS AND RELEVANCE Hypertensive patients on ACEI or ARB may be protective from severe pneumonia in COVID-19 and hence these therapies should not be ceased unless there is a strong indication or further epidemiological evidence.', 'Though none of the current antiviral and immunoregulation therapy showed benefit in preventing COVID-19 progression, chloroquine deserved further investigation.']\n",
            "unmatched tags:  [{'entity': 'chloroquine', 'type': 'Drug', 'start': 3184, 'end': 3195}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 3162, 'end': 3170}, {'entity': 'antiviral', 'type': 'Virus', 'start': 3094, 'end': 3103}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2938, 'end': 2946}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 2925, 'end': 2934}, {'entity': 'ACEI', 'type': 'Chemical', 'start': 2883, 'end': 2887}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 2719, 'end': 2728}, {'entity': 'chloroquine', 'type': 'Drug', 'start': 2690, 'end': 2701}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 2620, 'end': 2629}, {'entity': 'ACEI', 'type': 'Chemical', 'start': 2504, 'end': 2508}, {'entity': 'hypertension', 'type': 'Disease', 'start': 2473, 'end': 2485}, {'entity': 'ACEI', 'type': 'Chemical', 'start': 2271, 'end': 2275}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 2231, 'end': 2240}, {'entity': 'ACEI', 'type': 'Chemical', 'start': 2196, 'end': 2200}, {'entity': 'angiotensin-receptor blockers', 'type': 'Drug', 'start': 2165, 'end': 2194}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 2070, 'end': 2079}, {'entity': 'antiviral', 'type': 'Virus', 'start': 2005, 'end': 2014}, {'entity': 'shortness of breath', 'type': 'Phenotype', 'start': 1909, 'end': 1928}, {'entity': 'fever', 'type': 'Phenotype', 'start': 1867, 'end': 1872}, {'entity': 'cardiovascular disease', 'type': 'Disease', 'start': 1795, 'end': 1817}, {'entity': 'diabetes', 'type': 'Disease', 'start': 1750, 'end': 1758}, {'entity': 'hypertension', 'type': 'Disease', 'start': 1704, 'end': 1716}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 1590, 'end': 1599}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 1549, 'end': 1558}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 1254, 'end': 1263}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1245, 'end': 1253}, {'entity': 'chloroquine', 'type': 'Drug', 'start': 1179, 'end': 1190}, {'entity': 'antihypertensives', 'type': 'Drug', 'start': 1156, 'end': 1173}, {'entity': 'interferon', 'type': 'Gene', 'start': 1141, 'end': 1151}, {'entity': 'lopinavir/ritonavir', 'type': 'Drug', 'start': 1116, 'end': 1135}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cast nephropathy', 'type': 'Disease', 'start': 291, 'end': 307}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronaviruses', 'type': 'Virus', 'start': 537, 'end': 550}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'proteases', 'type': 'Gene', 'start': 828, 'end': 837}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronaviruses', 'type': 'Virus', 'start': 1232, 'end': 1245}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronavirus', 'type': 'Virus', 'start': 1232, 'end': 1243}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronavirus', 'type': 'Virus', 'start': 1387, 'end': 1398}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CoV', 'type': 'Virus', 'start': 110, 'end': 113}\n",
            "['Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV\\tSince 2002, beta coronaviruses (CoV) have caused three zoonotic outbreaks, SARS-CoV in 2002â\\x80\\x932003, MERS-CoV in 2012, and the newly emerged SARS-CoV-2 in late 2019.', 'However, little is currently known about the biology of SARS-CoV-2.', 'Here, using SARS-CoV-2 S protein pseudovirus system, we confirm that human angiotensin converting enzyme 2 (hACE2) is the receptor for SARS-CoV-2, find that SARS-CoV-2 enters 293/hACE2 cells mainly through endocytosis, that PIKfyve, TPC2, and cathepsin L are critical for entry, and that SARS-CoV-2 S protein is less stable than SARS-CoV S. Polyclonal anti-SARS S1 antibodies T62 inhibit entry of SARS-CoV S but not SARS-CoV-2 S pseudovirions.', 'Further studies using recovered SARS and COVID-19 patientsâ\\x80\\x99 sera show limited cross-neutralization, suggesting that recovery from one infection might not protect against the other.', 'Our results present potential targets for development of drugs and vaccines for SARS-CoV-2.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1054, 'end': 1064}, {'entity': 'vaccines', 'type': 'Drug', 'start': 1041, 'end': 1049}, {'entity': 'cross-neutralization', 'type': 'Disease', 'start': 871, 'end': 891}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 832, 'end': 840}, {'entity': 'SARS', 'type': 'Disease', 'start': 823, 'end': 827}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 763, 'end': 773}, {'entity': 'CoV', 'type': 'Virus', 'start': 749, 'end': 752}, {'entity': 'SARS-CoV S', 'type': 'Virus', 'start': 744, 'end': 754}, {'entity': 'SARS', 'type': 'Disease', 'start': 704, 'end': 708}, {'entity': 'Polyclonal', 'type': 'Gene', 'start': 688, 'end': 698}, {'entity': 'SARS-CoV S', 'type': 'Virus', 'start': 676, 'end': 686}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 635, 'end': 645}, {'entity': 'cathepsin L', 'type': 'Gene', 'start': 590, 'end': 601}, {'entity': 'TPC2', 'type': 'Gene', 'start': 580, 'end': 584}, {'entity': 'PIKfyve', 'type': 'Gene', 'start': 571, 'end': 578}, {'entity': 'hACE2', 'type': 'Chemical', 'start': 526, 'end': 531}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 504, 'end': 514}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 482, 'end': 492}, {'entity': 'receptor', 'type': 'Gene', 'start': 469, 'end': 477}, {'entity': 'hACE2', 'type': 'Chemical', 'start': 455, 'end': 460}, {'entity': 'angiotensin converting enzyme 2', 'type': 'Gene', 'start': 422, 'end': 453}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 359, 'end': 369}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 335, 'end': 345}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 254, 'end': 264}, {'entity': 'CoV', 'type': 'Virus', 'start': 219, 'end': 222}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 214, 'end': 222}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 189, 'end': 197}, {'entity': 'CoV', 'type': 'Virus', 'start': 146, 'end': 149}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 119, 'end': 128}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tumour', 'type': 'Disease', 'start': 153, 'end': 159}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'synovitis', 'type': 'Disease', 'start': 53, 'end': 62}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'synovitis', 'type': 'Disease', 'start': 461, 'end': 470}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'lymphoma', 'type': 'Disease', 'start': 358, 'end': 366}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'artemisinin', 'type': 'Drug', 'start': 52, 'end': 63}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'artemisinin', 'type': 'Drug', 'start': 326, 'end': 337}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 489, 'end': 497}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'influenza', 'type': 'Disease', 'start': 332, 'end': 341}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CNS infections', 'type': 'Disease', 'start': 105, 'end': 119}\n",
            "['Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study\\tA single episode of falciparum or vivax malaria in the first trimester of pregnancy can cause miscarriage.', 'No additional toxic effects associated with artesunate treatment occurred in early pregnancy.', 'Prospective studies should now be done to assess the safety and efficacy of artemisinin combination treatments in early pregnancy.']\n",
            "unmatched tags:  [{'entity': 'early pregnancy', 'type': 'Disease', 'start': 449, 'end': 464}, {'entity': 'artemisinin', 'type': 'Drug', 'start': 411, 'end': 422}, {'entity': 'early pregnancy', 'type': 'Disease', 'start': 318, 'end': 333}, {'entity': 'artesunate', 'type': 'Drug', 'start': 285, 'end': 295}, {'entity': 'malaria', 'type': 'Disease', 'start': 174, 'end': 181}, {'entity': 'vivax', 'type': 'Disease', 'start': 168, 'end': 173}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cytokine', 'type': 'Gene', 'start': 357, 'end': 365}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'autoantibodies', 'type': 'Gene', 'start': 366, 'end': 380}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 450, 'end': 457}\n",
            "['Modulation of cytochrome P450 activity: implications for cancer therapy\\tAlthough metabolism mediated by cytochrome P450 isoenzymes is known to play a major part in the biotransformation of anticancer agents in vivo, few clinical studies have investigated activity of cytochrome P450s and therapeutic outcome in people with cancer.', 'Variability between individuals in the pharmacokinetics of cancer chemotherapy has important consequences in terms of therapeutic efficacy and safety.', 'We discuss here the effect of drug metabolism mediated by cytochrome P450 on therapeutic outcome.']\n",
            "unmatched tags:  [{'entity': 'cytochrome P450', 'type': 'Gene', 'start': 540, 'end': 555}, {'entity': 'cancer', 'type': 'Disease', 'start': 390, 'end': 396}]\n",
            "['High transmissibility of COVID-19 near symptom onset\\tBackground The dynamics of coronavirus disease 2019 (COVID-19) transmissibility after symptom onset remains unknown.', 'Methods We conducted a prospective case-ascertained study on laboratory-confirmed COVID-19 cases and their contacts.', 'Secondary clinical attack rate (considering symptomatic cases only) was analyzed for different exposure windows after symptom onset of index cases and for different exposure settings.', 'Results Thirty-two confirmed patients were enrolled and 12 paired data (index-secondary cases) were identified among the 1,043 contacts.', 'The secondary clinical attack rate was 0.9% (95% CI 0.5-1.7%).', 'The attack rate was higher among those whose exposure to index cases started within five days of symptom onset (2.4%, 95% CI 1.1-4.5%) than those who were exposed later (zero case from 605 close contacts, 95% CI 0-0.61%).', 'The attack rate was also higher among household contacts (13.6%, 95% CI 4.7-29.5%) and non-household family contacts (8.5%, 95% CI 2.4-20.3%) than that in healthcare or other settings.', 'The higher secondary clinical attack rate for contacts near symptom onset remained when the analysis was restricted to household and family contacts.', 'There was a trend of increasing attack rate with the age of contacts (p for trend < 0.001).', 'Conclusions High transmissibility of COVID-19 near symptom onset suggests that finding and isolating symptomatic patients alone may not suffice to contain the epidemic, and more generalized social distancing measures are required.', 'Rapid reduction of transmissibility over time implies that prolonged hospitalization of mild cases might not be necessary in large epidemics.']\n",
            "unmatched tags:  [{'entity': 'symptom', 'type': 'Phenotype', 'start': 1424, 'end': 1431}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 1374, 'end': 1381}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNAs', 'type': 'Gene', 'start': 152, 'end': 156}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNAs', 'type': 'Gene', 'start': 484, 'end': 488}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'proteins', 'type': 'Gene', 'start': 844, 'end': 852}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'OAS', 'type': 'Disease', 'start': 1108, 'end': 1111}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'hepatitis C', 'type': 'Virus', 'start': 406, 'end': 417}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 126, 'end': 133}\n",
            "['Secret science: tobacco industry research on smoking behaviour and cigarette toxicity\\tA lack of scientific data remains the principal obstacle to regulating cigarette toxicity.', 'In particular, there is an immediate need to improve our understanding of the interaction between smoking behaviour and product design, and its influence on cigarette deliveries.', 'This article reviews internal tobacco industry documents on smoking behaviour research undertaken by Imperial Tobacco Limited (ITL) and British-American Tobacco (BAT).', 'BAT documents indicate that smokers vary their puffing behaviour to regulate nicotine levels and compensate for low-yield cigarettes by smoking them more intensely.']\n",
            "unmatched tags:  [{'entity': 'nicotine', 'type': 'Drug', 'start': 601, 'end': 609}, {'entity': 'ITL', 'type': 'Gene', 'start': 483, 'end': 486}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'ExoN', 'type': 'Gene', 'start': 1462, 'end': 1466}\n",
            "['Proofreading-deficient coronaviruses adapt over long-term passage for increased fidelity and fitness without reversion of exoribonuclease-inactivating mutations\\tThe coronavirus (CoV) RNA genome is the largest among single-stranded positive sense RNA viruses.', 'CoVs encode a proofreading 3′→5′exoribonuclease within nonstructural protein 14 (nsp14-ExoN) that is responsible for CoV high-fidelity replication.', 'Alanine substitution of ExoN catalytic residues [ExoN(-)] in SARS-CoV and murine hepatitis virus (MHV) disrupts ExoN activity, yielding viable mutant viruses with defective replication, up to 20-fold decreased fidelity, and increased susceptibility to nucleoside analogs.', 'To test the stability of the ExoN(-) genotype and phenotype, we passaged MHV-ExoN(-) 250 times in cultured cells (P250), in parallel with WT-MHV.', 'Compared to MHV-ExoN(-) P3, MHV-ExoN(-) P250 demonstrated enhanced replication, reduced susceptibility to nucleoside analogs, and increased competitive fitness.', 'However, passage did not select for complete or partial reversion at the ExoN-inactivating mutations.', 'We identified novel amino acid changes within the RNA-dependent RNA polymerase (nsp12-RdRp) and nsp14 of MHV-ExoN(-) P250 that partially account for the observed changes in replication, susceptibility to nucleoside analogs, and competitive fitness observed in the passaged virus population, indicating that additional determinants can compensate for the activities of nsp14-ExoN.', 'Our results suggest that while selection favors restoration of replication fidelity in ExoN(-) CoVs, there may be a significant barrier to ExoN(-) reversion.', 'These results also support the hypothesis that high-fidelity replication is linked to CoV fitness and identify additional candidate proteins that may regulate CoV replication fidelity.', 'IMPORTANCE Unique among RNA viruses, CoVs encode a proofreading exoribonuclease (ExoN) in nsp14 that mediates high-fidelity RNA genome replication.', 'Proofreading-deficient CoVs with disrupted ExoN activity [ExoN(-)] are either non-viable or have significant defects in replication, RNA synthesis, fidelity, fitness, and virulence.', 'In this study, we show that ExoN(-) murine hepatitis virus can adapt over long-term passage for increased replication and fitness without reverting the ExoN-inactivating mutations.', 'Passage-adapted ExoN(-) mutants also demonstrate increasing resistance to nucleoside analogs that is only partially explained by secondary mutations in nsp12 and nsp14.', 'These data suggest that enhanced resistance to nucleoside analogs is mediated by the interplay of multiple replicase proteins and support the proposed link between CoV fidelity and fitness.']\n",
            "unmatched tags:  [{'entity': 'CoV', 'type': 'Virus', 'start': 2655, 'end': 2658}, {'entity': 'proteins', 'type': 'Gene', 'start': 2608, 'end': 2616}, {'entity': 'nucleoside analogs', 'type': 'Gene', 'start': 2538, 'end': 2556}, {'entity': 'nsp12', 'type': 'Disease', 'start': 2474, 'end': 2479}, {'entity': 'nucleoside analogs', 'type': 'Gene', 'start': 2396, 'end': 2414}, {'entity': 'ExoN(-)', 'type': 'Gene', 'start': 2338, 'end': 2345}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'alleles', 'type': 'Gene', 'start': 1186, 'end': 1193}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'non-communicable diseases', 'type': 'Disease', 'start': 125, 'end': 150}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tumour-associated antigens', 'type': 'Gene', 'start': 113, 'end': 139}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 278, 'end': 285}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'stroke', 'type': 'Disease', 'start': 341, 'end': 347}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'protease', 'type': 'Gene', 'start': 886, 'end': 894}\n",
            "['A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV\\tThe outbreak of COVID-19, which is caused by SARS-CoV-2 virus, continues to spread globally, but there is currently very little understanding of the epitopes on the virus.', 'In this study, we have determined the crystal structure of the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein in complex with CR3022, a neutralizing antibody previously isolated from a convalescent SARS patient.', 'CR3022 targets a highly conserved epitope that enables cross-reactive binding between SARS-CoV-2 and SARS-CoV.', 'Structural modeling further demonstrates that the binding site can only be accessed when at least two RBDs on the trimeric S protein are in the “up” conformation.', 'Overall, this study provides structural and molecular insight into the antigenicity of SARS-CoV-2.', 'ONE SENTENCE SUMMARY Structural study of a cross-reactive SARS antibody reveals a conserved epitope on the SARS-CoV-2 receptor-binding domain.']\n",
            "unmatched tags:  [{'entity': 'receptor-binding domain', 'type': 'Gene', 'start': 988, 'end': 1011}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 977, 'end': 987}, {'entity': 'SARS', 'type': 'Disease', 'start': 928, 'end': 932}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 858, 'end': 868}, {'entity': 'RBDs', 'type': 'Gene', 'start': 710, 'end': 714}, {'entity': 'SARS-CoV.', 'type': 'Virus', 'start': 598, 'end': 607}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 583, 'end': 593}, {'entity': 'CR3022', 'type': 'Gene', 'start': 497, 'end': 503}, {'entity': 'SARS', 'type': 'Disease', 'start': 483, 'end': 487}, {'entity': 'neutralizing antibody', 'type': 'Gene', 'start': 421, 'end': 442}, {'entity': 'CR3022', 'type': 'Gene', 'start': 411, 'end': 417}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 366, 'end': 376}, {'entity': 'RBD', 'type': 'Gene', 'start': 354, 'end': 357}, {'entity': 'receptor-binding domain', 'type': 'Gene', 'start': 329, 'end': 352}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 139, 'end': 149}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 174, 'end': 181}\n",
            "['Variation in Aerosol Production Across Oxygen Delivery Devices in Spontaneously Breathing Human Subjects\\tWe sought to assess whether HHFNC results in greater production of aerosolized particles than 6 liters per minute nasal cannula, using state-of-the-art techniques of aerosol measurement, in spontaneously breathing human volunteers in a simulated hospital room.', 'For each volunteer, we first measured background aerosol levels in the room immediately prior to testing.', 'We then measured aerosol levels while the healthy volunteer laid in bed - - with the head of bed at 30 degrees - - wearing the following oxygen delivery devices: (a) 6L/min nasal canula (NC) with humidification; (b) non-re-breather mask (NRB) with 15L/min gas flow, non-humidified; (c) HHFNC with 30L/min gas flow; (d) HHFNC with 60L/min gas flow.', 'Two scanning mobility particle sizing (SMPS) systems (TSI 3080/3030, TSI 3080/3750) were used to measure aerosols 10 to 500 nanometer (nm) in size for each of the oxygen delivery devices.', 'There was no variation in aerosol level within patients between room air, 6 L/min NC, 15 L/min NRB, 30 L/min HHFNC, and 60 L/min HHFNC, regardless of coughing.']\n",
            "unmatched tags:  [{'entity': 'coughing', 'type': 'Phenotype', 'start': 1161, 'end': 1169}, {'entity': 'NC', 'type': 'Gene', 'start': 1143, 'end': 1145}, {'entity': 'NC', 'type': 'Gene', 'start': 1123, 'end': 1125}, {'entity': 'NC', 'type': 'Gene', 'start': 1093, 'end': 1095}, {'entity': 'TSI', 'type': 'Gene', 'start': 890, 'end': 893}, {'entity': 'TSI', 'type': 'Gene', 'start': 875, 'end': 878}, {'entity': 'NC', 'type': 'Gene', 'start': 795, 'end': 797}, {'entity': 'NC', 'type': 'Gene', 'start': 762, 'end': 764}, {'entity': 'NC', 'type': 'Gene', 'start': 660, 'end': 662}, {'entity': 'bed', 'type': 'Disease', 'start': 566, 'end': 569}, {'entity': 'bed', 'type': 'Disease', 'start': 541, 'end': 544}]\n",
            "['Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015\\tSeveral challenges to improving reproductive health lie ahead in the SDG era.', 'Countries should establish or renew systems for collection and timely dissemination of health data; expand coverage and improve quality of family planning services, including access to contraception and safe abortion to address high adolescent fertility; invest in improving health system capacity, including coverage of routine reproductive health care and of more advanced obstetric care—including EmOC; adapt health systems and data collection systems to monitor and reverse the increase in indirect, other direct, and late maternal deaths, especially in high SDI locations; and examine their own performance with respect to their SDI level, using that information to formulate strategies to improve performance and ensure optimum reproductive health of their population.']\n",
            "unmatched tags:  [{'entity': 'era', 'type': 'Gene', 'start': 528, 'end': 531}, {'entity': 'era', 'type': 'Gene', 'start': 326, 'end': 329}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'HBV', 'type': 'Virus', 'start': 351, 'end': 354}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 539, 'end': 545}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'malaria', 'type': 'Disease', 'start': 259, 'end': 266}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'arginine', 'type': 'Gene', 'start': 444, 'end': 452}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'azithromycin', 'type': 'Drug', 'start': 1431, 'end': 1443}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'headache', 'type': 'Phenotype', 'start': 77, 'end': 85}\n",
            "['Tension-type headache: current research and clinical management\\tTension-type headache (TTH) is the most common form of headache, and chronic tension-type headache (CTTH) is one of the most neglected and difficult types of headache to treat.', 'The pathogenesis of TTH is multifactorial and varies between forms and individuals.', 'Peripheral mechanisms (myofascial nociception) and central mechanisms (sensitisation and inadequate endogenous pain control) are intermingled: the former predominate in infrequent and frequent TTH, whereas the latter predominate in CTTH.', 'Acute therapy is effective for episodes of TTH, whereas preventive treatment—which is indicated for frequent and chronic TTH—is, on average, not effective.']\n",
            "unmatched tags:  [{'entity': 'TTH', 'type': 'Organization', 'start': 684, 'end': 687}, {'entity': 'TTH', 'type': 'Organization', 'start': 606, 'end': 609}, {'entity': 'TTH', 'type': 'Organization', 'start': 558, 'end': 561}, {'entity': 'TTH', 'type': 'Organization', 'start': 518, 'end': 521}, {'entity': 'TTH', 'type': 'Organization', 'start': 261, 'end': 264}]\n",
            "['Poststroke dementia\\tDementia is one of the major causes of dependency after stroke.', 'The prevalence of poststroke dementia (PSD)—defined as any dementia occurring after stroke—is likely to increase in the future.', 'In community-based studies, the prevalence of PSD in stroke survivors is about 30% and the incidence of new onset dementia after stroke increases from 7% after 1 year 48% after 25 years.', 'Having a stroke doubles the risk of dementia.', 'Patient-related variables associated with an increased risk of PSD are increasing age, low education level, dependency before stroke, prestroke cognitive decline without dementia, diabetes mellitus, atrial fibrillation, myocardial infarction, epileptic seizures, sepsis, cardiac arrhythmias, congestive heart failure, silent cerebral infarcts, global and medial-temporal-lobe atrophy, and white-matter changes.']\n",
            "unmatched tags:  [{'entity': 'silent cerebral infarcts', 'type': 'Disease', 'start': 763, 'end': 787}, {'entity': 'congestive heart failure', 'type': 'Disease', 'start': 737, 'end': 761}, {'entity': 'sepsis', 'type': 'Disease', 'start': 708, 'end': 714}, {'entity': 'epileptic seizures', 'type': 'Disease', 'start': 688, 'end': 706}, {'entity': 'myocardial infarction', 'type': 'Disease', 'start': 665, 'end': 686}, {'entity': 'diabetes mellitus', 'type': 'Disease', 'start': 625, 'end': 642}, {'entity': 'dementia', 'type': 'Disease', 'start': 615, 'end': 623}, {'entity': 'prestroke', 'type': 'Disease', 'start': 579, 'end': 588}, {'entity': 'stroke', 'type': 'Disease', 'start': 571, 'end': 577}, {'entity': 'PSD', 'type': 'Gene', 'start': 508, 'end': 511}, {'entity': 'dementia', 'type': 'Disease', 'start': 435, 'end': 443}, {'entity': 'stroke', 'type': 'Disease', 'start': 408, 'end': 414}, {'entity': 'stroke', 'type': 'Disease', 'start': 341, 'end': 347}, {'entity': 'dementia', 'type': 'Disease', 'start': 326, 'end': 334}, {'entity': 'stroke', 'type': 'Disease', 'start': 265, 'end': 271}, {'entity': 'PSD', 'type': 'Gene', 'start': 258, 'end': 261}, {'entity': 'stroke', 'type': 'Disease', 'start': 168, 'end': 174}, {'entity': 'dementia', 'type': 'Disease', 'start': 143, 'end': 151}, {'entity': 'PSD', 'type': 'Gene', 'start': 123, 'end': 126}, {'entity': 'dementia', 'type': 'Disease', 'start': 113, 'end': 121}, {'entity': 'stroke', 'type': 'Disease', 'start': 106, 'end': 112}, {'entity': 'stroke', 'type': 'Disease', 'start': 76, 'end': 82}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'epilepsies', 'type': 'Disease', 'start': 620, 'end': 630}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'multiple sclerosis', 'type': 'Disease', 'start': 142, 'end': 160}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'deubiquitinases', 'type': 'Gene', 'start': 1533, 'end': 1548}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'lymphoproliferative disorders', 'type': 'Disease', 'start': 338, 'end': 367}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diseases', 'type': 'Disease', 'start': 102, 'end': 110}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'HIV', 'type': 'Virus', 'start': 114, 'end': 117}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'thalassaemia', 'type': 'Disease', 'start': 129, 'end': 141}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'thalassaemia', 'type': 'Disease', 'start': 498, 'end': 510}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'non-Hodgkin lymphoma', 'type': 'Disease', 'start': 533, 'end': 553}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 132, 'end': 140}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'communicable disease', 'type': 'Disease', 'start': 319, 'end': 339}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'ORF', 'type': 'Gene', 'start': 1596, 'end': 1599}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 200, 'end': 208}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tumours', 'type': 'Disease', 'start': 76, 'end': 83}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 133, 'end': 141}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronavirus', 'type': 'Virus', 'start': 1284, 'end': 1295}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tuberculosis', 'type': 'Disease', 'start': 300, 'end': 312}\n",
            "['The legal determinants of health: harnessing the power of law for global health and sustainable development\\tHealth risks in the 21st century are beyond the control of any government in any country.', 'In an era of globalisation, promoting public health and equity requires cooperation and coordination both within and among states.', 'Law can be a powerful tool for advancing global health, yet it remains substantially underutilised and poorly understood.', \"Working in partnership, public health lawyers and health professionals can become champions for evidence-based laws to ensure the public's health and safety.\"]\n",
            "unmatched tags:  [{'entity': 'public health lawyers', 'type': 'Gene', 'start': 475, 'end': 496}, {'entity': 'partnership', 'type': 'Organization', 'start': 462, 'end': 473}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'fever', 'type': 'Phenotype', 'start': 42, 'end': 47}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccines', 'type': 'Drug', 'start': 702, 'end': 710}\n",
            "['Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)\\tProgression-free survival with IRIS is not inferior to that with FOLFIRI in patients receiving second-line chemotherapy for metastatic colorectal cancer.', 'Treatment with IRIS could be an additional therapeutic option for second-line chemotherapy in metastatic colorectal cancer.']\n",
            "unmatched tags:  [{'entity': 'metastatic colorectal cancer', 'type': 'Disease', 'start': 459, 'end': 487}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'sarcoidosis', 'type': 'Disease', 'start': 296, 'end': 307}\n",
            "['Association of inflammatory markers with the severity of COVID-19\\tBackground: The ongoing worldwide epidemic of Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has posed a huge threat to global public health.', 'However, with regard to the effects of inflammatory markers on the severity of COVID-19, studies have reported associations that vary in strength and direction.', 'Aims: In the meta-analysis, we aimed to provide an overview of the association of inflammatory markers with severity of COVID-19.', 'Methods: The following databases were searched: PubMed, Embase, Cochrane Library, Wanfang database and CNKI (China National Knowledge Infrastructure) database until March 20, 2020.', 'Weighted mean difference (WMD) and 95% confidence intervals (CIs) were pooled using random or fixed-effects models.', 'Results: A total of 16 studies were included in our analysis comprising of 3962 patients with COVID-19.', 'Random-effects results demonstrated that patients with COVID-19 in non-severe group had lower levels for CRP (WMD\\u2009=\\u2009-41.78\\u2009mg/l, 95% CI\\u2009=\\u2009[-52.43, -31.13], P\\u2009<\\u20090.001), PCT (WMD\\u2009=\\u2009-0.13\\u2009ng/ml, 95% CI\\u2009=\\u2009[-0.20, -0.05], P\\u2009<\\u20090.001), IL-6 (WMD\\u2009=\\u2009-21.32\\u2009ng/l, 95% CI\\u2009=\\u2009[-28.34, -14.31], P\\u2009<\\u20090.001), ESR (WMD\\u2009=\\u2009-8.40\\u2009mm/h, 95% CI\\u2009=\\u2009[-14.32, -2.48], P\\u2009=\\u20090.005), SAA (WMD\\u2009=\\u2009-43.35 μg/ml, 95% CI\\u2009=\\u2009[-80.85, -5.85], P\\u2009=\\u20090.020) and serum ferritin (WMD\\u2009=\\u2009-398.80\\u2009mg/l, 95% CI\\u2009=\\u2009[-625.89, -171.71], P\\u2009<\\u20090.001), compared with those in severe group.', 'Moreover, survivors had lower level for IL-6 than non-survivors with COVID-19 (WMD\\u2009=\\u2009-4.80\\u2009ng/ml, 95% CI\\u2009=\\u2009[-5.87, -3.73], P\\u2009<\\u20090.001).', 'These results were consistent through sensitivity analysis and publication bias assessment.', 'Conclusions: The meta-analysis highlights the association of inflammatory markers with the severity of COVID-19.', 'Measurement of inflammatory markers might help clinicians to monitor and evaluate the severity and prognosis of COVID-19.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1951, 'end': 1959}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1829, 'end': 1837}, {'entity': 'WMD', 'type': 'Gene', 'start': 1577, 'end': 1580}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1567, 'end': 1575}, {'entity': 'IL-6', 'type': 'Gene', 'start': 1538, 'end': 1542}, {'entity': 'WMD', 'type': 'Gene', 'start': 1400, 'end': 1403}, {'entity': 'WMD', 'type': 'Gene', 'start': 1323, 'end': 1326}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 458, 'end': 467}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'influenza', 'type': 'Disease', 'start': 1338, 'end': 1347}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancers', 'type': 'Disease', 'start': 185, 'end': 192}\n",
            "['Velopharyngeal incompetence and chromosome 22q11 deletion\\tChromosome 22q11 deletion gives rise to various phenotypes, including cardiac malformations, velopharyngeal abnormalities, absent thymus, and neurological defects.', 'We assessed, in a prospective study, chromosome 22q11 deletion in 50 of 144 patients with velopharyngeal incompetence in the absence of overt clefting.', '18 (12·5% of the whole cohort and 36% of patients tested for the deletion) had the 22q11 deletion.', 'This frequency differs from an estimated population prevalence of 0·025% and suggests a need for screening for the 22q11 deletion in these patients.']\n",
            "unmatched tags:  [{'entity': '22q11 deletion', 'type': 'Disease', 'start': 588, 'end': 602}, {'entity': '22q11 deletion', 'type': 'Disease', 'start': 457, 'end': 471}, {'entity': 'velopharyngeal incompetence', 'type': 'Disease', 'start': 312, 'end': 339}]\n",
            "['Public financing of health in developing countries: a cross-national systematic analysis\\tTo address the negative effect of DAH on domestic government health spending, we recommend strong standardised monitoring of government health expenditures and government spending in other health-related sectors; establishment of collaborative targets to maintain or increase the share of government expenditures going to health; investment in the capacity of developing countries to effectively receive and use DAH; careful assessment of the risks and benefits of expanded DAH to non-governmental sectors; and investigation of the use of global price subsidies or product transfers as mechanisms for DAH.']\n",
            "unmatched tags:  [{'entity': 'DAH', 'type': 'Drug', 'start': 690, 'end': 693}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 131, 'end': 138}\n",
            "['Anaemia after enalapril in a child with nephrotic syndrome\\tA girl aged 7 years with focal segmental glomerulosclerosis and nephrotic syndrome failed to respond to prednisolone for 7 weeks, and to prednisolone with cyclophosphamide for a further 8 weeks Blood pressure was normal and oedema was controlled with diuretics Creatinine had increased from 30 μmol/L to 50 μmol/L, and the urine protein/creatinine ratio from 2400 mg/mmol to 4000 mg/mmol From week 10 to week 40, creatinine rose from 30 μmol/L to 85 μmol/L and the urine albumin/creatinine ratio fluctuated between 2000 mg/mmol and 4000 mg/mmol She was started on enalapril 2·5 mg twice daily After 3 months, enalapril was discontinued because her haemoglobin had fallen from 127 g/L to 62 g/L with haematocrit of 0·16, but with normal ferritin, folate, and vitamin B']\n",
            "unmatched tags:  [{'entity': 'folate', 'type': 'Drug', 'start': 805, 'end': 811}, {'entity': 'haemoglobin', 'type': 'Drug', 'start': 707, 'end': 718}, {'entity': 'enalapril', 'type': 'Gene', 'start': 668, 'end': 677}, {'entity': 'enalapril', 'type': 'Gene', 'start': 623, 'end': 632}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 331, 'end': 338}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'arthritis', 'type': 'Disease', 'start': 120, 'end': 129}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 322, 'end': 330}\n",
            "['Disease X: accelerating the development of medical countermeasures for the next pandemic\\tWHO has listed several priority diseases with epidemic potential for which there are no, or insufficient, medical countermeasures.', 'In response, the Bill & Melinda Gates Foundation (with support from PricewaterhouseCoopers) coordinated subject matter experts to create a preparedness plan for Disease X.', 'Disease X is caused by Pathogen X, an infectious agent that is not currently known to cause human disease, but an aetiologic agent of a future outbreak with epidemic or pandemic potential.', 'We have identified crucial areas for acceleration in medical countermeasure product development and international coordination.']\n",
            "unmatched tags:  [{'entity': 'human disease', 'type': 'Disease', 'start': 484, 'end': 497}, {'entity': 'Disease X', 'type': 'Disease', 'start': 392, 'end': 401}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'statin', 'type': 'Drug', 'start': 102, 'end': 108}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'zoster', 'type': 'Drug', 'start': 135, 'end': 141}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 118, 'end': 126}\n",
            "['Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis\\tThe identification of factors that can affect the efficacy of immunomodulatory drugs in relapsing-remitting multiple sclerosis (MS) is important.', 'For the available interferon-beta products, neutralising antibodies (NAb) have been shown to affect treatment efficacy.', 'In June, 2009, a panel of experts in MS and NAbs to interferon-beta therapy convened in Amsterdam, Netherlands, under the auspices of the Neutralizing Antibodies on Interferon beta in Multiple Sclerosis consortium, a European-based project of the 6th Framework Programme of the European Commission, to review and discuss data on NAbs and their practical consequences for the treatment of patients with MS on interferon beta.']\n",
            "unmatched tags:  [{'entity': 'interferon beta', 'type': 'Gene', 'start': 791, 'end': 806}, {'entity': 'NAb', 'type': 'Chemical', 'start': 712, 'end': 715}, {'entity': 'Multiple Sclerosis', 'type': 'Disease', 'start': 567, 'end': 585}, {'entity': 'Interferon beta', 'type': 'Gene', 'start': 548, 'end': 563}, {'entity': 'Amsterdam', 'type': 'Disease', 'start': 471, 'end': 480}, {'entity': 'interferon-beta therapy', 'type': 'Gene', 'start': 435, 'end': 458}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cardiovascular disease', 'type': 'Disease', 'start': 374, 'end': 396}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'neoplasia', 'type': 'Disease', 'start': 212, 'end': 221}\n",
            "['Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study\\tTivantinib did not improve overall survival compared with placebo in patients with MET-high advanced hepatocellular carcinoma previously treated with sorafenib.', 'Although this METIV-HCC trial was negative, the study shows the feasibility of doing integral tissue biomarker studies in patients with advanced hepatocellular carcinoma.', 'Additional randomised studies are needed to establish whether MET inhibition could be a potential therapy for some subsets of patients with advanced hepatocellular carcinoma.']\n",
            "unmatched tags:  [{'entity': 'hepatocellular carcinoma', 'type': 'Disease', 'start': 646, 'end': 670}, {'entity': 'advanced hepatocellular carcinoma', 'type': 'Disease', 'start': 637, 'end': 670}, {'entity': 'MET', 'type': 'Gene', 'start': 559, 'end': 562}, {'entity': 'advanced hepatocellular carcinoma', 'type': 'Disease', 'start': 462, 'end': 495}, {'entity': 'MET', 'type': 'Gene', 'start': 340, 'end': 343}, {'entity': 'sorafenib', 'type': 'Drug', 'start': 315, 'end': 324}, {'entity': 'hepatocellular carcinoma', 'type': 'Disease', 'start': 266, 'end': 290}, {'entity': 'advanced hepatocellular carcinoma', 'type': 'Disease', 'start': 257, 'end': 290}]\n",
            "['Effectiveness of interventions targeting air travellers for delaying local outbreaks of SARS-CoV-2\\tBackground: We evaluated if interventions aimed at air travellers can delay local SARS-CoV-2 community transmission in a previously unaffected country.', 'Methods: We simulated infected air travellers arriving into countries with no sustained SARS-CoV-2 transmission or other introduction routes from affected regions.', 'We assessed the effectiveness of syndromic screening at departure and/or arrival & traveller sensitisation to the COVID-2019-like symptoms with the aim to trigger rapid self-isolation and reporting on symptom onset to enable contact tracing.', 'We assumed that syndromic screening would reduce the number of infected arrivals and that traveller sensitisation reduces the average number of secondary cases.', 'We use stochastic simulations to account for uncertainty in both arrival and secondary infections rates, and present sensitivity analyses on arrival rates of infected travellers and the effectiveness of traveller sensitisation.', 'We report the median expected delay achievable in each scenario and an inner 50% interval.', 'Results: Under baseline assumptions, introducing exit and entry screening in combination with traveller sensitisation can delay a local SARS-CoV-2 outbreak by 8 days (50% interval: 3-14 days) when the rate of importation is 1 infected traveller per week at time of introduction.', 'The additional benefit of entry screening is small if exit screening is effective: the combination of only exit screening and traveller sensitisation can delay an outbreak by 7 days (50% interval: 2-13 days).', 'In the absence of screening, with less effective sensitisation, or a higher rate of importation, these delays shrink rapidly to less than 4 days.', 'Conclusion: Syndromic screening and traveller sensitisation in combination may have marginally delayed SARS-CoV-2 outbreaks in unaffected countries.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1875, 'end': 1885}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1274, 'end': 1284}, {'entity': 'secondary infections', 'type': 'Disease', 'start': 895, 'end': 915}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 114, 'end': 122}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'incontinence', 'type': 'Phenotype', 'start': 73, 'end': 85}\n",
            "['A binning tool to reconstruct viral haplotypes from assembled contigs\\tMotivation Infections by RNA viruses such as Influenza, HIV still pose a serious threat to human health despite extensive research on viral diseases.', 'One challenge for producing effective prevention and treatment strategies is high intra-species genetic diversity.', 'As different strains may have different biological properties, characterizing the genetic diversity is thus important to vaccine and drug design.', 'Next-generation sequencing technology enables comprehensive characterization of both known and novel strains and has been widely adopted for sequencing viral populations.', 'However, genome-scale reconstruction of haplotypes is still a challenging problem.', 'In particular, haplotype assembly programs often produce contigs rather than full genomes.', 'As a mutation in one gene can mask the phenotypic effects of a mutation at another locus, clustering these contigs into genome-scale haplotypes is still needed.', 'Results We developed a contig binning tool, VirBin, which clusters contigs into different groups so that each group represents a haplotype.', 'Commonly used features based on sequence composition and contig coverage cannot effectively distinguish viral haplotypes because of their high sequence similarity and heterogeneous sequencing coverage for RNA viruses.', 'VirBin applied prototype-based clustering to cluster regions that are more likely to contain mutations specific to a haplotype.', 'The tool was tested on multiple simulated sequencing data with different haplotype abundance distributions and contig sizes, and also on mock quasispecies sequencing data.', 'The benchmark results with other contig binning tools demonstrated the superior sensitivity and precision of VirBin in contig binning for viral haplotype reconstruction.', 'Availability  https://github.com/chjiao/VirBin Contact  yannisun{at}cityu.edu.hk']\n",
            "unmatched tags:  [{'entity': 'VirBin', 'type': 'Chemical', 'start': 1855, 'end': 1861}, {'entity': 'VirBin', 'type': 'Chemical', 'start': 1754, 'end': 1760}, {'entity': 'binning tool', 'type': 'Gene', 'start': 1685, 'end': 1697}, {'entity': 'VirBin', 'type': 'Chemical', 'start': 1345, 'end': 1351}, {'entity': 'RNA viruses', 'type': 'Virus', 'start': 1332, 'end': 1343}, {'entity': 'gene', 'type': 'Gene', 'start': 1300, 'end': 1304}, {'entity': 'contigs', 'type': 'Organization', 'start': 1054, 'end': 1061}, {'entity': 'VirBin', 'type': 'Chemical', 'start': 1031, 'end': 1037}, {'entity': 'binning tool', 'type': 'Gene', 'start': 1017, 'end': 1029}, {'entity': 'genome-scale', 'type': 'Organization', 'start': 946, 'end': 958}, {'entity': 'contigs', 'type': 'Organization', 'start': 933, 'end': 940}, {'entity': 'gene', 'type': 'Gene', 'start': 847, 'end': 851}, {'entity': 'genomes', 'type': 'Gene', 'start': 817, 'end': 824}, {'entity': 'contigs', 'type': 'Organization', 'start': 792, 'end': 799}, {'entity': 'genome-scale', 'type': 'Organization', 'start': 661, 'end': 673}, {'entity': 'strains', 'type': 'Disease', 'start': 582, 'end': 589}, {'entity': 'gene', 'type': 'Gene', 'start': 486, 'end': 490}, {'entity': 'vaccine', 'type': 'Drug', 'start': 456, 'end': 463}, {'entity': 'gene', 'type': 'Gene', 'start': 417, 'end': 421}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'mesothelioma', 'type': 'Disease', 'start': 197, 'end': 209}\n",
            "['Emergency surgery in the era of molecular treatment of solid tumours\\tIn the advancing era of molecular therapy of solid tumours, emergency treatment of complications, such as bowel perforation, haemorrhage, and tumour rupture, is likely to evolve into one of the main challenges of surgical oncology.', 'These complications might be caused by disease progression from resistance to therapy, side-effects of therapy on normal vasculature, and therapeutic induction of excessively responding tumours.', 'This Review outlines the probability and management of emergency operations during molecularly targeted therapy of solid tumours.']\n",
            "unmatched tags:  [{'entity': 'solid tumours', 'type': 'Disease', 'start': 611, 'end': 624}, {'entity': 'era', 'type': 'Gene', 'start': 602, 'end': 605}, {'entity': 'era', 'type': 'Gene', 'start': 563, 'end': 566}, {'entity': 'tumours', 'type': 'Disease', 'start': 487, 'end': 494}, {'entity': 'era', 'type': 'Gene', 'start': 441, 'end': 444}, {'entity': 'era', 'type': 'Gene', 'start': 406, 'end': 409}, {'entity': 'era', 'type': 'Gene', 'start': 381, 'end': 384}, {'entity': 'tumour rupture', 'type': 'Disease', 'start': 211, 'end': 225}, {'entity': 'bowel perforation', 'type': 'Disease', 'start': 175, 'end': 192}, {'entity': 'tumours', 'type': 'Disease', 'start': 120, 'end': 127}, {'entity': 'solid tumours', 'type': 'Disease', 'start': 114, 'end': 127}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'stroke', 'type': 'Disease', 'start': 168, 'end': 174}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'stroke', 'type': 'Disease', 'start': 118, 'end': 124}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'elements', 'type': 'Chemical', 'start': 276, 'end': 284}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'UTR', 'type': 'Gene', 'start': 1005, 'end': 1008}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNA', 'type': 'Gene', 'start': 1262, 'end': 1265}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNA', 'type': 'Gene', 'start': 1553, 'end': 1556}\n",
            "['Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics\\tMany papers are emerging that describe the in vitro antiviral activity of drugs that may be repurposed for therapy or chemoprophylaxis against SARS-CoV-2.', 'However, no comprehensive evaluation of these molecules in the context of the achievable plasma pharmacokinetics after administration of approved doses and schedules to humans has been conducted.', 'Moreover, most publications have focussed on 50% maximum effective concentrations (EC50), which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration-response curve between drugs.', 'Accordingly, in vitro anti-SARS-CoV-2 activity data was digitised from all available publications up to 13th April 2020 and used to recalculate an EC90 value for each drug.', 'EC90 values were then expressed as a ratio to the achievable maximum plasma concentrations (Cmax) reported for each drug after administration of the approved dose to humans (Cmax/EC90 ratio).', 'Only 14 of the analysed drugs achieved a Cmax/EC90 ratio above 1 meaning that plasma Cmax concentrations exceeded those necessary to inhibit 90% of SARS-CoV-2 replication.', 'A more in-depth assessment of these drugs demonstrated that only nitazoxanide, nelfinavir, tipranavir (boosted with ritonavir) and sulfadoxine achieved plasma concentrations above their anti-SARS-CoV-2 activity across their entire approved dosing interval at their approved human dose.', 'For all drugs reported, the unbound lung to plasma tissue partition coefficient (KpUlung) was also simulated and used along with reported Cmax and fraction unbound in plasma to derive a lung Cmax/EC50  as a better indicator of potential human efficacy (lung Cmax/EC90 ratio was also calculable for a limited number of drugs).', 'Using this parameter hydroxychloroquine, chloroquine, mefloquine, atazanavir (boosted with ritonavir), tipranavir (boosted with ritonavir), ivermectin, azithromycin and lopinavir (boosted with ritonavir) were all predicted to achieve lung concentrations over 10-fold higher than their reported EC50.', 'This analysis was not possible for nelfinavir because insufficient data were available to calculate KpUlung but nitozoxanide and sulfadoxine were also predicted to exceed their reported EC50 by 3.1- and 1.5-fold in lung, respectively.', 'The antiviral activity data reported to date is of variable quality and conducted under different conditions by different investigators.', 'However, this analysis has prioritised candidates with the best chance for success in therapy or chemoprevention of Covid-19 based upon the currently available in vitro activity and human plasma pharmacokinetic data.', 'Future studies should focus on EC90 values and discuss findings in the context of achievable exposures in humans, especially within target compartments such as the lung, in order to maximise the potential for success of proposed human clinical trials.']\n",
            "unmatched tags:  [{'entity': 'EC90', 'type': 'Gene', 'start': 2867, 'end': 2871}, {'entity': 'Covid-19', 'type': 'Disease', 'start': 2735, 'end': 2743}, {'entity': 'EC50', 'type': 'Gene', 'start': 2433, 'end': 2437}, {'entity': 'sulfadoxine', 'type': 'Drug', 'start': 2376, 'end': 2387}, {'entity': 'nelfinavir', 'type': 'Drug', 'start': 2282, 'end': 2292}, {'entity': 'EC50', 'type': 'Gene', 'start': 2241, 'end': 2245}, {'entity': 'ritonavir', 'type': 'Drug', 'start': 2140, 'end': 2149}, {'entity': 'lopinavir', 'type': 'Drug', 'start': 2116, 'end': 2125}, {'entity': 'azithromycin', 'type': 'Drug', 'start': 2099, 'end': 2111}, {'entity': 'ivermectin', 'type': 'Drug', 'start': 2087, 'end': 2097}, {'entity': 'ritonavir', 'type': 'Drug', 'start': 2075, 'end': 2084}, {'entity': 'tipranavir', 'type': 'Drug', 'start': 2050, 'end': 2060}, {'entity': 'ritonavir', 'type': 'Drug', 'start': 2038, 'end': 2047}, {'entity': 'atazanavir', 'type': 'Drug', 'start': 2013, 'end': 2023}, {'entity': 'mefloquine', 'type': 'Drug', 'start': 2001, 'end': 2011}, {'entity': 'chloroquine', 'type': 'Drug', 'start': 1988, 'end': 1999}, {'entity': 'hydroxychloroquine', 'type': 'Drug', 'start': 1968, 'end': 1986}, {'entity': 'drug', 'type': 'Drug', 'start': 1939, 'end': 1943}, {'entity': 'EC90', 'type': 'Gene', 'start': 1884, 'end': 1888}, {'entity': 'EC50', 'type': 'Gene', 'start': 1817, 'end': 1821}, {'entity': 'drug', 'type': 'Drug', 'start': 1629, 'end': 1633}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1526, 'end': 1536}, {'entity': 'sulfadoxine', 'type': 'Drug', 'start': 1466, 'end': 1477}, {'entity': 'ritonavir', 'type': 'Drug', 'start': 1451, 'end': 1460}, {'entity': 'tipranavir', 'type': 'Drug', 'start': 1426, 'end': 1436}, {'entity': 'nelfinavir', 'type': 'Drug', 'start': 1414, 'end': 1424}, {'entity': 'nitazoxanide', 'type': 'Drug', 'start': 1400, 'end': 1412}, {'entity': 'drug', 'type': 'Drug', 'start': 1371, 'end': 1375}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1311, 'end': 1321}, {'entity': 'EC90', 'type': 'Gene', 'start': 1209, 'end': 1213}, {'entity': 'drug', 'type': 'Drug', 'start': 1187, 'end': 1191}, {'entity': 'EC90', 'type': 'Gene', 'start': 1150, 'end': 1154}, {'entity': 'drug', 'type': 'Drug', 'start': 1087, 'end': 1091}, {'entity': 'EC90', 'type': 'Gene', 'start': 971, 'end': 975}, {'entity': 'drug', 'type': 'Drug', 'start': 965, 'end': 969}, {'entity': 'EC90', 'type': 'Gene', 'start': 945, 'end': 949}, {'entity': 'digitised', 'type': 'Drug', 'start': 854, 'end': 863}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 825, 'end': 835}]\n",
            "['Early epidemiological and clinical manifestations of COVID-19 in Japan\\tBackground: Severe acute respiratory syndrome coronaviruses -2 (SARS-COV2) named as COVID-19 had spread worldwide and leading to 1,210,956 confirmed cases and 67,594 deaths Methods: A data of 1192 confirmed cases and 43 deaths due to COVID-19 in Japan collected from the Ministry of Health, Labour and Welfare of Japan and analysed for different epidemiological parameters and their clinical manifestations.', 'We used Clauset-Newman-Moore (CNM) clustering algorithm to develop web-network of confirmed cases to identified clusters of community transmission.', 'Results: Out of 1192 confirmed cases, 90.60% were symptomatic and 9.39% were asymptomatic.', 'The prevalence of COVID19 in males was 56.29% and 43.20 % in females.', 'The mean interval (SD) from symptom onset to diagnosis was 6-22.6 days while mean interval (SD) from contact to onset of symptoms was 5-19.5 days.', 'People of age range 40-79 were more infected and deaths median age was 80.', 'The main symptoms were fever, dry cough, fatigue and pneumonia.', 'The main infected cities were Tokyo (195/1192, 16.35%), Hokkaido (160/1192 13.42%), Aichi (150/1192, 12.58%) and Osaka (145/1192, 12.16%).', 'Only 2.34% cases had travel history from Wuhan China and Osaka music concert was identify as main cluster for community transmission.', 'While 556 (46.64%) cases were clinically diagnosed and 557 (46.72%) were confirmed by using RT-PCR.', 'Conclusions: Other than, declare emergency Japan need to change their approach of diagnosing COVID-19, as asymptomatic cases prevalence is high and maybe it is reason for current sudden increase of cases.', 'Screening centre should be establish away from hospitals, which are treating positive cases.']\n",
            "unmatched tags:  [{'entity': 'symptom', 'type': 'Phenotype', 'start': 1556, 'end': 1563}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1542, 'end': 1550}, {'entity': 'Aichi', 'type': 'Chemical', 'start': 1159, 'end': 1164}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 1064, 'end': 1073}, {'entity': 'dry cough', 'type': 'Phenotype', 'start': 1041, 'end': 1050}, {'entity': 'fever', 'type': 'Phenotype', 'start': 1034, 'end': 1039}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 817, 'end': 824}, {'entity': 'COVID19', 'type': 'Chemical', 'start': 737, 'end': 744}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'stroke', 'type': 'Disease', 'start': 101, 'end': 107}\n",
            "['Risk of drug-induced Long QT Syndrome associated with the use of repurposed COVID-19 drugs: a systematic review\\tBackground: The World Health Organization first declared SARS-CoV-2 (COVID-19) a pandemic on March 11, 2020.', 'There are currently no vaccines or therapeutic agents proven efficacious to treat COVID-19.', 'So, whether existing approved drugs could be repurposed and used off-label for the treatment of novel COVID-19 disease is being explored.', 'Methods: A thorough literature search was performed to gather information on the pharmacological properties and toxicity of 6 drugs (azithromycin, chloroquine, favipiravir, hydroxychloroquine, lopinavir/ritonavir, remdesivir) proposed to be repurposed to treat COVID-19.', 'Researchers emphasized affinity of these drugs to block the rapid component of the delayed rectifier cardiac potassium current (IKr) encoded by the human ether-a-go-go gene (hERG), their propensity to prolong cardiac repolarization (QT interval) and cause torsade de pointes (TdP).', 'Risk of drug-induced Long QT Syndrome (LQTS) for these drugs was quantified by comparing six indices used to assess such risk and by querying the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System database with specific key words.', 'Data are also provided to compare the level of risk for drug-induced LQTS by these drugs to 23 other, well-recognized, torsadogenic compounds.', 'Results: Estimators of LQTS risk levels indicated a very-high or high risk for all COVID-19 repurposed drugs except for azithromycin, although cases of TdP have been reported following the administration of this drug.', 'There was an excellent agreement among the various indices used to assess risk of drug-induced LQTS for the six repurposed drugs and the 23 torsadogenic compounds.', 'Conclusion: The risk-benefit assessment for the use of repurposed drugs to treat COVID-19 is complicated since benefits are currently anticipated, not proven.', 'Mandatory monitoring of the QT interval shall be performed as such monitoring is possible for hospitalized patients or by the use of biodevices for outpatients initiated on these drugs.']\n",
            "unmatched tags:  [{'entity': 'drug', 'type': 'Drug', 'start': 2118, 'end': 2122}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1861, 'end': 1869}, {'entity': 'drug', 'type': 'Drug', 'start': 1846, 'end': 1850}, {'entity': 'drug', 'type': 'Drug', 'start': 1739, 'end': 1743}, {'entity': 'drug', 'type': 'Drug', 'start': 1610, 'end': 1614}, {'entity': 'azithromycin', 'type': 'Drug', 'start': 1518, 'end': 1530}, {'entity': 'drug', 'type': 'Drug', 'start': 1501, 'end': 1505}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1481, 'end': 1489}, {'entity': 'drug', 'type': 'Drug', 'start': 1338, 'end': 1342}, {'entity': 'drug', 'type': 'Drug', 'start': 1059, 'end': 1063}, {'entity': 'torsade de pointes', 'type': 'Disease', 'start': 978, 'end': 996}, {'entity': 'hERG', 'type': 'Gene', 'start': 896, 'end': 900}, {'entity': 'ether-a-go-go gene', 'type': 'Gene', 'start': 876, 'end': 894}, {'entity': 'IKr', 'type': 'Gene', 'start': 850, 'end': 853}, {'entity': 'drug', 'type': 'Drug', 'start': 763, 'end': 767}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 712, 'end': 720}, {'entity': 'remdesivir', 'type': 'Chemical', 'start': 665, 'end': 675}, {'entity': 'lopinavir/ritonavir', 'type': 'Drug', 'start': 644, 'end': 663}, {'entity': 'hydroxychloroquine', 'type': 'Drug', 'start': 624, 'end': 642}, {'entity': 'favipiravir', 'type': 'Drug', 'start': 611, 'end': 622}, {'entity': 'chloroquine', 'type': 'Drug', 'start': 598, 'end': 609}, {'entity': 'azithromycin', 'type': 'Drug', 'start': 584, 'end': 596}, {'entity': 'drug', 'type': 'Drug', 'start': 577, 'end': 581}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 415, 'end': 423}, {'entity': 'drug', 'type': 'Drug', 'start': 343, 'end': 347}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 303, 'end': 311}, {'entity': 'therapeutic agents', 'type': 'Drug', 'start': 256, 'end': 274}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'inclusion body myositis', 'type': 'Disease', 'start': 473, 'end': 496}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 116, 'end': 124}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cervical cancer', 'type': 'Disease', 'start': 295, 'end': 310}\n",
            "['Ophthalmologic evidence against the interpersonal transmission of 2019 novel coronavirus through conjunctiva\\tBackground: The emerging 2019 novel coronavirus (2019−nCoV) has pushed several countries into state of emergency all over the world.', 'The possible transmission of 2019−nCoV by conjunctiva is controversial and has substantial public health implications.', 'Methods: A retrospective cohort study was initiated to investigate the possible transmission of 2019−nCoV through aerosol contact with conjunctiva.', 'We enrolled 67 cases of confirmed or suspected cases of novel coronavirus pneumonia (NCP) during 17−28 Jan 2020.', 'Nasopharyngeal and conjunctival swabs were collected for real time RT-PCR analysis to detect 2019−nCoV.', 'Results: 63 patients were identified as laboratory−confirmed NCP and the remaining four were suspected NCP.', 'Conjunctival swab samples from one NCP patient yielded positive PCR results and two NCP patients yielded probable positive PCR results.', 'None of the three patients had ocular symptoms.', 'The only one NCP patient with conjunctivitis as the first symptom had negative conjunctival sac 2019−nCoV test.', 'Conjunctival swab samples from the four suspected cases of NCIP were negative.', 'Conclusion: 2019−nCoV can be detected in the conjunctival sac of patients with NCP.', 'Through clinical analysis, viral transmission via the conjunctival route was not supported by the data.', 'Good clinical protection can effectively cut off the transmission path.']\n",
            "unmatched tags:  [{'entity': 'NCIP', 'type': 'Chemical', 'start': 1189, 'end': 1193}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 1076, 'end': 1083}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tuberculosis', 'type': 'Disease', 'start': 364, 'end': 376}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'obesity', 'type': 'Phenotype', 'start': 52, 'end': 59}\n",
            "['Identification and Referral to Improve Safety (IRIS) of women experiencing domestic violence with a primary care training and support programme: a cluster randomised controlled trial\\tA training and support programme targeted at primary care clinicians and administrative staff improved referral to specialist domestic violence agencies and recorded identification of women experiencing domestic violence.', 'Our findings reduce the uncertainty about the benefit of training and support interventions in primary care settings for domestic violence and show that screening of women patients for domestic violence is not a necessary condition for improved identification and referral to advocacy services.']\n",
            "unmatched tags:  [{'entity': 'domestic violence', 'type': 'Disease', 'start': 590, 'end': 607}, {'entity': 'domestic violence', 'type': 'Disease', 'start': 526, 'end': 543}, {'entity': 'domestic violence', 'type': 'Disease', 'start': 386, 'end': 403}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'stroke', 'type': 'Disease', 'start': 252, 'end': 258}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 1137, 'end': 1144}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CNS lymphoma', 'type': 'Disease', 'start': 153, 'end': 165}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'proteins', 'type': 'Gene', 'start': 422, 'end': 430}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'proteins', 'type': 'Gene', 'start': 859, 'end': 867}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'proteins', 'type': 'Gene', 'start': 1272, 'end': 1280}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'bladder cancer', 'type': 'Disease', 'start': 209, 'end': 223}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 180, 'end': 187}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tuberculosis', 'type': 'Disease', 'start': 97, 'end': 109}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tuberculosis', 'type': 'Disease', 'start': 313, 'end': 325}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'Angiotensin I', 'type': 'Gene', 'start': 340, 'end': 353}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'hypertension', 'type': 'Disease', 'start': 2142, 'end': 2154}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'African trypanosomiasis', 'type': 'Disease', 'start': 36, 'end': 59}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 302, 'end': 309}\n",
            "['Classification of Coronavirus Images using Shrunken Features\\tNecessary screenings must be performed to control the spread of the Corona Virus (COVID-19) in daily life and to make a preliminary diagnosis of suspicious cases.', 'The long duration of pathological laboratory tests and the wrong test results led the researchers to focus on different fields.', 'Fast and accurate diagnoses are essential for effective interventions with COVID-19.', 'The information obtained by using X-ray and Computed Tomography (CT) images is vital in making clinical diagnoses.', 'Therefore it was aimed to develop a machine learning method for the detection of viral epidemics by analyzing X-ray images.', 'In this study, images belonging to 6 situations, including coronavirus images, are classified.', 'Since the number of images in the dataset is deficient and unbalanced, it is more convenient to analyze these images with hand-crafted feature extraction methods.', 'For this purpose, firstly, all the images in the dataset are extracted with the help of four feature extraction algorithms.', 'These extracted features are combined in raw form.', 'The unbalanced data problem is eliminated by producing feature vectors with the SMOTE algorithm.', 'Finally, the feature vector is reduced in size by using a stacked auto-encoder and principal component analysis to remove interconnected features in the feature vector.', 'According to the obtained results, it is seen that the proposed method has leveraging performance, especially in order to make the diagnosis of COVID-19 in a short time and effectively.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1519, 'end': 1527}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': \"Parkinson's disease\", 'type': 'Disease', 'start': 292, 'end': 311}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes mellitus', 'type': 'Disease', 'start': 276, 'end': 293}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'virus infection', 'type': 'Disease', 'start': 2690, 'end': 2705}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'influenza', 'type': 'Disease', 'start': 409, 'end': 418}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cortical atrophy', 'type': 'Disease', 'start': 37, 'end': 53}\n",
            "['approach for designing of a multi-epitope based vaccine against novel Coronavirus (SARS-COV-2)\\tA novel Coronavirus (SARS-COV-2) has now become a global pandemic.', 'Considering the severity of infection and the associated mortalities, there is an urgent need to develop an effective preventive measure against this virus.', 'In this study, we have designed a novel vaccine construct using computational strategies.', 'Spike (S) glycoprotein is the major antigenic component that trigger the host immune responses.', 'Detailed investigation of S protein with various immunoinformatics tools enabled us to identify 5 MHC I and 5 MHC II B-cell derived T-cell epitopes with VaxiJen score > 1 and IC 50 value < 100nM.', 'These epitopes were joined with a suitable adjuvant and appropriate linkers to form a multi-epitope based vaccine construct.', 'Further, in silico testing of the vaccine construct for its antigenicity, allergenicity, solubility, and other physicochemical properties showed it to be safe and immunogenic.', 'Suitable tertiary structure of the vaccine protein was generated using 3Dpro of SCRATCH suite, refined with GalaxyRefine, and validated with ProSA, PROCHECK, and ERRAT server.', 'Finally, molecular docking studies were performed to ensure a favorable binding affinity between the vaccine construct and TLR3 receptor.', 'The designed multi-epitope vaccine showed potential to elicit specific immune responses against the SARS-COV-2.', 'However, further wet lab validation is necessary to confirm the actual effectiveness, safety and immunogenic potency of the vaccine construct against derived in this study.']\n",
            "unmatched tags:  [{'entity': 'vaccine construct', 'type': 'Gene', 'start': 1552, 'end': 1569}, {'entity': 'wet lab', 'type': 'Gene', 'start': 1445, 'end': 1452}, {'entity': 'SARS-COV-2', 'type': 'Virus', 'start': 1416, 'end': 1426}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1343, 'end': 1350}, {'entity': 'multi-epitope vaccine', 'type': 'Gene', 'start': 1329, 'end': 1350}, {'entity': 'TLR3 receptor', 'type': 'Gene', 'start': 1301, 'end': 1314}, {'entity': 'vaccine construct', 'type': 'Gene', 'start': 1279, 'end': 1296}, {'entity': 'ERRAT', 'type': 'Gene', 'start': 1164, 'end': 1169}, {'entity': 'GalaxyRefine', 'type': 'Chemical', 'start': 1110, 'end': 1122}, {'entity': 'SCRATCH', 'type': 'Disease', 'start': 1082, 'end': 1089}, {'entity': 'vaccine protein', 'type': 'Drug', 'start': 1037, 'end': 1052}, {'entity': 'vaccine construct', 'type': 'Gene', 'start': 860, 'end': 877}, {'entity': 'vaccine construct', 'type': 'Gene', 'start': 807, 'end': 824}, {'entity': 'multi-epitope', 'type': 'Gene', 'start': 787, 'end': 800}]\n",
            "['Vitamin D and solar ultraviolet radiation in the risk and treatment of tuberculosis\\tImproved understanding of the association between tuberculosis and vitamin D is needed to inform clinical practice.', 'Vitamin D has both immunostimulatory and immunosuppressive effects relevant to human antimycobacterial responses.', 'Ultraviolet radiation, the main source of vitamin D, also induces immunomodulation and could affect the relation between vitamin D and tuberculosis.', 'Clinical trials of vitamin D supplementation in patients with tuberculosis have produced largely negative results, prompting the review of dosing regimens—an explanation for low 25-hydroxyvitamin D status in patients with active tuberculosis is also needed.']\n",
            "unmatched tags:  [{'entity': 'active tuberculosis', 'type': 'Disease', 'start': 685, 'end': 704}]\n",
            "['Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells\\tThe COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, creates an urgent need for identifying molecular mechanisms that mediate viral entry, propagation, and tissue pathology.', 'Cell membrane bound angiotensin-converting enzyme 2 (ACE2) and associated proteases, transmembrane protease serine 2 (TMPRSS2) and Cathepsin L (CTSL), were previously identified as mediators of SARS-CoV2 cellular entry.', 'Here, we assess the cell type-specific RNA expression of ACE2 , TMPRSS2 , and CTSL through an integrated analysis of 107 single-cell and single-nucleus RNA-Seq studies, including 22 lung and airways datasets (16 unpublished), and 85 datasets from other diverse organs.', 'Joint expression of ACE2 and the accessory proteases identifies specific subsets of respiratory epithelial cells as putative targets of viral infection in the nasal passages, airways, and alveoli.', 'Cells that co-express ACE2 and proteases are also identified in cells from other organs, some of which have been associated with COVID-19 transmission or pathology, including gut enterocytes, corneal epithelial cells, cardiomyocytes, heart pericytes, olfactory sustentacular cells, and renal epithelial cells.', 'Performing the first meta-analyses of scRNA-seq studies, we analyzed 1,176,683 cells from 282 nasal, airway, and lung parenchyma samples from 164 donors spanning fetal, childhood, adult, and elderly age groups, associate increased levels of ACE2 , TMPRSS2 , and CTSL in specific cell types with increasing age, male gender, and smoking, all of which are epidemiologically linked to COVID-19 susceptibility and outcomes.', 'Notably, there was a particularly low expression of ACE2 in the few young pediatric samples in the analysis.', 'Further analysis reveals a gene expression program shared by ACE2 + TMPRSS2 + cells in nasal, lung and gut tissues, including genes that may mediate viral entry, subtend key immune functions, and mediate epithelial-macrophage cross-talk.', 'Amongst these are IL6, its receptor and co-receptor, IL1R , TNF response pathways, and complement genes.', 'Cell type specificity in the lung and airways and smoking effects were conserved in mice.', 'Our analyses suggest that differences in the cell type-specific expression of mediators of SARS-CoV-2 viral entry may be responsible for aspects of COVID-19 epidemiology and clinical course, and point to putative molecular pathways involved in disease susceptibility and pathogenesis.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2525, 'end': 2533}, {'entity': 'mediators', 'type': 'Drug', 'start': 2455, 'end': 2464}, {'entity': 'cell', 'type': 'Gene', 'start': 2422, 'end': 2426}, {'entity': 'mice', 'type': 'Gene', 'start': 2371, 'end': 2375}, {'entity': 'complement genes', 'type': 'Gene', 'start': 2269, 'end': 2285}, {'entity': 'TNF', 'type': 'Gene', 'start': 2242, 'end': 2245}, {'entity': 'IL1R', 'type': 'Gene', 'start': 2235, 'end': 2239}, {'entity': 'receptor', 'type': 'Gene', 'start': 2225, 'end': 2233}, {'entity': 'receptor', 'type': 'Gene', 'start': 2209, 'end': 2217}, {'entity': 'IL6', 'type': 'Gene', 'start': 2200, 'end': 2203}, {'entity': 'cell', 'type': 'Gene', 'start': 2022, 'end': 2026}, {'entity': 'TMPRSS2', 'type': 'Gene', 'start': 2012, 'end': 2019}, {'entity': 'ACE2', 'type': 'Gene', 'start': 2005, 'end': 2009}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1887, 'end': 1891}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1797, 'end': 1805}, {'entity': 'cell', 'type': 'Gene', 'start': 1694, 'end': 1698}, {'entity': 'CTSL', 'type': 'Gene', 'start': 1677, 'end': 1681}, {'entity': 'TMPRSS2', 'type': 'Gene', 'start': 1663, 'end': 1670}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1656, 'end': 1660}, {'entity': 'cell', 'type': 'Gene', 'start': 1494, 'end': 1498}, {'entity': 'cell', 'type': 'Gene', 'start': 1408, 'end': 1412}, {'entity': 'cell', 'type': 'Gene', 'start': 1380, 'end': 1384}, {'entity': 'cell', 'type': 'Gene', 'start': 1316, 'end': 1320}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1234, 'end': 1242}, {'entity': 'cell', 'type': 'Gene', 'start': 1169, 'end': 1173}, {'entity': 'proteases', 'type': 'Gene', 'start': 1136, 'end': 1145}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1127, 'end': 1131}, {'entity': 'co-express', 'type': 'Organization', 'start': 1116, 'end': 1126}, {'entity': 'viral infection', 'type': 'Virus', 'start': 1044, 'end': 1059}, {'entity': 'cell', 'type': 'Gene', 'start': 1015, 'end': 1019}, {'entity': 'proteases', 'type': 'Gene', 'start': 951, 'end': 960}, {'entity': 'ACE2', 'type': 'Gene', 'start': 928, 'end': 932}, {'entity': 'cell', 'type': 'Gene', 'start': 767, 'end': 771}, {'entity': 'CTSL', 'type': 'Gene', 'start': 717, 'end': 721}, {'entity': 'TMPRSS2', 'type': 'Gene', 'start': 703, 'end': 710}, {'entity': 'ACE2', 'type': 'Gene', 'start': 696, 'end': 700}, {'entity': 'RNA', 'type': 'Gene', 'start': 678, 'end': 681}, {'entity': 'cell', 'type': 'Gene', 'start': 659, 'end': 663}, {'entity': 'cell', 'type': 'Gene', 'start': 623, 'end': 627}, {'entity': 'mediators', 'type': 'Drug', 'start': 600, 'end': 609}, {'entity': 'CTSL', 'type': 'Gene', 'start': 563, 'end': 567}, {'entity': 'Cathepsin L', 'type': 'Gene', 'start': 550, 'end': 561}, {'entity': 'TMPRSS2', 'type': 'Gene', 'start': 537, 'end': 544}, {'entity': 'transmembrane protease serine 2', 'type': 'Gene', 'start': 504, 'end': 535}, {'entity': 'associated proteases', 'type': 'Gene', 'start': 482, 'end': 502}, {'entity': 'ACE2', 'type': 'Gene', 'start': 472, 'end': 476}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tumours', 'type': 'Disease', 'start': 335, 'end': 342}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'psoriatic arthritis', 'type': 'Disease', 'start': 215, 'end': 234}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'rotavirus', 'type': 'Virus', 'start': 335, 'end': 344}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'aneurysm', 'type': 'Disease', 'start': 101, 'end': 109}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 50, 'end': 56}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 517, 'end': 523}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'respiratory failure', 'type': 'Disease', 'start': 297, 'end': 316}\n",
            "['Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion\\tThe recent outbreak of coronavirus disease (COVID-19) caused by SARS-CoV-2 infection in Wuhan, China has posed a serious threat to global public health.', 'To develop specific anti-coronavirus therapeutics and prophylactics, the molecular mechanism that underlies viral infection must first be confirmed.', 'Therefore, we herein used a SARS-CoV-2 spike (S) protein-mediated cell-cell fusion assay and found that SARS-CoV-2 showed plasma membrane fusion capacity superior to that of SARS-CoV.', 'We solved the X-ray crystal structure of six-helical bundle (6-HB) core of the HR1 and HR2 domains in SARS-CoV-2 S protein S2 subunit, revealing that several mutated amino acid residues in the HR1 domain may be associated with enhanced interactions with HR2 domain.', 'We previously developed a pan-coronavirus fusion inhibitor, EK1, which targeted HR1 domain and could inhibit infection by divergent human coronaviruses tested, including SARS-CoV and MERS-CoV.', 'We then generated a series of lipopeptides and found that the EK1C4 was the most potent fusion inhibitor against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection with IC 50 s of 1.3 and 15.8 nM, about 241- and 149-fold more potent than that of EK1 peptide, respectively.', 'EK1C4 was also highly effective against membrane fusion and infection of other human coronavirus pseudoviruses tested, including SARS-CoV and MERS-CoV, as well as SARSr-CoVs, potently inhibiting replication of 4 live human coronaviruses, including SARS-CoV-2.', 'Intranasal application of EK1C4 before or after challenge with HCoV-OC43 protected mice from infection, suggesting that EK1C4 could be used for prevention and treatment of infection by currently circulating SARS-CoV-2 and emerging SARSr-CoVs.']\n",
            "unmatched tags:  [{'entity': 'SARSr-CoVs', 'type': 'Virus', 'start': 1924, 'end': 1934}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1900, 'end': 1910}, {'entity': 'EK1', 'type': 'Disease', 'start': 1813, 'end': 1816}, {'entity': 'mice', 'type': 'Gene', 'start': 1776, 'end': 1780}, {'entity': 'HCoV-OC43', 'type': 'Virus', 'start': 1756, 'end': 1765}, {'entity': 'EK1', 'type': 'Disease', 'start': 1719, 'end': 1722}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1681, 'end': 1691}, {'entity': 'coronaviruses', 'type': 'Virus', 'start': 1656, 'end': 1669}, {'entity': 'SARSr-CoVs', 'type': 'Virus', 'start': 1596, 'end': 1606}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 1575, 'end': 1583}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1562, 'end': 1570}, {'entity': 'coronavirus pseudoviruses', 'type': 'Virus', 'start': 1518, 'end': 1543}, {'entity': 'EK1', 'type': 'Disease', 'start': 1433, 'end': 1436}, {'entity': 'EK1 peptide', 'type': 'Chemical', 'start': 1406, 'end': 1417}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1252, 'end': 1262}, {'entity': 'fusion inhibitor', 'type': 'Drug', 'start': 1227, 'end': 1243}, {'entity': 'EK1', 'type': 'Disease', 'start': 1201, 'end': 1204}, {'entity': 'lipopeptides', 'type': 'Gene', 'start': 1169, 'end': 1181}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 1129, 'end': 1137}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1116, 'end': 1124}, {'entity': 'coronaviruses', 'type': 'Virus', 'start': 1084, 'end': 1097}, {'entity': 'HR1', 'type': 'Gene', 'start': 1026, 'end': 1029}, {'entity': 'EK1', 'type': 'Disease', 'start': 1006, 'end': 1009}, {'entity': 'fusion inhibitor', 'type': 'Drug', 'start': 988, 'end': 1004}, {'entity': 'pan-coronavirus', 'type': 'Virus', 'start': 972, 'end': 987}, {'entity': 'HR2 domain', 'type': 'Disease', 'start': 934, 'end': 944}]\n",
            "['GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study\\tThe addition of ATLG to standard GVHD prophylaxis improves the probability of surviving without disease relapse and cGVHD after myeloablative peripheral blood stem-cell transplantation from an HLA-identical sibling donor for patients with acute leukaemia in remission.', 'Further additional benefits are better QoL and shorter immunosuppressive treatment compared with standard GVHD prophylaxis without ATLG.', 'Therefore, in this setting, ATLG plus standard GVHD prophylaxis should be preferred over the standard GVHD prophylaxis alone.']\n",
            "unmatched tags:  [{'entity': 'GVHD', 'type': 'Disease', 'start': 791, 'end': 795}, {'entity': 'GVHD', 'type': 'Disease', 'start': 736, 'end': 740}, {'entity': 'GVHD', 'type': 'Disease', 'start': 658, 'end': 662}, {'entity': 'immunosuppressive treatment', 'type': 'Drug', 'start': 607, 'end': 634}, {'entity': 'QoL', 'type': 'Phenotype', 'start': 591, 'end': 594}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 389, 'end': 395}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 40, 'end': 47}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 621, 'end': 628}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'stroke', 'type': 'Disease', 'start': 76, 'end': 82}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'stroke', 'type': 'Disease', 'start': 505, 'end': 511}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'liver disease', 'type': 'Disease', 'start': 257, 'end': 270}\n",
            "['Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV\\tLiver disease is a leading cause of morbidity and mortality among people with HIV, and in this era of safer and more effective hepatitis C therapy, non-alcoholic fatty liver disease (NAFLD) could soon emerge as the most common liver disease in this population.', 'NAFLD is common among patients with HIV, and might be more likely to progress to non-alcoholic steatohepatitis (NASH) and NAFLD-related fibrosis or cirrhosis in these patients than in individuals without HIV.', 'Several mechanisms of NAFLD pathogenesis are postulated to explain the disease severity in patients with HIV; these mechanisms include the influence of the gut microbiome, and also metabolic, genetic, and immunological factors.']\n",
            "unmatched tags:  [{'entity': 'HIV', 'type': 'Virus', 'start': 664, 'end': 667}, {'entity': 'NAFLD', 'type': 'Disease', 'start': 581, 'end': 586}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': \"Sjögren's syndrome\", 'type': 'Disease', 'start': 322, 'end': 340}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'breast cancer', 'type': 'Disease', 'start': 86, 'end': 99}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'enzyme', 'type': 'Gene', 'start': 91, 'end': 97}\n",
            "['IFITM proteins inhibit HIV-1 protein synthesis\\tInterferon induced transmembrane proteins (IFITMs) inhibit the cellular entry of a broad range of viruses, but it has been suspected that for HIV-1 IFITMs may also inhibit a post-integration replicative step.', 'We show that IFITM expression reduces HIV-1 viral protein synthesis by preferentially excluding viral mRNA transcripts from translation and thereby restricts viral production.', 'Codon-optimization of proviral DNA rescues viral translation, implying that IFITM-mediated restriction requires recognition of viral RNA elements.', 'In addition, we find that expression of the viral accessory protein Nef can help overcome the IFITM-mediated inhibition of virus production.', 'Our studies identify a novel role for IFITMs in inhibiting HIV replication at the level of translation, but show that the effects can be overcome by the lentiviral protein Nef.']\n",
            "unmatched tags:  [{'entity': 'Nef', 'type': 'Gene', 'start': 892, 'end': 895}, {'entity': 'lentiviral protein', 'type': 'Gene', 'start': 873, 'end': 891}, {'entity': 'HIV', 'type': 'Virus', 'start': 779, 'end': 782}, {'entity': 'IFITM', 'type': 'Chemical', 'start': 758, 'end': 763}, {'entity': 'Nef', 'type': 'Gene', 'start': 647, 'end': 650}, {'entity': 'viral accessory protein', 'type': 'Gene', 'start': 623, 'end': 646}, {'entity': 'viral RNA elements', 'type': 'Chemical', 'start': 559, 'end': 577}, {'entity': 'IFITM-mediated restriction', 'type': 'Organization', 'start': 508, 'end': 534}, {'entity': 'proviral', 'type': 'Virus', 'start': 454, 'end': 462}, {'entity': 'Codon-optimization', 'type': 'Organization', 'start': 432, 'end': 450}, {'entity': 'transcripts', 'type': 'Gene', 'start': 363, 'end': 374}, {'entity': 'mRNA', 'type': 'Gene', 'start': 358, 'end': 362}]\n",
            "['Differential COVID-19-attributable mortality and BCG vaccine use in countries\\tWhile mortality attributable to COVID-19 has devastated global health systems and economies, striking regional differences have been observed.', 'The Bacille Calmette Guerin (BCG) vaccine has previously been shown to have non-specific protective effects on infections, as well as long-term efficacy against tuberculosis.', 'Using publicly available data we built a simple log-linear regression model to assess the association of BCG use and COVID-19-attributable mortality per 1 million population after adjusting for confounders including country economic status (GDP per capita), and proportion of elderly among the population.', 'The timing of country entry into the pandemic epidemiological trajectory was aligned by plotting time since the 100th reported case.', 'Countries with economies classified as lower-middle-income, upper-middle-income and high-income countries (LMIC, UMIC, HIC) had median crude COVID-19 log-mortality of 0.4 (Interquartile Range (IQR) 0.1, 0.4), 0.7 (IQR 0.2, 2.2) and 5.5 (IQR 1.6,  13.9), respectively.', 'COVID-19-attributable mortality among BCG-using countries was 5.8 times lower [95% CI 1.8-19.0] than in non BCG-using countries.', 'Notwithstanding limitations due to testing constraints in LMICs, case ascertainment bias and a plausible rise of cases as countries progress along the epidemiological trajectory, these analyses provide intriguing observations that urgently warrant mobilization of resources for prospective randomized interventional studies and institution of systematic disease surveillance, particularly in LMICs.']\n",
            "unmatched tags:  [{'entity': 'LMIC', 'type': 'Gene', 'start': 1624, 'end': 1628}, {'entity': 'systematic disease', 'type': 'Disease', 'start': 1575, 'end': 1593}, {'entity': 'case ascertainment', 'type': 'Gene', 'start': 1297, 'end': 1315}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'syndrome', 'type': 'Disease', 'start': 92, 'end': 100}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'yaws', 'type': 'Disease', 'start': 408, 'end': 412}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tumours', 'type': 'Disease', 'start': 50, 'end': 57}\n",
            "['A simple ecological model captures the transmission pattern of the coronavirus COVID-19 outbreak in China\\tThe rapid spread of the 2019 novel coronavirus (COVID-19), initially reported in the city of Wuhan in China, and quickly transmitted to the entire nation and beyond, has become an international public health emergency.', 'Estimating the final number of infection cases and the turning point (time with the fastest spreading rate) is crucial to assessing and improving the national and international control measures currently being applied.', 'In this paper we develop a simple model based on infectious growth with a time-varying infection rate, and estimate the final number of infections and the turning point using data updated daily from 3 February 2020, when China escalated its initial public health measures, to 10 February.', 'Our model provides an extremely good fit to the existing data and therefore a reasonable estimate of the time-varying infection rate that has largely captured the transmission pattern of this epidemic outbreak.', 'Our estimation suggests that (i) the final number of infections in China could reach 78,000 with an upper 95% confidence limit of 88,880; (ii) the turning point of the fastest spread was on the 4th or the 5th of February; and (iii) the projected period for the end of the outbreak (i.e., when 95% of the final predicted number of infection is reached) will be the 24th of February, with an upper 95% confidence limit on the 19th of March.', 'This suggests that the current control measures in China are excellent, and more than sufficient to contain the spread of this highly infectious novel coronavirus, and that the application of such measures could be considered internationally for the global control of this outbreak.']\n",
            "unmatched tags:  [{'entity': 'national', 'type': 'Organization', 'start': 1714, 'end': 1722}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 1634, 'end': 1645}, {'entity': 'turning point', 'type': 'Chemical', 'start': 1191, 'end': 1204}, {'entity': 'turning point', 'type': 'Chemical', 'start': 699, 'end': 712}, {'entity': 'national', 'type': 'Organization', 'start': 493, 'end': 501}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CJD', 'type': 'Gene', 'start': 480, 'end': 483}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'amyloidosis', 'type': 'Disease', 'start': 265, 'end': 276}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 50, 'end': 56}\n",
            "['Sudden hyposmia as a prevalent symptom of COVID-19 infection.', 'Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has recently caused a pandemic that has involved Italy as the second worldwide nation in terms of infected patients and deaths.', 'The clinical manifestation of Covid-19 ranges from asymptomatic carrier status to severe pneumonia.', 'Asymptomatic individuals in Covid-19 are those who are carriers of the virus but do not show clinical symptoms and are able to transmit the disease in the same degree as symptomatic carriers.', 'In order to contain contagions is of supreme importance to identify asymptomatic patients because this subpopulation is one of the main factors contributing to the spread of this disease.', 'We report on six Italian patients with COVID-19 who presented sudden hyposmia as the only or most prominent disease manifestation, without upper or lower respiratory tract involvement or other major features of the disease.', 'A supra-threshold olfaction test confirmed the hyposmia in all patients.', 'The onset of hyposmia during a Covid-19 outbreak should be considered as a warning sign of an infection that requires a diagnostic test for Covid-19']\n",
            "unmatched tags:  [{'entity': 'Covid-19', 'type': 'Disease', 'start': 1061, 'end': 1069}, {'entity': 'hyposmia', 'type': 'Phenotype', 'start': 1043, 'end': 1051}, {'entity': 'hyposmia', 'type': 'Phenotype', 'start': 1004, 'end': 1012}, {'entity': 'disease manifestation', 'type': 'Disease', 'start': 841, 'end': 862}, {'entity': 'hyposmia', 'type': 'Phenotype', 'start': 802, 'end': 810}, {'entity': 'sudden hyposmia', 'type': 'Phenotype', 'start': 795, 'end': 810}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 772, 'end': 780}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 614, 'end': 621}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 523, 'end': 530}, {'entity': 'clinical symptoms', 'type': 'Phenotype', 'start': 446, 'end': 463}, {'entity': 'Covid-19', 'type': 'Disease', 'start': 381, 'end': 389}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 354, 'end': 361}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 341, 'end': 350}]\n",
            "['Epidemic Landscape and Forecasting of SARS-CoV-2 in India\\tBACKGROUND India was one of the countries to institute strict measures for SARS-CoV-2 control in early phase.', 'Since, then, the epidemic growth trajectory was slow before registering an explosion of cases due to local cluster transmissions.', 'METHODS We estimated growth rate and doubling time of SARS-CoV-2 for India and high burden states using crowd sourced time series data.', 'Further, we also estimated Basic Reproductive Number (R0) and time dependent reproductive number (Rt) using serial intervals from the data.', 'We compared the R0 estimated from five different methods and R0 from SB was further used in analysis.', 'We modified standard SIR models to SIRD model to accommodate deaths using R0 with the Sequential Bayesian method (SBM) for simulation in SIRD models.', 'RESULTS On an average, 2.8 individuals were infected by an index case.', 'The mean serial interval was 3.9 days.', 'The R0 estimated from different methods ranged from 1.43 to 1.85.', 'The mean time to recovery was 14, SD 5.3 days.', 'Daily epidemic growth rate of India was 0.16 [95%CI; 0.14, 0.17] with a doubling time of 4.30 days [95%CI; 3.96, 4.70].', 'From the SIRD model, it can be deduced that the peak of SARS-CoV-2 in India will be around mid-July to early August 2020 with around 12.5% likely to be infected at peak time of incidence.', 'CONCLUSIONS The pattern of spread of SARS-CoV-2 in India is suggestive of community transmission.', 'There is a need to increase fund for infectious disease research and epidemiologic studies.', 'All the current gains may be reversed rapidly if air travel and social mixing resumes rapidly.', 'For the time being, these must be resumed only in a phased manner, and should be back to normal levels only after we are prepared to deal with the disease with efficient tools like vaccine or a medicine.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 1827, 'end': 1834}, {'entity': 'infectious disease', 'type': 'Disease', 'start': 1496, 'end': 1514}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1398, 'end': 1408}, {'entity': 'mid-July', 'type': 'Gene', 'start': 1263, 'end': 1271}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1228, 'end': 1238}, {'entity': 'R0', 'type': 'Organization', 'start': 943, 'end': 945}]\n",
            "['Serial interval and generation interval for respectively the imported and local infectors estimated using reported contact-tracing data of COVID-19 in China\\tBackgrounds: The emerging virus, COVID-19, has caused a massive outbreak worldwide.', 'Based on the publicly available contact-tracing data, we identified 337 transmission chains from 10 provinces in China and estimated the serial interval (SI) and generation interval (GI) of COVID-19 in China.', 'Methods: Inspired by possibly different values of the time-varying reproduction number for the imported cases and the local cases in China, we divided all transmission events into three subsets: imported (the zeroth generation) infecting 1st-generation locals, 1st-generation locals infecting 2nd-generation locals, and others transmissions among 2+ generations.', 'The corresponding SI (GI) is respectively denoted as  $\\\\mbox{SI}^{0}_{1}$ ($\\\\mbox{GI}^{0}_{1}$), $\\\\mbox{SI}^{1}_{2}$ ($\\\\mbox{GI}^{1}_{2}$), and $\\\\mbox{SI}^{2+}_{3+}$ ($\\\\mbox{GI}^{2+}_{3+}$).', 'A Bayesian approach with doubly interval-censored likelihood is employed to fit the lognormal, gamma, and Weibull distribution function of the SI and GI using the identified 337 transmission chains.', 'Findings: It is found that the estimated $\\\\mbox{SI}^{0}_{1}$ = 6.27 (95%CI : 5.62 - 6.98), $\\\\mbox{SI}^{1}_{2}$ = 5.92 (95%CI : 5.27 - 6.66),  $\\\\mbox{SI}^{2+}_{3+}$ = 4.36 (95%CI : 3.65 - 5.20), and $\\\\mbox{GI}^{0}_{1}$ = 8.15 (95%CI : 6.73 - 9.91), $\\\\mbox{GI}^{1}_{2}$ = 5.26 (95%CI : 4.25 - 6.69), $\\\\mbox{GI}^{2+}_{3+}$ = 3.85 (95%CI : 2.18 - 6.72), thus overall both SI and GI decrease when generation increases.']\n",
            "unmatched tags:  [{'entity': 'GI', 'type': 'Gene', 'start': 1578, 'end': 1580}, {'entity': 'SI', 'type': 'Gene', 'start': 1571, 'end': 1573}, {'entity': 'GI', 'type': 'Gene', 'start': 1508, 'end': 1510}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'stroke', 'type': 'Disease', 'start': 540, 'end': 546}\n",
            "['Synonymous mutations and the molecular evolution of SARS-Cov-2 origins\\tHuman severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is most closely related, by average genetic distance, to two coronaviruses isolated from bats, RaTG13 and RmYN02.', 'However, there is a segment of high amino acid similarity between human SARS-CoV-2 and a pangolin isolated strain, GD410721, in the receptor binding domain (RBD) of the spike protein, a pattern that can be caused by either recombination or by convergent amino acid evolution driven by natural selection.', 'We perform a detailed analysis of the synonymous divergence, which is less likely to be affected by selection than amino acid divergence, between human SARS-CoV-2 and related strains.', 'We show that the synonymous divergence between the bat derived viruses and SARS-CoV-2 is larger than between GD410721 and SARS-CoV-2 in the RBD, providing strong additional support for the recombination hypothesis.', 'However, the synonymous divergence between pangolin strain and SARS-CoV-2 is also relatively high, which is not consistent with a recent recombination between them, instead it suggests a recombination into RaTG13.', 'We also find a 14-fold increase in the d N / d S ratio from the lineage leading to SARS-CoV-2 to the strains of the current pandemic, suggesting that the vast majority of non-synonymous mutations currently segregating within the human strains have a negative impact on viral fitness.', 'Finally, we estimate that the time to the most recent common ancestor of SARS-CoV-2 and RaTG13 or RmYN02 based on synonymous divergence, is 51.71 years (95% C.I., 28.11-75.31) and 37.02 years (95% C.I., 18.19-55.85), respectively.']\n",
            "unmatched tags:  [{'entity': 'd', 'type': 'Drug', 'start': 1631, 'end': 1632}, {'entity': 'd', 'type': 'Drug', 'start': 1578, 'end': 1579}, {'entity': 'd', 'type': 'Drug', 'start': 1562, 'end': 1563}, {'entity': 'RmYN02', 'type': 'Gene', 'start': 1551, 'end': 1557}, {'entity': 'RaTG13', 'type': 'Gene', 'start': 1541, 'end': 1547}, {'entity': 'd', 'type': 'Drug', 'start': 1539, 'end': 1540}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1526, 'end': 1536}, {'entity': 'strains', 'type': 'Disease', 'start': 1404, 'end': 1411}, {'entity': 'd', 'type': 'Drug', 'start': 1296, 'end': 1297}, {'entity': 'strains', 'type': 'Disease', 'start': 1270, 'end': 1277}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1252, 'end': 1262}, {'entity': 'd', 'type': 'Drug', 'start': 1244, 'end': 1245}, {'entity': 'd', 'type': 'Drug', 'start': 1214, 'end': 1215}, {'entity': 'd', 'type': 'Drug', 'start': 1208, 'end': 1209}, {'entity': 'd', 'type': 'Drug', 'start': 1190, 'end': 1191}, {'entity': 'd', 'type': 'Drug', 'start': 1180, 'end': 1181}, {'entity': 'RaTG13', 'type': 'Gene', 'start': 1161, 'end': 1167}, {'entity': 'd', 'type': 'Drug', 'start': 1126, 'end': 1127}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1018, 'end': 1028}, {'entity': 'd', 'type': 'Drug', 'start': 1016, 'end': 1017}, {'entity': 'd', 'type': 'Drug', 'start': 979, 'end': 980}, {'entity': 'd', 'type': 'Drug', 'start': 904, 'end': 905}, {'entity': 'd', 'type': 'Drug', 'start': 903, 'end': 904}, {'entity': 'd', 'type': 'Drug', 'start': 890, 'end': 891}, {'entity': 'RBD', 'type': 'Gene', 'start': 880, 'end': 883}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 862, 'end': 872}, {'entity': 'd', 'type': 'Drug', 'start': 860, 'end': 861}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 815, 'end': 825}, {'entity': 'd', 'type': 'Drug', 'start': 813, 'end': 814}, {'entity': 'd', 'type': 'Drug', 'start': 801, 'end': 802}, {'entity': 'd', 'type': 'Drug', 'start': 795, 'end': 796}, {'entity': 'd', 'type': 'Drug', 'start': 768, 'end': 769}, {'entity': 'strains', 'type': 'Disease', 'start': 731, 'end': 738}, {'entity': 'd', 'type': 'Drug', 'start': 729, 'end': 730}, {'entity': 'd', 'type': 'Drug', 'start': 721, 'end': 722}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 708, 'end': 718}, {'entity': 'd', 'type': 'Drug', 'start': 682, 'end': 683}, {'entity': 'amino acid', 'type': 'Gene', 'start': 671, 'end': 681}, {'entity': 'd', 'type': 'Drug', 'start': 651, 'end': 652}, {'entity': 'd', 'type': 'Drug', 'start': 605, 'end': 606}, {'entity': 'd', 'type': 'Drug', 'start': 576, 'end': 577}, {'entity': 'd', 'type': 'Drug', 'start': 569, 'end': 570}, {'entity': 'd', 'type': 'Drug', 'start': 527, 'end': 528}, {'entity': 'amino acid', 'type': 'Gene', 'start': 506, 'end': 516}, {'entity': 'd', 'type': 'Drug', 'start': 463, 'end': 464}, {'entity': 'spike protein', 'type': 'Gene', 'start': 421, 'end': 434}, {'entity': 'RBD', 'type': 'Gene', 'start': 409, 'end': 412}, {'entity': 'd', 'type': 'Drug', 'start': 401, 'end': 402}, {'entity': 'd', 'type': 'Drug', 'start': 396, 'end': 397}, {'entity': 'd', 'type': 'Drug', 'start': 357, 'end': 358}, {'entity': 'd', 'type': 'Drug', 'start': 337, 'end': 338}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 324, 'end': 334}, {'entity': 'amino acid', 'type': 'Gene', 'start': 288, 'end': 298}, {'entity': 'RmYN02', 'type': 'Gene', 'start': 244, 'end': 250}, {'entity': 'd', 'type': 'Drug', 'start': 242, 'end': 243}, {'entity': 'RaTG13', 'type': 'Gene', 'start': 233, 'end': 239}, {'entity': 'd', 'type': 'Drug', 'start': 220, 'end': 221}, {'entity': 'coronaviruses', 'type': 'Virus', 'start': 199, 'end': 212}, {'entity': 'd', 'type': 'Drug', 'start': 182, 'end': 183}, {'entity': 'd', 'type': 'Drug', 'start': 160, 'end': 161}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 126, 'end': 136}, {'entity': 'acute respiratory syndrome coronavirus 2', 'type': 'Virus', 'start': 84, 'end': 124}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 49, 'end': 55}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 523, 'end': 529}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'thyroid disease', 'type': 'Disease', 'start': 40, 'end': 55}\n",
            "['Use of bednets given free to pregnant women in Kenya\\tIn 2001, UNICEF procured 70\\u2008000 bednets and insecticide treatments to be distributed free to pregnant women attending antenatal clinics in 35 (of 69) districts in Kenya.', '1 year later, we interviewed 294 pregnant women who had received a free net.', '267 (91%) nets had remained in the target homesteads, and only one of the nets had been sold.', 'In a district with high malarial transmission, 93 (84%) of 111 women who had not previously been sleeping under a bednet had used the net while pregnant, and 97 (91%) of the 107 surviving babies were also protected; in another district, which had low transmission, 73 (58%) of 126 women used the nets during pregnancy and 91 (80%) of 114 infants were protected by the nets.']\n",
            "unmatched tags:  [{'entity': 'nets', 'type': 'Gene', 'start': 762, 'end': 766}, {'entity': 'nets', 'type': 'Gene', 'start': 690, 'end': 694}, {'entity': 'surviving', 'type': 'Gene', 'start': 572, 'end': 581}, {'entity': 'malarial', 'type': 'Drug', 'start': 418, 'end': 426}, {'entity': 'nets', 'type': 'Gene', 'start': 374, 'end': 378}, {'entity': 'nets', 'type': 'Gene', 'start': 310, 'end': 314}, {'entity': 'insecticide', 'type': 'Chemical', 'start': 97, 'end': 108}, {'entity': 'nets', 'type': 'Gene', 'start': 88, 'end': 92}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNAs', 'type': 'Gene', 'start': 524, 'end': 528}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNAs', 'type': 'Gene', 'start': 715, 'end': 719}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNAs', 'type': 'Gene', 'start': 1023, 'end': 1027}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNAs', 'type': 'Gene', 'start': 1047, 'end': 1051}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNAs', 'type': 'Gene', 'start': 1075, 'end': 1079}\n",
            "['The International Health Regulations 10 years on: the governing framework for global health security\\tFundamental revisions to the International Health Regulations in 2005 were meant to herald a new era of global health security and cooperation.', 'Yet, 10 years later, the International Health Regulations face criticism, particularly after the west African Ebola epidemic.', 'Several high-level panels']\n",
            "unmatched tags:  [{'entity': 'era', 'type': 'Gene', 'start': 374, 'end': 377}, {'entity': 'Ebola', 'type': 'Disease', 'start': 355, 'end': 360}, {'entity': 'era', 'type': 'Gene', 'start': 236, 'end': 239}]\n",
            "['Optimization of Microbiological Laboratory Detection Strategy for Patients in A Designated Hospital Treating Novel Coronavirus Pneumonia in Anhui Province\\tNovel coronavirus pneumonia (NCP) is an emerging, highly contagious community acquired pneumonia (CAP) caused by severe acute respiratory syndrome  coronavirus 2 (SARS-CoV-2).', 'Highly efficient and accurate microbiological laboratory assay is essential to confirm the SARS-CoV-2 infection, rule out other pathogens that can cause CAP, and monitor secondary infections.', 'Here, we enrolled and provide microbiological analysis for 129 suspected and 52 transferred confirmed NCP patients hospitalized in the First Affiliated Hospital of University of Science and Technology of China (USTC) from Jan 21 to Feb 29, 2020.', 'By analyzing the dual swab samples (sputum and pharyngeal) from 129 suspected patients with realtime RT-PCR, we confirmed 33 SARS-CoV-2 infections, with two co-infection cases with adenovirus or rhinovirus.', 'We also used multiplex PCR to detect 13 common respiratory tract pathogens in 96 non-NCP patients, and found that 30 patients (31.25%) were infected with at least one respiratory tract pathogen that may cause CAP.', 'Further, we performed bacterial and fungal cultures as well as fungal serologic tests and found that there is no secondary bacterial/fungal infections in confirmed NCP patients.', 'Our studies suggest that, during the epidemic of NCP in Anhui province, there was a certain proportion of infection and co-infection of other common pathogens of CAP, and the secondary bacterial and fungal infection is not detectable in NCP patients.', 'In comparison with SARS-CoV-2 detection alone, this optimized strategy combining multiple pathogen detection for identification of NCP and other CAP patients as well as cultures and serologic tests for confirmed patients increases the diagnosis efficiency and facilitates the personalized medication.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1638, 'end': 1648}, {'entity': 'fungal infection', 'type': 'Phenotype', 'start': 1567, 'end': 1583}, {'entity': 'co-infection', 'type': 'Disease', 'start': 1488, 'end': 1500}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'syndrome', 'type': 'Disease', 'start': 369, 'end': 377}\n",
            "['Malaria control in Afghanistan: progress and challenges\\tFrom the 1950s until 1979 malaria control in Afghanistan was implemented through a vertical programme managed by the government, but little of the original programme remained functional by the early 1990s.', 'Delivery of basic health care including malaria diagnosis and treatment was done by non-governmental organisations (NGOs) and UN agencies, which organised cross-border operations from Pakistan and Iran and placed much less emphasis on vertical programming.', 'From 1992 the situation in the east of Afghanistan became stable enough to allow the establishment of a network of NGO-supported clinics and to introduce standardised training and monitoring of microscopists and clinical staff, coordinated by a lead agency specialising in malaria.']\n",
            "unmatched tags:  [{'entity': 'malaria', 'type': 'Disease', 'start': 792, 'end': 799}, {'entity': 'agency', 'type': 'Organization', 'start': 769, 'end': 775}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diseases', 'type': 'Disease', 'start': 153, 'end': 161}\n",
            "['Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a\\tOlaparib tablet maintenance treatment provided a significant progression-free survival improvement with no detrimental effect on quality of life in patients with platinum-sensitive, relapsed ovarian cancer and a']\n",
            "unmatched tags:  [{'entity': 'ovarian cancer', 'type': 'Disease', 'start': 298, 'end': 312}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 75, 'end': 81}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 52, 'end': 59}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'smallpox', 'type': 'Disease', 'start': 636, 'end': 644}\n",
            "['Optimum timing of treatment for hepatitis C infection relative to liver transplantation\\tThe approval of direct-acting antiviral agents that may be given orally in an interferon-free regimen has greatly changed the landscape of treatment for hepatitis C virus (HCV) infection, especially for patients with the most severe disease, who have decompensated cirrhosis, or who are waiting for or have undergone liver transplantation.', 'Treatment with interferon proved to be ineffective and poorly tolerated because of high risks of infection and transplant rejection.', 'The availability of new drugs poses new questions about the optimum time to give treatment to prevent HCV recurrence, taking into account efficacy, tolerance, and drug–drug interactions.']\n",
            "unmatched tags:  [{'entity': 'drug', 'type': 'Drug', 'start': 729, 'end': 733}, {'entity': 'drug', 'type': 'Drug', 'start': 724, 'end': 728}]\n",
            "['Hydroxychloroquine for the management of COVID-19: Hope or Hype?', 'A Systematic review of the current evidence\\tPurpose: The COVID-19 Pandemic has literally left the world breathless in the chase for Pharmacotherapy.', 'With the vaccine approval likely more than a year away and novel drugs in early clinical trials, repurposing of existing drugs takes the center stage.', 'A potential drug discussed both in geopolitical and global scientific community is hydroxychloroquine (HCQ).', 'We intend to systematically weigh and analyze the existing evidence of HCQ in the light of published and pre-print data available so far.', 'Methods: PubMed Ovid MEDLINE, EMBASE, Google scholar databases and official clinical trial Registries of the United States, China, WHO ICTRP were electronically searched for studies for the use of HCQ in patients with COVID-19.', 'Pre-proof article repositories like MedRxiv, BioRxiv, and ChemRxiv were also included in the search.', 'The literature was critically appraised.', 'Results: Total 71 articles were available as of 15 th April of which articles of relevance (three invitro studies, two open label non-randomized trials, two open label randomized control trials, one follow-up study, three reviews, ten short communications) and 88 clinical trials registered in three clinical trial registries were analyzed.', 'HCQ seems to be efficient in inhibiting of SARS CoV-2 in in-vitro cell lines; there is lack of strong evidence from human studies.', 'Conclusions: The in-vitro cell culture based data of viral inhibition does not suffice for the use of hydroxychloroquine in the patients with COVID-19.', 'Currently literature shows inadequate, low level evidence in human studies.', 'Scarcity of safety and efficacy data warrants medical communities, health care agencies and governments across the world against the widespread use of HCQ in COVID-19 prophylaxis and treatment, until robust evidence becomes available.', 'Keywords: Hydroxychloroquine, SARS-CoV-2, COVID-19, Corona virus, nCov2, systematic review']\n",
            "unmatched tags:  [{'entity': 'Corona virus', 'type': 'Disease', 'start': 1969, 'end': 1981}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1959, 'end': 1967}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1947, 'end': 1957}, {'entity': 'Hydroxychloroquine', 'type': 'Drug', 'start': 1927, 'end': 1945}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1840, 'end': 1848}, {'entity': 'HCQ', 'type': 'Drug', 'start': 1833, 'end': 1836}, {'entity': 'governments', 'type': 'Organization', 'start': 1774, 'end': 1785}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1596, 'end': 1604}, {'entity': 'hydroxychloroquine', 'type': 'Drug', 'start': 1556, 'end': 1574}, {'entity': 'SARS', 'type': 'Disease', 'start': 1366, 'end': 1370}, {'entity': 'HCQ', 'type': 'Drug', 'start': 1323, 'end': 1326}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 830, 'end': 838}, {'entity': 'HCQ', 'type': 'Drug', 'start': 809, 'end': 812}, {'entity': 'EMBASE', 'type': 'Chemical', 'start': 642, 'end': 648}, {'entity': 'pre-print', 'type': 'Chemical', 'start': 579, 'end': 588}, {'entity': 'HCQ', 'type': 'Drug', 'start': 545, 'end': 548}, {'entity': 'HCQ', 'type': 'Drug', 'start': 468, 'end': 471}, {'entity': 'hydroxychloroquine', 'type': 'Drug', 'start': 448, 'end': 466}, {'entity': 'drug', 'type': 'Drug', 'start': 377, 'end': 381}]\n",
            "['Peripheral nervous system involvement in patients with cancer\\tInvolvement of the peripheral nervous system (PNS) is common in patients with cancer and any part, including motor neurons, sensory ganglia, nerve roots, plexuses, cranial and peripheral nerves, and neuromuscular junctions, can be affected.', 'Different mechanisms can initiate damage associated with cancer-related PNS disorders.', 'These include tumour infiltration, toxicity of treatments, metabolic and nutritional perturbations, cachexia, virus infections, and paraneoplastic neurological syndromes.', 'The type of cancer, lymphoma, or solid tumour is a further determinant of a PNS disorder.']\n",
            "unmatched tags:  [{'entity': 'PNS disorder', 'type': 'Disease', 'start': 637, 'end': 649}, {'entity': 'solid tumour', 'type': 'Disease', 'start': 594, 'end': 606}, {'entity': 'lymphoma', 'type': 'Disease', 'start': 581, 'end': 589}, {'entity': 'cancer', 'type': 'Disease', 'start': 573, 'end': 579}, {'entity': 'paraneoplastic neurological syndromes', 'type': 'Disease', 'start': 522, 'end': 559}, {'entity': 'virus infections', 'type': 'Disease', 'start': 500, 'end': 516}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'nCoV', 'type': 'Virus', 'start': 70, 'end': 74}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'nCoV', 'type': 'Virus', 'start': 1094, 'end': 1098}\n",
            "['Beyond registration—measuring the public-health potential of new treatments for malaria in Africa\\tMalaria claims over one million lives a year in some of the poorest countries of the world.', 'Affected populations and governments cannot afford to pay for expensive new therapies.', 'Most antimalarial treatments are purchased from local shops and administered in the home.', 'These factors make for a complex set of requirements for any new treatment for malaria if a substantial reduction in mortality is ever to be achieved.', 'Thankfully there are several treatments being developed, mostly within public–private partnerships.']\n",
            "unmatched tags:  [{'entity': 'private partnerships', 'type': 'Organization', 'start': 596, 'end': 616}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNA', 'type': 'Gene', 'start': 765, 'end': 768}\n",
            "['Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts\\tBackground Rapid spread of SARS-CoV-2 in Wuhan prompted heightened surveillance in Shenzhen and elsewhere in China.', 'The resulting data provide a rare opportunity to measure key metrics of disease course, transmission, and the impact of control.', 'Methods The Shenzhen CDC identified 391 SARS-CoV-2 cases from January 14 to February 12, 2020 and 1286 close contacts.', 'We compare cases identified through symptomatic surveillance and contact tracing, and estimate the time from symptom onset to confirmation, isolation, and hospitalization.', 'We estimate metrics of disease transmission and analyze factors influencing transmission risk.', 'Findings Cases were older than the general population (mean age 45) and balanced between males (187) and females (204).', 'Ninety-one percent had mild or moderate clinical severity at initial assessment.', 'Three have died, 225 have recovered (median time to recovery is 21 days).', 'Cases were isolated on average 4.6 days after developing symptoms; contact tracing reduced this by 1.9 days.', 'Household contacts and those travelling with a case where at higher risk of infection (ORs 6 and 7) than other close contacts.', 'The household secondary attack rate was 15%, and children were as likely to be infected as adults.', 'The observed reproductive number was 0.4, with a mean serial interval of 6.3 days.', 'Interpretation Our data on cases as well as their infected and uninfected close contacts provide key insights into SARS-CoV-2 epidemiology.', 'This work shows that heightened surveillance and isolation, particularly contact tracing, reduces the time cases are infectious in the community, thereby reducing R. Its overall impact, however, is uncertain and highly dependent on the number of asymptomatic cases.', 'We further show that children are at similar risk of infection as the general population, though less likely to have severe symptoms; hence should be considered in analyses of transmission and control.']\n",
            "unmatched tags:  [{'entity': 'symptom', 'type': 'Phenotype', 'start': 1828, 'end': 1835}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1556, 'end': 1566}, {'entity': 'household secondary attack rate', 'type': 'Chemical', 'start': 1263, 'end': 1294}, {'entity': 'ORs', 'type': 'Drug', 'start': 1219, 'end': 1222}]\n",
            "[\"Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth\\tHIV protease inhibitors are antiretroviral drugs that block the enzyme required for production of infectious viral particles.\", 'Although these agents have been designed to selectively bind to the catalytic site of HIV protease, evidence indicates that other cellular and microbial enzymes and pathways are also affected.', \"It has been reported that patients treated with highly active anti-retroviral therapy (HAART) containing a protease inhibitor may be at reduced risk of Kaposi's sarcoma (KS) and some types of non-Hodgkin lymphomas; some disease regressions have also been described.\"]\n",
            "unmatched tags:  [{'entity': 'non-Hodgkin lymphomas', 'type': 'Disease', 'start': 586, 'end': 607}, {'entity': \"Kaposi's sarcoma\", 'type': 'Disease', 'start': 546, 'end': 562}, {'entity': 'protease inhibitor', 'type': 'Drug', 'start': 501, 'end': 519}, {'entity': 'enzymes', 'type': 'Gene', 'start': 354, 'end': 361}, {'entity': 'HIV protease', 'type': 'Gene', 'start': 287, 'end': 299}, {'entity': 'enzyme', 'type': 'Gene', 'start': 139, 'end': 145}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'transcription factor', 'type': 'Gene', 'start': 502, 'end': 522}\n",
            "['CHOP and IRE1α-XBP1/JNK signaling promote Newcastle Disease Virus induced apoptosis and benefit virus proliferation\\tNewcastle disease virus (NDV) causes severe infectious disease in poultry, and selectively kills tumor cells by inducing apoptosis.', 'In this report, we revealed the mechanisms underlying NDV-induced apoptosis via investigation of endoplasmic reticulum (ER) stress-related unfolded protein response (UPR) in HeLa cells.', 'We found that NDV infection induced the expression of pro-apoptotic transcription factor CHOP via PKR-eIF2α pathway.', 'Knock down and exogenous expression studies showed that CHOP promoted cell apoptosis by down-regulation of anti-apoptotic protein BCL-2 and MCL-1, promotion of pro-apoptotic JNK and p38 signaling, and suppression of pro-survival AKT signaling.', 'Meanwhile, CHOP facilitated NDV proliferation.', 'Furthermore, virus infection activated IRE1α, another ER stress sensor, thereby promoting the mRNA splicing of XBP1 and resulting in the translation of transcription factor XBP1s.', 'XBP1s entered into cell nucleus, promoted the expression of ER chaperones and components of ER associated degradation (ERAD).', 'Exogenous expression of XBP1s helped IBV proliferation, and silence of XBP1s reduced virus proliferation.', 'Meanwhile, exogenous expression and knock down studies demonstrated that IRE1α activated pro-apoptotic JNK signaling, promoted apoptosis and inflammation.', 'In conclusion, our current study demonstrates that the induction of CHOP and activation of IRE1α-XBP1/JNK signaling cascades promote apoptosis and benefit NDV proliferation.', 'IMPORTANCE It is well known that NDV kills host animal and tumor cells by inducing cell apoptosis.', 'Although several studies investigate the apoptotic phenomena in NDV-infected tumor cells, the molecular mechanisms underlying this oncolytic virus induced apoptosis is not well understood yet.', 'In this study, we focus on characterization of the ER stress responses in NDV-infected tumor cells, and find that virus induces apoptosis by up-regulation or activation of several unfolded protein responses (UPR) related transcription factors and signaling: such as ATF4, CHOP and XBP1s, and pro-apoptotic kinases (IRE1α, JNK, p38).', 'Moreover, activation of these transcription factors and signaling cascades helps virus proliferation.', 'Our study dissects the UPR induced apoptosis in NDV-infected tumor cells, and provides the evidence that UPR favors NDV proliferation.']\n",
            "unmatched tags:  [{'entity': 'NDV', 'type': 'Virus', 'start': 2426, 'end': 2429}, {'entity': 'transcription factors', 'type': 'Gene', 'start': 2238, 'end': 2259}, {'entity': 'p38', 'type': 'Gene', 'start': 2202, 'end': 2205}, {'entity': 'JNK', 'type': 'Gene', 'start': 2197, 'end': 2200}, {'entity': 'IRE1α', 'type': 'Gene', 'start': 2190, 'end': 2195}, {'entity': 'pro-apoptotic kinases', 'type': 'Gene', 'start': 2167, 'end': 2188}, {'entity': 'XBP1s', 'type': 'Chemical', 'start': 2156, 'end': 2161}, {'entity': 'ATF4', 'type': 'Gene', 'start': 2141, 'end': 2145}, {'entity': 'transcription factors', 'type': 'Gene', 'start': 2096, 'end': 2117}, {'entity': 'ER', 'type': 'Gene', 'start': 1926, 'end': 1928}, {'entity': 'oncolytic virus', 'type': 'Virus', 'start': 1813, 'end': 1828}, {'entity': 'NDV', 'type': 'Virus', 'start': 1616, 'end': 1619}, {'entity': 'NDV', 'type': 'Virus', 'start': 1564, 'end': 1567}, {'entity': 'JNK', 'type': 'Gene', 'start': 1511, 'end': 1514}, {'entity': 'XBP1', 'type': 'Gene', 'start': 1506, 'end': 1510}, {'entity': 'JNK', 'type': 'Gene', 'start': 1357, 'end': 1360}, {'entity': 'pro-apoptotic', 'type': 'Gene', 'start': 1343, 'end': 1356}, {'entity': 'IRE1α', 'type': 'Gene', 'start': 1327, 'end': 1332}, {'entity': 'XBP1s', 'type': 'Chemical', 'start': 1219, 'end': 1224}, {'entity': 'silence', 'type': 'Disease', 'start': 1208, 'end': 1215}]\n",
            "['A Mini Review on Current Clinical and Research Findings for Children Suffering from COVID-19\\tBackground: As the novel coronavirus triggering COVID-19 has broken out in Wuhan, China and spread rapidly worldwide, it threatens the lives of thousands of people and poses a global threat on the economies of the entire world.', 'However, infection with COVID-19 is currently rare in children.', 'Objective To discuss the latest findings and research focus on the basis of characteristics of children confirmed with COVID-19, and provide an insight into the future treatment and research direction.', 'Methods: We searched the terms \"COVID-19 OR coronavirus OR SARS-CoV-2\" AND \"Pediatric OR children\" on PubMed, Embase, Cochrane library, NIH, CDC, and CNKI.', 'The authors also reviewed the guidelines published on Chinese CDC and Chinese NHC.', 'Results: We included 25 published literature references related to the epidemiology, clinical manifestation, accessary examination, treatment, and prognosis of pediatric patients with COVID-19.', 'Conclusion: The numbers of children with COVID‐19 pneumonia infection are small, and most of them come from family aggregation.', 'Symptoms are mainly mild or even asymptomatic, which allow children to be a risk factor for transmission.', 'Thus, strict epidemiological history screening is needed for early diagnosis and segregation.', 'This holds especially for infants, who are more susceptible to infection than other age groups in pediatric age, but have most likely subtle and unspecific symptoms.', 'They need to be paid more attention to.', 'CT examination is a necessity for screening the suspected cases, because most of the pediatric patients are mild cases, and plain chest X-ray do not usually show the lesions or the detailed features.', 'Therefore, early chest CT examination combined with pathogenic detection is a recommended clinical diagnosis scheme in children.', 'The risk factors which may suggest severe or critical progress for children are: Fast respiratory rate and/or; lethargy and drowsiness mental state and/or; lactate progressively increasing and/or; imaging showed bilateral or multi lobed infiltration, pleural effusion or rapidly expending of lesions in a short period of time and/or; less than 3 months old or those who underly diseases.', 'For those critical pediatric patients with positive SARS-CoV-2 diagnosis, polypnea may be the most common symptom.', 'For treatment, the elevated PCT seen in children in contrast to adults suggests that the underlying coinfection/secondary infection may be more common in pediatric patients and appropriate antibacterial treatment should be considered.', 'Once cytokine storm is found in these patients, anti-autoimmune or blood-purifying therapy should be given in time.', 'Furthermore, effective isolation measures and appropriate psychological comfort need to be provided timely.']\n",
            "unmatched tags:  [{'entity': 'cytokine storm', 'type': 'Gene', 'start': 2629, 'end': 2643}, {'entity': 'antibacterial treatment', 'type': 'Drug', 'start': 2578, 'end': 2601}, {'entity': 'coinfection/secondary infection', 'type': 'Disease', 'start': 2489, 'end': 2520}, {'entity': 'PCT', 'type': 'Disease', 'start': 2417, 'end': 2420}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 2380, 'end': 2387}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2326, 'end': 2336}, {'entity': 'diseases', 'type': 'Disease', 'start': 2264, 'end': 2272}, {'entity': 'lactate', 'type': 'Drug', 'start': 2042, 'end': 2049}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'gene', 'type': 'Gene', 'start': 578, 'end': 582}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 185, 'end': 191}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'S1', 'type': 'Gene', 'start': 201, 'end': 203}\n",
            "['Repurposed Single Inhibitor for Serine Protease and Spike Glycoproteins of SAR-CoV-2\\tIn this research, structure of SARS-CoV-2 spike glycoprotein S1 and S2 along with TMPRSS2, TMPRSS4, TMPRSS11A, TMPRSS11D and TMPRSS11E serine protease (which activates S1 and S2) are used for docking with repurposed inhibitor drug molecules.', 'We searched for a universally active drug molecule which binds with glycoproteins and serine protease with binding energy above a pre-set threshold value, thus single handedly inhibits the virus glycoprotein interaction with ACE-II receptor on human cell preventing the virus RNA transfer to human cell.', 'Through data analysis performed on binding energies of the selected repurposed inhibitors, we found out five molecules to have high binding energies on both spike glycoproteins and serine protease, while showing less variance in their binding energies.', 'Among these five, Edoxaban is an FDA approved commercially available drug molecule.', 'Hence, high binding molecular inhibitors for spike glycoprotein and serine protease for treatment of SARS-CoV-2 were identified.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1069, 'end': 1079}, {'entity': 'serine protease', 'type': 'Gene', 'start': 1036, 'end': 1051}, {'entity': 'spike glycoprotein', 'type': 'Gene', 'start': 1013, 'end': 1031}, {'entity': 'Edoxaban', 'type': 'Drug', 'start': 902, 'end': 910}, {'entity': 'serine protease', 'type': 'Gene', 'start': 812, 'end': 827}, {'entity': 'spike glycoproteins', 'type': 'Drug', 'start': 788, 'end': 807}, {'entity': 'virus RNA transfer', 'type': 'Gene', 'start': 597, 'end': 615}, {'entity': 'serine protease', 'type': 'Gene', 'start': 413, 'end': 428}, {'entity': 'glycoproteins', 'type': 'Drug', 'start': 395, 'end': 408}]\n",
            "['Comparative analysis of gene expression in virulent and attenuated strains of infectious bronchitis virus at sub-codon resolution\\tInfectious bronchitis virus (IBV) is a member of the genus Gammacoronavirus and the causative agent of avian infectious bronchitis.', 'IBV has a single-stranded, positive-sense RNA genome ~27 kb in length and, like all coronaviruses, produces a set of sub-genomic messenger RNAs (sgmRNAs) synthesised via the viral polymerase.', 'Here, we used RNA sequencing (RNASeq) and ribosome profiling (RiboSeq) to delineate gene expression in the IBV M41-CK and Beau-CK strains at sub-codon resolution.', 'Quantification of reads flanking the programmed ribosomal frameshifting (PRF) signal at the genomic RNA ORF1a/ORF1b junction revealed that PRF in IBV is highly efficient (33–40%), consistent with in vitro measurements.', 'Triplet phasing of the profiling data allowed precise determination of reading frames and revealed the translation of two intergenic genes (4b and 4c on sgmRNA4), which are widely conserved across IBV isolates.', 'RNASeq revealed two novel transcription junction sites in the attenuated Beau-CK strain, one of which would generate a sgmRNA encoding a ribosomally occupied ORF in the viral 3’ untranslated region (dORF).', 'Within IBV transcripts, the nucleocapsid (N) protein was unexpectedly found to be inefficiently translated, despite being an abundant structural component of mature IBV virions.', 'Finally, we demonstrate that the host cell response to IBV occurs primarily at the level of transcription, with a global up-regulation of immune-related mRNA transcripts following infection, and comparatively modest changes in the translation efficiencies of host genes.', 'IMPORTANCE IBV is a major avian pathogen and presents a substantial economic burden to the poultry industry.', 'Improved vaccination strategies are urgently needed to curb the global spread of this pathogen, and the development of suitable vaccine candidates will be aided by an improved understanding of IBV molecular biology.', 'Our high-resolution data have enabled a precise study of transcription and translation in both pathogenic and attenuated forms of IBV, and expand our understanding of gammacoronaviral gene expression.', 'We demonstrate that gene expression shows considerable intra-species variation, with single nucleotide polymorphisms associated with altered production of sgmRNA transcripts, and our RiboSeq data sets enabled us to uncover novel ribosomally occupied ORFs in both strains.', 'We also identify numerous cellular genes and gene networks that are differentially expressed during virus infection, giving insights into the host cell reponse to IBV infection.']\n",
            "unmatched tags:  [{'entity': 'IBV', 'type': 'Gene', 'start': 2663, 'end': 2666}, {'entity': 'virus infection', 'type': 'Disease', 'start': 2600, 'end': 2615}, {'entity': 'strains', 'type': 'Disease', 'start': 2491, 'end': 2498}, {'entity': 'ORFs', 'type': 'Gene', 'start': 2478, 'end': 2482}, {'entity': 'ribosomally occupied', 'type': 'Organization', 'start': 2457, 'end': 2477}, {'entity': 'RiboSeq', 'type': 'Chemical', 'start': 2411, 'end': 2418}, {'entity': 'transcripts', 'type': 'Gene', 'start': 2390, 'end': 2401}, {'entity': 'mRNA', 'type': 'Gene', 'start': 2385, 'end': 2389}, {'entity': 'IBV', 'type': 'Gene', 'start': 2157, 'end': 2160}, {'entity': 'IBV', 'type': 'Gene', 'start': 2004, 'end': 2007}, {'entity': 'candidates', 'type': 'Gene', 'start': 1947, 'end': 1957}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1939, 'end': 1946}, {'entity': 'IBV', 'type': 'Gene', 'start': 1713, 'end': 1716}, {'entity': 'transcripts', 'type': 'Gene', 'start': 1589, 'end': 1600}, {'entity': 'mRNA', 'type': 'Gene', 'start': 1584, 'end': 1588}, {'entity': 'immune-related', 'type': 'Organization', 'start': 1569, 'end': 1583}, {'entity': 'IBV', 'type': 'Gene', 'start': 1486, 'end': 1489}, {'entity': 'IBV', 'type': 'Gene', 'start': 1418, 'end': 1421}, {'entity': 'nucleocapsid', 'type': 'Gene', 'start': 1281, 'end': 1293}, {'entity': 'transcripts', 'type': 'Gene', 'start': 1264, 'end': 1275}, {'entity': 'IBV', 'type': 'Gene', 'start': 1260, 'end': 1263}, {'entity': 'dORF', 'type': 'Gene', 'start': 1246, 'end': 1250}, {'entity': 'viral 3’ untranslated region', 'type': 'Gene', 'start': 1216, 'end': 1244}, {'entity': 'ORF', 'type': 'Gene', 'start': 1205, 'end': 1208}, {'entity': 'ribosomally occupied', 'type': 'Organization', 'start': 1184, 'end': 1204}, {'entity': 'mRNA', 'type': 'Gene', 'start': 1168, 'end': 1172}, {'entity': 'Beau-CK', 'type': 'Chemical', 'start': 1120, 'end': 1127}, {'entity': 'IBV', 'type': 'Gene', 'start': 1033, 'end': 1036}, {'entity': 'mRNA', 'type': 'Gene', 'start': 991, 'end': 995}, {'entity': 'profiling', 'type': 'Gene', 'start': 859, 'end': 868}, {'entity': 'IBV', 'type': 'Gene', 'start': 763, 'end': 766}, {'entity': 'PRF', 'type': 'Gene', 'start': 756, 'end': 759}, {'entity': 'ORF', 'type': 'Gene', 'start': 727, 'end': 730}, {'entity': 'ORF', 'type': 'Gene', 'start': 721, 'end': 724}, {'entity': 'PRF', 'type': 'Gene', 'start': 690, 'end': 693}, {'entity': 'strains', 'type': 'Disease', 'start': 584, 'end': 591}, {'entity': 'Beau-CK', 'type': 'Chemical', 'start': 576, 'end': 583}, {'entity': 'M41-CK', 'type': 'Gene', 'start': 565, 'end': 571}, {'entity': 'IBV', 'type': 'Gene', 'start': 561, 'end': 564}, {'entity': 'RiboSeq', 'type': 'Chemical', 'start': 516, 'end': 523}, {'entity': 'profiling', 'type': 'Gene', 'start': 505, 'end': 514}]\n",
            "['Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation\\t2019-nCov has caused more than 80 deaths as of 27 January 2020 in China, and infection cases have been reported in more than 10 countries.', 'However, there is no approved drug to treat the disease.', '2019-nCov M pro is a potential drug target to combat the virus.', 'We built homology models based on SARS M pro structures, and docked 1903 small molecule drugs to the models.', 'Based on the docking score and the 3D similarity of the binding mode to the known M pro ligands, 4 drugs were selected for binding free energy calculations.', 'Both MM/GBSA and SIE methods voted for nelfinavir, with the binding free energy of −24.69±0.52 kcal/mol and −9.42±0.04 kcal/mol, respectively.', 'Therefore, we suggested that nelfinavir might be a potential inhibitor against 2019-nCov M pro .']\n",
            "unmatched tags:  [{'entity': '2019-nCov', 'type': 'Virus', 'start': 939, 'end': 948}, {'entity': 'nelfinavir', 'type': 'Drug', 'start': 889, 'end': 899}, {'entity': 'nelfinavir', 'type': 'Drug', 'start': 756, 'end': 766}, {'entity': 'SIE', 'type': 'Organization', 'start': 734, 'end': 737}, {'entity': 'drug', 'type': 'Drug', 'start': 659, 'end': 663}, {'entity': 'M pro ligands', 'type': 'Chemical', 'start': 642, 'end': 655}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RAS', 'type': 'Drug', 'start': 95, 'end': 98}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 446, 'end': 453}\n",
            "['Pulmonary radiological change of COVID-19 patients with 99mTc-MDP treatment\\tBackground: As increasing cases of COVID-19 around world, urgent need for effective COVID-19-specific therapeutic drugs is necessary; therefore, we conducted a pilot randomized-controlled study to evaluate the efficacy of 99mTc-MDP for COVID-19 therapeutic treatment.', 'Methods: A total of 21 mild patients with COVID-19 were enrolled in this pilot RCT from February 2020 through March 2020, and then were assigned, in a 1:1 ratio, into control (11 patients) and 99mTc-MDP group (10 patients).', 'Patients in the control group received routine treatment and patients assigned to the 99mTc-MDP group received a combination of routine treatment and an administration of 99mTc-MDP injection of 5ml/day.', 'Both of the patients in the control and 99mTc-MDP groups were treated for 7 days with the primary end point of CT-based radiological pulmonary changes during 7-day follow-up.', 'Findings: From baseline to the day 7, 8 (80%) of 10 mild patients in the 99mTc-MDP group had a significant radiological improvement in lung and a decline in inflammatory infiltration, whereas only 1 (9.1%) of 11 patients in the control group had a radiological improvement in lung.', 'None of the patients in the 99mTc-MDP group had disease progression from mild to severe, as well as an inflammatory cytokine storm, and 2 mild patients (18.2%) in the control group developed severe.', 'During days 7 through 14, the number of patients with radiological improvement in the 99mTc-MDP group remained consistent, and only 1 additional case (22%) in the control group were reported.', 'Conclusion: In this randomized pilot study, 99mTc-MDP had an effective inhibitory effect on the inflammatory disease progression for the therapy of COVID-19, and it can accelerate the absorption of pulmonary inflammation in a short period of time during the process of treatment.']\n",
            "unmatched tags:  [{'entity': 'pulmonary inflammation', 'type': 'Disease', 'start': 1819, 'end': 1841}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1769, 'end': 1777}, {'entity': 'inflammatory disease', 'type': 'Disease', 'start': 1717, 'end': 1737}, {'entity': '99mTc-MDP', 'type': 'Drug', 'start': 1665, 'end': 1674}, {'entity': '99mTc-MDP group', 'type': 'Drug', 'start': 1515, 'end': 1530}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'lung diseases', 'type': 'Disease', 'start': 203, 'end': 216}\n",
            "['Occupational lung diseases: from old and novel exposures to effective preventive strategies\\tOccupational exposure is an important, global cause of respiratory disease.', 'Unlike many other non-communicable lung diseases, the proximal causes of many occupational lung diseases are well understood and they should be amenable to control with use of established and effective approaches.', 'Therefore, the risks arising from exposure to silica and asbestos are well known, as are the means of their prevention.', 'Although the incidence of occupational lung disease has decreased in many countries, in parts of the world undergoing rapid economic transition and population growth—often with large informal and unregulated workforces—occupational exposures continue to impose a heavy burden of disease.']\n",
            "unmatched tags:  [{'entity': 'occupational lung disease', 'type': 'Disease', 'start': 528, 'end': 553}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 678, 'end': 687}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'prolapse', 'type': 'Disease', 'start': 35, 'end': 43}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'midazolam', 'type': 'Drug', 'start': 129, 'end': 138}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cytomegalovirus', 'type': 'Virus', 'start': 429, 'end': 444}\n",
            "['DeepTracer: Predicting Backbone Atomic Structure from High Resolution Cryo-EM Density Maps of Protein Complexes\\tMotivation Accurately determining the atomic structure of proteins represents a fundamental problem in the field of structural bioinformatics.', 'A solution would be significant as protein structure information could be utilized in the medical field, e.g.', 'in the development of vaccines for new viruses.', 'This paper focuses on predicting the protein structure based on 3D images of the proteins captured through cryogenic electron microscopes (cryo-EM).', 'A fully automated computationally efficient protein structure prediction method would be particularly beneficial in the field of cryo-EM as the technology allows researchers to photograph multiple large protein complexes in a single study, which means that a fast prediction method could allow for a high throughput of derived protein structures.', 'We present a deep learning approach, DeepTracer, for predicting locations of the backbone atoms, secondary structure elements, and the amino acid types.', 'In order to connect the predicted amino acids into chains, we applied a modified traveling salesman algorithm.', 'Results We trained our deep learning model on experimental cryo-EM density maps and tested it on a set of 50 density maps.', 'We found that our new approach predicted protein structures with an average RMSD value of 1.18 and a coverage of 87.5%.', 'Furthermore, we detected secondary structure information for 87.2% of amino acids correctly.', 'We also showed preliminarily that 25.2% of amino acid types could be predicted directly from the 3D cryo-EM density map, considering 20 different types in total.', 'Finally, we noted that the prediction runtime of DeepTracer is significantly improved compared to other methods.', 'It predicts a large protein complex structure of more than 30,000 amino acids in only 2 hours.', 'Availability The repository of this project will be published.', 'Contact  dongsi{at}uw.edu Supplementary information Supplementary data will be available at Bioinformatics online.']\n",
            "unmatched tags:  [{'entity': 'amino acids', 'type': 'Gene', 'start': 1850, 'end': 1861}, {'entity': 'protein complex', 'type': 'Gene', 'start': 1804, 'end': 1819}, {'entity': 'DeepTracer', 'type': 'Disease', 'start': 1720, 'end': 1730}, {'entity': 'cryo-EM', 'type': 'Gene', 'start': 1609, 'end': 1616}, {'entity': 'amino acid types', 'type': 'Gene', 'start': 1552, 'end': 1568}, {'entity': 'amino acids', 'type': 'Gene', 'start': 1486, 'end': 1497}, {'entity': 'protein structures', 'type': 'Gene', 'start': 1337, 'end': 1355}, {'entity': 'cryo-EM', 'type': 'Gene', 'start': 1232, 'end': 1239}, {'entity': 'amino acids', 'type': 'Gene', 'start': 1096, 'end': 1107}, {'entity': 'amino acid types', 'type': 'Gene', 'start': 1044, 'end': 1060}, {'entity': 'DeepTracer', 'type': 'Disease', 'start': 946, 'end': 956}]\n",
            "['LONG-TERM CLINICAL OUTCOMES IN SURVIVORS OF CORONAVIRUS OUTBREAKS AFTER HOSPITALISATION OR ICU ADMISSION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF FOLLOW-UP STUDIES\\tObjective: To determine the long-term clinical problems in adult survivors of coronavirus (CoV) infection [Coronavirus disease 2019 (COVID-19), Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS)] after hospitalisation or Intensive Care Unit (ICU) admission.', 'Design: Systematic review and meta-analysis of the literature.', 'Data sources: Ovid MEDLINE, EMBASE, CINAHL Plus and PsycINFO were searched using the strategy: (Coronavirus OR Coronavirus Infections OR COVID OR SARS virus OR Severe acute respiratory syndrome OR MERS OR Middle east respiratory syndrome) AND (Follow-up OR Follow-up studies OR Prevalence).', 'Original studies reporting the clinical outcomes of adult survivors of coronavirus outbreaks two months after discharge or three months after admission were included.', 'The quality of the studies was assessed using the Oxford Centre for Evidence-Based Medicine (OCEBM) 2009 Level of Evidence Tool.', 'Meta-analysis was conducted to derive pooled estimates of prevalence and severity for different outcomes at time points up to 6 months follow-up and beyond 6 months follow-up.', 'Results: The search yielded 1169 studies of which 28 were included in this review.', 'There were 15 Level 1b, 8 Level 2b, 2 Level 3b and 3 Level 4 studies by OCEBM grading.', 'Pooled analysis of studies revealed that complications commonly observed were impaired diffusing capacity for carbon monoxide (DLCO) [prevalence of 27.26%, 95% CI 14.87 to 44.57] and reduced exercise capacity [(6-minute walking distance (6MWD) mean 461m, 95% CI 449.66 to 472.71] at 6 months with limited improvement beyond 6 months.', 'Coronavirus survivors had considerable prevalence of psychological disorders such as post-traumatic stress disorder (PTSD) [38.80%, CI 30.93 to 47.31], depression [33.20%, CI 19.80 to 50.02] and anxiety [30.04%, CI 10.44 to 61.26) beyond 6 months.', 'These complications were accompanied by low Short Form 36 (SF-36) scores at 6 months and beyond indicating reduced quality of life which is present long-term.', 'Conclusions: The long term clinical problems in survivors of CoV infections (SARS and MERS) after hospitalisation or Intensive Care Unit (ICU) admission include respiratory dysfunction, reduced exercise capacity, psychological problems such as PTSD, depression and anxiety, and reduced quality of life.', 'Critical care, rehabilitation and mental health services should anticipate a high prevalence of these problems following COVID-19 and ensure their adequate and timely management with the aim of restoring premorbid quality of life.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2619, 'end': 2627}, {'entity': 'depression', 'type': 'Disease', 'start': 2445, 'end': 2455}, {'entity': 'PTSD', 'type': 'Disease', 'start': 2439, 'end': 2443}, {'entity': 'MERS', 'type': 'Disease', 'start': 2281, 'end': 2285}, {'entity': 'SARS', 'type': 'Disease', 'start': 2272, 'end': 2276}, {'entity': 'depression', 'type': 'Disease', 'start': 1940, 'end': 1950}, {'entity': 'PTSD', 'type': 'Disease', 'start': 1905, 'end': 1909}, {'entity': 'post-traumatic stress disorder', 'type': 'Disease', 'start': 1873, 'end': 1903}, {'entity': 'psychological disorders', 'type': 'Disease', 'start': 1841, 'end': 1864}, {'entity': 'Coronavirus', 'type': 'Virus', 'start': 1788, 'end': 1799}, {'entity': '6MWD', 'type': 'Gene', 'start': 1692, 'end': 1696}, {'entity': 'carbon monoxide', 'type': 'Chemical', 'start': 1564, 'end': 1579}, {'entity': 'Level', 'type': 'Drug', 'start': 1420, 'end': 1425}, {'entity': 'Level', 'type': 'Drug', 'start': 1405, 'end': 1410}, {'entity': 'Level', 'type': 'Drug', 'start': 1393, 'end': 1398}, {'entity': 'Level', 'type': 'Drug', 'start': 1381, 'end': 1386}, {'entity': 'Level', 'type': 'Drug', 'start': 1083, 'end': 1088}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 882, 'end': 893}, {'entity': 'Middle east respiratory syndrome', 'type': 'Disease', 'start': 725, 'end': 757}, {'entity': 'MERS', 'type': 'Disease', 'start': 717, 'end': 721}, {'entity': 'acute respiratory syndrome', 'type': 'Disease', 'start': 687, 'end': 713}, {'entity': 'SARS', 'type': 'Disease', 'start': 666, 'end': 670}, {'entity': 'COVID', 'type': 'Virus', 'start': 657, 'end': 662}, {'entity': 'Coronavirus Infections', 'type': 'Disease', 'start': 631, 'end': 653}, {'entity': 'Coronavirus', 'type': 'Virus', 'start': 616, 'end': 627}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cholera', 'type': 'Drug', 'start': 184, 'end': 191}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cholera', 'type': 'Drug', 'start': 422, 'end': 429}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'pamoate', 'type': 'Drug', 'start': 97, 'end': 104}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'pamoate', 'type': 'Drug', 'start': 162, 'end': 169}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'pamoate', 'type': 'Drug', 'start': 222, 'end': 229}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'pamoate', 'type': 'Drug', 'start': 375, 'end': 382}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'pamoate', 'type': 'Drug', 'start': 509, 'end': 516}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diseases', 'type': 'Disease', 'start': 180, 'end': 188}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronary artery disease', 'type': 'Disease', 'start': 270, 'end': 293}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tumours', 'type': 'Disease', 'start': 242, 'end': 249}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tumours', 'type': 'Disease', 'start': 382, 'end': 389}\n",
            "['All-in-One Dual CRISPR-Cas12a (AIOD-CRISPR) Assay: A Case for Rapid, Ultrasensitive and Visual Detection of Novel Coronavirus SARS-CoV-2 and HIV virus\\tA recent outbreak of novel coronavirus (SARS-CoV-2), the causative agent of COVID-19, has spread rapidly all over the world.', 'Human immunodeficiency virus (HIV) is another deadly virus and causes acquired immunodeficiency syndrome (AIDS).', 'Rapid and early detection of these viruses will facilitate early intervention and reduce disease transmission risk.', 'Here, we present an A ll- I n- O ne D ual CRISPR -Cas12a (termed “AIOD-CRISPR”) assay method for simple, rapid, ultrasensitive, one-pot, and visual detection of coronavirus SARS-CoV-2 and HIV virus.', 'In our AIOD CRISPR assay, a pair of crRNAs was introduced to initiate dual CRISPR-Cas12a detection and improve detection sensitivity.', 'The AIOD-CRISPR assay system was successfully utilized to detect nucleic acids (DNA and RNA) of SARS-CoV-2 and HIV with a sensitivity of few copies.', 'Also, it was evaluated by detecting HIV-1 RNA extracted from human plasma samples, achieving a comparable sensitivity with real-time RT-PCR method.', 'Thus, our method has a great potential for developing next-generation point-of-care molecular diagnostics.']\n",
            "unmatched tags:  [{'entity': 'HIV-1 RNA', 'type': 'Virus', 'start': 1023, 'end': 1032}, {'entity': 'HIV', 'type': 'Virus', 'start': 949, 'end': 952}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 934, 'end': 944}, {'entity': 'RNA', 'type': 'Gene', 'start': 926, 'end': 929}, {'entity': 'DNA', 'type': 'Gene', 'start': 918, 'end': 921}, {'entity': 'nucleic acids', 'type': 'Gene', 'start': 903, 'end': 916}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tumours', 'type': 'Disease', 'start': 421, 'end': 428}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'nephropathy', 'type': 'Disease', 'start': 642, 'end': 653}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'syndrome', 'type': 'Disease', 'start': 110, 'end': 118}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 120, 'end': 129}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'doxycycline', 'type': 'Drug', 'start': 152, 'end': 163}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tuberculosis', 'type': 'Disease', 'start': 374, 'end': 386}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'fatty liver', 'type': 'Disease', 'start': 237, 'end': 248}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'fat', 'type': 'Drug', 'start': 237, 'end': 240}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'NOS', 'type': 'Gene', 'start': 496, 'end': 499}\n",
            "['COVID-19 pandemic scenario in India compared to China and rest of the world: a data driven and model analysis\\tThe COVID-19 is a rapidly spreading respiratory illness caused with the infection of SARS-CoV-2.', 'The COVID-19 data from India was compared with China and rest of the world.', 'The average values of daily growth rate (DGR), case recovery rate (CRR), case fatality rate (CFR), serial interval (SI) of COVID-19 in India was 17%, 8.25%, and 1.87%, and 5.76 days respectively, as of April 9, 2020.', 'The data driven estimates of basic reproduction number (R0), average reproduction number (R) and effective reproduction number (Re) were 1.03, 1.73, and 1.35, respectively.', 'The results of exponential and SIR model showed higher estimates of R0, R and Re.', 'The data driven as well as estimated COVID-19 cases reflect the growing nature of the epidemic in India and world excluding China, whereas the same in China reveal the involved population became infected with the disease and moved into the recovered stage.', 'The epidemic size of India was estimated to be ~30,284 (as of April 15, 2020 with 12,370 infectious cases) with an estimated end of the epidemic on June 9, 2020.', 'The Re values in India before and after lockdown were 1.62 and 1.37 respectively, with SI 5.52 days and 5.98 days, respectively, as of April 17, 2020, reflecting the effectiveness of lockdown strategies.', 'Beyond April 17, 2020, our estimate of 24,431 COVID-19 infected cases with lockdown is 78% lower compared to the 112,042 case estimates in absence of lockdown, on April 27, 2020.', 'To early end of the COVID-19 epidemic, strong social distancing is important.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1577, 'end': 1585}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1424, 'end': 1432}, {'entity': 'SI', 'type': 'Gene', 'start': 1261, 'end': 1263}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 792, 'end': 800}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'pancreatitis', 'type': 'Disease', 'start': 25, 'end': 37}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 191, 'end': 197}\n",
            "['An ecological study of socioeconomic predictors in detection of COVID-19 cases across neighborhoods in New York City\\tAbstract Background: New York City was the first major urban center of the COVID-19 pandemic in the USA.', 'Cases are clustered in the city, with certain neighborhoods experiencing more cases than others.', 'We investigate whether potential socioeconomic factors can explain between-neighborhood variation in the number of detected COVID-19 cases.', 'Methods: Data were collected from 177 Zip Code Tabulation Areas (ZCTA) in New York City (99.9% of the population).', 'We fit multiple Bayesian Besag-York-Mollié (BYM) mixed models using positive COVID-19 tests as the outcome and a set of 10 representative economic, demographic, and health-care associated ZCTA-level parameters as potential predictors.', 'The BYM model includes both spatial and nonspatial random effects to account for clustering and overdispersion.', 'Results: Multiple different regression approaches indicated a consistent, statistically significant association between detected COVID-19 cases and dependent (under 18 or 65+ years old) population, male to female ratio, and median household income.', 'In the final model, we found that an increase of only 1% in dependent population is associated with a 2.5% increase in detected COVID-19 cases (95% confidence interval (CI): 1.6% to 3.4%, p < 0.0005).', 'An increase of 1 male per 100 females is associated with a 1.0% (95% CI: 0.6% to 1.5%, p < 0.0005) increases in detected cases.', 'A decrease of $10,000 median household income is associated with a 2.5% (95% CI: 1.0% to 4.1% p = 0.002) increase in detected COVID-19 cases.', 'Conclusions: Our findings indicate associations between neighborhoods with a large dependent population, those with a high proportion of males, and low-income neighborhoods and detected COVID-19 cases.', 'Given the elevated mortality in aging populations, the study highlights the importance of public health management during and after the current COVID-19 pandemic.', 'Further work is warranted to fully understand the mechanisms by which these factors may have affected the number of detected cases, either in terms of the true number of cases or access to testing.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1990, 'end': 1998}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1830, 'end': 1838}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1627, 'end': 1635}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1300, 'end': 1308}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1052, 'end': 1060}]\n",
            "['Impact of Social Distancing Measures on COVID-19 Healthcare Demand in Central Texas\\tA novel coronavirus (SARS-CoV-2) emerged in Wuhan, China in late 2019 and rapidly spread worldwide.', 'In the absence of effective antiviral drugs and vaccines, well-targeted social distancing measures are essential for mitigating the COVID-19 pandemic, reducing strain on local health systems, and preventing mortality.', 'Here, we provide a quantitative assessment of the efficacy of social distancing to slow COVID-19 transmission and reduce hospital surge, depending on the timing and extent of the measures imposed for a metropolitan region and its health care systems.', 'We built a granular mathematical model of COVID-19 transmission that incorporated age-specific and risk-stratified heterogeneity, estimates for the transmission, and severity of COVID-19 using current best evidence.', 'We performed thousands of stochastic simulations of COVID-19 transmission in the Austin-Round Rock Metropolitan Area to project the impact of school closures coupled with social distancing measures that were estimated to reduce non-household contacts by 0%, 25%, 50%, 75% or 90%.', 'We compare early versus late implementation and estimate the number of COVID-19 hospitalizations, ICU patients, ventilator needs and deaths through mid-August, 2020.', 'We queried local emergency services and hospital systems to estimate total hospital bed, ICU, and ventilator capacity for the region.', 'We expected COVID-19 hospital beds and ICU requirements would surpass local capacity by mid-May if no intervention was taken.', 'Assuming a four-day epidemic doubling time, school closures alone would be expected to reduce peak hospitalizations by only 18% and cumulative deaths by less than 3%.', 'Immediate social distancing measures that reduced non-household contacts by over 75%, such as stay-at-home orders and closing of non-essential businesses, would be required to ensure that COVID-19 cases do not overwhelm local hospital surge capacity.', 'Peak ICU bed demand prior to mid August 2020 would be expected to be reduced from 2,121 (95% CI: 2,018-2,208) with no intervention to 698 (95% CI: 204-1,100) with 75% social distancing and 136 (95% CI: 38-308) with 90% social distancing; current ICU bed capacity was estimated at 680.', 'A two-week delay in implementation of such measures is projected to accelerate a local ICU bed shortage by four weeks.', 'School closures alone hardly impact the epidemic curve.', 'Immediate social distancing measures that reduce non-household contacts by over 75% were required to ensure that COVID-19 cases do not overwhelm local hospital surge capacity.', 'These findings helped inform the Stay Home-Work Safe order enacted by the city of Austin, Texas on March 24, 2020 as a means of mitigating the emerging COVID-19 epidemic.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2781, 'end': 2789}, {'entity': 'Austin', 'type': 'Drug', 'start': 2711, 'end': 2717}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2566, 'end': 2574}, {'entity': 'bed', 'type': 'Disease', 'start': 2369, 'end': 2372}, {'entity': 'bed', 'type': 'Disease', 'start': 2243, 'end': 2246}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'fibromatosis', 'type': 'Disease', 'start': 165, 'end': 177}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'polymerase', 'type': 'Gene', 'start': 154, 'end': 164}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 53, 'end': 59}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 294, 'end': 300}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'osteoporosis', 'type': 'Phenotype', 'start': 80, 'end': 92}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 120, 'end': 127}\n",
            "['Getting to zero quickly in the 2019-nCov epidemic with vaccines or rapid testing\\tAny plan for stopping the ongoing 2019-nCov epidemic must be based on a quantitative understanding of the proportion of the at-risk population that needs to be protected by effective control measures in order for transmission to decline sufficiently and quickly enough for the epidemic to end.', 'Using an SEIR-type transmission model, we contrasted two alternate strategies by modeling the proportion of the population that needs to be protected from infection by one-time vaccination (assuming 100% effectiveness) or by testing with isolation and treatment of individuals within six, 24, or 48 hours of symptom onset.', 'If R is currently 2.2, vaccination at the herd immunity coverage of 55% would drive R just below 1, but transmission could persist for years.', 'Over 80% of coverage is required to end the epidemic in 6 months with population-wide vaccination.', 'The epidemic could be ended in just under a year if testing with isolation and treatment reached 80% of symptomatically infected patients within 24 hours of symptom onset (assuming 10% asymptomatic transmission).', 'The epidemic could be ended in six months if testing with isolation and treatment reached 90% of symptomatic patients.', 'If 90% of symptomatic patients could be tested within six hours of symptoms appearing, the epidemic could be ended in under four months.']\n",
            "unmatched tags:  [{'entity': 'symptom', 'type': 'Phenotype', 'start': 1281, 'end': 1288}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 1249, 'end': 1256}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 1125, 'end': 1132}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 220, 'end': 226}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'breast cancer', 'type': 'Disease', 'start': 504, 'end': 517}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronavirus', 'type': 'Virus', 'start': 1027, 'end': 1038}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tau', 'type': 'Gene', 'start': 205, 'end': 208}\n",
            "['The effect of BCG vaccination on COVID-19 examined by a statistical approach: no positive results from the Diamond Princess and cross-national differences previously reported by world-wide comparisons are flawed in several ways\\tRecently, the controversial hypothesis that BCG (Bacillus Calmette-Guerin) vaccination reduces infection or severity of COVID-19 has been proposed.', 'The present study examined this hypothesis using statistical approaches based on the public data.', 'Three approaches were utilized: 1) comparing the infection and mortality ratio of people on the cruise ship Diamond Princess, 2) comparing the number of mortalities among nations, and 3) comparing the maximum daily increase rate of total mortalities among nations.', 'The result of 1) showed that there is no significant difference in infection per person onboard and mortality-infection between Japanese citizens vs. other nationalities and BCG obligatory nations vs. non-BCG obligatory nations on the Diamond Princess.', 'The result of 2) showed that the number of mortalities among nations is similar to the previous studies, but this analysis also considered the timing of COVID-19 arrival in each nation.', 'After correcting for arrival time, previously reported effect of BCG vaccination on decreasing total mortality disappeared.', 'This is because nations that lack BCG vaccination are concentrated in Western Europe, which is near an epicenter of COVID-19.', 'Therefore some previous reports are now considered to be affected by this artifact; the result may have been flawed by on-land dispersal from an epicenter.', 'However, some results showed weakly significant differences in the number of deaths at a particular time among BCG obligatory and non-BCG nations (especially the use of Japanese BCG strain Tokyo 172).', 'However, these results are affected by the results of three countries and the effect of BCG vaccination remains inconclusive.', 'The result of 3) showed that the maximum daily increasing rate in death among nations showed no significant difference among BCG vaccination policies.', 'In the present study, although some results showed statistically significant differences among BCG vaccination policies, they may be affected by the impact of various other factors, such as national infection-control policies, social distancing, behavioral changes of people, possible previous local epidemics of closely related viruses, or inter-population differences in ACE2 or other genetic polymorphism.', 'Further research is needed to better understand the underlying cause of the observed differences in infection and mortality of the disease among nations.', 'Nevertheless, our results show that the effect of BCG vaccination, if any, can be masked by many other factors.', 'Therefore, the possible effect might be relatively small.', 'In fact, in Japan, where almost all citizens have been vaccinated, COVID-19 cases are constantly increasing.', 'Given the importance of peoples behavior in preventing viral propagation, the spread of optimism triggered by this hypothesis would be harmful to BCG vaccination nations.']\n",
            "unmatched tags:  [{'entity': 'nation', 'type': 'Organization', 'start': 3066, 'end': 3072}, {'entity': 'nation', 'type': 'Organization', 'start': 3059, 'end': 3065}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2862, 'end': 2870}, {'entity': 'nation', 'type': 'Organization', 'start': 2684, 'end': 2690}, {'entity': 'nation', 'type': 'Organization', 'start': 2616, 'end': 2622}, {'entity': 'ACE2', 'type': 'Gene', 'start': 2435, 'end': 2439}, {'entity': 'nation', 'type': 'Organization', 'start': 2252, 'end': 2258}, {'entity': 'nation', 'type': 'Organization', 'start': 2166, 'end': 2172}, {'entity': 'nation', 'type': 'Organization', 'start': 2045, 'end': 2051}, {'entity': 'nation', 'type': 'Organization', 'start': 1989, 'end': 1995}, {'entity': 'nation', 'type': 'Organization', 'start': 1882, 'end': 1888}, {'entity': 'BCG strain Tokyo 172', 'type': 'Drug', 'start': 1762, 'end': 1782}, {'entity': 'nation', 'type': 'Organization', 'start': 1722, 'end': 1728}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1418, 'end': 1426}, {'entity': 'nation', 'type': 'Organization', 'start': 1345, 'end': 1351}, {'entity': 'nation', 'type': 'Organization', 'start': 1318, 'end': 1324}, {'entity': 'nation', 'type': 'Organization', 'start': 1252, 'end': 1258}, {'entity': 'nation', 'type': 'Organization', 'start': 1170, 'end': 1176}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1145, 'end': 1153}, {'entity': 'nation', 'type': 'Organization', 'start': 1053, 'end': 1059}, {'entity': 'Diamond Princess', 'type': 'Chemical', 'start': 974, 'end': 990}, {'entity': 'nation', 'type': 'Organization', 'start': 959, 'end': 965}, {'entity': 'nation', 'type': 'Organization', 'start': 928, 'end': 934}, {'entity': 'nation', 'type': 'Organization', 'start': 895, 'end': 901}, {'entity': 'nation', 'type': 'Organization', 'start': 730, 'end': 736}, {'entity': 'nation', 'type': 'Organization', 'start': 645, 'end': 651}, {'entity': 'Diamond Princess', 'type': 'Chemical', 'start': 582, 'end': 598}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 348, 'end': 356}, {'entity': 'nation', 'type': 'Organization', 'start': 308, 'end': 314}, {'entity': 'nation', 'type': 'Organization', 'start': 134, 'end': 140}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'abdominal aortic aneurysms', 'type': 'Disease', 'start': 186, 'end': 212}\n",
            "['The worldwide emergence of plasmid-mediated quinolone resistance\\tFluoroquinolone resistance is emerging in Gram-negative pathogens worldwide.', 'The traditional understanding that quinolone resistance is acquired only through mutation and transmitted only vertically does not entirely account for the relative ease with which resistance develops in exquisitely susceptible organisms, or for the very strong association between resistance to quinolones and to other agents.', 'The recent discovery of plasmid-mediated horizontally transferable genes encoding quinolone resistance might shed light on these phenomena.']\n",
            "unmatched tags:  [{'entity': 'quinolone resistance', 'type': 'Drug', 'start': 552, 'end': 572}]\n",
            "['Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective\\tIn the past decade, many tyrosine-kinase inhibitors have been introduced in oncology and haemato-oncology.', 'Because this new class of drugs is extensively used, serious drug–drug interactions are an increasing risk.', 'In this Review, we give a comprehensive overview of known or suspected drug–drug interactions between tyrosine-kinase inhibitors and other drugs.', 'We discuss all haemato-oncological and oncological tyrosine-kinase inhibitors that had been approved by Aug 1, 2013, by the US Food and Drug Administration or the European Medicines Agency.']\n",
            "unmatched tags:  [{'entity': 'European Medicines Agency', 'type': 'Chemical', 'start': 603, 'end': 628}, {'entity': 'Drug', 'type': 'Drug', 'start': 576, 'end': 580}, {'entity': 'tyrosine-kinase inhibitors', 'type': 'Drug', 'start': 491, 'end': 517}, {'entity': 'drug', 'type': 'Drug', 'start': 433, 'end': 437}, {'entity': 'tyrosine-kinase inhibitors', 'type': 'Drug', 'start': 396, 'end': 422}]\n",
            "['Spermatozoal RNA profiles of normal fertile men\\tThe microarray data from testes and spermatozoa (pooled and individual) were concordant, supporting the view that a spermatozoal mRNA fingerprint can be obtained from normal fertile men.', 'Thus, profiling can be used to monitor past events—ie, gene expression of spermatogenesis.', 'Moreover, the data suggest that, in addition to delivering the paternal genome, spermatozoa provide the zygote with a unique suite of paternal mRNAs.', 'Ejaculate spermatozoa can now be used as a non-invasive proxy for investigations of testis-specific infertility.']\n",
            "unmatched tags:  [{'entity': 'mRNAs', 'type': 'Gene', 'start': 469, 'end': 474}, {'entity': 'profiling', 'type': 'Gene', 'start': 241, 'end': 250}]\n",
            "['Effect of detailed fetal echocardiography as part of routine prenatal ultrasonographic screening on detection of congenital heart disease\\tInclusion of detailed fetal echocardiography as a screening examination has a substantial effect on detection of congenital heart disease since a major proportion of prenatally detectable cases occur in a low-risk population.']\n",
            "unmatched tags:  [{'entity': 'low-risk', 'type': 'Gene', 'start': 343, 'end': 351}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'ischaemic attack', 'type': 'Disease', 'start': 313, 'end': 329}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'toxoplasmosis', 'type': 'Disease', 'start': 387, 'end': 400}\n",
            "['Prevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease\\tOtitis media is a common childhood infection of the middle ear and a major cause of morbidity.', 'This multifactorial disease manifests as a spectrum of clinical syndromes from uncomplicated acute otitis media to more complex recurrent and chronic cases (frequently polymicrobial), with the major pathogens involved being']\n",
            "unmatched tags:  [{'entity': 'polymicrobial', 'type': 'Disease', 'start': 377, 'end': 390}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'meningitis', 'type': 'Phenotype', 'start': 199, 'end': 209}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'breast cancer', 'type': 'Disease', 'start': 417, 'end': 430}\n",
            "[\"Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study\\tAD is a common cause of SCI, naMCI, and aMCI and is associated with cognitive decline in patients with naMCI or aMCI.\", 'Patients with SCI might be in the early stages of AD, and cognitive decline might become apparent only after longer follow-up.']\n",
            "unmatched tags:  [{'entity': 'aMCI', 'type': 'Organization', 'start': 320, 'end': 324}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronavirus 2', 'type': 'Virus', 'start': 32, 'end': 45}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diseases', 'type': 'Disease', 'start': 1408, 'end': 1416}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'migraine', 'type': 'Disease', 'start': 137, 'end': 145}\n",
            "['Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study\\tWe noted no significant difference in clinical outcome between patients with HIV and uninfected controls with NSCLC.', 'Survival after curative surgical resection in early-stage patients was similar in HIV-infected individuals and uninfected controls.', 'These data suggest that HIV status should not affect therapeutic decision making in NSCLC.']\n",
            "unmatched tags:  [{'entity': 'NSCLC', 'type': 'Disease', 'start': 480, 'end': 485}, {'entity': 'era', 'type': 'Gene', 'start': 451, 'end': 454}, {'entity': 'HIV', 'type': 'Virus', 'start': 420, 'end': 423}, {'entity': 'HIV-infected', 'type': 'Disease', 'start': 346, 'end': 358}, {'entity': 'NSCLC', 'type': 'Disease', 'start': 257, 'end': 262}, {'entity': 'HIV', 'type': 'Virus', 'start': 224, 'end': 227}]\n",
            "['COVID-19: Modelling Local Transmission and Morbidity effects to provide an estimate of overall Relative Healthcare Resource Impact by General Practice Granularity\\tIntroduction Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the name given to the 2019 novel coronavirus.', 'COVID-19 is the name given to the disease associated with the virus.', 'SARS-CoV-2 is a new strain of coronavirus that has not been previously identified in humans.', 'Methods Two key factors were analysed which when multiplied together would give an estimate of relative demand on healthcare utilisation.', 'These factors were case incidence and case morbidity.', 'GP Practice data was used as this provided the most geographically granular source of published public population data.', 'To analyse case incidence, the latest values for indicators that could be associated with infection transmission rates were collected from the Office of National Statistics (ONS) and Quality Outcome Framework (QOF) sources.', 'These included population density, % age >16 at fulltime work/education, % age over 60, % BME ethnicity, social deprivation as IMD 2019, Location as latitude/longitude, and patient engagement as % self-confident in their own long term condition management.', 'Average case morbidity was calculated by applying the international mortality Odds Ratio to the local population relevant age and disease prevalences and then summing and dividing by the equivalent national figure.', 'To provide a comparative measure of overall healthcare resource impact, individual GP practice impact scores were compared against the median practice.', 'Results The case incidence regression is a dynamic situation with the significance of specific factors moderating over time as the balance between external infection, community transmission and impact of mitigation measures feeds through to the number of cases.', 'It showed that currently Urban, % Working and age >60 were the strongest determinants of case incidence.', 'The local population comorbidity remains unchanged.', 'The range of relative HC impact was wide with 80% of practices falling between 20%-250% of the national median.', 'Once practice population numbers were included it showed that the top 33% of GP practices supporting 45% of the patient population would require 68% of COVID-19 healthcare resources.', 'The model provides useful information about the relative impact of Covid-19 on healthcare workload at GP practice granularity in all parts of England.', 'Conclusion Covid-19 is impacting on the utilisation of health and social care resources across the country.', 'This model provides a method for predicting relative local levels of disease burden based on defined criteria and thereby providing a method for targeting limited (and perhaps soon to be scarce) care resources to optimise national, regional and local responses to the COVID-19 outbreak.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2859, 'end': 2867}, {'entity': 'national', 'type': 'Organization', 'start': 2813, 'end': 2821}, {'entity': 'Covid-19', 'type': 'Disease', 'start': 2493, 'end': 2501}, {'entity': 'GP', 'type': 'Gene', 'start': 2433, 'end': 2435}, {'entity': 'Covid-19', 'type': 'Disease', 'start': 2398, 'end': 2406}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2300, 'end': 2308}, {'entity': 'GP', 'type': 'Gene', 'start': 2225, 'end': 2227}, {'entity': 'national median', 'type': 'Organization', 'start': 2127, 'end': 2142}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tuberculosis', 'type': 'Disease', 'start': 286, 'end': 298}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'amblyopic', 'type': 'Disease', 'start': 534, 'end': 543}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'receptor', 'type': 'Gene', 'start': 116, 'end': 124}\n",
            "['Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator-days and deaths by US state in the next 4 months\\tKey Points  Question: Assuming social distancing measures are maintained, what are the forecasted gaps in available health service resources and number of deaths from the COVID-19 pandemic for each state in the United States?', 'Findings: Using a statistical model, we predict excess demand will be 64,175 (95% UI 7,977 to 251,059) total beds and 17,380 (95% UI 2,432 to 57,955) ICU beds at the peak of COVID-19.', 'Peak ventilator use is predicted to be 19,481 (95% UI 9,767 to 39,674) ventilators.', 'Peak demand will be in the second week of April.', 'We estimate 81,114 (95% UI 38,242 to 162,106) deaths in the United States from COVID-19 over the next 4 months.', 'Meaning: Even with social distancing measures enacted and sustained, the peak demand for hospital services due to the COVID-19 pandemic is likely going to exceed capacity substantially.', 'Alongside the implementation and enforcement of social distancing measures, there is an urgent need to develop and implement plans to reduce non-COVID-19 demand for and temporarily increase capacity of health facilities.', 'Abstract  Importance: This study presents the first set of estimates of predicted health service utilization and deaths due to COVID-19 by day for the next 4 months for each state in the US.', 'Objective: To determine the extent and timing of deaths and excess demand for hospital services due to COVID-19 in the US.', 'Design, Setting, and Participants: This study used data on confirmed COVID-19  deaths by day from WHO websites and local and national governments; data on hospital capacity and utilization for US states; and observed COVID-19 utilization data from select locations to develop a statistical model forecasting deaths and hospital utilization against capacity by state for the US over the next 4 months.', 'Exposure(s): COVID-19.', 'Main outcome(s) and measure(s): Deaths, bed and ICU occupancy, and ventilator use.', 'Results: Compared to licensed capacity and average annual occupancy rates, excess demand from COVID-19 at the peak of the pandemic in the second week of April is predicted to be 64,175 (95% UI 7,977 to 251,059) total beds and 17,380 (95% UI 2,432 to 57,955) ICU beds.', 'At the peak of the pandemic, ventilator use is predicted to be 19,481 (95% UI 9,767 to 39,674).', 'The date of peak excess demand by state varies from the second week of April through May.', 'We estimate that there will a total of 81,114 (95% UI 38,242 to 162,106) deaths from COVID-19 over the next 4 months in the US.', 'Deaths from COVID-19 are estimated to drop below 10 deaths per day between May 31 and June 6.', 'Conclusions and Relevance: In addition to a large number of deaths from COVID-19, the epidemic in the US will place a load well beyond the current capacity of hospitals to manage, especially for ICU care.', 'These estimates can help inform the development and implementation of strategies to mitigate this gap, including reducing non-COVID-19 demand for services and temporarily increasing system capacity.', 'These are urgently needed given that peak volumes are estimated to be only three weeks away.', 'The estimated excess demand on hospital systems is predicated on the enactment of social distancing measures in all states that have not done so already within the next week and maintenance of these measures throughout the epidemic, emphasizing the importance of implementing, enforcing, and maintaining these measures to mitigate hospital system overload and prevent deaths.']\n",
            "unmatched tags:  [{'entity': 'overload', 'type': 'Disease', 'start': 3543, 'end': 3551}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 3030, 'end': 3038}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2771, 'end': 2779}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2613, 'end': 2621}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2558, 'end': 2566}, {'entity': 'bed', 'type': 'Disease', 'start': 2281, 'end': 2284}, {'entity': 'bed', 'type': 'Disease', 'start': 2236, 'end': 2239}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2113, 'end': 2121}, {'entity': 'bed', 'type': 'Disease', 'start': 1975, 'end': 1978}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1924, 'end': 1932}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1726, 'end': 1734}, {'entity': 'national governments', 'type': 'Organization', 'start': 1634, 'end': 1654}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1578, 'end': 1586}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1487, 'end': 1495}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1318, 'end': 1326}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1111, 'end': 1119}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 898, 'end': 906}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 745, 'end': 753}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 523, 'end': 531}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'respiratory tract infections', 'type': 'Disease', 'start': 15, 'end': 43}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNA', 'type': 'Gene', 'start': 152, 'end': 155}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'PAR-2', 'type': 'Gene', 'start': 1360, 'end': 1365}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'deficiency', 'type': 'Disease', 'start': 421, 'end': 431}\n",
            "['Limited SARS-CoV-2 diversity within hosts and following passage in cell culture\\tSince the first reports of pneumonia associated with a novel coronavirus (COVID-19) emerged in Wuhan, Hubei province, China, there have been considerable efforts to sequence the causative virus, SARS-CoV-2 (also referred to as hCoV-19) and to make viral genomic information available quickly on shared repositories.', 'As of 30 March 2020, 7,680 consensus sequences have been shared on GISAID, the principal repository for SARS-CoV-2 genetic information.', 'These sequences are primarily consensus sequences from clinical and passaged samples, but few reports have looked at diversity of virus populations within individual hosts or cultures.', 'Understanding such diversity is essential to understanding viral evolutionary dynamics.', 'Here, we characterize within-host viral diversity from a primary isolate and passaged samples, all originally deriving from an individual returning from Wuhan, China, who was diagnosed with COVID-19 and subsequently sampled in Wisconsin, United States.', 'We use a metagenomic approach with Oxford Nanopore Technologies (ONT) GridION in combination with Illumina MiSeq to capture minor within-host frequency variants ≥1%.', 'In a clinical swab obtained from the day of hospital presentation, we identify 15 single nucleotide variants (SNVs) ≥1% frequency, primarily located in the largest gene – ORF1a.', 'While viral diversity is low overall, the dominant genetic signatures are likely secondary to population size changes, with some evidence for mild purifying selection throughout the genome.', 'We see little to no evidence for positive selection or ongoing adaptation of SARS-CoV-2 within cell culture or in the primary isolate evaluated in this study.', 'Author Summary Within-host variants are critical for addressing molecular evolution questions, identifying selective pressures imposed by vaccine-induced immunity and antiviral therapeutics, and characterizing interhost dynamics, including the stringency and character of transmission bottlenecks.', 'Here, we sequenced SARS-CoV-2 viruses isolated from a human host and from cell culture on three distinct Vero cell lines using Illumina and ONT technologies.', 'We show that SARS-CoV-2 consensus sequences can remain stable through at least two serial passages on Vero 76 cells, suggesting SARS-CoV-2 can be propagated in cell culture in preparation for in-vitro and in-vivo studies without dramatic alterations of its genotype.', 'However, we emphasize the need to deep-sequence viral stocks prior to use in experiments to characterize sub-consensus diversity that may alter outcomes.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2335, 'end': 2345}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2220, 'end': 2230}, {'entity': 'ONT', 'type': 'Organization', 'start': 2189, 'end': 2192}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2068, 'end': 2078}, {'entity': 'bottlenecks', 'type': 'Organization', 'start': 2036, 'end': 2047}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1669, 'end': 1679}, {'entity': 'gene', 'type': 'Gene', 'start': 1453, 'end': 1457}, {'entity': 'ORF1a', 'type': 'Gene', 'start': 1395, 'end': 1400}, {'entity': 'gene', 'type': 'Gene', 'start': 1388, 'end': 1392}, {'entity': 'ONT', 'type': 'Organization', 'start': 1123, 'end': 1126}, {'entity': 'Oxford Nanopore Technologies', 'type': 'Organization', 'start': 1093, 'end': 1121}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 512, 'end': 519}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'endocarditis', 'type': 'Disease', 'start': 132, 'end': 144}\n",
            "['Effectiveness and Safety of Glucocorticoids to Treat COVID-19: A Rapid Review and Meta-Analysis\\tBackground: Glucocorticoids are widely used in the treatment of various pulmonary inflammatory diseases, but they are also often accompanied by significant adverse reactions.', 'Published guidelines point out that low dose and short duration systemic glucocorticoid therapy may be considered for patients with rapidly progressing COVID-19 while the evidence is still limited.', 'Methods: We comprehensively searched electronic databases and supplemented the screening by conducting a manual search.', 'We included RCTs and cohort studies evaluating the effectiveness and safety of glucocorticoids in children and adults with COVID-19, SARS and MERS, and conducted meta-analyses of the main indicators that were identified in the studies.', 'Results: Our search retrieved 23 studies, including one RCT and 22 cohort studies, with a total of 13,815 patients.', 'In adults with COVID-19, the use of systemic glucocorticoid did not reduce mortality (RR=2.00, 95% CI: 0.69 to 5.75, I =90.9%) or the duration of lung inflammation (WMD=-1 days, 95% CI: -2.91 to 0.91), while a significant reduction was found in the duration of fever (WMD=-3.23 days, 95% CI: -3.56 to -2.90).', 'In patients with SARS, glucocorticoids also did not reduce the mortality (RR=1.52, 95% CI: 0.89 to 2.60, I =84.6%), duration of fever (WMD=0.82 days, 95% CI: -2.88 to 4.52, I =97.9%) or duration of lung inflammation absorption (WMD=0.95 days, 95% CI: -7.57 to 9.48, I =94.6%).', 'The use of systemic glucocorticoid therapy prolonged the duration of hospital stay in all patients (COVID-19, SARS and MERS).', 'Conclusions: Glucocorticoid therapy was found to reduce the duration of fever, but not mortality, duration of hospitalization or lung inflammation absorption.', 'Long-term use of high-dose glucocorticoids increased the risk of adverse reactions such as coinfections, so routine use of systemic glucocorticoids for patients with COVID-19 cannot be recommend.', 'Keywords: COVID-19; glucocorticoids; meta-analysis; rapid review']\n",
            "unmatched tags:  [{'entity': 'glucocorticoids', 'type': 'Drug', 'start': 2028, 'end': 2043}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2018, 'end': 2026}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1978, 'end': 1986}, {'entity': 'glucocorticoids', 'type': 'Drug', 'start': 1944, 'end': 1959}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'sucrose', 'type': 'Drug', 'start': 131, 'end': 138}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'ligand', 'type': 'Chemical', 'start': 1380, 'end': 1386}\n",
            "[\"Heparan sulphate proteoglycans in Alzheimer's disease and amyloid‐related disorders\\tProteoglycans are associated with all kinds of amyloid deposits in the human body.\", \"These complex macromolecules, in particular heparan sulphate proteoglycans, have also been implicated in several features of the pathogenesis of Alzheimer's disease (AD), including the genesis of senile plaques, cerebrovascular amyloid, and neurofibrillary tangles.\", 'In this review we focus on the role of proteoglycans and glycosaminoglycans in amyloidogenesis in general and in AD in particular.', 'Heparan sulphate proteoglycans may promote amyloid-β peptide (Aβ) or tau fibrillisation on the one hand, and provide resistance against proteolytic breakdown on the other.']\n",
            "unmatched tags:  [{'entity': 'fibrillisation', 'type': 'Gene', 'start': 637, 'end': 651}, {'entity': 'tau', 'type': 'Gene', 'start': 633, 'end': 636}, {'entity': 'amyloid-β peptide', 'type': 'Gene', 'start': 607, 'end': 624}, {'entity': 'proteoglycans', 'type': 'Gene', 'start': 581, 'end': 594}, {'entity': 'genesis', 'type': 'Gene', 'start': 520, 'end': 527}, {'entity': 'glycosaminoglycans', 'type': 'Drug', 'start': 490, 'end': 508}, {'entity': 'proteoglycans', 'type': 'Gene', 'start': 472, 'end': 485}, {'entity': 'genesis', 'type': 'Gene', 'start': 352, 'end': 359}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'influenza', 'type': 'Disease', 'start': 753, 'end': 762}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'avian influenza', 'type': 'Disease', 'start': 1021, 'end': 1036}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'influenza', 'type': 'Disease', 'start': 1254, 'end': 1263}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'avian influenza', 'type': 'Disease', 'start': 1389, 'end': 1404}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'influenza', 'type': 'Disease', 'start': 1515, 'end': 1524}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'influenza', 'type': 'Disease', 'start': 1794, 'end': 1803}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'dementia', 'type': 'Disease', 'start': 223, 'end': 231}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tumour', 'type': 'Disease', 'start': 561, 'end': 567}\n",
            "['Exploring Conformational Transition of 2019 Novel Coronavirus Spike Glycoprotein Between Its Closed and Open States Using Molecular Dynamics Simulations\\tSince its first recorded appearance in December 2019, a novel coronavirus (SARS-CoV-2) causing the disease COVID-19 has resulted in more than 2,000,000 infections and 128,000 deaths.', 'Currently there is no proven treatment for COVID-19 and there is an urgent need for the development of vaccines and therapeutics.', 'Coronavirus spike glycoproteins play a critical role in coronavirus entry into the host cells, as they provide host cell recognition and membrane fusion between virus and host cell.', 'Thus, they emerged as popular and promising drug targets.', 'Crystal structures of spike protein in its closed and open states were resolved very recently in March 2020.', 'These structures comprise 77% of the sequence and provide almost the complete protein structure.', 'Based on down and up positions of receptor binding domain (RBD), spike protein can be in a receptor inaccessible closed or receptor accessible open state, respectively.', 'Starting from closed and open state crystal structures, and also 16 intermediate conformations, an extensive set of all-atom molecular dynamics (MD) simulations in the presence of explicit water and ions were performed.', 'Simulations show that in its down position, RBD has significantly lower mobility compared to its up position; probably caused by the 6 interdomain salt bridges of RBD in down position compared to 3 in up position.', 'Free energy landscapes based on MD simulations revealed a semi-open state located between closed and open states.', 'Minimum energy pathway between down and up positions comprised a gradual salt bridge switching mechanism.', 'Furthermore, although significantly lower than open state, ACE2 binding surface of RBD contained a partial solvent accessibility in its closed state.']\n",
            "unmatched tags:  [{'entity': 'solvent', 'type': 'Chemical', 'start': 1842, 'end': 1849}, {'entity': 'RBD', 'type': 'Gene', 'start': 1818, 'end': 1821}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1794, 'end': 1798}, {'entity': 'ions', 'type': 'Chemical', 'start': 1677, 'end': 1681}, {'entity': 'ions', 'type': 'Chemical', 'start': 1557, 'end': 1561}, {'entity': 'RBD', 'type': 'Gene', 'start': 1464, 'end': 1467}, {'entity': 'RBD', 'type': 'Gene', 'start': 1345, 'end': 1348}, {'entity': 'ions', 'type': 'Chemical', 'start': 1308, 'end': 1312}, {'entity': 'ions', 'type': 'Chemical', 'start': 1280, 'end': 1284}, {'entity': 'water', 'type': 'Drug', 'start': 1270, 'end': 1275}, {'entity': 'ions', 'type': 'Chemical', 'start': 1237, 'end': 1241}, {'entity': 'ions', 'type': 'Chemical', 'start': 1171, 'end': 1175}, {'entity': 'receptor', 'type': 'Gene', 'start': 1035, 'end': 1043}, {'entity': 'receptor', 'type': 'Gene', 'start': 1003, 'end': 1011}, {'entity': 'spike protein', 'type': 'Gene', 'start': 977, 'end': 990}, {'entity': 'RBD', 'type': 'Gene', 'start': 971, 'end': 974}, {'entity': 'receptor', 'type': 'Gene', 'start': 946, 'end': 954}, {'entity': 'ions', 'type': 'Chemical', 'start': 938, 'end': 942}, {'entity': 'protein structure', 'type': 'Gene', 'start': 893, 'end': 910}, {'entity': 'spike protein', 'type': 'Gene', 'start': 728, 'end': 741}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 522, 'end': 533}, {'entity': 'Coronavirus spike glycoproteins', 'type': 'Gene', 'start': 466, 'end': 497}, {'entity': 'vaccines', 'type': 'Drug', 'start': 439, 'end': 447}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 379, 'end': 387}, {'entity': 'ions', 'type': 'Chemical', 'start': 311, 'end': 315}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 260, 'end': 268}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 228, 'end': 238}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 324, 'end': 330}\n",
            "['Identification of a pangolin niche for a 2019-nCoV-like coronavirus through an extensive meta-metagenomic search\\tIn numerous instances, tracking the biological significance of a nucleic acid sequence can be augmented through the identification of environmental niches in which the sequence of interest is present.', 'Many metagenomic datasets are now available, with deep sequencing of samples from diverse biological niches.', 'While any individual metagenomic dataset can be readily queried using web-based tools, meta-searches through all such datasets are less accessible.', 'In this brief communication, we demonstrate such a meta-meta-genomic approach, examining close matches to the Wuhan coronavirus 2019-nCoV in all high-throughput sequencing datasets in the NCBI Sequence Read Archive accessible with the keyword \"virome\".', 'In addition to the homology to bat coronaviruses observed in descriptions of the 2019-nCoV sequence (F. Wu et al.', '2020, Nature, doi.org/10.1038/s41586-020-2008-3; P. Zhou et al.', '2020, Nature, doi.org/10.1038/s41586-020-2012-7), we note a strong homology to numerous sequence reads in a metavirome dataset generated from the lungs of deceased Pangolins reported by Liu et al.', '(Viruses 11:11, 2019, http://doi.org/10.3390/v11110979).', 'Our observations are relevant to discussions of the derivation of 2019-nCoV and illustrate the utility and limitations of meta-metagenomic search tools in effective and rapid characterization of potentially significant nucleic acid sequences.']\n",
            "unmatched tags:  [{'entity': '2019-nCoV', 'type': 'Virus', 'start': 1327, 'end': 1336}, {'entity': 'Viruses', 'type': 'Virus', 'start': 1204, 'end': 1211}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'statin', 'type': 'Drug', 'start': 109, 'end': 115}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'drug', 'type': 'Drug', 'start': 117, 'end': 121}\n",
            "['Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments\\tAntithrombotic drugs, which include antiplatelet and anticoagulant therapies, prevent and treat many cardiovascular disorders and, as such, are some of the most commonly prescribed drugs worldwide.', 'The first drugs designed to inhibit platelets or coagulation factors, such as the antiplatelet clopidogrel and the anticoagulant warfarin, significantly reduced the risk of thrombotic events at the cost of increased bleeding in patients.', 'However, both clopidogrel and warfarin have some pharmacological limitations including interpatient variability in antithrombotic effects in part due to the metabolism, interactions (eg, drug, environment, and genetic), or targets of the drugs.']\n",
            "unmatched tags:  [{'entity': 'drug', 'type': 'Drug', 'start': 776, 'end': 780}, {'entity': 'drug', 'type': 'Drug', 'start': 725, 'end': 729}, {'entity': 'warfarin', 'type': 'Drug', 'start': 568, 'end': 576}, {'entity': 'clopidogrel', 'type': 'Drug', 'start': 552, 'end': 563}, {'entity': 'anticoagulant warfarin', 'type': 'Drug', 'start': 415, 'end': 437}, {'entity': 'clopidogrel', 'type': 'Drug', 'start': 395, 'end': 406}, {'entity': 'antiplatelet clopidogrel', 'type': 'Drug', 'start': 382, 'end': 406}, {'entity': 'coagulation factors', 'type': 'Gene', 'start': 349, 'end': 368}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'psychosis', 'type': 'Disease', 'start': 170, 'end': 179}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': \"Parkinson's disease\", 'type': 'Disease', 'start': 318, 'end': 337}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'stroke', 'type': 'Disease', 'start': 216, 'end': 222}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'rheumatoid arthritis', 'type': 'Disease', 'start': 222, 'end': 242}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cholera', 'type': 'Drug', 'start': 135, 'end': 142}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 143, 'end': 150}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 263, 'end': 270}\n",
            "['Impact of anti-vaccine movements on pertussis control: the untold story\\tTo assess the impact of anti-vaccine movements that targeted pertussis whole-cell vaccines, we compared pertussis incidence in countries where high coverage with diphtheria-tetanus-pertussis vaccines (DTP) was maintained (Hungary, the former East Germany, Poland, and the USA) with countries where immunisation was disrupted by antivaccine movements (Sweden, Japan, UK, The Russian Federation, Ireland, Italy, the former West Germany, and Australia).', 'Pertussis incidence was 10 to 100 times lower in countries where high vaccine coverage was maintained than in countries where immunisation programs were compromised by anti-vaccine movements.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 696, 'end': 703}, {'entity': 'vaccine', 'type': 'Drug', 'start': 593, 'end': 600}]\n",
            "['Aerosol drug delivery: developments in device design and clinical use\\tAerosolised drugs are prescribed for use in a range of inhaler devices and systems.', 'Delivering drugs by inhalation requires a formulation that can be successfully aerosolised and a delivery system that produces a useful aerosol of the drug; the particles or droplets need to be of sufficient size and mass to be carried to the distal lung or deposited on proximal airways to give rise to a therapeutic effect.', 'Patients and caregivers must use and maintain these aerosol drug delivery devices correctly.']\n",
            "unmatched tags:  [{'entity': 'drug', 'type': 'Drug', 'start': 540, 'end': 544}]\n",
            "['High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa\\tIt has been reported that ACE2 is the main host cell receptor of 2019-nCoV and plays a crucial role in the entry of virus into the cell to cause the final infection.', 'To investigate the potential route of 2019-nCov infection on the mucosa of oral cavity, bulk RNA-seq profiles from two public databases including The Cancer Genome Atlas (TCGA) and Functional Annotation of The Mammalian Genome Cap Analysis of Gene Expression (FANTOM5 CAGE) dataset were collected.', 'RNA-seq profiling data of 13 organ types with para-carcinoma normal tissues from TCGA and 14 organ types with normal tissues from FANTOM5 CAGE were analyzed in order to explore and validate the expression of ACE2 on the mucosa of oral cavity.', 'Further, single-cell transcriptomes from an independent data generated in-house were used to identify and confirm the ACE2-expressing cell composition and proportion in oral cavity.', 'The results demonstrated that the ACE2 expressed on the mucosa of oral cavity.', 'Interestingly, this receptor was highly enriched in epithelial cells of tongue.', 'Preliminarily, those findings have explained the basic mechanism that the oral cavity is a potentially high risk for 2019-nCoV infectious susceptibility and provided a piece of evidence for the future prevention strategy in dental clinical practice as well as daily life.']\n",
            "unmatched tags:  [{'entity': '2019-nCoV', 'type': 'Virus', 'start': 1250, 'end': 1259}, {'entity': 'cell', 'type': 'Gene', 'start': 1116, 'end': 1120}, {'entity': 'receptor', 'type': 'Gene', 'start': 1073, 'end': 1081}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1008, 'end': 1012}, {'entity': 'cell', 'type': 'Gene', 'start': 926, 'end': 930}, {'entity': 'cell', 'type': 'Gene', 'start': 808, 'end': 812}, {'entity': 'ACE2', 'type': 'Gene', 'start': 757, 'end': 761}, {'entity': 'CAGE', 'type': 'Gene', 'start': 687, 'end': 691}, {'entity': 'FANTOM5', 'type': 'Gene', 'start': 679, 'end': 686}, {'entity': 'para-carcinoma', 'type': 'Gene', 'start': 595, 'end': 609}, {'entity': 'CAGE', 'type': 'Gene', 'start': 519, 'end': 523}, {'entity': 'FANTOM5', 'type': 'Gene', 'start': 511, 'end': 518}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'mesylate', 'type': 'Drug', 'start': 161, 'end': 169}\n",
            "['Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact\\tEffective cervical cancer control requires a comprehensive strategy.', 'Even with HPV vaccination, radiotherapy treatment scale-up remains essential and produces large health benefits and a strong return on investment to countries at different levels of development.']\n",
            "unmatched tags:  [{'entity': 'era', 'type': 'Gene', 'start': 289, 'end': 292}, {'entity': 'HPV', 'type': 'Gene', 'start': 265, 'end': 268}, {'entity': 'cervical cancer', 'type': 'Disease', 'start': 196, 'end': 211}, {'entity': 'middle-income countries', 'type': 'Disease', 'start': 110, 'end': 133}, {'entity': 'low-income', 'type': 'Gene', 'start': 95, 'end': 105}, {'entity': 'papillomavirus vaccination', 'type': 'Drug', 'start': 65, 'end': 91}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'indometacin', 'type': 'Drug', 'start': 521, 'end': 532}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'breast cancer', 'type': 'Disease', 'start': 67, 'end': 80}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'heart disease', 'type': 'Disease', 'start': 261, 'end': 274}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'bullying', 'type': 'Disease', 'start': 221, 'end': 229}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cervical cancer', 'type': 'Disease', 'start': 637, 'end': 652}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNA', 'type': 'Gene', 'start': 329, 'end': 332}\n",
            "['A Library of Nucleotide Analogues Terminate RNA Synthesis Catalyzed by Polymerases of Coronaviruses Causing SARS and COVID-19\\tSARS-CoV-2, a member of the coronavirus family, is responsible for the current COVID-19 worldwide pandemic.', 'We previously demonstrated that five nucleotide analogues inhibit the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), including the active triphosphate forms of Sofosbuvir, Alovudine, Zidovudine, Tenofovir alafenamide and Emtricitabine.', 'We report here the evaluation of a library of additional nucleoside triphosphate analogues with a variety of structural and chemical features as inhibitors of the RdRps of SARS-CoV and SARS-CoV-2.', 'These features include modifications on the sugar (2′ or 3′ modifications, carbocyclic, acyclic, or dideoxynucleotides) or on the base.', 'The goal is to identify nucleotide analogues that not only terminate RNA synthesis catalyzed by these coronavirus RdRps, but also have the potential to resist the viruses′ exonuclease activity.', 'We examined these nucleotide analogues with regard to their ability to be incorporated by the RdRps in the polymerase reaction and then prevent further incorporation.', 'While all 11 molecules tested displayed incorporation, 6 exhibited immediate termination of the polymerase reaction (Carbovir triphosphate, Ganciclovir triphosphate, Stavudine triphosphate, Entecavir triphosphate, 3′-O-methyl UTP and Biotin-16-dUTP), 2 showed delayed termination (Cidofovir diphosphate and 2′-O-methyl UTP), and 3 did not terminate the polymerase reaction (2′-fluoro-dUTP, 2′-amino-dUTP and Desthiobiotin-16-UTP).', 'The coronavirus genomes encode an exonuclease that apparently requires a 2′-OH group to excise mismatched bases at the 3′-terminus.', 'In this study, all of the nucleoside triphosphate analogues we evaluated form Watson-Crick-like base pairs.', 'All the nucleotide analogues which demonstrated termination either lack a 2′-OH, have a blocked 2′-OH, or show delayed termination.', 'These nucleotides may thus have the potential to resist exonuclease activity, a property that we will investigate in the future.', 'Furthermore, prodrugs of five of these nucleotide analogues (Brincidofovir/Cidofovir, Abacavir, Valganciclovir/Ganciclovir, Stavudine and Entecavir) are FDA approved for other viral infections, and their safety profile is well known.', 'Thus, they can be evaluated rapidly as potential therapies for COVID-19.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2394, 'end': 2402}, {'entity': 'viral infections', 'type': 'Disease', 'start': 2273, 'end': 2289}, {'entity': 'Entecavir', 'type': 'Drug', 'start': 2235, 'end': 2244}, {'entity': 'Stavudine', 'type': 'Gene', 'start': 2221, 'end': 2230}, {'entity': 'Valganciclovir/Ganciclovir', 'type': 'Drug', 'start': 2193, 'end': 2219}, {'entity': 'Abacavir', 'type': 'Gene', 'start': 2183, 'end': 2191}, {'entity': 'Brincidofovir/Cidofovir', 'type': 'Drug', 'start': 2158, 'end': 2181}, {'entity': 'nucleotide analogues', 'type': 'Gene', 'start': 2136, 'end': 2156}, {'entity': 'exonuclease', 'type': 'Gene', 'start': 2024, 'end': 2035}, {'entity': 'nucleotides', 'type': 'Gene', 'start': 1974, 'end': 1985}, {'entity': 'nucleotide analogues', 'type': 'Gene', 'start': 1844, 'end': 1864}, {'entity': 'nucleoside triphosphate', 'type': 'Gene', 'start': 1754, 'end': 1777}, {'entity': 'exonuclease', 'type': 'Gene', 'start': 1630, 'end': 1641}, {'entity': 'genomes', 'type': 'Gene', 'start': 1612, 'end': 1619}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 1600, 'end': 1611}, {'entity': 'UTP', 'type': 'Gene', 'start': 1590, 'end': 1593}]\n",
            "['Estimating required lockdown cycles before immunity to SARS-CoV-2: Model-based analyses of susceptible population sizes, S0, in seven European countries including the UK and Ireland\\tBackground: Following stringent social distancing measures, some European countries are beginning to report a slowed or negative rate of growth of daily case numbers testing positive for the novel coronavirus.', 'The notion that the first wave of infection is close to its peak begs the question of whether future peaks or second waves are likely.', 'We sought to determine the current size of the effective (i.e.', 'susceptible) population for seven European countries - to estimate immunity levels following this first wave.', 'We compare these numbers to the total population sizes of these countries, in order to investigate the potential for future peaks.', 'Methods: We used Bayesian model inversion to estimate epidemic parameters from the reported case and death rates from seven countries using data from late January 2020 to April 5th 2020.', 'Two distinct generative model types were employed: first a continuous time dynamical-systems implementation of a Susceptible-Exposed-Infectious-Recovered (SEIR) model and second: a partially observable Markov Decision Process (MDP) or hidden Markov model (HMM) implementation of an SEIR model.', 'Both models parameterise the size of the initial susceptible population (S0), as well as epidemic parameters.', 'Parameter estimation (data fitting) was performed using a standard Bayesian scheme (variational Laplace) designed to allow for latent unobservable states and uncertainty in model parameters.', 'Results: Both models recapitulated the dynamics of transmissions and disease as given by case and death rates.', 'The peaks of the current waves were predicted to be in the past for four countries (Italy, Spain, Germany and Switzerland) and to emerge in 0.5-2 weeks in Ireland and 1-3 weeks in the UK.', 'For France one model estimated the peak within the past week and the other in the future in two weeks.', 'Crucially, Maximum a posteriori (MAP) estimates of S0 for each country indicated effective population sizes of below 20% (of total population size), under both the continuous time and HMM models.', 'Using for all countries, with a Bayesian weighted average across all seven countries and both models, we estimated that 6.4% of the total population would be immune.', 'From the two models the maximum percentage of the effective population was estimated at 19.6% of the total population for the UK, 16.7% for Ireland, 11.4% for Italy, 12.8% for Spain, 18.8% for France, 4.7% for Germany and 12.9% for Switzerland.', 'Conclusion: Our results indicate that after the current wave, a large proportion of the total population will remain without immunity.', 'This suggests that in the absence of strong seasonal effects, new medications or more comprehensive contact tracing, a further set of epidemic waves in different geographic centres are likely.', 'These findings may have implications for exit strategies from any lockdown stage.']\n",
            "unmatched tags:  [{'entity': 'wave', 'type': 'Gene', 'start': 2905, 'end': 2909}, {'entity': 'medications', 'type': 'Drug', 'start': 2828, 'end': 2839}, {'entity': 'wave', 'type': 'Gene', 'start': 2683, 'end': 2687}, {'entity': 'wave', 'type': 'Gene', 'start': 1752, 'end': 1756}, {'entity': 'MDP', 'type': 'Gene', 'start': 1246, 'end': 1249}]\n",
            "['Mental health status among family members of health care workers in Ningbo, China during the Coronavirus Disease 2019 (COVID-19) outbreak: a Cross-sectional Study\\tBackground: So far, the psychological impact of COVID-19 epidemic among family members of Health care workers (HCWs) in China has been neglected.', 'The present cross-sectional study aimed to investigate the mental health status and related factors of families of HCWs in Designated Hospitals in Ningbo, China.', 'Method: Family members of HCWs working in five designated hospitals in Ningbo, China were recruited between February 10th and 20th, 2020.', 'Information on demographic variables, the COVID-19-related events in the lives, knowledge of COVID-19 and the working status of family members (that is, HCWs) was collected using online self-administered questionnaires.', 'The mental health status were assessed using the Chinese version of Patient Health Questionnare-9 (PHQ-9) and Chinese version of Generalized Anxiety Disorder-7 (GAD-7 ).', 'Multivariable logistic regression analyses were conducted to identify the main factors associated with the mental health conditions.', 'Results: A total of 822 participants completed questionnaires correctly.', '(response rate of 95.80% ).', 'The overall prevalence of GAD and depressive symptoms were 33.73%, and 29.35%, respectively.', 'More times (hours) to focus on the COVID-19 (OR=1.215, 95%CI:1.061-1.391), family members (that is, HCWs) directly contact with confirmed or suspected COVID-19 patients (OR=1.477, 95%CI:1.069-2.040) were risk factors for GAD, while higher participants self-reported safety score for protective equipment of HCWs (OR=0.807, 95%CI:0.700-0.930) was a protective factor.', 'More times (hours) to focus on the COVID-19 (OR=1.215, 95%CI:1.061-1.391), longer average working times per week for family members (that is, HCWs) (OR=1.017, 95%CI:1.005-1.029), being parents and other next of kin of HCWs were risk factors for depressive symptoms (OR=3.526, 95%CI:1.609-7.728 and OR=1.639, 95%CI:1.096-2.451, respectively).', 'In addition, compared with participants who were HCWs, participants who were enterprise workers and were more likely to develop depressive symptoms(OR=1.750, 95%CI:1.104-2.776), while who were government employees or institutions employees were less likely to suffer depressive symptoms (OR=0.529, 95%CI:0.286-0.977).', 'Conclusions: Psychological responses to COVID-19 have been dramatic among family members of HCWs during the rising phase of the outbreak.', 'Our findings provide strong evidence to pay more attention on the mental health status of this vulnerable but often unseen populations during COVID-19 epidemic.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2634, 'end': 2642}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2394, 'end': 2402}, {'entity': 'depressive symptoms', 'type': 'Phenotype', 'start': 2303, 'end': 2322}, {'entity': 'depressive symptoms', 'type': 'Phenotype', 'start': 2164, 'end': 2183}, {'entity': 'depressive symptoms', 'type': 'Phenotype', 'start': 1939, 'end': 1958}, {'entity': 'kin', 'type': 'Gene', 'start': 1905, 'end': 1908}, {'entity': 'kin', 'type': 'Gene', 'start': 1787, 'end': 1790}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1729, 'end': 1737}, {'entity': 'GAD', 'type': 'Gene', 'start': 1548, 'end': 1551}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1478, 'end': 1486}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1362, 'end': 1370}, {'entity': 'depressive symptoms', 'type': 'Phenotype', 'start': 1268, 'end': 1287}, {'entity': 'GAD', 'type': 'Gene', 'start': 1260, 'end': 1263}, {'entity': 'Multivariable logistic regression analyses', 'type': 'Gene', 'start': 1000, 'end': 1042}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'antibiotics', 'type': 'Drug', 'start': 8, 'end': 19}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'peptide', 'type': 'Gene', 'start': 292, 'end': 299}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'antibiotics', 'type': 'Drug', 'start': 486, 'end': 497}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'antibiotic', 'type': 'Drug', 'start': 486, 'end': 496}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tumours', 'type': 'Disease', 'start': 280, 'end': 287}\n",
            "[\"Part II: Treatment of primary malignant non-Wilms' renal tumours in children\\tRenal-cell carcinoma, clear-cell sarcoma, (congenital) mesoblastic nephroma, rhabdoid tumour, and renal medullary carcinoma form a heterogeneous group of childhood renal malignancies known as non-Wilms' tumours.\", 'Progress has been slow in improving the management of these tumours to decrease morbidity and increase survival.', 'However, greater cooperation between national and international centres should engender specialisation, and an increased knowledge of the molecular biology of these tumours will inevitably lead to substantial progress over the next decade.']\n",
            "unmatched tags:  [{'entity': 'tumours', 'type': 'Disease', 'start': 567, 'end': 574}]\n",
            "['A model to estimate bed demand for COVID-19 related hospitalization\\tAs of March 23, 2020 there have been over 354,000 confirmed cases of coronavirus disease 2019 (COVID-19) in over 180 countries, the World Health Organization characterized COVID-19 as a pandemic, and the United States (US) announced a national state of emergency.1, 2, 3 In parts of China and Italy the demand for intensive care (IC) beds was higher than the number of available beds.4, 5 We sought to build an accessible interactive model that could facilitate hospital capacity planning in the presence of significant uncertainty about the proportion of the population that is COVID-19+ and the rate at which COVID-19 is spreading in the population.', 'Our approach was to design a tool with parameters that hospital leaders could adjust to reflect their local data and easily modify to conduct sensitivity analyses.', 'We developed a model to facilitate hospital planning with estimates of the number of Intensive Care (IC) beds, Acute Care (AC) beds, and ventilators necessary to accommodate patients who require hospitalization for COVID-19 and how these compare to the available resources.', 'Inputs to the model include estimates of the characteristics of the patient population and hospital capacity.', 'We deployed this model as an interactive online tool.6 The model is implemented in R 3.5, RStudio, RShiny 1.4.0 and Python 3.7.', 'The parameters used may be modified as data become available, for use at other institutions, and to generate sensitivity analyses.', 'We illustrate the use of the model by estimating the demand generated by COVID-19+ arrivals for a hypothetical acute care medical center.', 'The model calculated that the number of patients requiring an IC bed would equal the number of IC beds on Day 23, the number of patients requiring a ventilator would equal the number of ventilators available on Day 27,  and the number of patients requiring an AC bed and coverage by the Medicine Service would equal the capacity of the Medicine service on Day 21.', 'In response to the COVID-19 epidemic, hospitals must understand their current and future capacity to care for patients with severe illness.', 'While there is significant uncertainty around the parameters used to develop this model, the analysis is based on transparent logic and starts from observed data to provide a robust basis of projections for hospital managers.', 'The model demonstrates the need and provides an approach to address critical questions about staffing patterns for IC and AC, and equipment capacity such as ventilators.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2052, 'end': 2060}, {'entity': 'AC bed', 'type': 'Disease', 'start': 1928, 'end': 1934}, {'entity': 'bed', 'type': 'Disease', 'start': 1766, 'end': 1769}, {'entity': 'bed', 'type': 'Disease', 'start': 1733, 'end': 1736}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1603, 'end': 1611}, {'entity': 'RStudio', 'type': 'Gene', 'start': 1359, 'end': 1366}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1100, 'end': 1108}, {'entity': 'bed', 'type': 'Disease', 'start': 1012, 'end': 1015}, {'entity': 'bed', 'type': 'Disease', 'start': 990, 'end': 993}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'obesity', 'type': 'Phenotype', 'start': 622, 'end': 629}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'peptides', 'type': 'Gene', 'start': 1283, 'end': 1291}\n",
            "['Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial\\tThe 9vHPV vaccine prevents infection, cytological abnormalities, high-grade lesions, and cervical procedures related to HPV 31, 33, 45, 52, and 58.', 'Both the 9vHPV vaccine and qHPV vaccine had a similar immunogenicity profile with respect to HPV 6, 11, 16, and 18.', 'Vaccine efficacy was sustained for up to 6 years.', 'The 9vHPV vaccine could potentially provide broader coverage and prevent 90% of cervical cancer cases worldwide.']\n",
            "unmatched tags:  [{'entity': 'cervical cancer', 'type': 'Disease', 'start': 552, 'end': 567}, {'entity': 'HPV', 'type': 'Gene', 'start': 478, 'end': 481}, {'entity': 'Vaccine', 'type': 'Drug', 'start': 422, 'end': 429}, {'entity': 'HPV', 'type': 'Gene', 'start': 399, 'end': 402}, {'entity': 'qHPV vaccine', 'type': 'Gene', 'start': 333, 'end': 345}, {'entity': 'HPV', 'type': 'Gene', 'start': 317, 'end': 320}, {'entity': 'HPV', 'type': 'Gene', 'start': 278, 'end': 281}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tumours', 'type': 'Disease', 'start': 152, 'end': 159}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tumours', 'type': 'Disease', 'start': 471, 'end': 478}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'B-cell lymphoma', 'type': 'Disease', 'start': 87, 'end': 102}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'protein', 'type': 'Gene', 'start': 1625, 'end': 1632}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'liver disease', 'type': 'Disease', 'start': 107, 'end': 120}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'dystonias', 'type': 'Phenotype', 'start': 677, 'end': 686}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'pneumonia', 'type': 'Disease', 'start': 1711, 'end': 1720}\n",
            "['Tuberculosis: from prehistory to Robert Koch, as revealed by ancient DNA\\tDuring the past 10 years palaeomicrobiology, a new scientific discipline, has developed.', 'The study of ancient pathogens by direct detection of their DNA has answered several historical questions and shown changes to pathogens over time.', 'However, ancient DNA (aDNA) continues to be controversial and great care is needed to provide valid data.', 'Here we review the most successful application of the technology, which is the study of tuberculosis.', 'This has provided direct support for the current theory of']\n",
            "unmatched tags:  [{'entity': 'tuberculosis', 'type': 'Disease', 'start': 504, 'end': 516}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diseases', 'type': 'Disease', 'start': 112, 'end': 120}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'chemicals', 'type': 'Chemical', 'start': 269, 'end': 278}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'dyskinesia', 'type': 'Disease', 'start': 249, 'end': 259}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'mannose', 'type': 'Drug', 'start': 742, 'end': 749}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'mannose', 'type': 'Drug', 'start': 1184, 'end': 1191}\n",
            "['Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial\\tAddition of diaphragm pacing to standard care with non-invasive ventilation was associated with decreased survival in patients with ALS.', 'Our results suggest that diaphragmatic pacing should not be used as a routine treatment for patients with ALS in respiratory failure.']\n",
            "unmatched tags:  [{'entity': 'respiratory failure', 'type': 'Disease', 'start': 435, 'end': 454}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'lymphoma', 'type': 'Disease', 'start': 171, 'end': 179}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'lymphoma', 'type': 'Disease', 'start': 401, 'end': 409}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'lymphoma', 'type': 'Disease', 'start': 612, 'end': 620}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'aggressive non-Hodgkin lymphoma', 'type': 'Disease', 'start': 331, 'end': 362}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 876, 'end': 883}\n",
            "['The state of vaccine safety science: systematic reviews of the evidence\\tThis Review updates the scientific evidence assessing possible causal associations of adverse events following immunisation (AEFI) compiled in the 2012 report from the Institute of Medicine and the 2014 report from the Agency for Healthcare Research and Quality.', 'For 12 of 46 AEFI examined, a causal relationship has been established with at least one vaccine currently routinely recommended to the general USA population: anaphylaxis, arthralgia or arthritis (mild, acute, and transient, not chronic), deltoid bursitis (when vaccine is administered improperly), disseminated varicella infection (in immune deficient individuals for whom the varicella vaccine is contraindicated), encephalitis, febrile seizures, Guillain-Barré syndrome, hepatitis (in immune deficient individuals for whom the varicella vaccine is contraindicated), herpes zoster, immune thrombocytopenic purpura, meningitis, and syncope.']\n",
            "unmatched tags:  [{'entity': 'syncope', 'type': 'Phenotype', 'start': 969, 'end': 976}, {'entity': 'meningitis', 'type': 'Phenotype', 'start': 953, 'end': 963}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'stroke', 'type': 'Disease', 'start': 507, 'end': 513}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': \"Crohn's disease\", 'type': 'Disease', 'start': 252, 'end': 267}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'injury', 'type': 'Disease', 'start': 73, 'end': 79}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'seizures', 'type': 'Phenotype', 'start': 251, 'end': 259}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'lung injury', 'type': 'Disease', 'start': 563, 'end': 574}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'T-cell lymphoma', 'type': 'Disease', 'start': 209, 'end': 224}\n",
            "[\"Tracking progress towards universal childhood immunisation and the impact of global initiatives: a systematic analysis of three-dose diphtheria, tetanus, and pertussis immunisation coverage\\tSurvey-based DTP3 immunisation coverage has improved more gradually and not to the level suggested by countries' official reports or WHO and UNICEF estimates.\", 'There is an urgent need for independent and contestable monitoring of health indicators in an era of global initiatives that are target-oriented and disburse funds based on performance.']\n",
            "unmatched tags:  [{'entity': 'era', 'type': 'Gene', 'start': 443, 'end': 446}, {'entity': 'UNICEF', 'type': 'Organization', 'start': 331, 'end': 337}, {'entity': 'era', 'type': 'Gene', 'start': 224, 'end': 227}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'opioid', 'type': 'Drug', 'start': 464, 'end': 470}\n",
            "['Projecting the Spread of COVID19 for Germany\\tWe model the evolution of the number of individuals that are reported to be sick with COVID-19 in Germany.', 'Our theoretical framework builds on a continuous time Markov chain with four states: healthy without infection, sick, healthy after recovery or after infection but without symptoms and dead.', 'Our quantitative solution matches the number of sick individuals up to the most recent observation and ends with a share of sick individuals following from infection rates and sickness probabilities.', 'We employ this framework to study inter alia the expected peak of the number of sick individuals in a scenario without public regulation of social contacts.', 'We also study the effects of public regulations.', 'For all scenarios we report the expected end of the CoV-2 epidemic.', 'We have four general findings: First, current epidemiological thinking implies that the long-run effects of the epidemic only depend on the aggregate long-run infection rate and on the individual risk to turn sick after an infection.', 'Any measures by individuals and the public therefore only influence the dynamics of spread of CoV-2.', 'Second, predictions about the duration and level of the epidemic must strongly distinguish between the officially reported numbers (Robert Koch Institut, RKI) and actual numbers of sick individuals.', 'Third, given the current (scarce) medical knowledge about long-run infection rate and individual risks to turn sick, any prediction on the length (duration in months) and strength (e.g.', 'maximum numbers of sick individuals on a given day) is subject to a lot of uncertainty.', 'Our predictions therefore offer robustness analyses that provide ranges on how long the epidemic will last and how strong it will be.', 'Fourth, public interventions that are already in place and that are being discussed can lead to more and less severe outcomes of the epidemic.', 'If an intervention takes place too early, the epidemic can actually be stronger than with an intervention that starts later.', 'Interventions should therefore be contingent on current infection rates in regions or countries.', 'Concerning predictions about COVID-19 in Germany, we find that the long-run number of sick individuals (that are reported to the RKI), once the epidemic is over, will lie between 500 thousand and 5 million individuals.', 'While this seems to be an absurdly large range for a precise projection, this reflects the uncertainty about the long-run infection rate in Germany.', 'If we assume that Germany will follow the good scenario of Hubei (and we are even a bit more conservative given discussions about data quality), we will end up with 500 thousand sick individuals over the entire epidemic.', 'If by contrast we believe (as many argue) that once the epidemic is over 70% of the population will have been infected (and thereby immune), we will end up at 5 million cases.', 'Defining the end of the epidemic by less than 100 newly reported sick individuals per day, we find a large variation depending on the effectiveness of governmental pleas and regulations to reduce social contacts.', 'An epidemic that is not influenced by public health measures would end mid June 2020.', 'With public health measures lasting for few weeks, the end is delayed by around one month or two.', 'The advantage of the delay, however, is to reduce the peak number of individuals that are simultaneously sick.', 'When we believe in long-run infection rates of 70%, this number is equally high for all scenarios we went through and well above 1 million.', 'When we can hope for the Hubei-scenario, the maximum number of sick individuals will be around 200 thousand \\x93only\\x94.', 'Whatever value of the range of long-run infection rates we want to assume, the epidemic will last at least until June, with extensive and potentially future public health measures, it will last until July.', 'In the worst case, it will last until end of August.', 'We emphasize that all projections are subject to uncertainty and permanent monitoring of observed incidences are taken into account to update the projection.', 'The most recent projections are available at https://www.macro.economics.uni-mainz.de/corona-blog/.']\n",
            "unmatched tags:  [{'entity': 'sick', 'type': 'Phenotype', 'start': 3603, 'end': 3607}, {'entity': 'sick', 'type': 'Phenotype', 'start': 3394, 'end': 3398}, {'entity': 'governmental pleas', 'type': 'Organization', 'start': 3043, 'end': 3061}, {'entity': 'sick', 'type': 'Phenotype', 'start': 2957, 'end': 2961}, {'entity': 'sick', 'type': 'Phenotype', 'start': 2672, 'end': 2676}, {'entity': 'RKI', 'type': 'Gene', 'start': 2255, 'end': 2258}, {'entity': 'sick', 'type': 'Phenotype', 'start': 2212, 'end': 2216}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 152, 'end': 161}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'ACE2', 'type': 'Gene', 'start': 583, 'end': 587}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'ACE2', 'type': 'Gene', 'start': 1179, 'end': 1183}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diseases', 'type': 'Disease', 'start': 65, 'end': 73}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'azithromycin', 'type': 'Drug', 'start': 126, 'end': 138}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'azithromycin', 'type': 'Drug', 'start': 458, 'end': 470}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'meningitis', 'type': 'Phenotype', 'start': 364, 'end': 374}\n",
            "['COVID-19: Projecting the impact in Rohingya refugee camps and beyond\\tBackground: COVID-19 could have even more dire consequences among refugees living in camps than in general populations.', 'Bangladesh has confirmed COVID-19 cases and hosts almost 1 million Rohingya refugees from Myanmar with 600,000 concentrated in Kutupalong-Balukhali Expansion Site.', 'Projections of the potential COVID-19 infection burden, epidemic speed, and healthcare needs in such settings are critical to inform preparedness planning.', 'Methods: To explore the potential impact of the introduction of SARS-CoV-2 in Kutupalong-Balukhali Expansion Site, we used a stochastic disease transmission model with parameters derived from emerging literature.', 'We considered three scenarios with different assumptions about the transmission potential of SARS-CoV-2.', 'We estimated the number and daily rate of infections, hospitalizations, deaths, and healthcare needs expected under each scenario.', 'Findings: A large-scale outbreak is highly likely after a single introduction of the virus into the camp across scenarios with 65-95% of simulations leading to at least 1,000 infections.', 'Estimated infections range from 119-504 between low and high transmission scenarios in the first 30 days; and between 424,798 and 543,647 in 12 months.', 'Hospitalization needs exceeded the existing hospitalization capacity of 340 beds after 58-139 days between the low and high transmission scenarios.', 'Estimated deaths range from 1,647-2,109 between low and high transmission scenarios.', 'Interpretation: A COVID-19 epidemic in a refugee settlement may have profound consequences, requiring unrealistically large increases in healthcare capacity and infrastructure.', 'Detailed and realistic planning for the worst in Kutupalong-Balukhali and all refugee camps worldwide must begin now.', 'Plans should consider novel and radical strategies to reduce infectious contacts and fill health worker gaps while recognizing that refugees may not have access to national health systems.', 'As global resources to fight this pandemic become scarce, displaced persons must not be forgotten.']\n",
            "unmatched tags:  [{'entity': 'gaps', 'type': 'Gene', 'start': 1935, 'end': 1939}, {'entity': 'camp', 'type': 'Gene', 'start': 1799, 'end': 1803}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1554, 'end': 1562}, {'entity': 'camp', 'type': 'Gene', 'start': 1062, 'end': 1066}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 817, 'end': 827}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 575, 'end': 585}, {'entity': 'settings', 'type': 'Disease', 'start': 454, 'end': 462}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 382, 'end': 390}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 214, 'end': 222}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'multiple myeloma', 'type': 'Disease', 'start': 224, 'end': 240}\n",
            "['Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies\\tBenefits of olanzapine can be expected for patients across the full spectrum of symptom severity who are likely to be treated for acute mania.', 'Less severely ill patients seem to benefit less in terms of olanzapine efficacy, but still experience the same side-effects as more severely ill patients.', 'Thus, clinicians and patients should carefully consider the benefit-to-risk ratio of olanzapine and its additional, prophylactic effect against relapse in the long term.', 'The generalisability of these results to other antipsychotics, trial designs, and medical conditions remains to be established.']\n",
            "unmatched tags:  [{'entity': 'antipsychotics', 'type': 'Drug', 'start': 678, 'end': 692}, {'entity': 'olanzapine', 'type': 'Drug', 'start': 546, 'end': 556}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vesiculoviruses', 'type': 'Virus', 'start': 1886, 'end': 1901}\n",
            "['Association between genetic variation in the gene for insulin-like growth factor-l and low birthweight\\tLow birthweight is associated with later risk of type 2 diabetes and related disorders.', 'We aimed to show that a polymorphism in the gene for insulin-like growth factor-l, which has proved to raise risk of type 2 diabetes and myocardial infarction, is associated with low birthweight.', 'We recorded birthweight and obtained DNA for 463 adults.', 'Individuals who did not have the wild-type allele of the polymorphism had a 215 g lower birthweight than those homozygous for this allele (95% Cl −411 to −10).']\n",
            "unmatched tags:  [{'entity': 'allele', 'type': 'Gene', 'start': 575, 'end': 581}, {'entity': 'allele', 'type': 'Gene', 'start': 487, 'end': 493}, {'entity': 'wild-type', 'type': 'Drug', 'start': 477, 'end': 486}, {'entity': 'DNA', 'type': 'Gene', 'start': 424, 'end': 427}, {'entity': 'myocardial infarction', 'type': 'Disease', 'start': 328, 'end': 349}, {'entity': 'type 2 diabetes', 'type': 'Disease', 'start': 308, 'end': 323}, {'entity': 'insulin-like growth factor-l', 'type': 'Gene', 'start': 244, 'end': 272}, {'entity': 'gene', 'type': 'Gene', 'start': 235, 'end': 239}]\n",
            "['A Multi-hospital Study in Wuhan, China：Protective Effects of Non-menopause and Female Hormones on SARS-CoV-2 infection\\tObjective To determine the correlation between menstruation status/sex hormones and prognosis of COVID-19, and to identify potential protective factors for female patients.', 'Design, Setting, and Participants A cross-sectional study of COVID-19 patients who were hospitalized at Tongji and Mobile Cabin Hospitals from Jan 28, 2020 to March 8, 2020.', 'Sex differences in severity and composite endpoints (admission to intensive care unit (ICU), use of mechanical ventilation, or death) of COVID-19 patients were compared.', 'The correlation analysis and cox/logistic regression modeling of menstruation status/sex hormones and prognosis were conducted.', 'Correlation between cytokines related to immunity and inflammation and disease severity or estradiol (E2) was revealed.Results Chi square test indicated significant differences in distribution of composite endpoints (p<0.01) and disease severity (p=0.05) between male and female patients (n=1902).', '435 female COVID-19 patients with menstruation records were recruited.', 'By the end of Mar 8, 111 patients recovered and discharged (25.3%).', 'Multivariate Cox regression model adjusted for age and severity indicated that post-menopausal patients show the greater risk of hospitalization time than non-menopausal patients (relative hazard [RH], 1.91; 95% confidence interval [CI], 1.06-3.46)Logistic regression model showed that higher AMH as a control for age increases the risk of severity of COVID-19 (HR=0.146, 95%CI= (0.026-0.824) p=0.029).', 'E2 showed protective effect against disease severity (HR=0.335, 95%CI= (0.105-1.070), p=0.046).In the Mann-Whitney U test, the higher levels of IL6 and IL8 were found in severe group (p=0.040, 0.033).The higher levels of IL2R, IL6, IL8 and IL10 were also observed in patients with composite end points(p＜0.001,＜0.001, =0.009, = 0.040).E2 levels were negatively correlated with IL2R, IL6, IL8 and TNFα in luteal phase (Pearson Correlation=-0.592, -0.558, -0.545, -0.623; p=0.033, 0.048, 0.054, 0.023) and with C3 in follicular phase (Pearson Correlation=-0.651; p=0.030).', 'Conclusions and Relevance Menopause is an independent risk factor for COVID-19.', 'E2 and AMH are negatively correlated with COVID-19 severity probably due to their regulation of cytokines related to immunity and inflammation.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2297, 'end': 2305}, {'entity': 'AMH', 'type': 'Gene', 'start': 2262, 'end': 2265}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2245, 'end': 2253}, {'entity': 'Pearson', 'type': 'Disease', 'start': 2137, 'end': 2144}, {'entity': 'C3', 'type': 'Gene', 'start': 2113, 'end': 2115}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diseases', 'type': 'Disease', 'start': 186, 'end': 194}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 92, 'end': 98}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'receptors', 'type': 'Gene', 'start': 952, 'end': 961}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'haemophagocytic lymphohistiocytosis', 'type': 'Disease', 'start': 267, 'end': 302}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'heart failure', 'type': 'Phenotype', 'start': 262, 'end': 275}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'leukaemia', 'type': 'Disease', 'start': 302, 'end': 311}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'sarcoma', 'type': 'Disease', 'start': 448, 'end': 455}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'leishmaniasis', 'type': 'Disease', 'start': 124, 'end': 137}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'carcinomas', 'type': 'Disease', 'start': 291, 'end': 301}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'sarcomas', 'type': 'Disease', 'start': 328, 'end': 336}\n",
            "['Vascular cognitive impairment\\tCerebrovascular disease is the second most common cause of acquired cognitive impairment and dementia and contributes to cognitive decline in the neurodegenerative dementias.', \"The current narrow definitions of vascular dementia should be broadened to recognise the important part cerebrovascular disease plays in several cognitive disorders, including the hereditary vascular dementias, multi-infarct dementia, post-stroke dementia, subcortical ischaemic vascular disease and dementia, mild cognitive impairment, and degenerative dementias (including Alzheimer's disease, frontotemporal dementia, and dementia with Lewy bodies).\"]\n",
            "unmatched tags:  [{'entity': 'dementia', 'type': 'Disease', 'start': 630, 'end': 638}, {'entity': 'frontotemporal dementia', 'type': 'Disease', 'start': 601, 'end': 624}, {'entity': \"Alzheimer's disease\", 'type': 'Disease', 'start': 580, 'end': 599}, {'entity': 'dementia', 'type': 'Disease', 'start': 559, 'end': 567}, {'entity': 'mild cognitive impairment', 'type': 'Disease', 'start': 515, 'end': 540}, {'entity': 'dementia', 'type': 'Disease', 'start': 505, 'end': 513}, {'entity': 'dementia', 'type': 'Disease', 'start': 452, 'end': 460}, {'entity': 'multi-infarct dementia', 'type': 'Disease', 'start': 416, 'end': 438}, {'entity': 'dementia', 'type': 'Disease', 'start': 405, 'end': 413}, {'entity': 'hereditary vascular dementias', 'type': 'Disease', 'start': 385, 'end': 414}, {'entity': 'cognitive disorders', 'type': 'Disease', 'start': 350, 'end': 369}, {'entity': 'cerebrovascular disease', 'type': 'Disease', 'start': 309, 'end': 332}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'protein', 'type': 'Gene', 'start': 2508, 'end': 2515}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'base J', 'type': 'Gene', 'start': 2964, 'end': 2970}\n",
            "['Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapy\\tAlthough HIV-1 infection does not directly target B cells, B-cell numbers are reduced and their function is impaired during HIV infection.', 'Antibody titres against antigens previously encountered through vaccination or natural infection are low in patients with HIV.', 'Intrinsic B-cell defects might be involved in the impairment of humoral immunity during early HIV infection.', 'Abnormal T-cell activation and the altered expression of molecules involved in the B-cell homing process cause dysfunctional interaction between T and B cells in the germinal centres of lymphoid tissues, which might impair B-cell responses during HIV infection.']\n",
            "unmatched tags:  [{'entity': 'HIV infection', 'type': 'Phenotype', 'start': 756, 'end': 769}, {'entity': 'impair', 'type': 'Disease', 'start': 725, 'end': 731}, {'entity': 'HIV infection', 'type': 'Phenotype', 'start': 494, 'end': 507}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'thyroid', 'type': 'Gene', 'start': 71, 'end': 78}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'stroke', 'type': 'Disease', 'start': 372, 'end': 378}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'colorectal cancer', 'type': 'Disease', 'start': 253, 'end': 270}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diseases', 'type': 'Disease', 'start': 2044, 'end': 2052}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'neuropathy', 'type': 'Disease', 'start': 88, 'end': 98}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'varicella vaccine', 'type': 'Drug', 'start': 78, 'end': 95}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 132, 'end': 139}\n",
            "['Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies\\tEven in the late ART era, survival during the first 3 years of ART continues to improve, which probably reflects transition to less toxic antiretroviral drugs, improved adherence, prophylactic measures, and management of comorbidity.', 'Prognostic models and life expectancy estimates should be updated to account for these improvements.']\n",
            "unmatched tags:  [{'entity': 'antiretroviral drugs', 'type': 'Drug', 'start': 270, 'end': 290}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diseases', 'type': 'Disease', 'start': 68, 'end': 76}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tumour', 'type': 'Disease', 'start': 56, 'end': 62}\n",
            "['Molecular diagnostics in paediatric glial tumours\\tGlial tumours in children have distinct patterns of epigenetic alteration, chromosomal structure, and gene and protein expression that differentiate them from their histological counterparts in adults.', 'Understanding paediatric gliomas at the molecular level provides important prognostic and therapeutic insights, such as which genetic alterations confer a favourable response to adjuvant therapy, or which signalling pathways might be amenable to specific molecularly targeted agents.', 'For clinicians, the ultimate goal is to individualise therapeutic regimens on the basis of the molecular fingerprint of a particular tumour and the prognosis conferred by this profile.']\n",
            "unmatched tags:  [{'entity': 'tumour', 'type': 'Disease', 'start': 669, 'end': 675}, {'entity': 'gene', 'type': 'Gene', 'start': 378, 'end': 382}, {'entity': 'gliomas', 'type': 'Disease', 'start': 277, 'end': 284}]\n",
            "['Effectiveness of national and subnational infection prevention and control interventions in high-income and upper-middle-income countries: a systematic review\\tEvidence-based guidance for national infection prevention and control (IPC) programmes is needed to support national and global capacity building to reduce health-care-associated infection and antimicrobial resistance.', 'In this systematic review we investigate evidence on the effectiveness of IPC interventions implemented at national or subnational levels to inform the development of WHO guidelines on the core components of national IPC programmes.', 'We searched CENTRAL, CINAHL, Embase, MEDLINE, and WHO IRIS databases for publications between Jan 1, 2000, and April 19, 2017.']\n",
            "unmatched tags:  [{'entity': 'IPC', 'type': 'Gene', 'start': 595, 'end': 598}, {'entity': 'national', 'type': 'Organization', 'start': 586, 'end': 594}, {'entity': 'national', 'type': 'Organization', 'start': 500, 'end': 508}, {'entity': 'national', 'type': 'Organization', 'start': 485, 'end': 493}, {'entity': 'IPC', 'type': 'Gene', 'start': 452, 'end': 455}, {'entity': 'health-care-associated infection', 'type': 'Disease', 'start': 315, 'end': 347}, {'entity': 'national', 'type': 'Organization', 'start': 267, 'end': 275}, {'entity': 'IPC', 'type': 'Gene', 'start': 230, 'end': 233}, {'entity': 'national', 'type': 'Organization', 'start': 187, 'end': 195}, {'entity': 'upper-middle-income countries', 'type': 'Gene', 'start': 108, 'end': 137}]\n",
            "['Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial\\tAt 12 month follow-up, both very thin strut drug-eluting stents with dissimilar biodegradable polymer coatings (eluting either everolimus or sirolimus) were non-inferior to the durable polymer stent (eluting zotarolimus) in treating allcomers with a high proportion of patients with acute coronary syndromes.', 'The absence of a loss of 1 year safety and efficacy with the use of these two biodegradable polymer-coated stents is a prerequisite before assessing their potential longer-term benefits.']\n",
            "unmatched tags:  [{'entity': 'longer-term', 'type': 'Chemical', 'start': 713, 'end': 724}]\n",
            "['Unique properties of Zika NS2B-NS3pro complexes as decoded by experiments and MD simulations\\tZika virus can be passed from a pregnant woman to her fetus, thus leading to birth defects including more than microcephaly.', 'It has been recently estimated that one-third of the world population will be infected by Zika, but unfortunately no vaccine or medicine is available so far.', 'Zika NS2B-NS3pro is essential for its replication and thus represents an attractive target for drug discovery/design.', 'Here we characterized conformation, catalysis, inhibition and dynamics of linked and unlinked Zika NS2B-NS3pro complexes by both experiments and MD simulations.', 'The results unveil the unique properties of Zika NS2B-NS3pro which are very different from Dengue one.', 'Particularly, CD and NMR studies indicate that unlike Dengue, the C-terminal region of Zika NS2B with a significant sequence variation is highly disordered in the open conformation.', 'Indeed, MD simulations reveal that up to 100 ns, the Dengue NS2B C-terminus constantly has close contacts with its NS3pro domain.', 'By a sharp contrast, the Zika NS2B C-terminus loses the contacts with its NS3pro domain after 10 ns, further forming a short β-sheet characteristic of the closed conformation at 30 ns.', 'Furthermore, we found that a small molecule, previously identified as an active site inhibitor for other flaviviral NS2B-NS3pro, inhibited Zika NS2B-NS3pro potently in an allosteric manner.', 'Our study provides the first insight into the dynamics of Zika NS2B-NS3pro and further deciphers that it is susceptible to allosteric inhibition, which thus bears critical implications for the future development of therapeutic allosteric inhibitors.']\n",
            "unmatched tags:  [{'entity': 'Zika NS2B-NS3pro', 'type': 'Gene', 'start': 1503, 'end': 1519}, {'entity': 'Zika NS2B-NS3pro', 'type': 'Gene', 'start': 1394, 'end': 1410}, {'entity': 'flaviviral', 'type': 'Virus', 'start': 1360, 'end': 1370}, {'entity': 'small molecule', 'type': 'Drug', 'start': 1284, 'end': 1298}, {'entity': 'Zika NS2B', 'type': 'Gene', 'start': 1095, 'end': 1104}, {'entity': 'Zika NS2B C-terminus', 'type': 'Gene', 'start': 1095, 'end': 1115}, {'entity': 'Dengue', 'type': 'Disease', 'start': 993, 'end': 999}, {'entity': 'Zika NS2B', 'type': 'Gene', 'start': 845, 'end': 854}, {'entity': 'Dengue', 'type': 'Disease', 'start': 812, 'end': 818}, {'entity': 'Dengue', 'type': 'Disease', 'start': 746, 'end': 752}, {'entity': 'Zika NS2B-NS3pro', 'type': 'Gene', 'start': 699, 'end': 715}, {'entity': 'NS2B-NS3pro complexes', 'type': 'Gene', 'start': 593, 'end': 614}, {'entity': 'Zika', 'type': 'Virus', 'start': 588, 'end': 592}, {'entity': 'Zika NS2B-NS3pro', 'type': 'Gene', 'start': 376, 'end': 392}, {'entity': 'vaccine', 'type': 'Drug', 'start': 335, 'end': 342}, {'entity': 'Zika', 'type': 'Virus', 'start': 308, 'end': 312}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'fractures', 'type': 'Disease', 'start': 340, 'end': 349}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 555, 'end': 562}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'stroke', 'type': 'Disease', 'start': 357, 'end': 363}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'sepsis', 'type': 'Disease', 'start': 389, 'end': 395}\n",
            "['Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells\\tThe global pandemic of Coronavirus disease 2019 (COVID-19) is a disaster for human society.', 'A convenient and reliable in vitro neutralization assay is very important for the development of neutralizing antibodies, vaccines and other inhibitors.', 'In this study, G protein-deficient vesicular stomatitis virus (VSVdG) bearing full-length and truncated spike (S) protein of SARS-CoV-2 were evaluated.', 'The virus packaging efficiency of VSV-SARS-CoV-2-Sdel18 (S with C-terminal 18 amino acid truncation) is much higher than VSV-SARS-CoV-2-S. A neutralization assay for antibody screening and serum neutralizing titer quantification was established based on VSV-SARS-CoV-2-Sdel18 pseudovirus and human angiotensin-converting enzyme 2 (ACE2) overexpressed BHK21 cell (BHK21-hACE2).', 'The experimental results can be obtained by automatically counting EGFP positive cell number at 12 hours after infection, making the assay convenient and high-throughput.', 'The serum neutralizing titer of COVID-19 convalescent patients measured by VSV-SARS-CoV-2-Sdel18 pseudovirus assay has a good correlation with live SARS-CoV-2 assay.', 'Seven neutralizing monoclonal antibodies targeting receptor binding domain (RBD) of SARS-CoV-2-S were obtained.', 'This efficient and reliable pseudovirus assay model could facilitate the development of new drugs and vaccines.']\n",
            "unmatched tags:  [{'entity': 'vaccines', 'type': 'Drug', 'start': 1463, 'end': 1471}, {'entity': 'RBD', 'type': 'Gene', 'start': 1325, 'end': 1328}, {'entity': 'neutralizing monoclonal antibodies', 'type': 'Gene', 'start': 1255, 'end': 1289}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1231, 'end': 1241}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1115, 'end': 1123}, {'entity': 'EGFP', 'type': 'Gene', 'start': 979, 'end': 983}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'pulmonary disease', 'type': 'Disease', 'start': 231, 'end': 248}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'stroke', 'type': 'Disease', 'start': 134, 'end': 140}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'influenza vaccine', 'type': 'Drug', 'start': 26, 'end': 43}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'influenza', 'type': 'Disease', 'start': 26, 'end': 35}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'depressive disorders', 'type': 'Disease', 'start': 241, 'end': 261}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diseases', 'type': 'Disease', 'start': 37, 'end': 45}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 352, 'end': 358}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'amoxicillin', 'type': 'Drug', 'start': 153, 'end': 164}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'case-finding', 'type': 'Chemical', 'start': 617, 'end': 629}\n",
            "['MicrobioLink: An integrated computational pipeline to infer functional effects of microbiome-host interactions\\tMicrobiome-host interactions play significant roles in health and in various diseases including auto-immune disorders.', 'Uncovering these inter-kingdom cross-talks propels our understanding of disease pathogenesis, and provides useful leads on potential therapeutic targets.', 'Despite the biological significance of microbe-host interactions, there is a big gap in understanding the downstream effects of these interactions on host processes.', 'Computational methods are expected to fill this gap by generating, integrating and prioritizing predictions - as experimental detection remains challenging due to feasibility issues.', 'Here, we present MicrobioLink, a computational pipeline to integrate predicted interactions between microbial and host proteins together with host molecular networks.', 'Using the concept of network diffusion, MicrobioLink can analyse how microbial proteins in a certain context are influencing cellular processes by modulating gene or protein expression.', 'We demonstrated the applicability of the pipeline using a case study.', 'We used gut metaproteomic data from Crohns disease patients and healthy controls to uncover the mechanisms by which the microbial proteins can modulate host genes which belong to biological processes implicated in disease pathogenesis.', 'MicrobioLink, which is agnostic of the microbial protein sources (bacterial, viral etc), is freely available on GitHub (https://github.com/korcsmarosgroup/HMIpipeline).']\n",
            "unmatched tags:  [{'entity': 'GitHub', 'type': 'Organization', 'start': 1504, 'end': 1510}, {'entity': 'gene', 'type': 'Gene', 'start': 1383, 'end': 1387}, {'entity': 'gene', 'type': 'Gene', 'start': 1313, 'end': 1317}, {'entity': 'microbial proteins', 'type': 'Gene', 'start': 1276, 'end': 1294}, {'entity': 'Crohns disease', 'type': 'Disease', 'start': 1192, 'end': 1206}, {'entity': 'gene', 'type': 'Gene', 'start': 1058, 'end': 1062}, {'entity': 'microbial proteins', 'type': 'Gene', 'start': 969, 'end': 987}, {'entity': 'host proteins', 'type': 'Gene', 'start': 847, 'end': 860}, {'entity': 'gene', 'type': 'Gene', 'start': 605, 'end': 609}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diseases', 'type': 'Disease', 'start': 145, 'end': 153}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 593, 'end': 601}\n",
            "['Performance of late pregnancy biometry for gestational age dating in low-income and middle-income countries: a prospective, multicountry, population-based cohort study from the WHO Alliance for Maternal and Newborn Health Improvement (AMANHI) Study Group\\tIncorporation of TCD and the use of new formulas in late pregnancy ultrasound scans could improve the accuracy of gestational age estimation in both appropriate-for-gestational-age and small-for-gestational-age infants in LMICs.', 'Given the high rates of small-for-gestational-age infants in LMICs, these results might be especially relevant.', 'Validation of this new formula in other LMIC populations is needed to establish whether the accuracy of the late pregnancy ultrasound can be narrowed to within approximately 2 weeks.']\n",
            "unmatched tags:  [{'entity': 'LMIC', 'type': 'Gene', 'start': 636, 'end': 640}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'phages', 'type': 'Virus', 'start': 500, 'end': 506}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'phage', 'type': 'Virus', 'start': 500, 'end': 505}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'phages', 'type': 'Virus', 'start': 765, 'end': 771}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'phage', 'type': 'Virus', 'start': 879, 'end': 884}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'phages', 'type': 'Virus', 'start': 1019, 'end': 1025}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'phage', 'type': 'Virus', 'start': 1019, 'end': 1024}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'Acute Respiratory Syndrome', 'type': 'Disease', 'start': 246, 'end': 272}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNA', 'type': 'Gene', 'start': 1058, 'end': 1061}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CoV', 'type': 'Virus', 'start': 1207, 'end': 1210}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CoV', 'type': 'Virus', 'start': 1239, 'end': 1242}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancers', 'type': 'Disease', 'start': 167, 'end': 174}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'hepatitis B', 'type': 'Virus', 'start': 562, 'end': 573}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 55, 'end': 61}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 617, 'end': 623}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 374, 'end': 380}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'astroviruses', 'type': 'Virus', 'start': 579, 'end': 591}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'influenza vaccine', 'type': 'Drug', 'start': 247, 'end': 264}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 257, 'end': 264}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 50, 'end': 56}\n",
            "['Invoking human rights to reduce maternal deaths\\tMaternal health is one of the most neglected issues of our time, especially in the developing world, where the UN estimates that every year, nearly half a million women die from mostly preventable, pregnancy-related causes.', 'By contrast with treatment for HIV/AIDS, human rights are only just beginning to be applied to safe motherhood.', 'In this article, we describe how human rights are being invoked, nationally and internationally, to encourage governments to promote the human rights of women during pregnancy and childbirth.']\n",
            "unmatched tags:  [{'entity': 'governments', 'type': 'Organization', 'start': 494, 'end': 505}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diseases', 'type': 'Disease', 'start': 123, 'end': 131}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 108, 'end': 116}\n",
            "['4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease\\tA genetic predisposition to produce high concentrations of PAI-1 is associated with poor outcome of meningococcal sepsis.', 'This finding suggests that impaired fibrinolysis is an important factor in the pathophysiology of meningococcal sepsis.']\n",
            "unmatched tags:  [{'entity': 'meningococcal sepsis', 'type': 'Disease', 'start': 331, 'end': 351}, {'entity': 'meningococcal sepsis', 'type': 'Disease', 'start': 211, 'end': 231}, {'entity': 'PAI-1', 'type': 'Gene', 'start': 170, 'end': 175}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 169, 'end': 175}\n",
            "['30 years of second-generation antiseizure medications: impact and future perspectives\\tSince 1989, 18 second-generation antiseizure medications have reached the market, resulting in a greatly increased range of treatment options for patients and prescribers.', '30 years have passed and now is the time for an appraisal of the effect of these medications on clinical outcomes.', 'Every antiseizure medication needs to be assessed individually, but overall second-generation drugs are less likely to cause pharmacokinetic interactions than their older counterparts.', 'Some second-generation antiseizure medications have shown advantages in tolerability and safety, particularly in the treatment of older patients and women of childbearing potential.']\n",
            "unmatched tags:  [{'entity': 'antiseizure medication', 'type': 'Phenotype', 'start': 581, 'end': 603}, {'entity': 'second-generation', 'type': 'Drug', 'start': 563, 'end': 580}, {'entity': 'second-generation drugs', 'type': 'Drug', 'start': 449, 'end': 472}, {'entity': 'antiseizure medication', 'type': 'Phenotype', 'start': 379, 'end': 401}, {'entity': 'medications', 'type': 'Drug', 'start': 339, 'end': 350}, {'entity': 'medications', 'type': 'Drug', 'start': 131, 'end': 142}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'deficiency', 'type': 'Disease', 'start': 191, 'end': 201}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'deficiency', 'type': 'Disease', 'start': 533, 'end': 543}\n",
            "['Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population\\tPeople living with HIV have significantly lower HRQoL than do the general population, despite most HIV positive individuals in this study being virologically and immunologically stable.', 'Although this difference could in part be due to factors other than HIV, this study provides additional evidence of the loss of health that can be avoided through prevention of further HIV infections.']\n",
            "unmatched tags:  [{'entity': 'HIV infections', 'type': 'Disease', 'start': 530, 'end': 544}, {'entity': 'HIV', 'type': 'Virus', 'start': 413, 'end': 416}, {'entity': 'HIV', 'type': 'Virus', 'start': 258, 'end': 261}, {'entity': 'era', 'type': 'Gene', 'start': 228, 'end': 231}, {'entity': 'HIV', 'type': 'Virus', 'start': 178, 'end': 181}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'influenza A', 'type': 'Drug', 'start': 1140, 'end': 1151}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'malignancy', 'type': 'Disease', 'start': 124, 'end': 134}\n",
            "['Mechanisms of glutamate toxicity in multiple sclerosis: biomarker and therapeutic opportunities\\tResearch advances support the idea that excessive activation of the glutamatergic pathway plays an important part in the pathophysiology of multiple sclerosis.', 'Beyond the well established direct toxic effects on neurons, additional sites of glutamate-induced cell damage have been described, including effects in oligodendrocytes, astrocytes, endothelial cells, and immune cells.', 'Such toxic effects could provide a link between various pathological aspects of multiple sclerosis, such as axonal damage, oligodendrocyte cell death, demyelination, autoimmunity, and blood–brain barrier dysfunction.']\n",
            "unmatched tags:  [{'entity': 'dysfunction', 'type': 'Disease', 'start': 680, 'end': 691}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'deficiency', 'type': 'Disease', 'start': 190, 'end': 200}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diseases', 'type': 'Disease', 'start': 53, 'end': 61}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 318, 'end': 327}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 598, 'end': 607}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 97, 'end': 103}\n",
            "['Promoting protection and pleasure: amplifying the effectiveness of barriers against sexually transmitted infections and pregnancy\\tThe global burden of morbidity and mortality associated with sexually transmitted infection (STI) and unwanted pregnancy is a prominent global public-health issue.', 'For example, HIV/AIDS and other STI cause 12·9% of the burden of disease in disability-adjusted life years.']\n",
            "unmatched tags:  [{'entity': 'STI', 'type': 'Disease', 'start': 326, 'end': 329}, {'entity': 'HIV/AIDS', 'type': 'Disease', 'start': 307, 'end': 315}, {'entity': 'global public-health', 'type': 'Chemical', 'start': 266, 'end': 286}, {'entity': 'STI', 'type': 'Disease', 'start': 223, 'end': 226}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tuberculosis', 'type': 'Disease', 'start': 532, 'end': 544}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'receptors', 'type': 'Gene', 'start': 419, 'end': 428}\n",
            "['Lipidome profiles of postnatal day 2 vaginal swabs reflect fat composition of gilt’s postnatal diet\\tWe hypothesized that postnatal development of the vagina is impacted by early nutritional environment.', 'Our objective was to determine if lipid profiles of vaginal swabs were different between gilts suckled by sow or fed milk replacer the first 48 h postpartum, with and without a lard-based fat supplement.', 'Gilts (>1.3 kg) were selected at birth across 8 litters and assigned to treatments: colostrum suckled (S, n=8); S plus fat supplement (SF, n=5); bottle-fed milk replacer (B, n=8); or B plus fat supplement (BF, n=7).', 'At 48 h postnatal, vaginal swabs were taken with a cytology brush, immersed in ultrapure water to burst cells, and lipids extracted for analysis using multiple reaction monitoring (MRM)-profiling.', 'Lipids extracted from serum collected at 48 h from gilts and milk collected from sows at 24 h were also analyzed with MRM-profiling.', 'Receiver operating characteristic curve analysis found 18 lipids highly distinguished [area-under-the-curve (AUC) > 0.9] between S and B gilts, including phosphatidylethanolamine with 34 carbon and four unsaturations in the fatty acyl residues [PE(34:4)].', 'Twelve lipids from vaginal swabs highly correlated ( r > 0.6; p < 0.01) with nutrition source.', 'Lipids more abundant in milk replacer drove association.', 'For example, mean intensity of PE (34:4) was 149-fold higher in milk replacer than colostrum, with 1.6- and 2.12-fold higher levels in serum and vaginal swab samples ( p < 0.001), respectively, of B versus S gilts.', 'Findings support that vaginal swabs can be used to noninvasively study effects of perinatal nutrition on tissue composition.', 'Summary sentence Vaginal swab lipidome profiles at 48 h reflect the fat composition of neonatal diet during first two days postnatal.']\n",
            "unmatched tags:  [{'entity': 'fat', 'type': 'Drug', 'start': 1769, 'end': 1772}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'stroke', 'type': 'Disease', 'start': 128, 'end': 134}\n",
            "['Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial\\tThere is no evidence for a difference in efficacy and safety between epinephrine alone and norepinephrine plus dobutamine for the management of septic shock.']\n",
            "unmatched tags:  [{'entity': 'dobutamine', 'type': 'Drug', 'start': 218, 'end': 228}, {'entity': 'epinephrine', 'type': 'Drug', 'start': 201, 'end': 212}, {'entity': 'epinephrine', 'type': 'Drug', 'start': 176, 'end': 187}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 428, 'end': 436}\n",
            "['Full-length genome sequence of segmented RNA virus from ticks was obtained using small RNA sequencing data\\tIn 2014, A novel tick-borne virus of the genus Flavivirus was first reported from the Mogiana region in Brazil.', 'This virus was named the Mogiana tick virus (MGTV).', 'Later, MGTV was also named as Jingmen tick virus (JMTV), Kindia tick virus (KDTV), Guangxi tick virus (GXTV) etc.', 'In the present study, we used small RNA sequencing (sRNA-seq) to detect viruses in ticks and detected MGTV in Amblyomma testudinarium ticks, which had been captured in Yunnan province of China in the year of 2016.', 'The full-length genome sequence of a new MGTV strain Yunnan2016 (GenBank: MT080097 , MT080098 , MT080099 and MT080100 ) was obtained and recommended to be included into the NCBI RefSeq database for the future studies of MGTV.', 'Our phylogenetic analyses showed that viruses named MGTV, JMTV, KDTV and GXTV are monophyletic: the MGTV group (lineage) of viruses.', 'We show, for the first time, that 5′ and 3′ sRNAs can be used to obtain full-length sequences of the 5’ and 3’ ends of, but not limited to genome sequences of RNA viruses.', 'And we proved the feasibility of using the sRNA-seq based method for the detection of viruses in a sample containing miniscule RNA.']\n",
            "unmatched tags:  [{'entity': 'RNA', 'type': 'Gene', 'start': 1257, 'end': 1260}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'syndrome', 'type': 'Disease', 'start': 119, 'end': 127}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'VEGFR1', 'type': 'Gene', 'start': 885, 'end': 891}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 369, 'end': 375}\n",
            "['Significant expression of FURIN and ACE2 on oral epithelial cells may facilitate the efficiency of SARS-CoV-2 entry\\tBackground Leading to a sustained epidemic spread with >2,000,000 confirmed human infections, including >100,000 deaths, COVID-19 was caused by SARS-CoV-2 and resulted in acute respiratory distress syndrome (ARDS) and sepsis, which brought more challenges to the patient’s treatment.', 'The S-glycoprotein, which recognized as the key factor for the entry of SARS-CoV-2 into the cell, contains two functional domains: an ACE2 receptor binding domain and a second domain necessary for fusion of the coronavirus and cell membranes.', 'FURIN activity, exposes the binding and fusion domains, is essential for the zoonotic transmission of SARS-CoV-2.', 'Moreover, it has been reported that ACE2 is likely to be the receptor for SARS-CoV-2.', 'In addition, FURIN enzyme and ACE2 receptor were expressed in airway epithelia, cardiac tissue, and enteric canals, which considered as the potential target organ of the virus.', 'However, report about the expression of FURIN and ACE2 in oral tissues was limited.', 'Methods In order to investigate the potential infective channel of new coronavirus in oral cavity, we analyze the expression of ACE2 and FURIN that mediate the new coronavirus entry into host cells in oral mucosa using the public single-cell sequence datasets.', 'Furthermore, immunohistochemical staining experiment was performed to confirm the expression of ACE2 and FURIN in the protein level.', 'Results The bioinformatics results indicated the differential expression of ACE2 and FURIN on epithelial cells of different oral mucosal tissues and the proportion of FURIN-positive cells was obviously higher than that of ACE2-positive cells.', 'IHC experiments revealed that both the ACE2-positive and FURIN-positive cells in the target tissues were mainly positioned in the epithelial layers, partly expressed in fibroblasts, which further confirm the bioinformatics results.', 'Conclusions Based on these findings, we speculated that SARS-CoV-2 could effectively invade oral mucosal cells though two possible routes: binding to the ACE2 receptor and fusion with cell membrane activated by FURIN protease.', 'Our results indicated that oral mucosa tissues are susceptible to SARS-CoV-2, which provides valuable information for virus-prevention strategy in clinical care as well as daily life.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2266, 'end': 2276}, {'entity': 'FURIN protease', 'type': 'Gene', 'start': 2184, 'end': 2198}, {'entity': 'cell', 'type': 'Gene', 'start': 2157, 'end': 2161}, {'entity': 'receptor', 'type': 'Gene', 'start': 2132, 'end': 2140}, {'entity': 'ACE2 receptor', 'type': 'Gene', 'start': 2127, 'end': 2140}, {'entity': 'cell', 'type': 'Gene', 'start': 2078, 'end': 2082}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2029, 'end': 2039}, {'entity': 'cell', 'type': 'Gene', 'start': 1813, 'end': 1817}, {'entity': 'ACE2-positive cells', 'type': 'Gene', 'start': 1720, 'end': 1739}, {'entity': 'cell', 'type': 'Gene', 'start': 1680, 'end': 1684}, {'entity': 'cell', 'type': 'Gene', 'start': 1603, 'end': 1607}, {'entity': 'FURIN', 'type': 'Gene', 'start': 1583, 'end': 1588}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1574, 'end': 1578}, {'entity': 'FURIN', 'type': 'Gene', 'start': 1470, 'end': 1475}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1461, 'end': 1465}, {'entity': 'cell', 'type': 'Gene', 'start': 1341, 'end': 1345}, {'entity': 'cell', 'type': 'Gene', 'start': 1296, 'end': 1300}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 1268, 'end': 1279}, {'entity': 'FURIN', 'type': 'Gene', 'start': 1241, 'end': 1246}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1232, 'end': 1236}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 1175, 'end': 1186}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1070, 'end': 1074}, {'entity': 'FURIN', 'type': 'Gene', 'start': 1060, 'end': 1065}, {'entity': 'ACE2 receptor', 'type': 'Gene', 'start': 873, 'end': 886}, {'entity': 'enzyme', 'type': 'Gene', 'start': 862, 'end': 868}, {'entity': 'FURIN', 'type': 'Gene', 'start': 856, 'end': 861}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 831, 'end': 841}, {'entity': 'receptor', 'type': 'Gene', 'start': 818, 'end': 826}, {'entity': 'ACE2', 'type': 'Gene', 'start': 793, 'end': 797}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 745, 'end': 755}, {'entity': 'FURIN', 'type': 'Gene', 'start': 643, 'end': 648}, {'entity': 'cell', 'type': 'Gene', 'start': 627, 'end': 631}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 611, 'end': 622}, {'entity': 'ACE2 receptor', 'type': 'Gene', 'start': 534, 'end': 547}, {'entity': 'cell', 'type': 'Gene', 'start': 492, 'end': 496}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 472, 'end': 482}, {'entity': 'S-glycoprotein', 'type': 'Gene', 'start': 404, 'end': 418}, {'entity': 'sepsis', 'type': 'Disease', 'start': 334, 'end': 340}, {'entity': 'ARDS', 'type': 'Disease', 'start': 324, 'end': 328}, {'entity': 'acute respiratory distress syndrome', 'type': 'Phenotype', 'start': 287, 'end': 322}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 260, 'end': 270}]\n",
            "['Chasing the ghost of infection past: identifying thresholds of change during the COVID-19 infection in Spain\\tCOVID-19 pandemic has spread worldwide rapidly from its first outbreak in China, with different impacts depending on the age and social structure of the populations, and the measures taken by each government.', 'Within Europe, the first countries to be strongly affected have been Italy and Spain.', 'In Spain, infection has expanded in highly populated areas, resulting in one of the largest nationwide bursts so far by early April.', 'We analyze the evolution of the growth curve of the epidemic in both the whole of Spain and Madrid Autonomous Region (the second largest conurbation in Europe), based on the cumulative numbers of reported cases and deaths.', 'We conducted segmented, linear regressions on log-transformed data to identify changes in the slope of these curves and/or sudden shifts in the number of cases (i.e.', 'changes in the intercept) at fitted breaking points, and compared their results with a timeline including both key events of the epidemic and containment measures taken by the national and regional governments.', 'Results were largely consistent in the four curves analyzed (reported infections and deaths for Spain and Madrid, respectively), showing two major shifts in slopes (growth rates) at 14-15 and 26-29 March that resulted in 37-65% reductions of slope, and originated in infection on 4-5 and 16-18 March (for case detections) and 14-23 February and 5-6 March (for deaths).', 'Small upward shifts in the progress of the disease in Madrid were not associated with significant changes in the intercept of the curve, and seem related with unevenness in case reporting.', 'These results evidence an early deceleration in the spread of COVID-19 coinciding with personal hygiene and social distancing recommendations, as well as the general awareness of the population; and a second, stronger decrease when harder isolation measures were enforced.', 'The combination of both breakpoints seemingly led to the start of the contention of the disease outbreak by early April, the limit of our time series.', 'This highlights the importance of adopting public health strategies that include disseminating basic knowledge on personal hygiene and reduced social contact at the onset of the epidemic, and the importance of early enforcement of hard contention measures for its subsequent contention.']\n",
            "unmatched tags:  [{'entity': 'breakpoints', 'type': 'Gene', 'start': 1992, 'end': 2003}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1757, 'end': 1765}, {'entity': 'intercept', 'type': 'Drug', 'start': 1619, 'end': 1628}, {'entity': 'Madrid', 'type': 'Chemical', 'start': 1560, 'end': 1566}, {'entity': 'Madrid', 'type': 'Chemical', 'start': 1243, 'end': 1249}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'leukaemia', 'type': 'Disease', 'start': 143, 'end': 152}\n",
            "['Management of rheumatic diseases in the times of COVID-19 pandemic- perspectives of rheumatology practitioners from India\\tBackground.', 'The Coronavirus disease 19 (COVID-19) pandemic has led to widespread concerns about the risk of infection in patients with rheumatic diseases (RD) receiving disease modifying ant-rheumatic drugs (DMARDs) and other immunosuppressants (IS).', 'Methods.', 'A SurveyMonkey based electronic survey was conducted amongst members of the Indian Rheumatology Association to understand the need for changes in prevailing practices.', 'Results.', 'Of the 861 invitees, 221 responded.', 'In the wake of the pandemic, 47.5% would reduce biological DMARDs (bDMARDs) while only 12.2% would reduce the use of conventional synthetic DMARDs.', '64.2% were likely to defer change in IS, the reluctance being most with rituximab (58.3%) followed by cyclophosphamide (53.3%), anti-tumor necrosis factor alpha agents (52.4%) and Janus kinase inhibitors (34.39%).', 'Hydroxychloroquine was the preferred choice (81.9%) for the treatment of COVID-19 followed by protease inhibitors (22.1%) and intravenous immunoglobulin (8.1%).', 'Chloroquine was less preferred (19%).', 'More than two-thirds (70.5%) believed that  COVID-19 might trigger macrophage activation syndrome.', 'Social distancing (98.1%) and hand hygiene (74.6%) were recommended by majority.', '62.8% would avoid touch for clinical examination whenever feasible.', 'Conclusion.', 'Most rheumatologists perceived the need to change treatment of RDs during the COVID-19 pandemic; reduce immunosuppression and defer the usage of rituximab and bDMARDs.']\n",
            "unmatched tags:  [{'entity': 'DMARDs', 'type': 'Drug', 'start': 1588, 'end': 1594}, {'entity': 'rituximab', 'type': 'Gene', 'start': 1573, 'end': 1582}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1506, 'end': 1514}, {'entity': 'macrophage activation syndrome', 'type': 'Disease', 'start': 1232, 'end': 1262}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1209, 'end': 1217}, {'entity': 'Chloroquine', 'type': 'Drug', 'start': 1127, 'end': 1138}, {'entity': 'intravenous immunoglobulin', 'type': 'Gene', 'start': 1092, 'end': 1118}, {'entity': 'protease inhibitors', 'type': 'Drug', 'start': 1060, 'end': 1079}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1039, 'end': 1047}, {'entity': 'Hydroxychloroquine', 'type': 'Drug', 'start': 966, 'end': 984}, {'entity': 'anti-tumor necrosis factor alpha agents', 'type': 'Drug', 'start': 878, 'end': 917}, {'entity': 'cyclophosphamide', 'type': 'Drug', 'start': 852, 'end': 868}, {'entity': 'rituximab', 'type': 'Gene', 'start': 822, 'end': 831}]\n",
            "['Confronting the threat of bioterrorism: realities, challenges, and defensive strategies\\tGlobal terrorism is a rapidly growing threat to world security, and increases the risk of bioterrorism.', 'In this Review, we discuss the potential threat of bioterrorism, agents that could be exploited, and recent developments in technologies and policy for detecting and controlling epidemics that have been initiated intentionally.', 'The local and international response to infectious disease epidemics, such as the severe acute respiratory syndrome and west African Ebola virus epidemic, revealed serious shortcomings which bioterrorists might exploit when intentionally initiating an epidemic.']\n",
            "unmatched tags:  [{'entity': 'Ebola virus', 'type': 'Virus', 'start': 553, 'end': 564}, {'entity': 'acute respiratory syndrome', 'type': 'Disease', 'start': 509, 'end': 535}, {'entity': 'infectious disease', 'type': 'Disease', 'start': 460, 'end': 478}, {'entity': 'terrorism', 'type': 'Disease', 'start': 246, 'end': 255}, {'entity': 'terrorism', 'type': 'Disease', 'start': 181, 'end': 190}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'optic neuritis', 'type': 'Disease', 'start': 209, 'end': 223}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tuberculosis', 'type': 'Disease', 'start': 262, 'end': 274}\n",
            "['Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis\\tBackground: Recently, Coronavirus Disease 2019 (COVID-19) outbreak started in Wuhan, China.', 'Although the clinical features of COVID-19 have been reported previously, data regarding the risk factors associated with the clinical outcomes are lacking.', 'Objectives: To summary and analyze the clinical characteristics and identify the predictors of disease severity and mortality.', 'Methods: The PubMed, Web of Science Core Collection, Embase, Cochrane and MedRxiv databases were searched through February 25, 2020.', 'Meta-analysis of Observational Studies in Epidemiology (MOOSE) recommendations were followed.', 'We extracted and pooled data using random-effects meta-analysis to summary the clinical feature of the confirmed COVID-19 patients, and further identify risk factors for disease severity and death.', 'Heterogeneity was evaluated using the I2 method and explained with subgroup analysis and meta-regression.', 'Results: A total of 30 studies including 53000 patients with COVID-19 were included in this study, the mean age was 49.8 years (95% CI, 47.5-52.2 yrs) and 55.5% were male.', 'The pooled incidence of severity and mortality were 20.2% (95% CI, 15.1-25.2%) and 3.1% (95% CI, 1.9-4.2%), respectively.', 'The predictor for disease severity included old age (≥ 50 yrs, odds ratio [OR] = 2.61; 95% CI, 2.29-2.98), male (OR =1.348, 95% CI, 1.195-1.521), smoking (OR =1.734, 95% CI, 1.146-2.626) and any comorbidity (OR = 2.635, 95% CI, 2.098-3.309), especially chronic kidney disease (CKD, OR = 6.017; 95% CI, 2.192-16.514), chronic obstructive pulmonary disease (COPD, OR = 5.323; 95% CI, 2.613-10.847) and cerebrovascular disease (OR = 3.219; 95% CI, 1.486-6.972).', 'In terms of laboratory results, increased lactate dehydrogenase (LDH), C-reactive protein (CRP) and D-dimer and decreased blood platelet and lymphocytes count were highly associated with severe COVID-19 (all for P < 0.001).', 'Meanwhile, old age (≥ 60 yrs, RR = 9.45; 95% CI, 8.09-11.04), followed by cardiovascular disease (RR = 6.75; 95% CI, 5.40-8.43) hypertension (RR = 4.48; 95% CI, 3.69-5.45) and diabetes (RR = 4.43; 95% CI, 3.49-5.61) were found to be independent prognostic factors for the COVID-19 related death.', 'Conclusions: To our knowledge, this is the first evidence-based medicine research to explore the risk factors of prognosis in patients with COVID-19, which is helpful to identify early-stage patients with poor prognosis and adapt effective treatment.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2444, 'end': 2452}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2280, 'end': 2288}, {'entity': 'diabetes', 'type': 'Disease', 'start': 2184, 'end': 2192}, {'entity': 'hypertension', 'type': 'Disease', 'start': 2136, 'end': 2148}, {'entity': 'cardiovascular disease', 'type': 'Disease', 'start': 2082, 'end': 2104}, {'entity': 'yrs', 'type': 'Gene', 'start': 2033, 'end': 2036}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1978, 'end': 1986}, {'entity': 'C-reactive protein', 'type': 'Gene', 'start': 1855, 'end': 1873}, {'entity': 'LDH', 'type': 'Gene', 'start': 1849, 'end': 1852}, {'entity': 'lactate dehydrogenase', 'type': 'Gene', 'start': 1826, 'end': 1847}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'syndrome', 'type': 'Disease', 'start': 80, 'end': 88}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'syndrome', 'type': 'Disease', 'start': 477, 'end': 485}\n",
            "['CAR T-cell product performance in haematological malignancies before and after marketing authorisation\\tChimeric antigen receptor (CAR) T cells represent a potent new approach to treat haematological malignancies.', 'Two CAR T-cell therapies, tisagenlecleucel and axicabtagene ciloleucel, have been approved in Europe and the USA, as well as several other countries, for the treatment of leukaemia and lymphoma.', 'These approvals marked a major milestone in the field of cell and gene therapies.', 'However, the clinical development and regulatory evaluation of these innovative therapies faced several challenges that are considered important lessons learned for future similar products.']\n",
            "unmatched tags:  [{'entity': 'cell', 'type': 'Gene', 'start': 465, 'end': 469}, {'entity': 'lymphoma', 'type': 'Disease', 'start': 398, 'end': 406}, {'entity': 'leukaemia', 'type': 'Disease', 'start': 384, 'end': 393}, {'entity': 'axicabtagene ciloleucel', 'type': 'Chemical', 'start': 260, 'end': 283}, {'entity': 'cell', 'type': 'Gene', 'start': 223, 'end': 227}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'NSP16', 'type': 'Gene', 'start': 913, 'end': 918}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CoV', 'type': 'Virus', 'start': 1177, 'end': 1180}\n",
            "['MERS-CoV NSP16 necessary for IFN resistance and viral pathogenesis\\tCoronaviruses encode a mix of highly conserved and novel genes as well as genetic elements necessary for infection and pathogenesis, raising the possibility for common targets for attenuation and therapeutic design.', 'In this study, we focus on the highly conserved nonstructural protein (NSP) 16, a viral 2’O methyl-transferase (MTase) that encodes critical functions in immune modulation and infection.', 'Using reverse genetics, we disrupted a key motif in the conserved KDKE motif of MERS NSP16 (D130A) and evaluated the effect on viral infection and pathogenesis.', 'While the absence of 2’O MTase activity had only marginal impact on propagation and replication in Vero cells, the MERS dNSP16 mutant demonstrated significant attenuation relative to control both in primary human airway cultures and in vivo.', 'Further examination indicated the MERS dNSP16 mutant had a type I IFN based attenuation and was partially restored in the absence of IFIT molecules.', 'Importantly, the robust attenuation permitted use of MERS dNSP16 as a live attenuated vaccine platform protecting from challenge with a mouse adapted MERS-CoV strain.', 'These studies demonstrate the importance of the conserved 2’O MTase activity for CoV pathogenesis and highlight NSP16 as a conserved universal target for rapid live attenuated vaccine design in an expanding CoV outbreak setting.', 'Significance Coronavirus emergence in both human and livestock represents a significant threat to global public health, as evidenced by the sudden emergence of SARS-CoV, MERS-CoV, PEDV and swine delta coronavirus in the 21 st century.', 'These studies describe an approach that effectively targets the highly conserved 2’O methyl-transferase activity of coronaviruses for attenuation.', 'With clear understanding of the IFN/IFIT based mechanism, NSP16 mutants provide a suitable target for a live attenuated vaccine platform as well as therapeutic development for both current and future emergent CoV strains.', 'Importantly, other approaches targeting other conserved pan-coronavirus functions have not yet proven effective against MERS-CoV, illustrating the broad applicability of targeting viral 2’O MTase function across coronaviruses.']\n",
            "unmatched tags:  [{'entity': 'coronaviruses', 'type': 'Virus', 'start': 2234, 'end': 2247}, {'entity': 'MTase', 'type': 'Gene', 'start': 2212, 'end': 2217}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 2142, 'end': 2150}, {'entity': 'pan-coronavirus', 'type': 'Virus', 'start': 2078, 'end': 2093}, {'entity': 'CoV', 'type': 'Virus', 'start': 2009, 'end': 2012}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1920, 'end': 1927}, {'entity': 'NSP16', 'type': 'Gene', 'start': 1858, 'end': 1863}, {'entity': 'IFIT', 'type': 'Gene', 'start': 1836, 'end': 1840}, {'entity': 'IFN', 'type': 'Gene', 'start': 1832, 'end': 1835}, {'entity': 'coronaviruses', 'type': 'Virus', 'start': 1769, 'end': 1782}, {'entity': 'swine delta coronavirus', 'type': 'Virus', 'start': 1607, 'end': 1630}, {'entity': 'PEDV', 'type': 'Virus', 'start': 1598, 'end': 1602}, {'entity': 'CoV', 'type': 'Virus', 'start': 1593, 'end': 1596}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 1588, 'end': 1596}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1578, 'end': 1586}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'headache', 'type': 'Phenotype', 'start': 199, 'end': 207}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'meningitis', 'type': 'Phenotype', 'start': 377, 'end': 387}\n",
            "['Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study\\tCytomegalovirus viraemia is associated with an increased risk of overall mortality in the first year after haemopoietic stem cell transplantation, independent of the use of pre-emptive therapy, and with evidence of a positive dose-response relationship.', 'These data indicate the suitability of viral load as a surrogate clinical endpoint for clinical trials for cytomegalovirus vaccines, biologics, and drugs.']\n",
            "unmatched tags:  [{'entity': 'cytomegalovirus vaccines', 'type': 'Drug', 'start': 511, 'end': 535}, {'entity': 'era', 'type': 'Gene', 'start': 337, 'end': 340}, {'entity': 'era', 'type': 'Gene', 'start': 217, 'end': 220}, {'entity': 'Cytomegalovirus viraemia', 'type': 'Disease', 'start': 150, 'end': 174}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'venous thromboembolism', 'type': 'Disease', 'start': 555, 'end': 577}\n",
            "['SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors.', 'It is of paramount importance to evaluate the prevalence of both asymptomatic and symptomatic cases of SARS-CoV-2 infection and their antibody response profile.', 'Here, we performed a pilot study to assess the levels of anti-SARS-CoV-2 antibodies in samples taken from 491 pre- epidemic individuals, 51 patients from Hopital Bichat (Paris), 209 pauci-symptomatic individuals in the French Oise region and 200 contemporary Oise blood donors.', 'Two in-house ELISA assays, that recognize the full-length nucleoprotein (N) or trimeric Spike (S) ectodomain were implemented.', 'We also developed two novel assays: the S-Flow assay, which is based on the recognition of S at the cell surface by flow-cytometry, and the LIPS assay that recognizes diverse antigens (including S1 or N C- terminal domain) by immunoprecipitation.', 'Overall, the results obtained with the four assays were similar, with differences in sensitivity that can be attributed to the technique and the antigen in use.', 'High antibody titers were associated with neutralisation activity, assessed using infectious SARS-CoV- 2 or lentiviral-S pseudotypes.', 'In hospitalized patients, seroconversion and neutralisation occurred on 5-14 days post symptom onset, confirming previous studies.', 'Seropositivity was detected in 29% of pauci-symptomatic individuals within 15 days post-symptoms and 3 % of blood of healthy donors collected in the area of a cluster of COVID cases.', 'Altogether, our assays allow for a broad evaluation of SARS-CoV2 seroprevalence and antibody profiling in different population subsets.']\n",
            "unmatched tags:  [{'entity': 'COVID', 'type': 'Virus', 'start': 1524, 'end': 1529}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 1442, 'end': 1449}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 1398, 'end': 1405}, {'entity': 'Seropositivity', 'type': 'Disease', 'start': 1354, 'end': 1368}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 1310, 'end': 1317}, {'entity': 'post', 'type': 'Gene', 'start': 1305, 'end': 1309}, {'entity': 'SARS-CoV- 2', 'type': 'Virus', 'start': 1182, 'end': 1193}, {'entity': 'S1', 'type': 'Gene', 'start': 876, 'end': 878}, {'entity': 'flow-cytometry', 'type': 'Chemical', 'start': 797, 'end': 811}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 464, 'end': 471}, {'entity': 'Paris', 'type': 'Gene', 'start': 446, 'end': 451}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 197, 'end': 204}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'virus infection', 'type': 'Disease', 'start': 770, 'end': 785}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNA', 'type': 'Gene', 'start': 700, 'end': 703}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNA', 'type': 'Gene', 'start': 1785, 'end': 1788}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'communicable diseases', 'type': 'Disease', 'start': 241, 'end': 262}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'communicable', 'type': 'Disease', 'start': 241, 'end': 253}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 567, 'end': 574}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'kidney disease', 'type': 'Disease', 'start': 510, 'end': 524}\n",
            "['Re-examining causes of surgical site infections following elective surgery in the era of asepsis\\tThe currently accepted assumption that most surgical site infections (SSIs) occurring after elective surgery under standard methods of antisepsis are due to an intraoperative contamination event, remains unproven.', 'We examined the available evidence in which microbial cultures of surgical wounds were taken at the conclusion of an operation and determined that such studies provide more evidence to refute that an SSI is due to intraoperative contamination than support it.', 'We propose that alternative mechanisms of SSI development should be considered, such as when a sterile postoperative wound becomes infected by a pathogen originating from a site remote from the operative wound—eg, from the gums or intestinal tract (ie, the Trojan Horse mechanism).']\n",
            "unmatched tags:  [{'entity': 'Trojan Horse', 'type': 'Chemical', 'start': 828, 'end': 840}, {'entity': 'era', 'type': 'Gene', 'start': 767, 'end': 770}, {'entity': 'era', 'type': 'Gene', 'start': 680, 'end': 683}, {'entity': 'SSI', 'type': 'Gene', 'start': 613, 'end': 616}, {'entity': 'era', 'type': 'Gene', 'start': 532, 'end': 535}, {'entity': 'SSI', 'type': 'Gene', 'start': 511, 'end': 514}, {'entity': 'era', 'type': 'Gene', 'start': 430, 'end': 433}, {'entity': 'surgical wounds', 'type': 'Disease', 'start': 377, 'end': 392}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'malignant pleural mesothelioma', 'type': 'Disease', 'start': 460, 'end': 490}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'anaemia', 'type': 'Disease', 'start': 423, 'end': 430}\n",
            "['A database resource for Genome-wide dynamics analysis of Coronaviruses on a historical and global scale\\tThe recent outbreak of a new zoonotic origin Coronavirus has ring the bell for the potential spread of epidemic Coronavirus crossing the species.', 'With the urgent needs to assist the control of the Coronavirus spread and to provide valuable scientific information, we developed a coronavirus database (CoVdb), an online genomics and proteomics analysis platform.', 'Based on public available coronavirus genomic information, the database annotates the genome of every strain and identifies 780 possible ORFs of all strains available in Genebank.', 'In addition, the comprehensive evaluation of all the published genomes of Coronavirus strains, including population genetics analysis, functional analysis and structural analysis on a historical and global scale were presented in the CoVdb.', 'In the database, the researcher can easily obtain the basic information of a Coronavirus gene with the distribution of the gene among strains, conserved or high mutation regions, possible subcellular location and topology of the gene.', 'Moreover, sliding windows for population genetics analysis results is provided, thereby facilitating genetics and evolutional analysis at the genomic level.', 'CoVdb can be accessed freely at http://covdb.popgenetics.net .']\n",
            "unmatched tags:  [{'entity': 'gene', 'type': 'Gene', 'start': 1327, 'end': 1331}, {'entity': 'gene', 'type': 'Gene', 'start': 1223, 'end': 1227}, {'entity': 'gene', 'type': 'Gene', 'start': 1163, 'end': 1167}, {'entity': 'sliding windows', 'type': 'Chemical', 'start': 1132, 'end': 1147}, {'entity': 'gene', 'type': 'Gene', 'start': 1116, 'end': 1120}, {'entity': 'strains', 'type': 'Disease', 'start': 1021, 'end': 1028}, {'entity': 'gene', 'type': 'Gene', 'start': 1010, 'end': 1014}]\n",
            "['Structure of M\\tA new coronavirus (CoV) identified as COVID-19 virus is the etiological agent responsible for the 2019-2020 viral pneumonia outbreak that commenced in Wuhan 1 – 4 .', 'Currently there is no targeted therapeutics and effective treatment options remain very limited.', 'In order to rapidly discover lead compounds for clinical use, we initiated a program of combined structure-assisted drug design, virtual drug screening and high-throughput screening to identify new drug leads that target the COVID-19 virus main protease (M pro ).', 'M pro is a key CoV enzyme, which plays a pivotal role in mediating viral replication and transcription, making it an attractive drug target for this virus 5 , 6 .', 'Here, we identified a mechanism-based inhibitor, N3, by computer-aided drug design and subsequently determined the crystal structure of COVID-19 virus M pro in complex with this compound.', 'Next, through a combination of structure-based virtual and high-throughput screening, we assayed over 10,000 compounds including approved drugs, drug candidates in clinical trials, and other pharmacologically active compounds as inhibitors of M pro .', 'Six of these inhibit M pro with IC 50 values ranging from 0.67 to 21.4 μM.', 'Ebselen also exhibited promising antiviral activity in cell-based assays.', 'Our results demonstrate the efficacy of this screening strategy, which can lead to the rapid discovery of drug leads with clinical potential in response to new infectious diseases where no specific drugs or vaccines are available.']\n",
            "unmatched tags:  [{'entity': 'vaccines', 'type': 'Drug', 'start': 1499, 'end': 1507}, {'entity': 'drug', 'type': 'Drug', 'start': 1490, 'end': 1494}, {'entity': 'infectious diseases', 'type': 'Disease', 'start': 1452, 'end': 1471}, {'entity': 'drug', 'type': 'Drug', 'start': 1398, 'end': 1402}, {'entity': 'screening strategy', 'type': 'Gene', 'start': 1337, 'end': 1355}, {'entity': 'cell-based assays', 'type': 'Gene', 'start': 1273, 'end': 1290}, {'entity': 'Ebselen', 'type': 'Drug', 'start': 1218, 'end': 1225}]\n",
            "['Clinical Characteristics of 24 Asymptomatic Infections with COVID-19 Screened among Close Contacts in Nanjing, China\\tBackground: Previous studies have showed clinical characteristics of patients with the 2019 novel coronavirus disease (COVID-19) and the evidence of person-to-person transmission.', 'Limited data are available for asymptomatic infections.', 'This study aims to present the clinical characteristics of 24 cases with asymptomatic infection screened from close contacts and to show the transmission potential of asymptomatic COVID-19 virus carriers.', 'Methods: Epidemiological investigations were conducted among all close contacts of COVID-19 patients (or suspected patients) in Nanjing, Jiangsu Province, China, from Jan 28 to Feb 9, 2020, both in clinic and in community.', 'Asymptomatic carriers were laboratory-confirmed positive for the COVID-19 virus by testing the nucleic acid of the pharyngeal swab samples.', 'Their clinical records, laboratory assessments, and chest CT scans were reviewed.', 'Findings: None of the 24 asymptomatic cases presented any obvious symptoms before nucleic acid screening.', 'Five cases (20.8%) developed symptoms (fever, cough, fatigue and etc.)', 'during hospitalization.', 'Twelve (50.0%) cases showed typical CT images of ground-glass chest and five (20.8%) presented stripe shadowing in the lungs.', 'The remaining seven (29.2%) cases showed normal CT image and had no symptoms during hospitalization.', 'These seven cases were younger (median age: 14.0 years; P = 0.012) than the rest.', 'None of the 24 cases developed severe COVID-19 pneumonia or died.', 'The median communicable period, defined as the interval from the first day of positive nucleic acid tests to the first day of continuous negative tests, was 9.5 days (up to 21 days among the 24 asymptomatic cases).', 'Through epidemiological investigation, we observed a typical asymptomatic transmission to the cohabiting family members, which even caused severe COVID-19 pneumonia.', 'Interpretation: The asymptomatic carriers identified from close contacts were prone to be mildly ill during hospitalization.', 'However, the communicable period could be up to three weeks and the communicated patients could develop severe illness.', 'These results highlighted the importance of close contact tracing and longitudinally surveillance via virus nucleic acid tests.', 'Further isolation recommendation and continuous nucleic acid tests may also be recommended to the patients discharged.']\n",
            "unmatched tags:  [{'entity': 'nucleic acid', 'type': 'Gene', 'start': 2386, 'end': 2398}, {'entity': 'nucleic acid', 'type': 'Gene', 'start': 2318, 'end': 2330}, {'entity': 'communicable', 'type': 'Disease', 'start': 2103, 'end': 2115}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1944, 'end': 1952}, {'entity': 'nucleic acid', 'type': 'Gene', 'start': 1670, 'end': 1682}, {'entity': 'communicable', 'type': 'Disease', 'start': 1594, 'end': 1606}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1555, 'end': 1563}, {'entity': 'ground-glass chest', 'type': 'Chemical', 'start': 1257, 'end': 1275}, {'entity': 'cough', 'type': 'Phenotype', 'start': 1159, 'end': 1164}, {'entity': 'fever', 'type': 'Phenotype', 'start': 1152, 'end': 1157}, {'entity': 'nucleic acid', 'type': 'Gene', 'start': 1089, 'end': 1101}, {'entity': 'nucleic acid', 'type': 'Gene', 'start': 877, 'end': 889}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 847, 'end': 855}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 642, 'end': 650}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 533, 'end': 541}]\n",
            "['Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)\\tTacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide was the most promising intervention, yielding the best GRFS; this regimen is thus being prospectively compared with tacrolimus and methotrexate in a phase 3 randomised trial.']\n",
            "unmatched tags:  [{'entity': 'methotrexate', 'type': 'Drug', 'start': 628, 'end': 640}, {'entity': 'tacrolimus', 'type': 'Drug', 'start': 613, 'end': 623}]\n",
            "['Transcriptional Difference between SARS-COV-2 and other Human Coronaviruses Revealed by Sub-genomic RNA Profiling\\tSARS-COV-2 and all other coronaviruses express its 3 prime genes by forming sub-genomic RNA.', 'As the genome of these virus exist in RNA form, only by profiling the relative abundance of these sgRNAs, can the viral transcriptome be revealed.', 'Utilizing publically available meta-transcriptomic data generated from patient samples, we were able to infer the viral transcriptome in vivo, which is distinct from the in vitro one derived from cell culture.', 'Inter-sample diversity was also observed and a sample specific transcript was identified.', 'By doing the same analysis to MERS and SARS data, we were able to compare the three in terms of transcription.', 'Among the differences, SARS-COV-2 has significantly elevated expression of the Spike gene, which may contribute to its high transmissibility.', 'Highlights The in vivo transcriptome of SARS-CoV-2 revealed by sgRNA profiling, for 25 patient samples around the globe.', 'The Spike protein expression is an order of magnitude higher in SARS-CoV-2 than MERS-CoV or SARS-CoV, possibly contributing to the virus’ elevated transmissibility.', 'The in vivo SARS-CoV-2 transcriptomes, as inferred from human patient data was distinct from the in vitro one derived from cell line culture, all the accessory genes were up-regulated in vivo , suggesting intricate expression regulation mechanism for the small viral genome.']\n",
            "unmatched tags:  [{'entity': 'transcript', 'type': 'Gene', 'start': 1216, 'end': 1226}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1205, 'end': 1215}, {'entity': 'virus’', 'type': 'Virus', 'start': 1159, 'end': 1165}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1120, 'end': 1128}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 1108, 'end': 1116}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1092, 'end': 1102}, {'entity': 'Spike protein', 'type': 'Gene', 'start': 1032, 'end': 1045}, {'entity': 'patient samples', 'type': 'Chemical', 'start': 994, 'end': 1009}, {'entity': 'profiling', 'type': 'Gene', 'start': 976, 'end': 985}, {'entity': 'RNA', 'type': 'Gene', 'start': 972, 'end': 975}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 947, 'end': 957}, {'entity': 'transcript', 'type': 'Gene', 'start': 930, 'end': 940}, {'entity': 'SARS-COV-2', 'type': 'Virus', 'start': 788, 'end': 798}, {'entity': 'transcript', 'type': 'Gene', 'start': 750, 'end': 760}, {'entity': 'SARS', 'type': 'Disease', 'start': 693, 'end': 697}, {'entity': 'MERS', 'type': 'Disease', 'start': 684, 'end': 688}, {'entity': 'transcript', 'type': 'Gene', 'start': 627, 'end': 637}, {'entity': 'transcript', 'type': 'Gene', 'start': 474, 'end': 484}, {'entity': 'patient samples', 'type': 'Chemical', 'start': 425, 'end': 440}, {'entity': 'transcript', 'type': 'Gene', 'start': 390, 'end': 400}, {'entity': 'transcript', 'type': 'Gene', 'start': 327, 'end': 337}]\n",
            "['The impact of social distancing and epicenter lockdown on the COVID-19 epidemic in mainland China: A data-driven SEIQR model study\\tThe outbreak of coronavirus disease 2019 (COVID-19) which originated in Wuhan, China, constitutes a public health emergency of international concern with a very high risk of spread and impact at the global level.', 'We developed data-driven susceptible-exposed-infectious-quarantine-recovered (SEIQR) models to simulate the epidemic with the interventions of social distancing and epicenter lockdown.', 'Population migration data combined with officially reported data were used to estimate model parameters, and then calculated the daily exported infected individuals by estimating the daily infected ratio and daily susceptible population size.', 'As of Jan 01, 2020, the estimated initial number of latently infected individuals was 380.1 (95%-CI: 379.8~381.0).', 'With 30 days of substantial social distancing, the reproductive number in Wuhan and Hubei was reduced from 2.2 (95%-CI: 1.4~3.9) to 1.58 (95%-CI: 1.34~2.07), and in other provinces from 2.56 (95%-CI: 2.43~2.63) to 1.65 (95%-CI: 1.56~1.76).', 'We found that earlier intervention of social distancing could significantly limit the epidemic in mainland China.', 'The number of infections could be reduced up to 98.9%, and the number of deaths could be reduced by up to 99.3% as of Feb 23, 2020.', 'However, earlier epicenter lockdown would partially neutralize this favorable effect.', 'Because it would cause in situ deteriorating, which overwhelms the improvement out of the epicenter.', 'To minimize the epidemic size and death, stepwise implementation of social distancing in the epicenter city first, then in the province, and later the whole nation without the epicenter lockdown would be practical and cost-effective.']\n",
            "unmatched tags:  [{'entity': 'nation', 'type': 'Organization', 'start': 1717, 'end': 1723}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'breast cancer', 'type': 'Disease', 'start': 593, 'end': 606}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 219, 'end': 228}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 298, 'end': 305}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'ovarian cancer', 'type': 'Disease', 'start': 189, 'end': 203}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diseases', 'type': 'Disease', 'start': 323, 'end': 331}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'communicable', 'type': 'Disease', 'start': 432, 'end': 444}\n",
            "['A considerable proportion of individuals with asymptomatic SARS-CoV-2 infection in Tibetan population\\tSevere acute respiratory syndrome coronavirus 2 (SARS-Cov-2) quickly became a major epidemic threat in the whole China.', 'We analysed SARS-Cov-2 infected cases from Tibetan Autonomous Prefecture, and noted divergent characteristics of these Tibetans infected cases compared to Han Chinese, characterizing by a considerable proportion of asymptomatic carriers (21.7%), and few symptomatic patients with initial symptom of fever (7.7%).', 'Here, we did a descriptive study on clinical characteristics of 18 asymptomatic individuals with SARS-CoV-2 infection.', 'The median age of these asymptomatic carriers was 31 years and one third of them were students, aged under 20 years.', 'Notably, some of asymptomatic carriers had recognizable changes in radiological and laboratory indexes.', 'Our finding indicates a potentially big number of SARS-CoV-2 asymptomatic carriers in prevalent area, highlighting a necessity of screening individuals with close contact of infected patients, for a better control on the spread of SARS-CoV-2 infection.']\n",
            "unmatched tags:  [{'entity': 'symptom', 'type': 'Phenotype', 'start': 937, 'end': 944}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 789, 'end': 796}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 679, 'end': 686}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 603, 'end': 610}, {'entity': 'fever', 'type': 'Phenotype', 'start': 521, 'end': 526}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 510, 'end': 517}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 476, 'end': 483}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 438, 'end': 445}, {'entity': 'SARS-Cov-2', 'type': 'Virus', 'start': 234, 'end': 244}, {'entity': 'SARS-Cov-2', 'type': 'Virus', 'start': 151, 'end': 161}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'ulcerative colitis', 'type': 'Disease', 'start': 252, 'end': 270}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 118, 'end': 127}\n",
            "['Loss of smell and taste in combination with other symptoms is a strong predictor of COVID-19 infection\\tImportance: A strategy for preventing further spread of the ongoing COVID-19 epidemic is to detect infections and isolate infected individuals without the need of extensive bio-specimen testing.', 'Objectives: Here we investigate the prevalence of loss of smell and taste among COVID-19 diagnosed individuals and we identify the combination of symptoms, besides loss of smell and taste, most likely to correspond to a positive COVID-19 diagnosis in non-severe cases.', 'Design: Community survey.', 'Setting and Participants: Subscribers of RADAR COVID-19, an app that was launched for use among the UK general population asking about COVID-19 symptoms.', 'Main Exposure: Loss of smell and taste.', 'Main Outcome Measures: COVID-19.', 'Results: Between 24 and 29 March 2020, 1,573,103 individuals reported their symptoms via the app; 26% reported suffering from one or more symptoms of COVID-19.', 'Of those, n=1702 reported having had a RT-PCR COVID-19 test and gave full report on symptoms including loss of smell and taste; 579 were positive and 1123 negative.', 'In this subset, we find that loss of smell and taste were present in 59% of COVID-19 positive individuals compared to 18% of those negative to the test,  yielding an odds ratio (OR) of COVID-19 diagnosis of OR[95%CI]=6.59[5.25; 8.27], P= 1.90x10-59 .', 'We also find that a combination of loss of smell and taste, fever, persistent cough, fatigue, diarrhoea, abdominal pain and loss of appetite is predictive of COVID-19 positive test with sensitivity 0.54[0.44; 0.63], specificity 0.86[0.80; 0.90], ROC-AUC 0.77[0.72; 0.82] in the test set, and cross-validation ROC-AUC   0.75[0.72; 0.77].', 'When applied to the 410,598 individuals reporting symptoms but not formally tested, our model predicted that 13.06%[12.97%;13.15] of these might have been already infected by the virus.', 'Conclusions and Relevance: Our study suggests that loss of taste and smell is a strong predictor of having been infected by the COVID-19 virus.', 'Also, the combination of symptoms that could be used to identify and isolate individuals includes anosmia, fever, persistent cough, diarrhoea, fatigue, abdominal pain and loss of appetite.', 'This is particularly relevant to healthcare and other key workers in constant contact with the public who have not yet been tested for COVID-19.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2389, 'end': 2397}, {'entity': 'app', 'type': 'Gene', 'start': 2244, 'end': 2247}, {'entity': 'abdominal pain', 'type': 'Phenotype', 'start': 2217, 'end': 2231}, {'entity': 'diarrhoea', 'type': 'Drug', 'start': 2197, 'end': 2206}, {'entity': 'persistent cough', 'type': 'Phenotype', 'start': 2179, 'end': 2195}, {'entity': 'fever', 'type': 'Phenotype', 'start': 2172, 'end': 2177}, {'entity': 'anosmia', 'type': 'Phenotype', 'start': 2163, 'end': 2170}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2049, 'end': 2057}, {'entity': 'loss of taste', 'type': 'Phenotype', 'start': 1972, 'end': 1985}, {'entity': 'app', 'type': 'Gene', 'start': 1739, 'end': 1742}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1555, 'end': 1563}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'lupus', 'type': 'Disease', 'start': 364, 'end': 369}\n",
            "['pH Dependent Differential Binding Behavior of Prtotease Inhibitor Molecular Drugs for SARS-COV-2\\tIn this research we used the structure of SARS-CoV-2 main protease (Mpro) for docking with Anti-HIV protease inhibitor drug molecules within pH 4-8.', 'By carrying out the variance analysis of binding energies at pH 4-8, it was revealed that the binding energy and mode of interaction of the potential ligands with SARS-CoV-2 Mpro, was dependent on variation of pH.', 'We found out that two of the selected protease inhibitors have differential binding characteristics with changing pH hence their binding energies and mode of interaction depends upon intracellular pH.', 'This differential binding behavior can lead to development of pH selective potent drug molecules for binding with viral protease at lowered intracellular pH of virus infected cell.']\n",
            "unmatched tags:  [{'entity': 'cell', 'type': 'Gene', 'start': 837, 'end': 841}, {'entity': 'cell', 'type': 'Gene', 'start': 807, 'end': 811}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'personality disorder', 'type': 'Disease', 'start': 527, 'end': 547}\n",
            "['Heparin therapy improving hypoxia in COVID-19 patients - a case series\\tINTRODUCTION: Elevated D-dimer is predictor of severity and mortality in COVID-19 patients and heparin use during in hospital stay has been associated to decreased mortality.', 'COVID-19 patient autopsies have revealed thrombi in the microvasculature, suggesting intravascular coagulation as a prominent feature of organ failure in these patients.', 'Interestingly, in COVID-19, pulmonary compliance is preserved despite severe hypoxemia corroborating the hypothesis that perfusion mismatch may play a significant role in the development of respiratory failure.', 'METHODS:  We describe a series of 27 consecutive COVID-19 patients admitted to the Pulmonology service at Sirio-Libanes Hospital in Sao Paulo-Brazil treated with heparin in therapeutic doses tailored to clinical severity.', 'RESULTS: PaO2/FiO2 ratio increased significantly over the 72 hours following the start of anticoagulation, from 254(SD 90) to 325(SD 80), p=0.013, and over half of the patients were discharged home within an average time of 7.3 (SD 4.0) days.', 'Half of mechanically ventilated patients were extubated within 10.3 (SD 1.5) days.', 'The remaining patients showed progressive improvement and there were no bleeding complications or fatal events.', 'DISCUSSION: Even though this uncontrolled case series does not offer absolute proof of DIC as the underlying mechanism of respiratory failure in COVID-19, as well as patients positive response to tailored dose heparinization, it contributes to the understanding of the physiopathological mechanism of the disease and provides valuable information for the treatment of these very sick patients while we await the results of further prospective controlled studies']\n",
            "unmatched tags:  [{'entity': 'sick', 'type': 'Phenotype', 'start': 1668, 'end': 1672}]\n",
            "['Bipolar disorder diagnosis: challenges and future directions\\tBipolar disorder refers to a group of affective disorders, which together are characterised by depressive and manic or hypomanic episodes.', 'These disorders include: bipolar disorder type I (depressive and manic episodes: this disorder can be diagnosed on the basis of one manic episode); bipolar disorder type II (depressive and hypomanic episodes); cyclothymic disorder (hypomanic and depressive symptoms that do not meet criteria for depressive episodes); and bipolar disorder not otherwise specified (depressive and hypomanic-like symptoms that do not meet the diagnostic criteria for any of the aforementioned disorders).']\n",
            "unmatched tags:  [{'entity': 'disorders', 'type': 'Disease', 'start': 674, 'end': 683}, {'entity': 'depressive', 'type': 'Disease', 'start': 564, 'end': 574}, {'entity': 'bipolar disorder', 'type': 'Disease', 'start': 522, 'end': 538}, {'entity': 'depressive episodes', 'type': 'Disease', 'start': 496, 'end': 515}, {'entity': 'depressive symptoms', 'type': 'Phenotype', 'start': 446, 'end': 465}, {'entity': 'cyclothymic disorder', 'type': 'Disease', 'start': 410, 'end': 430}, {'entity': 'manic episodes', 'type': 'Disease', 'start': 393, 'end': 407}, {'entity': 'depressive', 'type': 'Disease', 'start': 374, 'end': 384}, {'entity': 'bipolar disorder type II', 'type': 'Disease', 'start': 348, 'end': 372}, {'entity': 'manic episode', 'type': 'Disease', 'start': 332, 'end': 345}, {'entity': 'manic episodes', 'type': 'Disease', 'start': 265, 'end': 279}, {'entity': 'depressive', 'type': 'Disease', 'start': 250, 'end': 260}, {'entity': 'bipolar disorder type I', 'type': 'Disease', 'start': 225, 'end': 248}, {'entity': 'disorders', 'type': 'Disease', 'start': 206, 'end': 215}]\n",
            "['Estimating cases of COVID-19 from Daily Death Data in Italy\\tCOVID-19 is an emerging infectious disease which has been declared a pan- demic by the World Health Organisation.', 'Due to limited testing capacity for this new virus, variable symptomatology the majority of infected showing non-specific mild or no symptoms it is likely current prevalence data is an underestimate.', 'Methods: We present an estimate of the number of cases of COVID-19 com- pared to the number of confirmed case in Italy based on the daily reported deaths and information about the incubation period, time from symptom on- set to death and reported case fatality rate.', 'Results: Our model predicts that on the 31st of January 2020 when the first 3 infected cases had been identified by Italian authorise there were already nearly 30 cases in Italy, and by the 24th of February 2020 only 0.5% cases had been detected and confirmed by Italian authorities.', 'While official statistics had 132 confirmed case we believe a more accurate estimate would be closer to 26000.', 'With a case-doubling period of about 2.5 days.']\n",
            "unmatched tags:  [{'entity': 'symptom', 'type': 'Phenotype', 'start': 583, 'end': 590}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 432, 'end': 440}, {'entity': 'underestimate', 'type': 'Organization', 'start': 359, 'end': 372}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 113, 'end': 121}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 407, 'end': 415}\n",
            "['Deducing the N- and O- glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2\\tThe current emergence of the novel coronavirus pandemic caused by SARS-CoV-2 demands the development of new therapeutic strategies to prevent rapid progress of mortalities.', 'The coronavirus spike (S) protein, which facilitates viral attachment, entry and membrane fusion is heavily glycosylated and plays a critical role in the elicitation of the host immune response.', 'The spike protein is comprised of two protein subunits (S1 and S2), which together possess 22 potential N-glycosylation sites.', 'Herein, we report the glycosylation mapping on spike protein subunits S1 and S2 expressed on human cells through high resolution mass spectrometry.', 'We have characterized the quantitative N-glycosylation profile on spike protein and interestingly, observed unexpected O-glycosylation modifications on the receptor binding domain (RBD) of spike protein subunit S1.', 'Even though O-glycosylation has been predicted on the spike protein of SARS-CoV-2, this is the first report of experimental data for both the site of O-glycosylation and identity of the O-glycans attached on the subunit S1.', 'Our data on the N- and O-glycosylation is strengthened by extensive manual interpretation of each glycopeptide spectra in addition to using bioinformatics tools to confirm the complexity of glycosylation in the spike protein.', 'The elucidation of the glycan repertoire on the spike protein provides insights into the viral binding studies and more importantly, propels research towards the development of a suitable vaccine candidate.']\n",
            "unmatched tags:  [{'entity': 'candidate', 'type': 'Gene', 'start': 1602, 'end': 1611}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1594, 'end': 1601}, {'entity': 'spike protein', 'type': 'Gene', 'start': 1454, 'end': 1467}, {'entity': 'glycan', 'type': 'Drug', 'start': 1429, 'end': 1435}, {'entity': 'spike protein', 'type': 'Gene', 'start': 1391, 'end': 1404}, {'entity': 'glycopeptide spectra', 'type': 'Gene', 'start': 1278, 'end': 1298}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CoV', 'type': 'Virus', 'start': 953, 'end': 956}\n",
            "['Energetics based epitope screening in SARS CoV-2 (COVID 19) spike glycoprotein by Immuno-informatic analysis aiming to a suitable vaccine development\\tThe recent outbreak by SARS-CoV-2 has generated a chaos in global health and economy and claimed/infected a large number of lives.', 'Closely resembling with SARS CoV, the present strain has manifested exceptionally higher degree of spreadability, virulence and stability possibly due to some unidentified mutations.', 'The viral spike glycoprotein is very likely to interact with host Angiotensin-Converting Enzyme 2 (ACE2) and transmits its genetic materials and hijacks host machinery with extreme fidelity for self propagation.', 'Few attempts have been made to develop a suitable vaccine or ACE2 blocker or virus-receptor inhibitor within this short period of time.', 'Here, attempt was taken to develop some therapeutic and vaccination strategies with a comparison of spike glycoproteins among SARS-CoV, MERS-CoV and the SARS-CoV-2.', 'We verified their structure quality (SWISS-MODEL, Phyre2, Pymol) topology (ProFunc), motifs (MEME Suite, GLAM2Scan), gene ontology based conserved domain (InterPro database) and screened several epitopes (SVMTrip) of SARS CoV-2 based on their energetics, IC50 and antigenicity with regard to their possible glycosylation and MHC/paratopic binding (Vaxigen v2.0, HawkDock, ZDOCK Server) effects.', 'We screened here few pairs of spike protein epitopic regions and selected their energetic, IC50, MHC II reactivity and found some of those to be very good target for vaccination.', 'A possible role of glycosylation on epitopic region showed profound effects on epitopic recognition.', 'The present work might be helpful for the urgent development of a suitable vaccination regimen against SARS CoV-2.']\n",
            "unmatched tags:  [{'entity': 'SARS', 'type': 'Disease', 'start': 1755, 'end': 1759}, {'entity': 'epitopic region', 'type': 'Organization', 'start': 1587, 'end': 1602}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 144, 'end': 152}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 108, 'end': 116}\n",
            "['Distribution and genetic diversity of adeno-associated viruses in bats from coastal areas of Southeast China\\tBats are associated with several important zoonotic viruses from different families.', 'One example includes adeno-associated viruses (AAVs), that are extensively detected in several animals, especially primates.', 'To understand AAVs distribution and genetic diversity in the coastal areas of Southeast China, a total of 415 intestine samples were mostly collected from two provinces of southeast China, i.e., Zhejiang and Fujian province.', 'Intestine samples from five bat species were collected for AAVs detection.', 'The average prevalence rate for AAV detection among these samples was 18.6% (77 positives out of 415 samples) and ranged from 11.8 to 28.9% between the five bat species.', 'This suggests that AAVs are widely distributed in diverse bat populations in southeast coastal areas of China.', 'Based on the genome sequence of bat adeno-associated virus-CXC1(BtAAV-CXC1) from one AAV-positive sample, the genetic diversity of the detected AAVs were assessed and analyzed.', 'Phylogenetic analysis revealed that BtAAV-CXC1 was comparatively distant to other major AAVs from mammals and non-mammals, with only a 52.9~64.7% nucleotide identity.', 'However, they were phylogenetically closer to Rhinolophus sinicus bat adeno-associated virus (Rs-BtAAV1), with a 74.5% nt similarity.', 'Partial analysis of the rep and cap overlapping open reading frame (ORF) sequences from bat AAV samples revealed 48 partial rep sequences and 23 partial cap sequences from positive samples shared 86.9 to 100% and 72.3 to 98.8% nucleotide identities among themselves, respectively.', 'This suggests that the detected AAVs had a distinctly high genetic diversity.', 'These findings led us to conclude that diverse AAVs may be widely distributed in bat populations from the southeast regions of China.']\n",
            "unmatched tags:  [{'entity': 'AAVs', 'type': 'Organization', 'start': 1784, 'end': 1788}, {'entity': 'AAVs', 'type': 'Organization', 'start': 1691, 'end': 1695}, {'entity': 'nucleotide identities', 'type': 'Gene', 'start': 1605, 'end': 1626}, {'entity': 'AAV', 'type': 'Gene', 'start': 1470, 'end': 1473}, {'entity': 'open reading frame', 'type': 'Gene', 'start': 1426, 'end': 1444}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': \"Sjögren's syndrome\", 'type': 'Disease', 'start': 89, 'end': 107}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'proteins', 'type': 'Gene', 'start': 1153, 'end': 1161}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 159, 'end': 167}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'hydroxychloroquine', 'type': 'Drug', 'start': 293, 'end': 311}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'chloroquine', 'type': 'Drug', 'start': 300, 'end': 311}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 410, 'end': 417}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'B-cell non-Hodgkin lymphoma', 'type': 'Disease', 'start': 259, 'end': 286}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'pain', 'type': 'Phenotype', 'start': 281, 'end': 285}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'desferrioxamine', 'type': 'Drug', 'start': 206, 'end': 221}\n",
            "['Off-label use of anticancer drugs\\tUse of a drug outside the terms of its official labelling is referred to as off-label prescription.', 'Many categories of use exist because labelling of anticancer agents is very precise in terms of type or subtype of tumour, association, line, and duration of treatment.', 'Off-label prescription of anticancer drugs is thought to be frequent but, in fact, very few surveys have been done to ascertain its real extent.', 'Findings of prospective studies undertaken between 1990 and 2002 showed proportions of off-label drug use in children and adults of 6·7–33·2%.']\n",
            "unmatched tags:  [{'entity': 'drug', 'type': 'Drug', 'start': 545, 'end': 549}, {'entity': 'drug', 'type': 'Drug', 'start': 340, 'end': 344}, {'entity': 'duration of', 'type': 'Drug', 'start': 280, 'end': 291}, {'entity': 'line', 'type': 'Gene', 'start': 270, 'end': 274}, {'entity': 'tumour', 'type': 'Disease', 'start': 249, 'end': 255}, {'entity': 'type', 'type': 'Gene', 'start': 241, 'end': 245}, {'entity': 'type', 'type': 'Gene', 'start': 230, 'end': 234}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 48, 'end': 57}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronavirus', 'type': 'Virus', 'start': 719, 'end': 730}\n",
            "['The first report of the prevalence of COVID-19 in Chronic myelogenous leukemia patients in the core epidemic area of China:multicentre, cross-sectional survey\\tBackground Since late December 2019, the outbreak of the novel coronavirus disease, COVID-19, that began in Wuhan, has become endemic in China and more than 100 countries and regions in the world.', 'So far, there is rare data on the prevalence of COVID-19 in patients with chronic myelogenous leukemia (CML).', 'We aimed to describe the clinical course, outcomes of CML patients with COVID-19 and prevalence of COVID-19 in CML patients.', 'Methods  In this multi-center survey, cross-sectional survey, observational study, the clinical data of CML patients with COVID-19 in each center were collected.', 'Simultaneously, an online survey was conducted for information about the CML patients under the management at each center by asking the CML patients to complete a questionnaire,from February 15, 2020 to February 21, 2020.', 'The questionnaire includes demographic data, place of residence, smoking status, CML diagnosis and treatment, comorbidities, combined medications, epidemiological history,  symptoms(fever, cough, shortness of breath, etc) during the epidemic.', 'Additional clinical data was collected on respondents suspected or confirmed to have COVID-19.', 'We described and analyzed the prevalence of COVID-19 in CML patients, and focus on the clinical characteristics and outcomes of COVID-19 patients.', 'Data were compared between the CML patients with optimal response and those with non-optimal response.', 'The primary outcome was prevalence of COVID-19 in CML patients, as of Feb 21, 2020.', 'Secondary outcomes included the history of epidemiology of CML patients, the clinical characteristics and outcomes of CML patients with COVID-19 .', 'Findings  Of 392 respondents, 223( 56.9%) were males, and 240( 61.2%) were 50 years or younger.', 'Only 10 patients took drugs irregularly due to the influence of the epidemic because of traffic control, pharmacies unable to operate normally, etc.', 'In the history of epidemiology, there were 4 patients with definite contact with COVID-19, of which 3 were remote contact and 1 was close contact.', '12 respondents had fever, cough or shortness of breath during the epidemic, 1 case (common type) was confirmed with COVID-19 and cured after treatment.', '1 patient was clinically diagnosed and succumbed.', '1 of 299 (0.3%) patients with an optimal response was diagnosed with COVID-19.', 'Of the 50 patients who failed to respond to CML treatment or had a poor response, 1 patient (2%) had a clinical diagnosis of COVID-19.', 'Interpretation While the 392 CML respondents required regular referrals to hospitals, they did not have much contact with COVID-19 patients during the outbreak.', 'Patients who failed to achieved an optimal response to CML therapy appear more likely to have a symptomatic infection with SARS-CoV-2.', 'Older patients with comorbidities are at increased risk of death.', \"Dan-Yu Wang, Jing-Ming Guo, Zhuang-Zhi Yang   Co first author Dan-Yu Wang,Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, Guangdong Medical University, Shenzhen Guangdong, China,E-mail: 15818662864@139.com Jing-Ming Guo, Department of Hematology,Yi Chang Central People's Hospital, The First College of Clinical Medical Science, China Three Gorges University, Yichang Hubei, China,E-mail:gjm425@163.com Zhuang-Zhi Yang, Department of Hematology,Suizhou Central Hospital, Suizhou Hubei, China,E-mail:yzhzh88@163.com Correspondence author:  Guo-Lin Yuan, MD, Department of Hematology, Xiangyang Central Hospital, The Affiliated Hospital of Hubei University of Arts and Science, Xiangyang Hubei, China.\", 'E-mail: yuanguo1973@163.com Li Meng, MD, Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan Hubei, China.', 'E-mail: mengli@tjh.tjmu.edu.cn Wei-Ming Li, MD, Department of Hematology, Union hospital, Tongji Medical college, Huazhong University of science and Technology, Wuhan Hubei, China.', 'E-mail: lee937@126.com']\n",
            "unmatched tags:  [{'entity': 'Li', 'type': 'Gene', 'start': 3930, 'end': 3932}, {'entity': 'Tongji Hospital', 'type': 'Chemical', 'start': 3783, 'end': 3798}, {'entity': 'Li', 'type': 'Gene', 'start': 3744, 'end': 3746}]\n",
            "['A Toolkit for Rapid Modular Construction of Biological Circuits in Mammalian Cells\\tThe ability to rapidly assemble and prototype cellular circuits is vital for biological research and its applications in biotechnology and medicine.', 'Current methods that permit the assembly of DNA circuits in mammalian cells are laborious, slow, expensive and mostly not permissive of rapid prototyping of constructs.', 'Here we present the Mammalian ToolKit (MTK), a Golden Gate-based cloning toolkit for fast, reproducible and versatile assembly of large DNA vectors and their implementation in mammalian models.', 'The MTK consists of a curated library of characterized, modular parts that can be easily mixed and matched to combinatorially assemble one transcriptional unit with different characteristics, or a hierarchy of transcriptional units weaved into complex circuits.', 'MTK renders many cell engineering operations facile, as showcased by our ability to use the toolkit to generate single-integration landing pads, to create and deliver libraries of protein variants and sgRNAs, and to iterate through Cas9-based prototype circuits.', 'As a biological proof of concept, we used the MTK to successfully design and rapidly construct in mammalian cells a challenging multicistronic circuit encoding the Ebola virus (EBOV) replication complex.', 'This construct provides a non-infectious biosafety level 2 (BSL2) cellular assay for exploring the transcription and replication steps of the EBOV viral life cycle in its host.', 'Its construction also demonstrates how the MTK can enable important and time sensitive applications such as the rapid testing of pharmacological inhibitors of emerging BSL4 viruses that pose a major threat to human health.']\n",
            "unmatched tags:  [{'entity': 'MTK', 'type': 'Chemical', 'start': 1544, 'end': 1547}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'government', 'type': 'Organization', 'start': 1317, 'end': 1327}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'affective disorder', 'type': 'Disease', 'start': 37, 'end': 55}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'typhoid', 'type': 'Disease', 'start': 182, 'end': 189}\n",
            "['Comparative analysis of primer-probe sets for the laboratory confirmation of SARS-CoV-2\\tCoronavirus disease 2019 (COVID-19) is newly emerging human infectious diseases, which is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, also previously known as 2019-nCoV).', 'Within two months of the outbreak, more than 80,000 cases of COVID-19 have been confirmed worldwide.', 'Since the human to human transmission occurred easily and the human infection is rapidly increasing, the sensitive and early diagnosis is essential to prevent the global outbreak.', 'Recently, World Health Organization (WHO) announced various primer and probe sets for SARS-CoV-2 previously developed in China, Germany, Hong Kong, Japan, Thailand, and USA.', 'In this study, we compared the ability to detect SARS-CoV-2 RNA among the seven primer-probe sets for N gene and the three primer-probe sets for Orf1 gene.', 'The result of the comparative analysis represented that the ‘2019-nCoV_N2, N3’ of USA and the ‘ORF1ab’ of China are the most sensitive primer-probe sets for N and Orf1 genes, respectively.', 'Therefore, the appropriate combination from ORF1ab (China), 2019-nCoV_N2, N3 (USA), and NIID_2019-nCOV_N (Japan) sets should be selected for the sensitive and reliable laboratory confirmation of SARS-CoV-2.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1281, 'end': 1291}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 365, 'end': 371}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'spasm', 'type': 'Phenotype', 'start': 250, 'end': 255}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronavirus', 'type': 'Virus', 'start': 224, 'end': 235}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'pain', 'type': 'Phenotype', 'start': 160, 'end': 164}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'pain', 'type': 'Phenotype', 'start': 538, 'end': 542}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'arthritis', 'type': 'Disease', 'start': 50, 'end': 59}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronavirus', 'type': 'Virus', 'start': 264, 'end': 275}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'dementia', 'type': 'Disease', 'start': 386, 'end': 394}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diseases', 'type': 'Disease', 'start': 200, 'end': 208}\n",
            "['COVID-19 Outbreak Situations in Bangladesh: An Empirical Analysis\\tCOVID-19 disease, as popularly known as Coronavirus 2019 disease, has been emerged from Wuhan, China in December 2019 and now is a pandemic for almost every nation in the earth.', \"It affects every country without considering country's race, nationality and economic status.\", 'This paper aims at analysing primarily the current situations of Bangladesh and predicting infections and deaths for moderated term intervals by a proposed projection technique called Infection Trajectory-Pathway Strategy (ITPS) and for short term intervals prediction for total infections, deaths along with total number of severe patients and Intensive Care Unit (ICU) patients by polynomial regression modeling approach.', 'Since April 7, Bangladesh has started to face critical situations as the number of infections has accelerated very fast in the following days.', 'However, the fatality rate decreases considerably from 15.7 on April 1 to 4.9 on April 14, which is still high among the south asian countries.', 'Of the 1012 cases reported on April 14, almost 70\\\\% are the male, 42\\\\% are from the capital Dhaka.', 'We have found that the potential pathway of infections for Bangldesh would be the similar pathways that are experienced by Austria, Netherlands, Israel, France and United Kingdom.', 'These countries are ahead a number of weeks and days in terms of infection cases since their 100-th confirmed cases.', 'Our proposed projection method ITPS suggests that by May 10, Bangladesh will cross 12000 incidences and 720 deaths which, by May 16 will be 27000 and 1644 respectively.', 'On the other hand, the regression model suggests that by the end of April, total number of infections, deaths, severe patients and ICU patients will be 5780, 347, 775, and 694 respectively.', 'This study will be favorable for the administrative units of Bangladesh to plan for the next few weeks and to consider various aspects related to the control of COVID-19 outspread in Bangladesh']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1965, 'end': 1973}]\n",
            "['Aberrant pathogenic GM-CSF\\tPathogenic human coronavirus infections, such as severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV), cause high morbidity and mortality 1 , 2 .', 'Recently, a severe pneumonia-associated respiratory syndrome caused by a new coronavirus was reported at December 2019 (2019-nCoV) in the city Wuhan, Hubei province, China 3 – 5 , which was also named as pneumonia-associated respiratory syndrome (PARS) 6 .', 'Up to 9th of February 2020, at least 37, 251 cases have been reported with 812 fatal cases according to the report from China CDC.', 'However, the immune mechanism that potential orchestrated acute mortality from patients of 2019-nCoV is still unknown.', 'Here we show that after the 2019-nCoV infection, CD4 + T lymphocytes are rapidly activated to become pathogenic T helper (Th) 1 cells and generate GM-CSF etc.', 'The cytokines environment induces inflammatory CD14 + CD16 + monocytes with high expression of IL-6 and accelerates the inflammation.', 'These aberrant and excessive immune cells may enter the pulmonary circulation in huge numbers and play an immune damaging role to causing lung functional disability and quick mortality.', 'Our results demonstrate that excessive non-effective host immune responses by pathogenic T cells and inflammatory monocytes may associate with severe lung pathology.', 'Therefore, we suggest that monoclonal antibody that targets the GM-CSF or interleukin 6 receptor may potentially curb immunopathology caused by 2019-nCoV and consequently win more time for virus clearance.']\n",
            "unmatched tags:  [{'entity': '2019-nCoV', 'type': 'Virus', 'start': 1517, 'end': 1526}, {'entity': 'interleukin 6 receptor', 'type': 'Gene', 'start': 1447, 'end': 1469}, {'entity': 'GM-CSF', 'type': 'Gene', 'start': 1437, 'end': 1443}, {'entity': 'monoclonal antibody', 'type': 'Drug', 'start': 1400, 'end': 1419}, {'entity': 'Th', 'type': 'Gene', 'start': 1373, 'end': 1375}, {'entity': 'Th', 'type': 'Gene', 'start': 1021, 'end': 1023}, {'entity': 'IL-6', 'type': 'Gene', 'start': 982, 'end': 986}, {'entity': 'CD16', 'type': 'Gene', 'start': 941, 'end': 945}, {'entity': 'CD14 +', 'type': 'Gene', 'start': 934, 'end': 940}]\n",
            "['Effect of mutated\\tactivation by genotoxic drugs can induce apoptosis or cell-cycle arrest.', 'Thus, whether the gene is mutated or wild type could affect the response of a tumour to chemotherapy.', 'Clinical data are unclear, possibly as a result of heterogeneity of tumours, drugs, methods of assessing response, or']\n",
            "unmatched tags:  [{'entity': 'tumours', 'type': 'Disease', 'start': 261, 'end': 268}]\n",
            "['Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action\\tThe Millennium Development Goal target for tuberculosis control is to halt the spread of tuberculosis by 2015, and begin to reverse the worldwide incidence.', 'After the introduction of standard control practices in 1995, 36 million people were cured and about 6 million deaths were averted.', 'However, substantial scientific advances and innovative solutions are urgently needed together with creative new strategies.', 'Strong international and national political commitment is essential.', 'Urgent action is needed by national governments to fund their own programmes, and for the G8 countries and other donor governments and organisations to support governmental and non-governmental efforts.']\n",
            "unmatched tags:  [{'entity': 'governmental', 'type': 'Organization', 'start': 782, 'end': 794}, {'entity': 'governmental', 'type': 'Organization', 'start': 761, 'end': 773}, {'entity': 'donor governments', 'type': 'Organization', 'start': 714, 'end': 731}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronavirus', 'type': 'Virus', 'start': 1153, 'end': 1164}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronavirus', 'type': 'Virus', 'start': 1626, 'end': 1637}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tuberculosis', 'type': 'Disease', 'start': 123, 'end': 135}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'drug-resistant tuberculosis', 'type': 'Disease', 'start': 201, 'end': 228}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tuberculosis', 'type': 'Disease', 'start': 317, 'end': 329}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tuberculosis', 'type': 'Disease', 'start': 635, 'end': 647}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'constipation', 'type': 'Phenotype', 'start': 622, 'end': 634}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'ACE2', 'type': 'Gene', 'start': 488, 'end': 492}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNA', 'type': 'Gene', 'start': 666, 'end': 669}\n",
            "['Serum-dependent and independent regulation of PARP2\\tPARP2 belongs to a family of proteins involved in cell differentiation, DNA damage repair, cellular energy expenditure, chromatin modeling and cell differentiation.', 'In addition to these overlapping functions with PARP1, PARP2 participates in spermatogenesis, T-cell maturation, extraembryonic endoderm formation and adipogenesis.', 'The function(s) of PARP2 is far from complete, and the mechanism(s) by which the gene and protein are regulated are unknown.', 'In this study, we found that two different mechanisms are used in vitro to regulate PARP2 levels.', 'In the presence of serum, PARP2 is degraded through the ubiquitin-proteasome pathway, however, when serum is removed, PARP2 is rapidly sequestered into an SDS- and urea-insoluble fraction.', 'This sequestration is relieved by serum in a dose-dependent manner, and again PARP2 is detected by immunoblotting.', 'Furthermore, and despite the presence of a putative serum response element in the PARP2 gene, transcription is not affected by serum deprivation.', 'These observations that PARP2 is tightly regulated by distinct pathways highlights the critical roles PARP2 plays under different physiological conditions.']\n",
            "unmatched tags:  [{'entity': 'PARP2', 'type': 'Gene', 'start': 1157, 'end': 1162}, {'entity': 'PARP2', 'type': 'Gene', 'start': 1079, 'end': 1084}, {'entity': 'PARP2 gene', 'type': 'Gene', 'start': 991, 'end': 1001}, {'entity': 'serum response element', 'type': 'Gene', 'start': 961, 'end': 983}, {'entity': 'PARP2', 'type': 'Gene', 'start': 872, 'end': 877}, {'entity': 'PARP2', 'type': 'Gene', 'start': 723, 'end': 728}, {'entity': 'PARP2', 'type': 'Gene', 'start': 631, 'end': 636}, {'entity': 'PARP2', 'type': 'Gene', 'start': 591, 'end': 596}, {'entity': 'protein', 'type': 'Gene', 'start': 472, 'end': 479}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'syndrome', 'type': 'Disease', 'start': 163, 'end': 171}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'herpes', 'type': 'Phenotype', 'start': 250, 'end': 256}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CNS lymphoma', 'type': 'Disease', 'start': 469, 'end': 481}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'leukaemia', 'type': 'Disease', 'start': 309, 'end': 318}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CoV', 'type': 'Virus', 'start': 973, 'end': 976}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CoV', 'type': 'Virus', 'start': 1207, 'end': 1210}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CoV', 'type': 'Virus', 'start': 1646, 'end': 1649}\n",
            "['Stapled versus excision haemorrhoidectomy: long-term follow up of a randomised controlled trial\\tAdvantages of the stapling procedure for haemorrhoids include reduced postoperative pain and shortened convalescence; however, there are few data with respect to functional and symptomatic outcome.', 'At a dedicated clinic, we reviewed patients between Dec, 2001, and March, 2002, who had taken part in a randomised controlled trial undertaken at the unit in 1999, which compared outcomes after open or stapled haemorrhoidectomy.', 'We noted the presence or absence of haemorrhoid specific symptoms, and assessed overall satisfaction, continence, and quality of life.']\n",
            "unmatched tags:  [{'entity': 'continence', 'type': 'Disease', 'start': 625, 'end': 635}, {'entity': 'haemorrhoid', 'type': 'Disease', 'start': 559, 'end': 570}, {'entity': 'haemorrhoid', 'type': 'Disease', 'start': 504, 'end': 515}, {'entity': 'postoperative pain', 'type': 'Phenotype', 'start': 166, 'end': 184}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'varicella', 'type': 'Disease', 'start': 126, 'end': 135}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'ataxias', 'type': 'Phenotype', 'start': 115, 'end': 122}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'ACE2', 'type': 'Gene', 'start': 1203, 'end': 1207}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 34, 'end': 43}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 212, 'end': 221}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'dermatomyositis', 'type': 'Disease', 'start': 190, 'end': 205}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'proteins', 'type': 'Gene', 'start': 898, 'end': 906}\n",
            "[\"MHC class II region, CTLA4 gene, and ophthalmopathy in patients with Graves' disease\\tUp to half of patients with Graves' hyperthyroidism have signs of thyroid associated ophthalmopathy, but the factors that cause this disorder are unknown.\", \"We investigated two major genetic susceptibility loci for Graves' disease in ophthalmopathy; the MHC class II region and the cytotoxic T lymphocyte antigen-4 (CTLA4) gene.\", \"Allelic frequencies of these genes in patients with Graves' disease who did and did not have concurrent thyroid-associated ophthalmopathy did not differ, and are, therefore, unlikely to contribute to its development.\"]\n",
            "unmatched tags:  [{'entity': 'thyroid-associated ophthalmopathy', 'type': 'Disease', 'start': 516, 'end': 549}, {'entity': \"Graves' disease\", 'type': 'Disease', 'start': 464, 'end': 479}, {'entity': 'gene', 'type': 'Gene', 'start': 406, 'end': 410}, {'entity': 'cytotoxic T lymphocyte antigen-4', 'type': 'Gene', 'start': 365, 'end': 397}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'undernutrition', 'type': 'Disease', 'start': 76, 'end': 90}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'epidural spinal cord compression', 'type': 'Disease', 'start': 55, 'end': 87}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'protease inhibitors', 'type': 'Drug', 'start': 138, 'end': 157}\n",
            "['Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy\\tThe introduction of HIV-1 protease inhibitors and non-nucleoside reverse transcriptase inhibitors in 1996 began an era described as that of highly active antiretroviral therapy.', 'In addition, the more recent development and availability of HIV-1 genotypic and phenotypic resistance tests and advances in pharmacological assays that support therapeutic drug monitoring (TDM) have created tools that may help clinicians to provide more individualised treatment with HIV-1 protease inhibitors.', 'All current treatment guidelines provide fixed doses of protease inhibitors with vague recommendations for the use of TDM in selected clinical situations.']\n",
            "unmatched tags:  [{'entity': 'clinical situations', 'type': 'Chemical', 'start': 736, 'end': 755}, {'entity': 'protease inhibitors', 'type': 'Drug', 'start': 658, 'end': 677}, {'entity': 'HIV-1 protease inhibitors', 'type': 'Drug', 'start': 575, 'end': 600}, {'entity': 'era', 'type': 'Gene', 'start': 453, 'end': 456}, {'entity': 'HIV-1', 'type': 'Virus', 'start': 351, 'end': 356}, {'entity': 'era', 'type': 'Gene', 'start': 283, 'end': 286}, {'entity': 'era', 'type': 'Gene', 'start': 227, 'end': 230}]\n",
            "['Fluoroquinolones, tuberculosis, and resistance\\tAlthough the fluoroquinolones are presently used to treat tuberculosis primarily in cases involving resistance or intolerance to first-line antituberculosis therapy, these drugs are potential first-line agents and are under study for this indication.', 'However, there is concern about the development of fluoroquinolone resistance in']\n",
            "unmatched tags:  [{'entity': 'fluoroquinolone', 'type': 'Drug', 'start': 349, 'end': 364}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vitamin D', 'type': 'Drug', 'start': 167, 'end': 176}\n",
            "['Estimation of incubation period distribution of COVID-19 using disease onset forward time: a novel cross-sectional and forward follow-up study\\tBackground:  The current outbreak of coronavirus disease 2019 (COVID-19) has quickly spread across countries and become a global crisis.', 'However, one of the most important clinical characteristics in epidemiology, the distribution of the incubation period, remains unclear.', 'Different estimates of the incubation period of COVID-19 were reported in recent published studies, but all have their own limitations.', 'In this study, we propose a novel low-cost and accurate method to estimate the incubation distribution.', 'Methods: We have conducted a cross-sectional and forward follow-up study by identifying those asymptomatic individuals at their time of departure from Wuhan and then following them until their symptoms developed.', 'The renewal process is hence adopted by considering the incubation period as a renewal and the duration between departure and symptom onset as a forward recurrence time.', 'Under mild assumptions, the observations of selected forward times can be used to consistently estimate the parameters in the distribution of the incubation period.', 'Such a method enhances the accuracy of estimation by reducing recall bias and utilizing the abundant and readily available forward time data.', 'Findings:  The estimated distribution of forward time fits the observations in the collected data well.', 'The estimated median of incubation period is 8.13 days (95% confidence interval [CI]: 7.37-8.91), the mean is 8.62 days (95% CI: 8.02-9.28), the 90th percentile is 14.65 days (95% CI: 14.00-15.26), and the 99th percentile is 20.59 days (95% CI: 19.47, 21.62).', 'Compared with results in other studies, the incubation period estimated in this study is longer.', 'Interpretation: Based on the estimated incubation distribution in this study, about 10% of patients with COVID-19 would not develop symptoms until 14 days after infection.', 'Further study of the incubation distribution is warranted to directly estimate the proportion with long incubation periods.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1918, 'end': 1926}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 998, 'end': 1005}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'leukaemia', 'type': 'Disease', 'start': 139, 'end': 148}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'ischaemic attack', 'type': 'Disease', 'start': 219, 'end': 235}\n",
            "['Aquaporin 4 and neuromyelitis optica\\tNeuromyelitis optica is an inflammatory demyelinating disorder of the CNS.', 'The discovery of circulating IgG1 antibodies against the astrocyte water channel protein aquaporin 4 (AQP4) and the evidence that AQP4-IgG is involved in the development of neuromyelitis optica revolutionised our understanding of the disease.', 'However, important unanswered questions remain—for example, we do not know the cause of AQP4-IgG-negative disease, how astrocyte damage causes demyelination, the role of T cells, why peripheral AQP4-expressing organs are undamaged, and how circulating AQP4-IgG enters neuromyelitis optica lesions.']\n",
            "unmatched tags:  [{'entity': 'neuromyelitis optica', 'type': 'Disease', 'start': 623, 'end': 643}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tenofovir disoproxil fumarate', 'type': 'Gene', 'start': 591, 'end': 620}\n",
            "['BCG protects against COVID-19?', 'A word of caution\\tThe COVID-19 pandemic, caused by type 2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2), puts all of us to the test.', 'Epidemiologic observations could critically aid the development of protective measures to combat this devastating viral outbreak.', 'A recent publication, linked nation based universal Bacillus Calmette-Guerin (BCG) vaccination to potential protection against morbidity and mortality from SARS-CoV-2, and received much attention in public media, even before its peer review.', 'We wished to validate the findings by examining the association between daily rates of COVID-19 case fatality (i.e.', 'Death Per Case /Days of the endemic [dpc/d]) and the presence of universal BCG vaccination before 1980, or the year of the establishment of universal vaccination.', 'There was no significant association in either analysis.', 'In this work we emphasize caution amidst the publication surge on COVID-19, and highlight the political/economical-, arbitrary selection-, and fear/anxiety related biases, which may obscure scientific rigor.', 'It is underscored that physical (social) distancing (i.e.', 'quarantine) and use of personal protective equipment (PPE) are the only epidemiologic measures (Iceland being a great example, where universal BCG vaccination policy was never in place), which consistently associate with successful counteraction of morbidity and mortality during the pandemic.']\n",
            "unmatched tags:  [{'entity': 'counteraction', 'type': 'Drug', 'start': 1383, 'end': 1396}, {'entity': 'nation', 'type': 'Organization', 'start': 1303, 'end': 1309}, {'entity': 'PPE', 'type': 'Gene', 'start': 1205, 'end': 1208}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 951, 'end': 959}, {'entity': 'nation', 'type': 'Organization', 'start': 820, 'end': 826}, {'entity': 'nation', 'type': 'Organization', 'start': 749, 'end': 755}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 636, 'end': 644}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 463, 'end': 473}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'endometrial carcinoma', 'type': 'Disease', 'start': 176, 'end': 197}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'anxiety disorder', 'type': 'Disease', 'start': 52, 'end': 68}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 507, 'end': 513}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'adenoma', 'type': 'Disease', 'start': 198, 'end': 205}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'pneumonia', 'type': 'Disease', 'start': 311, 'end': 320}\n",
            "['AN EPIDEMIOLOGICAL MODEL TO AID DECISION-MAKING FOR COVID-19 CONTROL IN SRI LANKA\\tBackground: Sri Lanka diagnosed its first local case of COVID-19 on 11 March 2020.', 'The government acted swiftly to contain transmission, with extensive public health measures.', 'At the end of 30 days, Sri Lanka had 197 cases, 54 recovered and 7 deaths; a staged relaxing of the lockdown is now underway.', 'This paper proposes a theoretical basis for estimating the limits within which transmission should be constrained in order to ensure that the case load remains within the capacity of the health system.', 'Methods: We used the Susceptible, Infected, Recovered (SIR) model to explore the number of new infections and estimate ICU bed requirement at different levels of R0 values after lockout.', 'We developed a web-based application that enables visualization of cases and ICU bed requirements with time, with adjustable parameters that include: population exposed; proportion asymptomatic; number of active and recovered cases; infectious period; R0 or doubling time; proportion critically ill; available ICU beds; duration of ICU stay; and uncertainty of projection.', 'Results: The three-day moving average of the caseload suggested two waves of transmission from Day 0 to 17 (R0=3.32, 95% CI 1.85 - 5.41) and from Day 18 - 30 (R=1.25, 95%CI: 0.93 - 1.63).', 'We estimate that if there are 156 active cases with 91 recovered at the time of lockout, and R increases to 1.5 (doubling time 19 days), under the standard parameters for Sri Lanka, the ICU bed capacity of 300 is likely to be saturated by about 100 days days, signalled by 18 new infections (95% CI 15 - 22) on Day 14 after lockout.', 'Conclusion: Our model suggests that to ensure that the case load remains within the available capacity of the health system after lockout, transmission should not exceed R=1.5.', 'This model and the web-based application may be useful in other low and middle income countries which have similar constraints on health resources.']\n",
            "unmatched tags:  [{'entity': 'middle income countries', 'type': 'Disease', 'start': 1923, 'end': 1946}, {'entity': 'bed', 'type': 'Disease', 'start': 1529, 'end': 1532}, {'entity': 'R0', 'type': 'Organization', 'start': 1259, 'end': 1261}, {'entity': 'three-day', 'type': 'Disease', 'start': 1164, 'end': 1173}, {'entity': 'bed', 'type': 'Disease', 'start': 1089, 'end': 1092}, {'entity': 'critically ill', 'type': 'Phenotype', 'start': 1059, 'end': 1073}, {'entity': 'R0', 'type': 'Organization', 'start': 1027, 'end': 1029}, {'entity': 'bed', 'type': 'Disease', 'start': 856, 'end': 859}, {'entity': 'R0', 'type': 'Organization', 'start': 750, 'end': 752}, {'entity': 'bed', 'type': 'Disease', 'start': 711, 'end': 714}, {'entity': 'government', 'type': 'Organization', 'start': 170, 'end': 180}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 138, 'end': 146}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'multiple sclerosis', 'type': 'Disease', 'start': 247, 'end': 265}\n",
            "['Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis\\tRegulatory agencies take responsibility for the safety and efficacy of the drugs they license.', 'Over the past few years, however, several serious failings in the approval procedure have raised widespread concern that the present process of drug regulation is inadequate to guarantee the defence of public health.', 'We discuss the approval process of drotrecogin alfa (activated), a non-antibacterial drug for the treatment of severe sepsis.', 'The US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) approved drotrecogin alfa following a phase III trial that showed efficacy of the drug.']\n",
            "unmatched tags:  [{'entity': 'drug', 'type': 'Drug', 'start': 731, 'end': 735}, {'entity': 'drotrecogin alfa', 'type': 'Gene', 'start': 658, 'end': 674}, {'entity': 'EMEA', 'type': 'Chemical', 'start': 643, 'end': 647}, {'entity': 'European Medicines Agency', 'type': 'Chemical', 'start': 616, 'end': 641}, {'entity': 'sepsis', 'type': 'Disease', 'start': 558, 'end': 564}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'syndrome', 'type': 'Disease', 'start': 108, 'end': 116}\n",
            "['Biased and unbiased estimation of the average lengths of stay in intensive care units in the COVID-19 pandemic\\tBackground: The average length of stay (LOS) in the intensive care unit (ICU_ALOS) is a helpful parameter summarizing critical bed occupancy.', 'During the outbreak of a novel virus, estimating early a reliable ICU_ALOS estimate of infected patients is critical to accurately parameterize models examining mitigation and preparedness scenarios.', 'Methods: Two estimation methods of ICU ALOS were compared: the average LOS of already discharged patients at the date of estimation (DPE), and a standard parametric method used for analyzing time-to-event data which fits a given distribution to observed data and includes the censored stays of patients still treated in the ICU at the date of estimation (CPE).', 'Methods were compared on a series of all COVID-19 consecutive cases (n=59) admitted in an ICU devoted to such patients.', 'At the last follow-up date, 99 days after the first admission, all patients but one had been discharged.', \"A simulation study investigated the generalizability of the methods' patterns.\", 'CPE and DPE estimates were also compared to COVID-19 estimates reported to date.', 'Findings: LOS ≥ 30 days concerned 14 out of the 59 patients (24%), including 8 of the 21 deaths observed.', 'Two months after the first admission, 38 (64%) patients had been discharged, with corresponding DPE and CPE estimates of ICU_ALOS (95%CI) at 13.0 days (10.4, 15.6) and 23.1 days (18.1, 29.7), respectively.', \"Series' true ICU_ALOS was greater than 21 days, well above reported estimates to date.\", 'Interpretation: Discharges of short stays are more likely observed earlier during the course of an outbreak.', 'Cautious unbiased ICU_ALOS estimates suggest parameterizing a higher burden of ICU bed occupancy than that adopted to date in COVID-19 forecasting models.', 'Funding: Support by the National Natural Science Foundation of China (81900097 to Dr. Zhou) and the Emergency Response Project of Hubei Science and Technology Department (2020FCA023 to Pr.', 'Zhao).']\n",
            "unmatched tags:  [{'entity': 'Pr', 'type': 'Gene', 'start': 2048, 'end': 2050}, {'entity': 'Pr', 'type': 'Gene', 'start': 1982, 'end': 1984}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1834, 'end': 1842}, {'entity': 'LOS', 'type': 'Organization', 'start': 1731, 'end': 1734}, {'entity': 'LOS', 'type': 'Organization', 'start': 1529, 'end': 1532}, {'entity': 'LOS', 'type': 'Organization', 'start': 1431, 'end': 1434}, {'entity': 'CPE', 'type': 'Gene', 'start': 1409, 'end': 1412}, {'entity': 'DPE', 'type': 'Drug', 'start': 1401, 'end': 1404}, {'entity': 'LOS', 'type': 'Organization', 'start': 1209, 'end': 1212}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1162, 'end': 1170}, {'entity': 'DPE', 'type': 'Drug', 'start': 1126, 'end': 1129}, {'entity': 'CPE', 'type': 'Gene', 'start': 1118, 'end': 1121}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 855, 'end': 863}, {'entity': 'CPE', 'type': 'Gene', 'start': 808, 'end': 811}, {'entity': 'DPE', 'type': 'Drug', 'start': 586, 'end': 589}, {'entity': 'LOS', 'type': 'Organization', 'start': 524, 'end': 527}]\n",
            "['Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study\\tOur findings suggest that for people with virological failure of a first-line regimen containing efavirenz plus tenofovir and lamivudine or emtricitabine, the WHO-recommended switch to a ritonavir-boosted protease inhibitor plus zidovudine (a thymidine analogue nucleoside reverse transcriptase inhibitor) and lamivudine might come at the cost of peripheral lipoatrophy.', 'Further study could help to define specific groups of people who might benefit from a switch to an N(t)RTI-sparing second-line ART regimen.']\n",
            "unmatched tags:  [{'entity': 'peripheral lipoatrophy', 'type': 'Disease', 'start': 712, 'end': 734}, {'entity': 'lamivudine', 'type': 'Gene', 'start': 675, 'end': 685}, {'entity': 'thymidine analogue nucleoside reverse transcriptase inhibitor', 'type': 'Drug', 'start': 608, 'end': 669}]\n",
            "['Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses\\tThe new coronavirus (2019-nCoV) outbreak from December 2019 in Wuhan, Hubei, China, has been declared a global public health emergency.', 'Angiotensin I converting enzyme 2 (ACE2), is the host receptor by 2019-nCov to infect human cells.', 'Although ACE2 is reported to be expressed in lung, liver, stomach, ileum, kidney and colon, its expressing levels are rather low, especially in the lung.', '2019-nCoV may use co-receptors/auxiliary proteins as ACE2 partner to facilitate the virus entry.', 'To identify the potential candidates, we explored the single cell gene expression atlas including 119 cell types of 13 human tissues and analyzed the single cell co-expression spectrum of 51 reported RNA virus receptors and 400 other membrane proteins.', 'Consistent with other recent reports, we confirmed that ACE2 was mainly expressed in lung AT2, liver cholangiocyte, colon colonocytes, esophagus keratinocytes, ileum ECs, rectum ECs, stomach epithelial cells, and kidney proximal tubules.', 'Intriguingly, we found that the candidate co-receptors, manifesting the most similar expression patterns with ACE2 across 13 human tissues, are all peptidases, including ANPEP, DPP4 and ENPEP.', 'Among them, ANPEP and DPP4 are the known receptors for human CoVs, suggesting ENPEP as another potential receptor for human CoVs.', 'We also conducted “CellPhoneDB” analysis to understand the cell crosstalk between CoV-targets and their surrounding cells across different tissues.', 'We found that macrophages frequently communicate with the CoVs targets through chemokine and phagocytosis signaling, highlighting the importance of tissue macrophages in immune defense and immune pathogenesis.']\n",
            "unmatched tags:  [{'entity': 'chemokine', 'type': 'Gene', 'start': 1631, 'end': 1640}, {'entity': 'CoVs', 'type': 'Virus', 'start': 1610, 'end': 1614}, {'entity': 'CoVs', 'type': 'Virus', 'start': 1398, 'end': 1402}, {'entity': 'receptor', 'type': 'Gene', 'start': 1379, 'end': 1387}, {'entity': 'ENPEP', 'type': 'Gene', 'start': 1352, 'end': 1357}, {'entity': 'CoVs', 'type': 'Virus', 'start': 1335, 'end': 1339}, {'entity': 'receptors', 'type': 'Gene', 'start': 1315, 'end': 1324}, {'entity': 'DPP4', 'type': 'Gene', 'start': 1296, 'end': 1300}, {'entity': 'ANPEP', 'type': 'Gene', 'start': 1286, 'end': 1291}, {'entity': 'ENPEP', 'type': 'Gene', 'start': 1267, 'end': 1272}, {'entity': 'DPP4', 'type': 'Gene', 'start': 1258, 'end': 1262}, {'entity': 'ANPEP', 'type': 'Gene', 'start': 1251, 'end': 1256}, {'entity': 'peptidases', 'type': 'Gene', 'start': 1229, 'end': 1239}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1191, 'end': 1195}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 170, 'end': 177}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'malaria', 'type': 'Disease', 'start': 119, 'end': 126}\n",
            "[\"Human monoclonal thyroid stimulating autoantibody\\tA monoclonal autoantibody (MAb) with powerful thyroid stimulating activity has been produced from lymphocytes from a patient with Graves' disease.\", 'The autoantibody and its Fab fragment bind to the thyroid stimulating hormone (TSH) receptor (TSHR) with high affinity, inhibit labelled TSH binding to the receptor and stimulate cyclic AMP production in Chinese hamster ovary cells transfected with TSHR.', \"TSHR autoantibodies with TSH agonist or antagonist activities from patients' serum samples are effective inhibitors of labelled monoclonal autoantibody binding to TSHR.\"]\n",
            "unmatched tags:  [{'entity': 'TSHR', 'type': 'Gene', 'start': 615, 'end': 619}, {'entity': 'monoclonal autoantibody binding', 'type': 'Gene', 'start': 580, 'end': 611}]\n",
            "['Development and Evaluation of A CRISPR-based Diagnostic For 2019-novel Coronavirus\\tBackground: The recent outbreak of infections by the 2019 novel coronavirus (2019-nCoV), the third zoonotic CoV has raised great public health concern.', 'The demand for rapid and accurate diagnosis of this novel pathogen brought significant clinical and technological challenges.', 'Currently, metagenomic next-generation sequencing (mNGS) and reverse-transcription PCR (RT-PCR) are the most widely used molecular diagnostics.', 'Methods: 2019-nCoV infections were confirmed in 52 specimens by mNGS.', 'Genomic information was analyzed and used for the design and development of an isothermal, CRISPR-based diagnostic for this novel virus.', 'The diagnostic performance of CRISPR-nCoV was assessed and compared across three technology platforms (mNGS, RT-PCR and CRISPR).', 'Results: 2019-nCoVs sequenced in our study were conserved with the Wuhan strain, and shared certain genetic similarity with SARS-CoV.', 'A high degree of variation in the level of viral RNA was observed in clinical specimens.', 'CRISPR-nCoV demonstrated a near single-copy sensitivity and great clinical sensitivity with a shorter turn-around time than RT-PCR.', 'Conclusion: CRISPR-nCoV presents as a promising diagnostic option for the emerging pathogen.']\n",
            "unmatched tags:  [{'entity': 'viral RNA', 'type': 'Gene', 'start': 1021, 'end': 1030}]\n",
            "['Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial\\tRhabdomyosarcoma is an aggressive tumour that can develop in almost any part of the body.', 'Doxorubicin is an effective drug against rhabdomyosarcoma, but its role in combination with an established multidrug regimen remains controversial.', 'Therefore, we aimed to evaluate the possible benefit of early dose intensification with doxorubicin in patients with non-metastatic rhabdomyosarcoma.']\n",
            "unmatched tags:  [{'entity': 'non-metastatic rhabdomyosarcoma', 'type': 'Disease', 'start': 524, 'end': 555}, {'entity': 'doxorubicin', 'type': 'Drug', 'start': 495, 'end': 506}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'drug', 'type': 'Drug', 'start': 4, 'end': 8}\n",
            "['New drugs for aggressive B-cell and T-cell lymphomas\\tOver the past decade an unprecedented number of new drugs for lymphomas have been developed.', 'Most of these new drugs target molecules or pathways that are important for the growth and proliferation of lymphomas.', 'The introduction of the B-lymphoma specific monoclonal anti-CD20 antibody, rituximab, has improved the prognosis of patients with B-cell lymphomas more than any other drug in the past 50 years; today less than half of the patients with aggressive B-cell lymphomas die of their disease than in the pre-rituximab era.']\n",
            "unmatched tags:  [{'entity': 'era', 'type': 'Gene', 'start': 576, 'end': 579}, {'entity': 'pre-rituximab', 'type': 'Gene', 'start': 562, 'end': 575}, {'entity': 'lymphomas', 'type': 'Disease', 'start': 519, 'end': 528}, {'entity': 'aggressive B-cell lymphomas', 'type': 'Disease', 'start': 501, 'end': 528}, {'entity': 'drug', 'type': 'Drug', 'start': 432, 'end': 436}, {'entity': 'B-cell lymphomas', 'type': 'Disease', 'start': 395, 'end': 411}, {'entity': 'rituximab', 'type': 'Gene', 'start': 340, 'end': 349}, {'entity': 'B-lymphoma', 'type': 'Disease', 'start': 289, 'end': 299}, {'entity': 'lymphomas', 'type': 'Disease', 'start': 254, 'end': 263}, {'entity': 'era', 'type': 'Gene', 'start': 243, 'end': 246}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diseases', 'type': 'Disease', 'start': 150, 'end': 158}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 468, 'end': 477}\n",
            "['ACE2shedding and furin abundance in target organs may influence the efficiency of SARS-CoV-2 entry\\tSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently identified lineage Bcoronavirus, causing rapid worldwide outbreak of Corona Virus Disease 2019 (COVID-19).', 'Despitegenetically closed to SARS-CoV, SARS-CoV-2 seems to possess enhanced infectivity and subtledifferent clinical features, which may hamper the early screening of suspected patients as wellas the control of virus transmission.', 'Unfortunately, there are few tools to predict thepotential target organ damage and possible clinical manifestations caused by such novelcoronavirus.', 'To solve this problem, we investigate the potential host cell entry mechanisms ofSARS-CoV-2 through bioinformatics.', 'Using the online single-cell sequence datasets, we analyzethe expression of major receptor in host cells that mediates the virus entry, includingangiotensin converting enzyme 2 (ACE2), and its co-expressed membrane endopeptidases.', 'Theresults indicated the differential expression of ADAM10 and ADAM17 might contribute to the ACE2shedding and affect the membrane ACE2 abundance.', 'We further confirm a putative furin-cleavagesite reported recently in the spike protein of SARS-CoV-2, which may facilitate the virus-cellfusion.', 'Based on these findings, we develop a novel approach that comprehensively analyzed thevirus receptor expression, ACE2 shedding, membrane fusion activity, virus uptake and virusreplication to evaluate the infectivity of SARS-CoV-2 to different human organs.', 'Our resultsindicate that, in addition to airway epithelia, cardiac tissue and enteric canals aresusceptible to SARS-CoV-2 as well.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1669, 'end': 1679}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1520, 'end': 1530}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1414, 'end': 1418}, {'entity': 'thevirus receptor', 'type': 'Gene', 'start': 1384, 'end': 1401}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1246, 'end': 1256}, {'entity': 'spike protein', 'type': 'Gene', 'start': 1229, 'end': 1242}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1139, 'end': 1143}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1102, 'end': 1106}, {'entity': 'ADAM17', 'type': 'Gene', 'start': 1071, 'end': 1077}, {'entity': 'ADAM10', 'type': 'Gene', 'start': 1060, 'end': 1066}, {'entity': 'membrane endopeptidases', 'type': 'Gene', 'start': 983, 'end': 1006}, {'entity': 'ACE2', 'type': 'Gene', 'start': 955, 'end': 959}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 314, 'end': 320}\n",
            "['An Efficient Ethanol-Vacuum Method for the Decontamination and Restoration of Polypropylene Microfiber Medical Masks & Respirators\\tA critical shortage of respirators, masks and other personal protective equipment (PPE) exists across all sectors of society afflicted by the COVID-19 pandemic, placing medical staff and service workers at heightened risk and hampering efforts to reduce transmission rates.', 'Of particular need are the N95 medical face respirators that filter 95% of all airborne particles at and above 0.3 um in diameter, many of which use meltblown microfibers of charged polypropylene (e.g, the 3M 8200).', 'An intensive search is underway to find reliable methods to lengthen the useful life of these normally disposable units.', 'It is currently believed that these masks and respirators cannot be cleaned with 70 to 75% alcohol-water solutions, as past wet/dry experiments show that filtration efficiency can drop by ~40% after the first such treatment.', 'This has been interpreted as the liquids disrupting the surface charge on the fibers and has led to a recent CDC/NIOSH advisory against using alcohol for their decontamination.', 'We have replicated the drop in efficiency after alcohol treatment.', 'However, we find that the efficiency can be recovered by more effective drying, which we achieve with a vacuum chamber.', 'Drying at pressures of < ~6 mBar (0.6 kPa) restores the measured filtering efficiency to within 2% or so of the pre-washing value, which we have sustained for 5 cleaning-drying cycles so far in three models of N95 masks.', 'The mechanism seems to be the removal of water molecules adsorbed on the fiber surfaces, a hypothesis which is supported by two independent observations: (A) the filtering efficiency increases non-linearly with the weight loss during drying, and (B) filtration efficiency shows an abrupt recovery as the vacuum pressure drops from 13 to 6 mBar, the range physically attributable to the removal of adsorbed water.', 'These results are not compatible with the electrostatic discharge hypothesis, and rather suggest that water molecules adsorbed to the fiber surface are reducing the filtration efficiency via surface tension interactions (e.g., wicking between the fibers and coating their surfaces with a film).', 'Such a degradation mechanism has two implications: (A) Respirators decontaminated by a soak in 70% v/v ethanol regain their filtration efficiency once they are fully dry.', 'We employ vacuum chambers in this study, which are inexpensive and commonly available.', '(B) This mechanism presents the possibility that mask filtration performance may be subject to degradation by other sources of moisture, and that the mask would continue to be compromised even if it appears dry.', 'The mask would need to be vacuum-dried to restore its performance.', 'This study introduces a number of methods which could be developed and validated for use in resource-limited settings.', 'As the pandemic spreads to rural areas and developing nations, these would allow for local efforts to decontaminate, restore, monitor, and test medical masks.']\n",
            "unmatched tags:  [{'entity': 'ethanol', 'type': 'Drug', 'start': 2374, 'end': 2381}, {'entity': 'fiber', 'type': 'Drug', 'start': 2222, 'end': 2227}, {'entity': 'fiber', 'type': 'Drug', 'start': 2109, 'end': 2114}, {'entity': 'adsorbed', 'type': 'Gene', 'start': 2093, 'end': 2101}, {'entity': 'adsorbed', 'type': 'Gene', 'start': 1958, 'end': 1966}, {'entity': 'fiber', 'type': 'Drug', 'start': 1634, 'end': 1639}, {'entity': 'adsorbed', 'type': 'Gene', 'start': 1618, 'end': 1626}, {'entity': 'alcohol treatment', 'type': 'Drug', 'start': 1198, 'end': 1215}, {'entity': 'alcohol', 'type': 'Drug', 'start': 1114, 'end': 1121}, {'entity': 'fiber', 'type': 'Drug', 'start': 1050, 'end': 1055}, {'entity': 'charged polypropylene', 'type': 'Drug', 'start': 580, 'end': 601}, {'entity': 'fiber', 'type': 'Drug', 'start': 570, 'end': 575}, {'entity': 'society', 'type': 'Organization', 'start': 248, 'end': 255}]\n",
            "['Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme\\tDespite advances in the molecular pathogenesis of glioblastoma multiforme, no reliable prognostic markers have been identified.', 'We analysed telomerase activity and telomere lengths in glioblastoma multiformes from 77 patients.', '19 patients (25%) had tumours with the alternative-lengthening-of-telomere (ALT) phenotype.', 'Median survival for patients with this phenotype was 542 days (95% CI 114–970) compared with 247 days (224–270) for glioblastoma multiformes with normal telomeres (p=0·0003).', \"Cox's regression analysis showed that this association is independent of age.\"]\n",
            "unmatched tags:  [{'entity': 'multiformes', 'type': 'Disease', 'start': 539, 'end': 550}, {'entity': 'glioblastoma multiforme', 'type': 'Disease', 'start': 526, 'end': 549}, {'entity': 'ALT', 'type': 'Gene', 'start': 394, 'end': 397}, {'entity': 'tumours', 'type': 'Disease', 'start': 340, 'end': 347}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'autoimmune diseases', 'type': 'Disease', 'start': 377, 'end': 396}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'sickle-cell disease', 'type': 'Disease', 'start': 264, 'end': 283}\n",
            "['Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial\\tWe found no evidence of benefit of lithium on survival in patients with ALS, but nor were there safety concerns, which had been identified in previous studies with less conventional designs.', 'This finding emphasises the importance of pursuing adequately powered trials with clear endpoints when testing new treatments.']\n",
            "unmatched tags:  [{'entity': 'ALS', 'type': 'Gene', 'start': 211, 'end': 214}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronavirus', 'type': 'Virus', 'start': 570, 'end': 581}\n",
            "['Host and infectivity prediction of Wuhan 2019 novel coronavirus using deep learning algorithm\\tThe recent outbreak of pneumonia in Wuhan, China caused by the 2019 Novel Coronavirus (2019-nCoV) emphasizes the importance of detecting novel viruses and predicting their risks of infecting people.', 'In this report, we introduced the VHP (Virus Host Prediction) to predict the potential hosts of viruses using deep learning algorithm.', 'Our prediction suggests that 2019-nCoV has close infectivity with other human coronaviruses, especially the severe acute respiratory syndrome coronavirus (SARS-CoV), Bat SARS-like Coronaviruses and the Middle East respiratory syndrome coronavirus (MERS-CoV).', 'Based on our prediction, compared to the Coronaviruses infecting other vertebrates, bat coronaviruses are assigned with more similar infectivity patterns with 2019-nCoVs.', 'Furthermore, by comparing the infectivity patterns of all viruses hosted on vertebrates, we found mink viruses show a closer infectivity pattern to 2019-nCov.', 'These consequences of infectivity pattern analysis illustrate that bat and mink may be two candidate reservoirs of 2019-nCov.These results warn us to beware of 2019-nCoV and guide us to further explore the properties and reservoir of it.', 'One Sentence Summary It is of great value to identify whether a newly discovered virus has the risk of infecting human.', 'Guo et al.', 'proposed a virus host prediction method based on deep learning to detect what kind of host a virus can infect with DNA sequence as input.', 'Applied to the Wuhan 2019 Novel Coronavirus, our prediction demonstrated that several vertebrate-infectious coronaviruses have strong potential to infect human.', 'This method will be helpful in future viral analysis and early prevention and control of viral pathogens.']\n",
            "unmatched tags:  [{'entity': 'coronaviruses', 'type': 'Virus', 'start': 1632, 'end': 1645}, {'entity': 'Coronavirus', 'type': 'Virus', 'start': 1556, 'end': 1567}, {'entity': 'virus host', 'type': 'Virus', 'start': 1397, 'end': 1407}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 1177, 'end': 1186}, {'entity': '2019-nCov', 'type': 'Virus', 'start': 1132, 'end': 1141}, {'entity': 'mink', 'type': 'Gene', 'start': 1092, 'end': 1096}, {'entity': '2019-nCov', 'type': 'Virus', 'start': 1006, 'end': 1015}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronavirus', 'type': 'Virus', 'start': 2444, 'end': 2455}\n",
            "['The deubiquitinating activity of Middle East respiratory syndrome coronavirus papain-like protease delays the innate immune response and enhances virulence in a mouse model\\tMiddle East respiratory syndrome coronavirus (MERS-CoV) continues to cause zoonotic infections and serious disease, primarily in the Arabian Peninsula, due to repeated spill-over from dromedary camels and subsequent nosocomial transmission.', 'Approved MERS vaccines for use in animals or humans are not currently available.', 'MERS-CoV replication requires the virus-encoded papain-like protease (PL pro ) to cleave multiple sites in the viral replicase polyproteins, thereby releasing functional non-structural proteins.', 'Additionally, PL pro is a deubiquitinating enzyme (DUB) that can remove ubiquitin(-like) moieties from substrates, presumably to counteract host antiviral responses.', 'In previous work, we determined the crystal structure of MERS-CoV PL pro in complex with ubiquitin, facilitating the design of PL pro mutations that impair DUB activity without affecting viral polyprotein cleavage.', 'Here, we introduced these DUB-inactivating mutations into the viral genome and examined their impact on MERS-CoV infection both in cell culture and in a lethal mouse model.', 'Although overall replication of DUB-negative and wild-type (wt) recombinant MERS-CoV was comparable in multiple cell lines, infection with DUB-negative virus markedly increased mRNA levels for interferon (IFN)-β and IFN-stimulated genes.', 'Moreover, compared to a wt virus infection, the survival rate was significantly increased when DUB-negative MERS-CoV was used to infect transgenic mice expressing a human MERS-CoV receptor.', 'Interestingly, DUB-negative and wt MERS-CoV replicated to the same titers in lungs of infected mice, but the DUB-negative virus was cleared faster, likely due to the observed accelerated and better-regulated innate immune responses, in contrast to delayed and subsequently excessive responses in wt virus-infected mice.', 'This study provides the first direct evidence that the DUB activity of a coronaviral protease contributes to innate immune evasion and can profoundly enhance virulence in an animal model.', 'Thus, reduction or removal of the innate immune-suppressive DUB activity of PL pro s is a promising strategy for coronavirus attenuation in the context of rational vaccine development.', 'Author Summary Although zoonotic coronaviruses such as Middle East respiratory coronavirus (MERS-CoV) have pandemic potential, therapeutics and vaccines that counteract this public health threat are not currently available.', 'Coronaviruses typically employ multiple strategies to evade the host’s innate immune response, which may enhance clinical disease and/or reduce the efficacy of modified live vaccines.', 'The MERS-CoV-encoded papain-like protease (PL pro ) is not only crucial for the expression of functional replicase proteins, but has also been postulated to antagonize ubiquitination-dependent steps during the activation of the innate immune response.', 'Here, we report the generation of engineered MERS-CoVs mutants in which PL pro ’s deubiquitinating (DUB) activity was specifically disrupted without affecting virus viability.', 'In this manner, we could demonstrate that the DUB activity of PL pro suppresses the interferon response in MERS-CoV-infected cells.', 'Strikingly, in the lungs of mice infected with DUB-negative MERS-CoV, innate immune responses were induced at an earlier stage of infection than in wt virus-infected mice.', 'This group also showed a clearly increased survival, indicating that the DUB activity is an important MERS-CoV virulence factor.', 'This proof-of-concept study establishes that the engineering of DUB-negative coronaviruses, which elicit a more effective immune response in the host, is a viable strategy for vaccine development.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 3810, 'end': 3817}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 3711, 'end': 3722}, {'entity': 'DUB-negative', 'type': 'Organization', 'start': 3698, 'end': 3710}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 3607, 'end': 3615}, {'entity': 'DUB', 'type': 'Organization', 'start': 3578, 'end': 3581}, {'entity': 'virus-infected mice', 'type': 'Disease', 'start': 3484, 'end': 3503}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 3393, 'end': 3401}, {'entity': 'DUB-negative', 'type': 'Organization', 'start': 3380, 'end': 3392}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'gene', 'type': 'Gene', 'start': 196, 'end': 200}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'ACE2', 'type': 'Gene', 'start': 827, 'end': 831}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'gene', 'type': 'Gene', 'start': 1413, 'end': 1417}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'protein', 'type': 'Gene', 'start': 1516, 'end': 1523}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'gene', 'type': 'Gene', 'start': 2102, 'end': 2106}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'parvovirus', 'type': 'Virus', 'start': 799, 'end': 809}\n",
            "['Reassessment of the prevalence of soil-transmitted helminth infections in Sri Lanka to enable a more focused control programme: a cross-sectional national school survey with spatial modelling\\tOur survey findings indicate that the national prevalence of soil-transmitted helminth infection has continued to decline in Sri Lanka.', 'On the basis of WHO guidelines, we recommend discontinuation of routine deworming in low-risk areas, continuation of annual deworming in high-risk areas, and deworming once every 2 years in intermediate-risk areas, for at least 4 years.']\n",
            "unmatched tags:  [{'entity': 'helminth infection', 'type': 'Disease', 'start': 270, 'end': 288}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diseases', 'type': 'Disease', 'start': 106, 'end': 114}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diseases', 'type': 'Disease', 'start': 269, 'end': 277}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'polio', 'type': 'Disease', 'start': 193, 'end': 198}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'LecB', 'type': 'Chemical', 'start': 527, 'end': 531}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'asthma', 'type': 'Phenotype', 'start': 265, 'end': 271}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 81, 'end': 87}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'pyrimethamine', 'type': 'Drug', 'start': 165, 'end': 178}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'paclitaxel', 'type': 'Drug', 'start': 11, 'end': 21}\n",
            "['Messenger RNAs transcribed from yeast linear cytoplasmic plasmids possess unconventional 5’ and 3’ UTRs and suggest a novel mechanism of translation\\tLinear plasmids with almost identical compact genetic organization have been found in the cytoplasm of yeast species from nine genera.', 'We employed pGKL1,2 plasmids from Kluyveromyces lactis as a model to investigate the previously unstudied transcriptome of yeast cytoplasmic linear plasmids.', 'We performed 5’ and 3’ RACE analysis of all the pGKL1,2 mRNAs and found them not 3’ polyadenylated and containing mostly uncapped 5’ poly(A) leaders that are not complementary to the plasmid DNA.', 'The degree of 5’ capping and/or 5’ polyadenylation is specific to each gene and is controlled by the corresponding promoter regions.', 'We refined the description of the pGKL1,2 promoters and found new alternative promoters of several genes.', 'We also provide evidence that K2ORF3 encodes an mRNA cap guanine-N 7 -methyltransferase and that 5’ capped pGKL1,2 transcripts contain N 7 -methylated caps.', 'Translation of pGKL1,2 transcripts is enhanced in Ism1Δ and pab1Δ strains and is independent of eIF4E and Pab1 translation factors.', 'We suggested a model of a primitive regulation of pGKL1,2 plasmids gene expression where degree of 5’ mRNA capping, degree of 5’ non-template polyadenylation and presence of negative regulators as PAB1 and Lsm1 play an important role.', 'Our data also suggest a close relationship between linear plasmids and poxviruses.']\n",
            "unmatched tags:  [{'entity': 'poxviruses', 'type': 'Virus', 'start': 1472, 'end': 1482}, {'entity': 'linear plasmids', 'type': 'Gene', 'start': 1452, 'end': 1467}, {'entity': 'Lsm1', 'type': 'Gene', 'start': 1372, 'end': 1376}, {'entity': 'PAB1', 'type': 'Gene', 'start': 1363, 'end': 1367}, {'entity': 'mRNA', 'type': 'Gene', 'start': 1268, 'end': 1272}, {'entity': 'gene', 'type': 'Gene', 'start': 1233, 'end': 1237}, {'entity': 'translation factors', 'type': 'Gene', 'start': 1145, 'end': 1164}, {'entity': 'Pab1', 'type': 'Gene', 'start': 1140, 'end': 1144}, {'entity': 'eIF4E', 'type': 'Gene', 'start': 1130, 'end': 1135}, {'entity': 'transcripts', 'type': 'Gene', 'start': 1057, 'end': 1068}, {'entity': 'transcripts', 'type': 'Gene', 'start': 992, 'end': 1003}, {'entity': 'mRNA', 'type': 'Gene', 'start': 925, 'end': 929}, {'entity': 'promoters', 'type': 'Gene', 'start': 849, 'end': 858}, {'entity': 'promoters', 'type': 'Gene', 'start': 813, 'end': 822}, {'entity': 'promoter regions', 'type': 'Gene', 'start': 753, 'end': 769}, {'entity': 'gene', 'type': 'Gene', 'start': 709, 'end': 713}, {'entity': 'plasmid DNA', 'type': 'Gene', 'start': 625, 'end': 636}, {'entity': 'polyadenylated', 'type': 'Gene', 'start': 526, 'end': 540}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'epilepsy', 'type': 'Disease', 'start': 166, 'end': 174}\n",
            "['Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins\\tThe glycoprotein spike (S) on the surface of SARS-CoV-2 is a determinant for viral invasion and host immune response.', 'Herein, we characterized the site-specific N-glycosylation of S protein at the level of intact glycopeptides.', 'All 22 potential N-glycosites were identified in the S-protein protomer and were found to be preserved among the 753 SARS-CoV-2 genome sequences.', 'The glycosite occupancy by different glycoforms exhibited remarkable heterogeneity in human cell-expressed protein subunits, including up to 157 N-glycans, mainly of the complex type.', 'In contrast, the insect cell-expressed S protein contained 38 N-glycans, primarily of the high-mannose type.', 'Our results revealed that the glycan types were highly determined by the differential processing of N-glycans among human and insect cells.', 'This N-glycosylation landscape and the differential N-glycan patterns among distinct host cells are expected to shed light on the infection mechanism and present a positive view for the development of vaccines and targeted drugs.']\n",
            "unmatched tags:  [{'entity': 'vaccines', 'type': 'Drug', 'start': 1096, 'end': 1104}, {'entity': 'glycan', 'type': 'Drug', 'start': 949, 'end': 955}, {'entity': 'N-glycan', 'type': 'Gene', 'start': 947, 'end': 955}, {'entity': 'insect', 'type': 'Drug', 'start': 881, 'end': 887}, {'entity': 'N-glycans', 'type': 'Gene', 'start': 855, 'end': 864}, {'entity': 'glycan', 'type': 'Drug', 'start': 785, 'end': 791}, {'entity': 'glycan', 'type': 'Drug', 'start': 710, 'end': 716}, {'entity': 'N-glycans', 'type': 'Gene', 'start': 708, 'end': 717}, {'entity': 'S protein', 'type': 'Gene', 'start': 685, 'end': 694}, {'entity': 'insect', 'type': 'Drug', 'start': 663, 'end': 669}, {'entity': 'N-glycans', 'type': 'Gene', 'start': 607, 'end': 616}, {'entity': 'glycosite', 'type': 'Drug', 'start': 466, 'end': 475}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 433, 'end': 443}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'lupus erythematosus', 'type': 'Disease', 'start': 223, 'end': 242}\n",
            "['Mono-ADP-ribosylation by ARTD10 restricts Chikungunya virus replication by interfering with the proteolytic activity of nsP2\\tA subset of intracellular mono-ADP-ribosyltransferases diphtheria toxin-like (ARTDs, aka mono-PARPs) is induced by type I interferons.', 'Some of these mono-ARTDs feature antiviral activity while certain RNA viruses, including Chikungunya virus (CHIKV), encode mono-ADP-ribosylhydrolases, suggesting a role for mono-ADP-ribosylation (MARylation) in host-virus conflicts.', 'CHIKV expresses four non-structural proteins (nsP1-nsP4), with nsP3 containing a macrodomain that hydrolyzes and thereby reverses protein MARylation in vitro and in cells.', 'This de-MARylation activity is essential as hydrolase inactivating mutations result in replication defective virus.', 'However, the substrates of MARylation during CHIKV infection are unknown and thus it is unclear how the macrodomain contributes to virus replication and how mono-ARTD-dependent MARylation confers antiviral immunity.', 'We identified ARTD10 and ARTD12 as restriction factors for CHIKV replication in a catalytic activity-dependent manner.', 'CHIKV replication requires processing of the non-structural polyprotein nsP1-4 by the nsP2-encoded protease and the assembly of the four individual nsPs into a functional replication complex.', 'Expression of ARTD10 and ARTD12 resulted in a reduction of processed nsPs.', 'Similarly, MAR hydrolase inactive CHIKV replicon mutants revealed a decrease in processed nsPs, comparable to an nsP2 protease defective mutant.', 'This suggested that the macrodomain contributes to nsP2 protease activity.', 'In support, a hydrolase-deficient virus was complemented by a protease-deficient virus.', 'We hypothesized that MARylation regulates the proteolytic function of nsP2.', 'Indeed, we found that nsP2 is MARylated by ARTD10.', 'This inhibited nsP2 protease activity, thereby preventing polyprotein processing and consequently virus replication.', 'This inhibition was antagonized by the MAR hydrolase activity of nsP3.', 'Together, our findings provide a mechanistic explanation for the need of the viral MAR hydrolase for efficient replication of CHIKV.', 'Author Summary Infectious diseases still pose major health threats.', 'Especially fast evolving viruses find ever new strategies to manipulate the immune response.', 'With climate warming and increased human mobility vector-borne pathogens like Chikungunya virus (CHIKV) spread and cause world-wide epidemics.', 'Beyond the acute phase, CHIKV patients regularly suffer from chronic rheumatism.', 'This entails a decline in life quality and an economic burden.', 'To date no drugs are approved and the mode of pathogenesis remains elusive.', 'Here we describe a mechanistic function of the CHIKV nsP3 macrodomain.', 'We found that the viral nsP2 is mono-ADP-ribosylated interfering with its auto-proteolytic function.', 'The nsP3 macrodomain removes this modification and restores the protease activity that is essential for replication.', 'Because macrodomains are highly conserved they might represent broad antiviral targets.']\n",
            "unmatched tags:  [{'entity': 'macrodomain', 'type': 'Gene', 'start': 2960, 'end': 2971}, {'entity': 'macrodomain', 'type': 'Gene', 'start': 2844, 'end': 2855}, {'entity': 'nsP3 macrodomain', 'type': 'Disease', 'start': 2839, 'end': 2855}, {'entity': 'proteolytic function', 'type': 'Gene', 'start': 2813, 'end': 2833}, {'entity': 'nsP2', 'type': 'Gene', 'start': 2758, 'end': 2762}, {'entity': 'viral nsP2', 'type': 'Gene', 'start': 2752, 'end': 2762}, {'entity': 'nsP3 macrodomain', 'type': 'Disease', 'start': 2716, 'end': 2732}, {'entity': 'CHIKV', 'type': 'Organization', 'start': 2710, 'end': 2715}, {'entity': 'chronic rheumatism', 'type': 'Disease', 'start': 2504, 'end': 2522}, {'entity': 'CHIKV', 'type': 'Organization', 'start': 2467, 'end': 2472}, {'entity': 'CHIKV', 'type': 'Organization', 'start': 2397, 'end': 2402}, {'entity': 'Chikungunya virus', 'type': 'Virus', 'start': 2378, 'end': 2395}, {'entity': 'Author Summary Infectious diseases', 'type': 'Disease', 'start': 2139, 'end': 2173}, {'entity': 'CHIKV', 'type': 'Organization', 'start': 2132, 'end': 2137}, {'entity': 'hydrolase', 'type': 'Gene', 'start': 2093, 'end': 2102}, {'entity': 'viral MAR hydrolase', 'type': 'Gene', 'start': 2083, 'end': 2102}, {'entity': 'nsP3', 'type': 'Gene', 'start': 2000, 'end': 2004}, {'entity': 'MAR hydrolase', 'type': 'Gene', 'start': 1974, 'end': 1987}, {'entity': 'nsP2 protease', 'type': 'Gene', 'start': 1833, 'end': 1846}, {'entity': 'ARTD10', 'type': 'Gene', 'start': 1810, 'end': 1816}, {'entity': 'nsP2', 'type': 'Gene', 'start': 1789, 'end': 1793}, {'entity': 'nsP2', 'type': 'Gene', 'start': 1761, 'end': 1765}, {'entity': 'proteolytic function', 'type': 'Gene', 'start': 1737, 'end': 1757}, {'entity': 'nsP2 protease', 'type': 'Gene', 'start': 1579, 'end': 1592}, {'entity': 'macrodomain', 'type': 'Gene', 'start': 1552, 'end': 1563}, {'entity': 'nsP2 protease', 'type': 'Gene', 'start': 1496, 'end': 1509}, {'entity': 'replicon', 'type': 'Gene', 'start': 1423, 'end': 1431}, {'entity': 'CHIKV', 'type': 'Organization', 'start': 1417, 'end': 1422}, {'entity': 'MAR hydrolase', 'type': 'Gene', 'start': 1394, 'end': 1407}, {'entity': 'ARTD12', 'type': 'Gene', 'start': 1333, 'end': 1339}, {'entity': 'ARTD10', 'type': 'Gene', 'start': 1322, 'end': 1328}, {'entity': 'CHIKV', 'type': 'Organization', 'start': 1116, 'end': 1121}, {'entity': 'CHIKV', 'type': 'Organization', 'start': 1056, 'end': 1061}, {'entity': 'ARTD12', 'type': 'Gene', 'start': 1022, 'end': 1028}, {'entity': 'ARTD10', 'type': 'Gene', 'start': 1011, 'end': 1017}, {'entity': 'macrodomain', 'type': 'Gene', 'start': 885, 'end': 896}, {'entity': 'CHIKV', 'type': 'Organization', 'start': 826, 'end': 831}, {'entity': 'replication defective virus', 'type': 'Virus', 'start': 752, 'end': 779}, {'entity': 'hydrolase', 'type': 'Gene', 'start': 709, 'end': 718}, {'entity': 'macrodomain', 'type': 'Gene', 'start': 574, 'end': 585}, {'entity': 'nsP3', 'type': 'Gene', 'start': 556, 'end': 560}, {'entity': 'nsP1-nsP4', 'type': 'Gene', 'start': 539, 'end': 548}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'headache', 'type': 'Phenotype', 'start': 84, 'end': 92}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'headache', 'type': 'Phenotype', 'start': 321, 'end': 329}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tuberculosis', 'type': 'Disease', 'start': 300, 'end': 312}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'lung injury', 'type': 'Disease', 'start': 127, 'end': 138}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'hypertension', 'type': 'Disease', 'start': 131, 'end': 143}\n",
            "['Clinical analysis and early differential diagnosis of suspected pediatric patients with 2019 novel coronavirus infection\\tAbstract Background: Early differential diagnosis of suspected pediatric patients is difficult during the 2019-nCoV epidemic.', 'Objective: To identify clinical characteristics and key points of early differential diagnosis.', 'Methods: A retrospective analysis was performed on suspected pediatric cases.', 'Results:A total of 77 suspected cases were admitted from Jan 22nd to Mar 1st.', 'Compared with non-2019-nCoV group (n=33),2019-nCoV confirmed group (n=35) had fewer fever (OR[95% CI] 0.39[0.242 to 0.628];P<.001) and symptoms of ARI (0.454[0.287 to 0.719];P<.001),more asymptomatic (15.086[2.117 to 107.475];P<.001), and more family cluster infections (5.469[2.405 to 12.433]; P<.001),while chest CT had more positive findings of viral pneumonia (1.813[1.131 to 2.908];P=.014).There were significant statistical differences between the two groups in age (7.2[3.9 to 11.4] vs 5[2.1 to 7.8];P=.031),body temperature (36.7[36.2 to 36.9] vs 37[36.7 to 37.9];P=.001), heart rate ([97.1 and 16.8] vs [109.7 and 15.6];P=.002),percentage ([39.4 and 14.9] vs [52.5 and 17.5]; P=.001) and count (2.25[1.43 to 3.53] vs 3.33[2.8 to 5.18];P=.007) of neutrophil, percentage (45.3[39.2 to 56.6] vs 33.2[22.7 to 42.5];P=.001) of lymphocyte,hs-CRP (5.52[1.1 to 9.04] vs 9.04[7.35 to 9.54];P=.002) and PCT (0.05[0.03 to 0.08] vs 0.1[0.05 to 0.21];P<.001),while gender (42.9% vs 57.6%;P=.332),respiratory rate (22[20 to 22] vs 22[20 to 24];P=.092),WBC (5.37[4.67 to 8.08] vs 6.94[5.72 to 8.87];P=.198), lymphocyte count (2.68[1.99 to 4.01] vs 2.26[1.66 to 2.92];P=.096),Hb (128[124 to 142] vs 130[119 to 137];P=.572) and PLT ([279.1 and 77.5] vs [263.4 and 65.1];P=.37) were statistically insignificant.', 'Conclusions: Asymptoms or mild symptoms,positive CT findings and family cluster infection are the main clinical characteristics of infected pediatric patients.', 'The CBC, hs-CRP and PCT can provide an important basis for early differential diagnosis.', 'Compared with other non-bacterial infections,hs-CRP and PCT in 2019-nCoV infection are reduced,but further evidence is needed to support whether their reduction is specific.', 'Keywords: 2019 novel coronavirus;acute respiratory infection; pediatric;differential diagnosis;suspected infection.', 'Abbreviations:2019-nCoV,2019 novel coronavirus;CT,computed tomography; RT-PCR,real-time reverse transcriptase polymerase chain reaction;IQR,interquartile range;OR,odds ratio;CI,confidence interval;SD,standard deviation;ARI,acute respiratory infection; CAP,community-acquired pneumonia;RSV, respiratory syncytial virus; MP, mycoplasma pneumoniae; INF A,B,influenza A,B;CBC,complete blood count;WBC,white blood cell;N%, percentage of neutrophil; L%, percentage of lymphocyte; Hb, Hemoglobin;PLT, platelet; hs-CRP,high sensitivity C-reactive protein; PCT, procalcitonin.']\n",
            "unmatched tags:  [{'entity': 'procalcitonin', 'type': 'Gene', 'start': 2894, 'end': 2907}, {'entity': 'PCT', 'type': 'Disease', 'start': 2889, 'end': 2892}, {'entity': 'C-reactive protein', 'type': 'Gene', 'start': 2869, 'end': 2887}, {'entity': 'hs-CRP', 'type': 'Chemical', 'start': 2845, 'end': 2851}, {'entity': 'Hb', 'type': 'Gene', 'start': 2815, 'end': 2817}, {'entity': 'influenza A', 'type': 'Drug', 'start': 2695, 'end': 2706}, {'entity': 'INF', 'type': 'Drug', 'start': 2687, 'end': 2690}, {'entity': 'MP', 'type': 'Disease', 'start': 2660, 'end': 2662}, {'entity': 'respiratory syncytial virus', 'type': 'Virus', 'start': 2631, 'end': 2658}, {'entity': 'community-acquired pneumonia;RSV', 'type': 'Disease', 'start': 2597, 'end': 2629}, {'entity': 'respiratory infection', 'type': 'Disease', 'start': 2570, 'end': 2591}, {'entity': 'acute respiratory infection', 'type': 'Disease', 'start': 2564, 'end': 2591}, {'entity': 'ARI', 'type': 'Gene', 'start': 2560, 'end': 2563}, {'entity': 'coronavirus;CT', 'type': 'Virus', 'start': 2376, 'end': 2390}, {'entity': 'acute respiratory infection', 'type': 'Disease', 'start': 2258, 'end': 2285}, {'entity': 'PCT', 'type': 'Disease', 'start': 2107, 'end': 2110}, {'entity': 'hs-CRP', 'type': 'Chemical', 'start': 2096, 'end': 2102}, {'entity': 'non-bacterial infections', 'type': 'Disease', 'start': 2071, 'end': 2095}, {'entity': 'PCT', 'type': 'Disease', 'start': 1982, 'end': 1985}, {'entity': 'hs-CRP', 'type': 'Chemical', 'start': 1971, 'end': 1977}, {'entity': 'Asymptoms', 'type': 'Phenotype', 'start': 1815, 'end': 1824}, {'entity': 'Hb', 'type': 'Gene', 'start': 1668, 'end': 1670}, {'entity': 'PCT', 'type': 'Disease', 'start': 1401, 'end': 1404}, {'entity': 'hs-CRP', 'type': 'Chemical', 'start': 1341, 'end': 1347}]\n",
            "['Alcohol consumption and risk of non-Hodgkin lymphoma: a pooled analysis\\tPeople who drink alcoholic beverages might have a lower risk of NHL than those who do not, and this risk might vary by NHL subtype.', 'Further study designs are needed to determine whether confounding lifestyle factors or immunomodulatory effects of alcohol explain this association.']\n",
            "unmatched tags:  [{'entity': 'alcohol', 'type': 'Drug', 'start': 319, 'end': 326}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'stroke', 'type': 'Disease', 'start': 190, 'end': 196}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'stroke', 'type': 'Disease', 'start': 403, 'end': 409}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'viral infection', 'type': 'Virus', 'start': 327, 'end': 342}\n",
            "['A proposal of alternative primers for the ARTIC Network’s multiplex PCR to improve coverage of SARS-CoV-2 genome sequencing\\tA group of biologists, ARTIC Network, has proposed a multiplexed PCR primer set for whole-genome analysis of the novel coronavirus, SARS-CoV-2, soon after the start of COVID-19 epidemics was realized.', 'The primer set was adapted by many researchers worldwide and has already contributed to the high-quality and prompt genome epidemiology of this rapidly spreading viral disease.', 'We have also seen the great performance of their primer set and protocol; the primer set amplifies all desired 98 PCR amplicons with fairly small amplification bias from clinical samples with relatively high viral load.', 'However, we also observed an acute drop of reads derived from some amplicons especially amplicon 18 and 76 in “pool 2” as a sample’s viral load decreases.', 'We suspected this low coverage issue was due to dimer formation between primers targeting those two amplicons.', 'Indeed, replacement of just one of those primers, nCoV-2019_76_RIGHT, to a newly designed primer resulted in a drastic improvement of coverages at both regions targeted by the amplicons 18 and 76.', 'Given this result, we further replaced four primers in “pool 1” with each respective alternative.', 'These modifications also improved coverage in eight amplicons particularly in samples with low viral load.', 'The results of our experiments clearly indicate that primer dimer formation is one critical cause of coverage bias in ARTIC protocol.', 'Importantly, some of the problematic primers are detectable by observing primer dimers in raw NGS sequence reads and replacing them with alternatives as shown in this study.', 'We expect a continuous improvement of the ARTIC primer set will extend the limit for completion of SARS-CoV-2 genomes to samples with lower viral load, that supports better genomic epidemiology and mitigation of spread of this pathogen.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1797, 'end': 1807}, {'entity': 'primer set', 'type': 'Gene', 'start': 1746, 'end': 1756}, {'entity': 'NGS', 'type': 'Organization', 'start': 1618, 'end': 1621}, {'entity': 'primer dimer', 'type': 'Gene', 'start': 1597, 'end': 1609}, {'entity': 'primer dimer', 'type': 'Gene', 'start': 1443, 'end': 1455}, {'entity': 'amplicon', 'type': 'Organization', 'start': 1335, 'end': 1343}, {'entity': 'amplicon', 'type': 'Organization', 'start': 1164, 'end': 1172}, {'entity': 'primer', 'type': 'Gene', 'start': 1078, 'end': 1084}, {'entity': 'nCoV-2019_76_RIGHT', 'type': 'Gene', 'start': 1038, 'end': 1056}, {'entity': 'amplicon', 'type': 'Organization', 'start': 977, 'end': 985}, {'entity': 'amplicon', 'type': 'Organization', 'start': 810, 'end': 818}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronavirus', 'type': 'Virus', 'start': 801, 'end': 812}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'chronic myeloid leukaemia', 'type': 'Disease', 'start': 49, 'end': 74}\n",
            "['Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials\\tIn the era of treatment with tyrosine-kinase inhibitors, patients diagnosed with CML-CP can expect a 5-year survival that is only slightly lower than that of the general population.', 'With access to tyrosine-kinase inhibitors, most patients with chronic myeloid leukaemia could enjoy a near normal life expectancy.']\n",
            "unmatched tags:  [{'entity': 'chronic myeloid leukaemia', 'type': 'Disease', 'start': 419, 'end': 444}, {'entity': 'tyrosine-kinase inhibitors', 'type': 'Drug', 'start': 372, 'end': 398}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 82, 'end': 88}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 620, 'end': 626}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'immune activation', 'type': 'Gene', 'start': 202, 'end': 219}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'receptors', 'type': 'Gene', 'start': 491, 'end': 500}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': \"multicentric Castleman's disease\", 'type': 'Disease', 'start': 196, 'end': 228}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'antitoxin', 'type': 'Drug', 'start': 177, 'end': 186}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'trivalent influenza vaccine', 'type': 'Drug', 'start': 271, 'end': 298}\n",
            "['A Multicentre Study of 2019 Novel Coronavirus Disease Outcomes of Cancer Patients in Wuhan, China\\tBackground: At present, there is a global pandemic of coronavirus disease 2019 (COVID-19) pneumonia.', 'Two previous case series from China have suggested that cancer patients are at a higher risk of COVID-19 pneumonia, but the reports were limited by small numbers and few clinical information.', 'Objective: To study clinical characteristics and outcomes of cancer patients infected with COVID-19.', 'Design: Retrospective study.', 'Setting: Four designated COVID-16 hospitals in Wuhan, Hubei province, China.', 'Participants: Medical records of 67 cancer patients admitted to hospitals between Jan 5, 2020 to Feb 18, 2020 were included.', 'Measurements: Demographic, clinical, laboratory, radiological and treatment data were collected.', 'Survival data of the cohort was cut-off on Mar 10, 2020.', 'Results: Of the 67 patients (median age: 66 years), the median age of patients who had severe illness was older than that of patients who had mild symptoms (P<0.001).', 'Forty-three (64.2%) patients had other concurrent chronic diseases, and the proportion of severe patients had co-morbidities was higher than patients with mild disease (P=0.004).', 'Twenty-three (34.3%) patients were still at the anticancer treatment phase, but no tumour progression and recurrence was observed for all the patients during the treatment of COVID-19 pneumonia.', 'About 70% of these patients had fever (n=53, 79.1%) and/or cough (n=50, 74.6%).', 'Lymphocytopenia was the main laboratory finding accompanying increased C-reactive protein and procalcitonin in cancer patients, especially in severe cases.', 'By Mar 10, 2020, 18 (26.9%) patients died from COVID-19, and 39 (58.2%) patients have been discharged.', 'The median age of survivors was younger than that of deaths (P=0.014).', 'Lung cancer (n=15, 22.4%) with COVID-19 was the most common cancer type and accounted for the highest proportion COVID-19 resulted deaths (33.3%, 5/15).', 'We observed a tendency that patients at the follow-up phase had a better prognosis than that at anticancer treatment phase (P=0.095).', 'Limitation: This is a retrospective study with only 67 cases from four hospitals.', 'And some specific clinical information was insufficient.', 'Conclusion: This study showed COVID-19 patients with cancer seem to have a higher proportion of severe cases and poorer prognosis.', 'The tendency of poor prognosis was more obvious in patients at anticancer treatment phase.', 'We should pay more intensive attentions to cancer patients infected with COVID-19.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2551, 'end': 2559}, {'entity': 'cancer', 'type': 'Disease', 'start': 2521, 'end': 2527}, {'entity': 'cancer', 'type': 'Disease', 'start': 2454, 'end': 2460}, {'entity': 'cancer', 'type': 'Disease', 'start': 2309, 'end': 2315}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2286, 'end': 2294}, {'entity': 'cancer', 'type': 'Disease', 'start': 2082, 'end': 2088}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1942, 'end': 1950}, {'entity': 'cancer', 'type': 'Disease', 'start': 1889, 'end': 1895}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1860, 'end': 1868}, {'entity': 'Lung cancer', 'type': 'Disease', 'start': 1829, 'end': 1840}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1702, 'end': 1710}, {'entity': 'cancer', 'type': 'Disease', 'start': 1610, 'end': 1616}, {'entity': 'procalcitonin', 'type': 'Gene', 'start': 1593, 'end': 1606}, {'entity': 'C-reactive protein', 'type': 'Gene', 'start': 1570, 'end': 1588}, {'entity': 'cough', 'type': 'Phenotype', 'start': 1478, 'end': 1483}, {'entity': 'fever', 'type': 'Phenotype', 'start': 1451, 'end': 1456}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 1408, 'end': 1417}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1399, 'end': 1407}]\n",
            "['Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial\\tFingolimod 0·5 mg once-daily was not better than placebo for the treatment of CIDP.', 'Future trial designs should take account of the possibility that if IVIg is stopped abruptly, some patients might relapse soon afterwards whereas others might remain in remission.']\n",
            "unmatched tags:  [{'entity': 'IVIg', 'type': 'Gene', 'start': 304, 'end': 308}, {'entity': 'CIDP', 'type': 'Disease', 'start': 230, 'end': 234}]\n",
            "['Analysis of meteorological conditions and prediction of epidemic trend of 2019-nCoV infection in 2020\\tObjective: To investigate the meteorological condition for incidence and spread of 2019-nCoV infection, to predict the epidemiology of the infectious disease, and to provide a scientific basis for prevention and control measures against the new disease.', 'Methods: The meteorological factors during the outbreak period of the novel coronavirus pneumonia in Wuhan in 2019 were collected and analyzed, and were confirmed with those of Severe Acute Respiratory Syndrome (SARS) in China in 2003.', 'Data of patients infected with 2019-nCoV and SARS coronavirus were collected from WHO website and other public sources.', 'Results: This study found that the suitable temperature range for 2019-nCoV coronavirus survival is (13-24 degree Celsius), among which 19 degree Celsius lasting about 60 days is conducive to the spread between the vector and humans; the humidity range is 50%-80%, of which about 75% humidity is conducive to the survival of the coronavirus; the suitable precipitation range is below 30 mm/ month.', 'Cold air and continuous low temperature over one week are helpful for the elimination of the virus.', 'The prediction results show that with the approach of spring, the temperature in north China gradually rises, and the coronavirus spreads to middle and high latitudes along the temperature line of 13-18 degree Celsius.', 'The population of new coronavirus infections is concentrated in Beijing, Tianjin, Hebei, Jiangsu, Zhejiang, Shanghai and other urban agglomerations.', 'Starting from May 2020, the Beijing-Tianjin-Hebei urban agglomeration, the Central China Zhengzhou-Wuhan urban agglomeration, the eastern Jiangsu-Zhejiang-Shanghai urban agglomeration, and the southern Pearl River Delta urban agglomeration are all under a high temperature above 24 degree Celsius, which is not conducive to the survival and reproduction of coronaviruses, so the epidemic is expected to end.', 'Conclusions: A wide range of continuous warm and dry weather is conducive to the survival of 2019-nCoV.', 'The coming of spring, in addition to the original Wuhan-Zhengzhou urban agglomeration in central China, means that the prevention and control measures in big cities located in mid-latitude should be strengthened, especially the monitoring of transportation hubs.', 'The Pearl River Delta urban agglomeration is a concentrated area of population in south China, with a faster temperature rise than those in mid-high latitudes, and thus the prevention in this area should be prioritized.', 'From a global perspective, cities with a mean temperature below 24 degree Celsius are all high-risk cities for 2019-nCoV transmission before June.']\n",
            "unmatched tags:  [{'entity': '2019-nCoV', 'type': 'Virus', 'start': 2685, 'end': 2694}, {'entity': 'agglomeration', 'type': 'Disease', 'start': 2382, 'end': 2395}, {'entity': 'Pearl River Delta', 'type': 'Gene', 'start': 2358, 'end': 2375}, {'entity': 'transportation hubs', 'type': 'Organization', 'start': 2333, 'end': 2352}, {'entity': 'agglomeration', 'type': 'Disease', 'start': 2163, 'end': 2176}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 2080, 'end': 2089}, {'entity': 'coronaviruses', 'type': 'Virus', 'start': 1936, 'end': 1949}, {'entity': 'agglomeration', 'type': 'Disease', 'start': 1805, 'end': 1818}, {'entity': 'Pearl River Delta', 'type': 'Gene', 'start': 1781, 'end': 1798}, {'entity': 'agglomeration', 'type': 'Disease', 'start': 1749, 'end': 1762}, {'entity': 'agglomeration', 'type': 'Disease', 'start': 1690, 'end': 1703}, {'entity': 'agglomeration', 'type': 'Disease', 'start': 1635, 'end': 1648}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'syndrome', 'type': 'Disease', 'start': 37, 'end': 45}\n",
            "['ACE2 Homo-dimerization, Human Genomic variants and Interaction of Host Proteins Explain High Population Specific Differences in Outcomes of COVID19\\tSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive single stranded RNA virus that causes a highly contagious Corona Virus Disease (COVID19).', 'Entry of SARS-CoV-2 in human cells depends on binding of the viral spike (S) proteins to cellular receptor Angiotensin-converting enzyme 2 (ACE2) and on S protein priming by host cell serine protease TMPRSS2.', 'Recently COVID19 has been declared pandemic by World Health Organization yet high differences in disease outcomes across countries have been seen.', 'We provide evidences based on analyses of existing public datasets and by using various in-silico approaches to explain some of these as factors that may explain population level differences.', 'One of the key factors might be entry of virus in host cells due to differential interaction of viral proteins with host cell proteins due to different genetic backgrounds.', 'Based on our findings, we conclude that higher expression of ACE2 facilitated by natural variations, acting as Expression quantitative trait loci (eQTLs) and with different frequencies in different populations, results in ACE2 homo-dimerization which is disadvantageous for TMPRSS2 mediated cleavage of ACE2 and becomes more difficult in presence of broad neutral amino acid transporter, B0AT1 (coded by SLC6A19), that usually does not express in Lungs.', 'We also propose that the monomeric ACE2 has higher preferential binding with SARS-CoV-2 S-Protein vis-a-vis its dimerized counterpart.', 'Further, eQTLs in TMPRSS2 and natural structural variations in the gene may also result in differential outcomes towards priming of viral S-protein, a critical step for entry of Virus in host cells.', 'In addition, we suggest some other potential key host genes like ADAM17, RPS6, HNRNPA1, SUMO1, NACA, BTF3 and some other proteases as Cathepsins, that might have a critical role.', 'Understanding these population specific differences may help in developing appropriate management strategies.']\n",
            "unmatched tags:  [{'entity': 'Cathepsins', 'type': 'Gene', 'start': 1956, 'end': 1966}, {'entity': 'proteases', 'type': 'Gene', 'start': 1943, 'end': 1952}, {'entity': 'BTF3', 'type': 'Gene', 'start': 1923, 'end': 1927}, {'entity': 'NACA', 'type': 'Gene', 'start': 1917, 'end': 1921}, {'entity': 'SUMO1', 'type': 'Gene', 'start': 1910, 'end': 1915}, {'entity': 'HNRNPA1', 'type': 'Gene', 'start': 1901, 'end': 1908}, {'entity': 'RPS6', 'type': 'Gene', 'start': 1895, 'end': 1899}, {'entity': 'ADAM17', 'type': 'Gene', 'start': 1887, 'end': 1893}, {'entity': 'gene', 'type': 'Gene', 'start': 1876, 'end': 1880}, {'entity': 'Virus', 'type': 'Virus', 'start': 1801, 'end': 1806}, {'entity': 'viral S-protein', 'type': 'Gene', 'start': 1755, 'end': 1770}, {'entity': 'gene', 'type': 'Gene', 'start': 1690, 'end': 1694}, {'entity': 'TMPRSS2', 'type': 'Gene', 'start': 1641, 'end': 1648}, {'entity': 'eQTLs', 'type': 'Chemical', 'start': 1632, 'end': 1637}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1565, 'end': 1575}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1523, 'end': 1527}, {'entity': 'SLC6A19', 'type': 'Gene', 'start': 1438, 'end': 1445}, {'entity': 'neutral amino acid transporter', 'type': 'Gene', 'start': 1390, 'end': 1420}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1337, 'end': 1341}, {'entity': 'TMPRSS2', 'type': 'Gene', 'start': 1308, 'end': 1315}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1256, 'end': 1260}, {'entity': 'eQTLs', 'type': 'Chemical', 'start': 1181, 'end': 1186}, {'entity': 'quantitative trait loci', 'type': 'Gene', 'start': 1156, 'end': 1179}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 383, 'end': 391}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'appendicitis', 'type': 'Disease', 'start': 90, 'end': 102}\n",
            "[\"Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma\\tAreas within the HLA class I and class III regions are associated with susceptibility to Hodgkin's lymphoma, the association with class I being specific for EBV-positive disease.\", \"This finding strongly suggests that antigenic presentation of EBV-derived peptides is involved in the pathogenesis of EBV-involved Hodgkin's lymphoma.\"]\n",
            "unmatched tags:  [{'entity': \"EBV-involved Hodgkin's lymphoma\", 'type': 'Disease', 'start': 430, 'end': 461}, {'entity': 'peptides', 'type': 'Gene', 'start': 386, 'end': 394}, {'entity': \"Hodgkin's lymphoma\", 'type': 'Disease', 'start': 222, 'end': 240}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'dementia', 'type': 'Disease', 'start': 27, 'end': 35}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 448, 'end': 454}\n",
            "['Forecasting ultra-early intensive care strain from COVID-19 in England\\tThe COVID-19 pandemic has led to unprecedented strain on intensive care unit (ICU) admission in parts of the world.', 'Strategies to create surge ICU capacity requires complex local and national service reconfiguration and reduction or cancellation of elective activity.', 'Theses measures require time to implement and have an inevitable lag before additional capacity comes on-line.', 'An accurate short-range forecast would be helpful in guiding such difficult, costly and ethically challenging decisions.', 'At the time this work began, cases in England were starting to increase.', 'Here we present an attempt at an agile short-range forecast based on published real-time COVID-19 case data from the seven National Health Service commissioning regions in England (East of England, London, Midlands, North East and Yorkshire, North West, South East and South West).', 'We use a Monte Carlo approach to model the likely impact of current diagnoses on regional ICU capacity over a 14 day horizon.', 'Our model is designed to be parsimonious and based on plausible epidemiological data from the literature available.', 'On the basis of the modelling assumptions made, ICU occupancy is likely to increase dramatically in the the days following the time of modelling.', 'If the current exponential growth continues, 5 out of 7 commissioning regions will have more critically ill COVID-19 patients than there are ICU beds within two weeks\\\\todo{last thing to do}.', 'Despite variable growth in absolute patients, all commissioning regions are forecast to be heavily burdened under the assumptions used.', 'Whilst, like any forecast model, there remain uncertainties both in terms of model specification and robust epidemiological data in this early prospective phase, it would seem that surge capacity will be required in the very near future.', 'We hope that our model will help policy decision makers with their preparations.', 'The uncertainties in the data highlight the urgent need for ongoing real-time surveillance to allow forecasts to be constantly updated using high quality local patient-facing data as it emerges.']\n",
            "unmatched tags:  [{'entity': 'ill', 'type': 'Phenotype', 'start': 2046, 'end': 2049}, {'entity': 'decision makers', 'type': 'Gene', 'start': 1922, 'end': 1937}, {'entity': 'ill', 'type': 'Phenotype', 'start': 1906, 'end': 1909}, {'entity': 'ill', 'type': 'Phenotype', 'start': 1841, 'end': 1844}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1424, 'end': 1432}]\n",
            "['Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial\\tMaraviroc had no significant effect on development of IRIS after ART initiation.', 'Inclusion of this CCR5 inhibitor in an initial treatment regimen does not confer a meaningful protection from the occurrence of IRIS in people with advanced HIV infection.']\n",
            "unmatched tags:  [{'entity': 'HIV infection', 'type': 'Phenotype', 'start': 414, 'end': 427}, {'entity': 'IRIS', 'type': 'Drug', 'start': 385, 'end': 389}, {'entity': 'CCR5', 'type': 'Gene', 'start': 275, 'end': 279}, {'entity': 'IRIS', 'type': 'Drug', 'start': 230, 'end': 234}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 352, 'end': 359}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'encephalitis', 'type': 'Disease', 'start': 485, 'end': 497}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 432, 'end': 439}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'NS3', 'type': 'Disease', 'start': 308, 'end': 311}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'NS3', 'type': 'Disease', 'start': 939, 'end': 942}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'NS3', 'type': 'Disease', 'start': 1414, 'end': 1417}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'Zika virus infection', 'type': 'Disease', 'start': 569, 'end': 589}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'immune thrombocytopenia', 'type': 'Disease', 'start': 214, 'end': 237}\n",
            "['Human infection with avian influenza A H6N1 virus: an epidemiological analysis\\tThis is the first report of human infection with a wild avian influenza A H6N1 virus.', 'A unique clade of H6N1 viruses with a G228S substitution of haemagglutinin have circulated persistently in poultry in Taiwan.', 'These viruses continue to evolve and accumulate changes, increasing the potential risk of human-to-human transmission.', 'Our report highlights the continuous need for preparedness for a pandemic of unpredictable and complex avian influenza.']\n",
            "unmatched tags:  [{'entity': 'complex avian influenza', 'type': 'Disease', 'start': 505, 'end': 528}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'stroke', 'type': 'Disease', 'start': 104, 'end': 110}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'colorectal cancer', 'type': 'Disease', 'start': 303, 'end': 320}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'haemorrhagic fever', 'type': 'Disease', 'start': 26, 'end': 44}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cystic echinococcosis', 'type': 'Disease', 'start': 244, 'end': 265}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'herpesviruses', 'type': 'Virus', 'start': 63, 'end': 76}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 79, 'end': 88}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'hyperactivity', 'type': 'Disease', 'start': 130, 'end': 143}\n",
            "['Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine\\tPrecision medicine has emerged as a mantra for therapeutic approaches to complex diseases.', 'The defining concept relies on a detailed insight into disease pathogenesis and therapeutic mechanism.', 'Although the type 1 diabetes field has gained new insights into disease endotypes and indications of efficacy for several therapies, none of these is yet licensed, partly because of immune suppressive side-effects beyond control of islet autoimmunity.', 'New strategies designed to regulate the immune system continue to emerge as basic science discoveries are made, including the use of antigen-based immunotherapies.']\n",
            "unmatched tags:  [{'entity': 'era', 'type': 'Gene', 'start': 692, 'end': 695}, {'entity': 'era', 'type': 'Gene', 'start': 409, 'end': 412}, {'entity': 'era', 'type': 'Gene', 'start': 402, 'end': 405}, {'entity': 'type 1 diabetes field', 'type': 'Disease', 'start': 298, 'end': 319}, {'entity': 'era', 'type': 'Gene', 'start': 264, 'end': 267}, {'entity': 'complex diseases', 'type': 'Disease', 'start': 164, 'end': 180}, {'entity': 'era', 'type': 'Gene', 'start': 140, 'end': 143}]\n",
            "['Loss of health professionals from sub-Saharan Africa: the pivotal role of the UK\\tThe already inadequate health systems of sub-Saharan Africa have been badly damaged by the emigration of their health professionals, a process in which the UK has played a prominent part.', 'In 2005, there are special opportunities for the UK to take the lead in addressing that damage, and in focusing the attention of the G8 on the wider problems of health-professional migration from poor to rich countries.', 'We suggest some practical measures to these ends.', 'These include action the UK could take on its own, with the African countries most affected, and with other developed countries and WHO.']\n",
            "unmatched tags:  [{'entity': 'G8', 'type': 'Gene', 'start': 402, 'end': 404}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronavirus', 'type': 'Virus', 'start': 147, 'end': 158}\n",
            "['Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2\\tHuman coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead global epidemics with high morbidity and mortality.', 'However, there are currently no effective drugs targeting 2019-nCoV/SARS-CoV-2.', 'Drug repurposing, representing as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery.', 'In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoVâ\\x80\\x93host interactome and drug targets in the human proteinâ\\x80\\x93protein interaction network.', 'Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%).', 'Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV.', 'Using network proximity analyses of drug targets and HCoVâ\\x80\\x93host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines.', 'We further identify three potential drug combinations (e.g., sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin) captured by the â\\x80\\x9cComplementary Exposureâ\\x80\\x9d pattern: the targets of the drugs both hit the HCoVâ\\x80\\x93host subnetwork, but target separate neighborhoods in the human interactome network.', 'In summary, this study offers powerful network-based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations targeting 2019-nCoV/SARS-CoV-2.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2031, 'end': 2041}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 2021, 'end': 2030}, {'entity': 'drug combinations', 'type': 'Drug', 'start': 1993, 'end': 2010}, {'entity': 'HCoV', 'type': 'Virus', 'start': 1763, 'end': 1767}, {'entity': 'emodin', 'type': 'Drug', 'start': 1663, 'end': 1669}, {'entity': 'toremifene', 'type': 'Drug', 'start': 1647, 'end': 1657}, {'entity': 'melatonin', 'type': 'Drug', 'start': 1632, 'end': 1641}, {'entity': 'mercaptopurine', 'type': 'Drug', 'start': 1612, 'end': 1626}, {'entity': 'dactinomycin', 'type': 'Gene', 'start': 1598, 'end': 1610}, {'entity': 'sirolimus', 'type': 'Drug', 'start': 1583, 'end': 1592}, {'entity': 'drug combinations', 'type': 'Drug', 'start': 1558, 'end': 1575}, {'entity': 'sirolimus', 'type': 'Drug', 'start': 1378, 'end': 1387}, {'entity': 'mercaptopurine', 'type': 'Drug', 'start': 1358, 'end': 1372}, {'entity': 'melatonin', 'type': 'Drug', 'start': 1347, 'end': 1356}, {'entity': 'HCoV', 'type': 'Virus', 'start': 1316, 'end': 1320}, {'entity': 'HCoV', 'type': 'Virus', 'start': 1233, 'end': 1237}, {'entity': 'SARS-CoV.', 'type': 'Virus', 'start': 1170, 'end': 1179}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1042, 'end': 1052}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 1032, 'end': 1041}, {'entity': 'nucleocapsid proteins', 'type': 'Gene', 'start': 1007, 'end': 1028}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'melanoma', 'type': 'Disease', 'start': 236, 'end': 244}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diseases', 'type': 'Disease', 'start': 146, 'end': 154}\n",
            "['Early prediction of mortality risk among severe COVID-19 patients using machine learning\\tAbstract Background Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been spreading globally.', 'The number of deaths has increased with the increase in the number of infected patients.', 'We aimed to develop a clinical model to predict the outcome of severe COVID-19 patients early.', 'Methods Epidemiological, clinical, and first laboratory findings after admission of 183 severe COVID-19 patients (115 survivors and 68 nonsurvivors) from the Sino-French New City Branch of Tongji Hospital were used to develop the predictive models.', \"Five machine learning approaches (logistic regression, partial least squares regression, elastic net, random forest, and bagged flexible discriminant analysis) were used to select the features and predict the patients' outcomes.\", \"The area under the receiver operating characteristic curve (AUROC) was applied to compare the models' performance.\", 'Sixty-four severe COVID-19 patients from the Optical Valley Branch of Tongji Hospital were used to externally validate the final predictive model.', 'Results The baseline characteristics and laboratory tests were significantly different between the survivors and nonsurvivors.', 'Four variables (age, high-sensitivity C-reactive protein level, lymphocyte count, and d-dimer level) were selected by all five models.', 'Given the similar performance among the models, the logistic regression model was selected as the final predictive model because of its simplicity and interpretability.', 'The AUROCs of the derivation and external validation sets were 0.895 and 0.881, respectively.', 'The sensitivity and specificity were 0.892 and 0.687 for the derivation set and 0.839 and 0.794 for the validation set, respectively, when using a probability of death of 50% as the cutoff.', 'The individual risk score based on the four selected variables and the corresponding probability of death can serve as indexes to assess the mortality risk of COVID-19 patients.', 'The predictive model is freely available at https://phenomics.fudan.edu.cn/risk_scores/.', \"Conclusions Age, high-sensitivity C-reactive protein level, lymphocyte count, and d-dimer level of COVID-19 patients at admission are informative for the patients' outcomes.\"]\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2264, 'end': 2272}, {'entity': 'predictive model', 'type': 'Chemical', 'start': 2079, 'end': 2095}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2056, 'end': 2064}]\n",
            "['Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort\\tDespite the availability of free treatment and care in the UK, AIDS continues to account for the majority of deaths in HIV-positive people, and mortality remains higher in HIV-positive people than in the general population.', 'These findings highlight the importance of prompt diagnosis, care engagement, and optimum management of comorbidities in reducing mortality in people with HIV.']\n",
            "unmatched tags:  [{'entity': 'HIV', 'type': 'Virus', 'start': 574, 'end': 577}, {'entity': 'era', 'type': 'Gene', 'start': 402, 'end': 405}, {'entity': 'HIV-positive', 'type': 'Gene', 'start': 367, 'end': 379}, {'entity': 'HIV-positive', 'type': 'Gene', 'start': 314, 'end': 326}, {'entity': 'AIDS', 'type': 'Disease', 'start': 258, 'end': 262}, {'entity': 'era', 'type': 'Gene', 'start': 131, 'end': 134}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'malaria', 'type': 'Disease', 'start': 540, 'end': 547}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'mesylate', 'type': 'Drug', 'start': 2247, 'end': 2255}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'neoplasms', 'type': 'Disease', 'start': 232, 'end': 241}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 505, 'end': 511}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tuberculosis', 'type': 'Disease', 'start': 406, 'end': 418}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'headache', 'type': 'Phenotype', 'start': 119, 'end': 127}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'injury', 'type': 'Disease', 'start': 285, 'end': 291}\n",
            "['Confirmedasymptomatic carrier of SARS-CoV-2\\tHere we reported a case of asymptomatic carrier of SARS-CoV-2 infection.', 'A 50-year old woman,lived with her husband in Anqing(Anhui, China) with no significant past medical history, travelhistory to Wuhan or adjacent area, or exposure to wild animals.', 'She took throat swab test forSARS-CoV-2 nucleic acid due to her husband’s close contact with patients who had SARS-CoV-2infection.', 'Her results were confirmed positive on February 6, 2020.', 'But she did not reportelevation of temperature measurement, nor respiratory or gastrointestinal symptoms and her chestCT scan showed no significant abnormalities.', 'She was hospitalized on February 6 and treated withantiviral agents.', 'During her hospitalization, apart from a mild elevation of liver enzymes after10-day treatment of lopinavir/ritonavir, she was asymptomatic, with her blood cell count, liveand renal function largely normal.', 'Her subcutaneous oxygen saturation stayed above 97%.', 'Chest CTscan was repeated on February 11 and 20, and both were negative for signs of viral pneumonia.Notably, a second set of throat swabs and anal swabs were sent to test for SARS-CoV-2 onFebruary 19, and the results were still confirmed positive.', 'This is a confirmed case ofasymptomatic carrier of SARS-CoV-2 infection.', 'Her persistent positive findings in both throatand anal swabs suggested the possibility of healthy carrier of the virus, which adds to thedifficulty in preventing transmission of the disease.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1276, 'end': 1286}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1152, 'end': 1162}, {'entity': 'viral pneumonia', 'type': 'Disease', 'start': 1061, 'end': 1076}, {'entity': 'lopinavir/ritonavir', 'type': 'Drug', 'start': 814, 'end': 833}, {'entity': 'withantiviral agents', 'type': 'Drug', 'start': 694, 'end': 714}]\n",
            "['Difference in nature of ruptured and unruptured cerebral aneurysms\\tAlthough small aneurysms have an extremely low probability of rupture, most aneurysms that rupture are found to be less than 10 mm in diameter.', 'Histological study of aneurysms and epidemiological analysis of subarachnoid haemorrhage revealed that ruptured and unruptured aneurysms are of a different nature.']\n",
            "unmatched tags:  [{'entity': 'unruptured aneurysms', 'type': 'Disease', 'start': 327, 'end': 347}, {'entity': 'rupture', 'type': 'Disease', 'start': 314, 'end': 321}, {'entity': 'subarachnoid haemorrhage', 'type': 'Disease', 'start': 275, 'end': 299}, {'entity': 'aneurysms', 'type': 'Disease', 'start': 233, 'end': 242}, {'entity': 'rupture', 'type': 'Disease', 'start': 158, 'end': 165}, {'entity': 'aneurysms', 'type': 'Disease', 'start': 143, 'end': 152}, {'entity': 'rupture', 'type': 'Disease', 'start': 129, 'end': 136}, {'entity': 'aneurysms', 'type': 'Disease', 'start': 82, 'end': 91}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'melphalan', 'type': 'Gene', 'start': 508, 'end': 517}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'bronchodilators', 'type': 'Drug', 'start': 64, 'end': 79}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'leukaemia', 'type': 'Disease', 'start': 106, 'end': 115}\n",
            "['Knowledge and Beliefs towards Universal Safety Precautions to flatten the curve during Novel Coronavirus Disease (nCOVID-19) Pandemic among general Public in India: Explorations from a National Perspective\\tBackground: The novel Coronavirus disease (COVID-19) is being considered as the most serious health threat that the world has never witnessed in the recent times and significantly affecting the daily routine of mankind by emerging as a global pandemic.', 'Yet, as there is no treatment nor a vaccine that was approved so far, universal safety precautions (USPs) and mitigating strategies are the only way to deal with this emergency crisis.', 'However, knowledge and beliefs towards USPs among the general public in countries such as India with a large population are lacking.', 'Methods: A prospective, cross-sectional, web-based online survey was conducted among the general public in India during March 2020.', 'A 20-items self-administered survey questionnaire was developed and randomly distributed among the public using google document forms through social media networks.', 'Descriptive statistics were used in representing the study characteristics, and the Chi-square test was used in assessing the associations among the study variables with a p-value of < 0.05 was considered as statistically significant.', 'Results: Of 1287 participants, 1117 have given their consent of willingness and completed the questionnaire with a response rate of 86.8%.', 'The mean age of the study participants was 28.8 ± 10.9 years, where the majority of them belong to the age category <25 years, and sex was equally distributed.', 'Based upon the socio-demographic information, the majority were post-graduates (32.9%), professional job holders (45%) and belonged to the upper-middle (40%) economic class.', 'Overall, the knowledge and beliefs towards USPs and mitigating strategies among participants varied between moderate to high, with statistically significant associations with their socio-demographic characteristics.', 'Conclusions: Although the knowledge and beliefs of the general public in India towards USPs are encouraging, there is a need for long-term educational interventions as the dynamics and severity of COVID-19 have been changing day-by-day rapidly.', 'The findings of this study could guide the public health authorities in making and implementing decisions to combat this pandemic.', 'Keywords:  Coronavirus, COVID-19, outbreak, Pandemic, universal precautions, SARS-CoV-2.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2459, 'end': 2469}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2406, 'end': 2414}, {'entity': 'Coronavirus', 'type': 'Virus', 'start': 2393, 'end': 2404}, {'entity': 'combat', 'type': 'Disease', 'start': 2355, 'end': 2361}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2198, 'end': 2206}, {'entity': 'socio-demographic', 'type': 'Organization', 'start': 1966, 'end': 1983}, {'entity': 'socio-demographic', 'type': 'Organization', 'start': 1626, 'end': 1643}, {'entity': 'vaccine', 'type': 'Drug', 'start': 495, 'end': 502}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 249, 'end': 257}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tumours', 'type': 'Disease', 'start': 144, 'end': 151}\n",
            "['Establishment of a Replicon System for Bourbon Virus and Identification of Small Molecules that Efficiently Inhibit Virus Replication\\tBourbon virus (BRBV) was first isolated from a patient hospitalized at the University of Kansas Hospital in 2014.', 'Since then, several deaths have been reported to be caused by BRBV infection in the Midwest and Southern United States.', 'BRBV is a tick-borne virus that is widely carried by lone star ticks.', 'It belongs to genus Thogotovirus of the Orthomyxoviridae family.', 'Currently, there are no treatments or vaccines available for BRBV or thogotovirus infection caused diseases.', \"In this study, we reconstituted a replicon reporter system, composed of plasmids expressing the RNA-dependent RNA polymerase (RdRP) complex (PA, PB1 and PB2), nucleocapsid (NP) protein, and a reporter gene flanked by the 3' and 5' UTR of the envelope glycoprotein (GP) genome segment.\", 'By using the luciferase reporter, we screened a few small molecule compounds of anti-endonuclease that inhibited the nicking activity by parvovirus B19 (B19V) NS1, as well as FDA-approved drugs targeting the RdRP of influenza virus.', 'Our results demonstrated that myricetin, and an anti-B19V NS1 nicking inhibitor, efficiently inhibited the RdRP activity of BRBV and virus replication.', 'The IC50 and EC50 of myricetin are 2.22 uM and 4.6 uM, respectively, in cells.', 'Myricetin had minimal cytotoxicity in cells, and therefore the therapeutic index of the compound is high.', 'In conclusion, the BRBV replicon system is a useful tool to study viral RNA replication and to develop antivirals, and myricetin may hold promise in treatment of BRBV infected patients.']\n",
            "unmatched tags:  [{'entity': 'BRBV', 'type': 'Chemical', 'start': 1629, 'end': 1633}, {'entity': 'myricetin', 'type': 'Drug', 'start': 1586, 'end': 1595}, {'entity': 'antivirals', 'type': 'Drug', 'start': 1570, 'end': 1580}, {'entity': 'viral RNA', 'type': 'Gene', 'start': 1533, 'end': 1542}, {'entity': 'BRBV', 'type': 'Chemical', 'start': 1486, 'end': 1490}, {'entity': 'compound', 'type': 'Chemical', 'start': 1449, 'end': 1457}, {'entity': 'Myricetin', 'type': 'Drug', 'start': 1361, 'end': 1370}, {'entity': 'myricetin', 'type': 'Drug', 'start': 1303, 'end': 1312}, {'entity': 'EC50', 'type': 'Gene', 'start': 1295, 'end': 1299}, {'entity': 'BRBV', 'type': 'Chemical', 'start': 1254, 'end': 1258}, {'entity': 'NS1', 'type': 'Disease', 'start': 1188, 'end': 1191}, {'entity': 'B19V', 'type': 'Chemical', 'start': 1183, 'end': 1187}, {'entity': 'myricetin', 'type': 'Drug', 'start': 1160, 'end': 1169}, {'entity': 'influenza virus', 'type': 'Virus', 'start': 1113, 'end': 1128}, {'entity': 'NS1', 'type': 'Disease', 'start': 1056, 'end': 1059}, {'entity': 'B19V', 'type': 'Chemical', 'start': 1050, 'end': 1054}, {'entity': 'parvovirus B19', 'type': 'Virus', 'start': 1034, 'end': 1048}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 70, 'end': 76}\n",
            "['Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial\\tCoformulated elvitegravir, cobicistat, emtricitabine, and tenofovir seems to be efficacious and well tolerated in virologically suppressed adults with HIV and might be a suitable alternative for patients on an NNRTI with emtricitabine and tenofovir regimen considering a regimen modification or simplification.']\n",
            "unmatched tags:  [{'entity': 'tenofovir', 'type': 'Gene', 'start': 561, 'end': 570}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'fever', 'type': 'Phenotype', 'start': 52, 'end': 57}\n",
            "['Efficient high throughput SARS-CoV-2 testing to detect asymptomatic carriers\\tThe COVID-19 pandemic is rapidly spreading throughout the world.', 'Recent reports suggest that 10-30% of SARS-CoV-2 infected patients are asymptomatic.', 'Other studies report that some subjects have significant viral shedding prior to symptom onset.', 'Since both asymptomatic and pre-symptomatic subjects can spread the disease, identifying such individuals is critical for effective control of the SARS-CoV-2 pandemic.', 'Therefore, there is an urgent need to increase diagnostic testing capabilities in order to also screen asymptomatic carriers.', 'In fact, such tests will be routinely required until a vaccine is developed.', 'Yet, a major bottleneck of managing the COVID-19 pandemic in many countries is diagnostic testing, due to limited laboratory capabilities as well as limited access to genome-extraction and Polymerase Chain Reaction (PCR) reagents.', 'We developed P-BEST - a method for Pooling-Based Efficient SARS-CoV-2 Testing, using a non-adaptive group-testing approach, which significantly reduces the number of tests required to identify all positive subjects within a large set of samples.', 'Instead of testing each sample separately, samples are pooled into groups and each pool is tested for SARS-CoV-2 using the standard clinically approved PCR-based diagnostic assay.', 'Each sample is part of multiple pools, using a combinatorial pooling strategy based on compressed sensing designed for maximizing the ability to identify all positive individuals.', 'We evaluated P-BEST using leftover samples that were previously clinically tested for COVID-19.', 'In our current proof-of-concept study we pooled 384 patient samples into 48 pools providing an 8-fold increase in testing efficiency.', 'Five sets of 384 samples, containing 1-5 positive carriers were screened and all positive carriers in each set were correctly identified.', 'P-BEST provides an efficient and easy-to-implement solution for increasing testing capacity that will work with any clinically approved genome-extraction and PCR-based diagnostic methodologies.']\n",
            "unmatched tags:  [{'entity': 'patient samples', 'type': 'Chemical', 'start': 1679, 'end': 1694}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1617, 'end': 1625}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1273, 'end': 1283}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 984, 'end': 994}, {'entity': 'reagents', 'type': 'Chemical', 'start': 915, 'end': 923}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 734, 'end': 742}, {'entity': 'vaccine', 'type': 'Drug', 'start': 672, 'end': 679}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 595, 'end': 602}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 470, 'end': 480}, {'entity': 'pre-symptomatic', 'type': 'Disease', 'start': 351, 'end': 366}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 335, 'end': 342}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 308, 'end': 315}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vascular cognitive impairment', 'type': 'Disease', 'start': 39, 'end': 68}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'carcinoma', 'type': 'Disease', 'start': 384, 'end': 393}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CoV', 'type': 'Virus', 'start': 808, 'end': 811}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CoV', 'type': 'Virus', 'start': 1289, 'end': 1292}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CoV', 'type': 'Virus', 'start': 1396, 'end': 1399}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CoV', 'type': 'Virus', 'start': 1480, 'end': 1483}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tuberculosis', 'type': 'Disease', 'start': 179, 'end': 191}\n",
            "['Bipolar disorder\\tBipolar, or manic-depressive, disorder is a frequent, severe, mostly recurrent mood disorder associated with great morbidity.', 'The lifetime prevalence of bipolar disorder is 1·3 to 1·6%.', 'The mortality rate of the disease is two to three times higher than that of the general population.', 'About 10–20% of individuals with bipolar disorder take their own life, and nearly one third of patients admit to at least one suicide attempt.', 'The clinical manifestations of the disease are exceptionally diverse.', 'They range from mild hypomania or mild depression to severe forms of mania or depression accompanied by profound psychosis.']\n",
            "unmatched tags:  [{'entity': 'psychosis', 'type': 'Disease', 'start': 629, 'end': 638}, {'entity': 'depression', 'type': 'Disease', 'start': 594, 'end': 604}, {'entity': 'mania', 'type': 'Disease', 'start': 585, 'end': 590}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'lupus erythematosus', 'type': 'Disease', 'start': 353, 'end': 372}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'proteins', 'type': 'Gene', 'start': 153, 'end': 161}\n",
            "['Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial\\tIn patients with CLL, ruxolitinib was associated with significant improvements in disease-related symptoms as measured by BFI, MDASI, and symptom interference scores.', 'Further studies to test the therapeutic efficacy of ruxolitinib in CLL are warranted.']\n",
            "unmatched tags:  [{'entity': 'CLL', 'type': 'Disease', 'start': 344, 'end': 347}, {'entity': 'ruxolitinib', 'type': 'Drug', 'start': 329, 'end': 340}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'NMDAR', 'type': 'Gene', 'start': 230, 'end': 235}\n",
            "['Recombinant vector vaccines and within-host evolution\\tMany recombinant vector vaccines are capable of replication within the host.', 'They consist of a fully competent vector backbone engineered to express an antigen from a foreign transgene.', 'From the perspective of viral replication, the transgene is not only dispensable but may even be intrinsically detrimental.', 'Thus vaccine revertants that delete the transgene may evolve to dominate the within-host population and in doing so reduce the antigenicity of the vaccine.', 'We apply mathematical and computational models to study this process, including the dynamics of vaccine and revertant growth plus the dynamics of innate and adaptive immunity.', 'Although the selective basis of vaccine evolution is easy to comprehend, the immunological consequences are not.', 'One complication is that, despite possible fitness differences between vaccine and revertant, the opportunity for vaccine evolution is limited by the short period of growth before the viral population is cleared.', 'Even less obvious, revertant per se does not interfere with immunity to vaccine except as the revertant suppresses vaccine abundance; the magnitude of this interference depends on mechanisms and timing of viral suppression.', 'Adaptive immunity targeting the foreign antigen is also a possible basis of vaccine inferiority, but it is not worsened by vaccine evolution.', 'Overall, we find that within-host vaccine evolution can sometimes matter to the adaptive immune response targeting the foreign antigen, but even when it does matter, simple principles of vaccine design and the control of inoculum composition can largely mitigate the effects.', 'Author Summary Recombinant vector vaccines are live replicating viruses that are engineered to carry extra genes derived from a pathogen – and these produce proteins against which we want to generate immunity.', 'These genes may evolve to be lost during the course of replication within an individual, and there is a concern that this can severely limit the vaccine’s efficacy.', 'The dynamics of this process are studied here with mathematical models.', 'The potential for vaccine evolution is somewhat reduced by the short-term growth of the vaccine population before it is suppressed by the immune response.', 'Even when within-host evolution can be a problem, the models show that increasing the vaccine inoculum size or ensuring that the inoculum is mostly pure vaccine can largely avoid the loss of immunity arising from evolution.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 2419, 'end': 2426}, {'entity': 'vaccine', 'type': 'Drug', 'start': 2352, 'end': 2359}, {'entity': 'vaccine', 'type': 'Drug', 'start': 2199, 'end': 2206}, {'entity': 'vaccine', 'type': 'Drug', 'start': 2129, 'end': 2136}, {'entity': 'vaccine', 'type': 'Drug', 'start': 2019, 'end': 2026}, {'entity': 'proteins', 'type': 'Gene', 'start': 1821, 'end': 1829}, {'entity': 'Recombinant vector vaccines', 'type': 'Gene', 'start': 1679, 'end': 1706}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1575, 'end': 1582}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1422, 'end': 1429}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1369, 'end': 1376}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1322, 'end': 1329}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1137, 'end': 1144}, {'entity': 'revertant', 'type': 'Gene', 'start': 1116, 'end': 1125}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1094, 'end': 1101}, {'entity': 'revertant', 'type': 'Gene', 'start': 1041, 'end': 1050}, {'entity': 'vaccine', 'type': 'Drug', 'start': 923, 'end': 930}, {'entity': 'revertant', 'type': 'Gene', 'start': 892, 'end': 901}, {'entity': 'vaccine', 'type': 'Drug', 'start': 880, 'end': 887}, {'entity': 'vaccine', 'type': 'Drug', 'start': 728, 'end': 735}, {'entity': 'revertant', 'type': 'Gene', 'start': 628, 'end': 637}, {'entity': 'vaccine', 'type': 'Drug', 'start': 616, 'end': 623}, {'entity': 'vaccine', 'type': 'Drug', 'start': 511, 'end': 518}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 23, 'end': 29}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 270, 'end': 276}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'hepatocellular carcinoma', 'type': 'Disease', 'start': 238, 'end': 262}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'seizures', 'type': 'Phenotype', 'start': 135, 'end': 143}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'seizures', 'type': 'Phenotype', 'start': 296, 'end': 304}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'obesity', 'type': 'Phenotype', 'start': 401, 'end': 408}\n",
            "['Headache arising from idiopathic changes in CSF pressure\\tNew onset of sudden or progressive headache can have various causes, including disorders of intracranial pressure (ICP).', 'Headache is the most common—and often the presenting—symptom of both intracranial hypertension and intracranial hypotension syndromes, which can be symptomatic or idiopathic.', 'Despite the widespread availability of diagnostic tests, including ocular ophthalmoscopy, neuroimaging, and measurement of CSF pressure, delays in diagnosis or misdiagnosis of idiopathic intracranial hypertension and spontaneous intracranial hypotension remain common.']\n",
            "unmatched tags:  [{'entity': 'spontaneous intracranial hypotension', 'type': 'Disease', 'start': 570, 'end': 606}, {'entity': 'idiopathic intracranial hypertension', 'type': 'Disease', 'start': 529, 'end': 565}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'malignancies', 'type': 'Disease', 'start': 410, 'end': 422}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 39, 'end': 45}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 202, 'end': 208}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 466, 'end': 472}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'breast cancer', 'type': 'Disease', 'start': 364, 'end': 377}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'heart failure', 'type': 'Phenotype', 'start': 108, 'end': 121}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'endometrial cancer', 'type': 'Disease', 'start': 267, 'end': 285}\n",
            "['A Web-based, Mobile Responsive Application to Screen Healthcare Workers for COVID Symptoms: Descriptive Study\\tBackground: The COVID-19 pandemic has impacted over 1 million people across the globe, with over 330,000 cases in the United States.', 'To help limit the spread in Massachusetts, the Department of Public Health required that all healthcare workers must be screened for symptoms daily - individuals with symptoms may not work.', 'We rapidly created a digital COVID-19 symptom screening tool for a large, academic, integrated healthcare delivery system, Partners HealthCare, in Boston, Massachusetts.', 'Objective: We describe the design and development of the COVID-19 symptom screening application and report on aggregate usage data from the first week of use across the organization.', 'Methods: Using agile principles, we designed, tested and implemented a solution over the span of a week using progressively custom development approaches as the requirements and use case become more solidified.', 'We developed the minimum viable product (MVP) of a mobile responsive, web-based self-service application using REDCap (Research Electronic Data Capture).', 'For employees without access to a computer or mobile device to use the self-service application, we established a manual process where in-person, socially distanced screeners asked employees entering the site if they have symptoms and then manually recorded the responses in an Office 365 Form.', 'A custom .NET Framework application was developed solution as COVID Pass was scaled.', 'We collected log data from the .NET application, REDCap and Office 365 from the first week of full enterprise deployment (March 30, 2020 - April 5, 2020).', 'Aggregate descriptive statistics including overall employee attestations by day and site, employee attestations by application method (COVID Pass automatic screening vs. manual screening), employee attestations by time of day, and percentage of employees reporting COVID-19 symptoms  Results: We rapidly created the MVP and gradually deployed it across the hospitals in our organization.', 'By the end of the first week of enterprise deployment, the screening application was being used by over 25,000 employees each weekday.', 'Over the first full week of deployment, 154,730 employee attestation logs were processed across the system.', 'Over this 7-day period, 558 (0.36%) employees reported positive symptoms.', 'In most clinical locations, the majority of employees (~80-90%) used the self-service application, with a smaller percentage (~10-20%) using manual attestation.', 'Hospital staff continued to work around the clock, but as expected, staff attestations peaked during shift changes between 7-8am, 2-3pm, 4-6pm, and 11pm-midnight.', 'Conclusions: Using rapid, agile development, we quickly created and deployed a dedicated employee attestation application that gained widespread adoption and use within our health system.', 'Further, we have identified over 500 symptomatic employees that otherwise would have possibly come to work, potentially putting others at risk.', 'We share the story of our implementation, lessons learned, and source code (via GitHub) for other institutions who may want to implement similar solutions.']\n",
            "unmatched tags:  [{'entity': 'GitHub', 'type': 'Organization', 'start': 3146, 'end': 3152}]\n",
            "['Sphingolipid Biosynthesis Inhibition As A Host Strategy Against Diverse Pathogens\\tChloroquine is an anti-malarial and immunosuppressant drug that has cationic amphipathic chemical properties.', 'We performed genome-wide screens in human cells with chloroquine and several other widely used cationic amphipathic drugs (CADs) including the anti-depressants, sertraline (Zoloft) and fluoxetine (Prozac), the analgesic nortriptyline (Pamelor), the anti-arrhythmic amiodarone (Cordarone), and the anti-hypertensive verapamil (Calan) to characterize their molecular similarities and differences.', 'Despite CADs having different disease indications but consistent with them sharing key chemical properties, we found CADs to have remarkably similar phenotypic profiles compared with non-CADs we and others have previously screened ( 1 – 5 ).', 'The most significant genetic interaction for all CADs was the initiating step in sphingolipid biosynthesis catalyzed by serine palmitoyltransferase (SPT).', 'A comparison of genome-wide screens performed with diverse pathogens from viruses, bacteria, plants, and parasites including Ebola ( 6 ), adeno-associated virus AAV2 ( 7 ), HIV ( 8 ), Rotavirus ( 9 ), Influenza A ( 10 ), Zika virus ( 11 ), Picornavirus ( 12 ), Exotoxin A ( 13 ), Cholera toxin ( 14 ), Type III secretion system and Shiga toxin ( 15 , 16 ), Ricin toxin ( 17 ), and Toxoplasma gondii ( 18 ) showed SPT as a top common host factor and 80% overlap overall in top hits specifically with CADs.', 'Potential sphingolipid-mediated mechanisms for the host response- and virulence-modulating effects of CADs involve autophagy and SERPINE1/PAI-1 (plasminogen activator inhibitor-1).', 'Chloroquine has recently shown potential as an anti-viral agent for the novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease ( 19 , 20 ).', 'Our study demonstrates that numerous readily available drugs molecularly function highly similar to chloroquine, which suggests they might be considered for further pre-clinical investigation in the context of SARS-CoV-2.', 'More generally, our work suggests the diverse pathogen mitigating potential of drugs that inhibit host sphingolipid biosynthesis such as CADs.', 'Brief Summary Our study demonstrates that numerous readily available drugs molecularly function highly similar to chloroquine, which suggests they might be considered for further pre-clinical investigation in the context of SARS-CoV-2.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2426, 'end': 2436}, {'entity': 'chloroquine', 'type': 'Drug', 'start': 2316, 'end': 2327}, {'entity': 'CADs', 'type': 'Gene', 'start': 2196, 'end': 2200}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2047, 'end': 2057}, {'entity': 'chloroquine', 'type': 'Drug', 'start': 1937, 'end': 1948}, {'entity': 'COVID-19 respiratory disease', 'type': 'Disease', 'start': 1795, 'end': 1823}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1760, 'end': 1770}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronavirus', 'type': 'Virus', 'start': 264, 'end': 275}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CA', 'type': 'Drug', 'start': 914, 'end': 916}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 122, 'end': 130}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cholera', 'type': 'Drug', 'start': 162, 'end': 169}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 170, 'end': 177}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'stroke', 'type': 'Disease', 'start': 341, 'end': 347}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 634, 'end': 643}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'stroke', 'type': 'Disease', 'start': 399, 'end': 405}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'disorders', 'type': 'Disease', 'start': 835, 'end': 844}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'insensitivity syndrome', 'type': 'Disease', 'start': 41, 'end': 63}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'syndrome', 'type': 'Disease', 'start': 55, 'end': 63}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'chloroquine', 'type': 'Drug', 'start': 632, 'end': 643}\n",
            "['Sensitive one-step isothermal detection of pathogen-derived RNAs\\tThe recent outbreaks of Ebola, Zika, MERS, and SARS-CoV-2 (2019-nCoV) require fast, simple, and sensitive onsite nucleic acid diagnostics that can be developed rapidly to prevent the spread of diseases.', 'We have developed a SENsitive Splint-based one-step isothermal RNA detection (SENSR) method for rapid and straightforward onsite detection of pathogen RNAs with high sensitivity and specificity.', 'SENSR consists of two simple enzymatic reactions: a ligation reaction by SplintR ligase and subsequent transcription by T7 RNA polymerase.', 'The resulting transcript forms an RNA aptamer that induces fluorescence.', 'Here, we demonstrate that SENSR is an effective and highly sensitive method for the detection of the current epidemic pathogen, (SARS-CoV-2).', 'We also show that the platform can be extended to the detection of five other pathogens.', 'Overall, SENSR is a molecular diagnostic method that can be developed rapidly for onsite uses requiring high sensitivity, specificity, and short assaying times.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 804, 'end': 814}, {'entity': 'RNA aptamer', 'type': 'Gene', 'start': 636, 'end': 647}, {'entity': 'transcript', 'type': 'Gene', 'start': 616, 'end': 626}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'syndrome', 'type': 'Disease', 'start': 68, 'end': 76}\n",
            "['Modelling and analysis of COVID-19 epidemic in India.', 'COVID-19 epidemic is declared as the public health emergency of international concern by the World Health Organisation in the second week of March 2020.', 'This disease originated from China in December 2019 has already caused havoc around the world, including India.', 'The first case in India was reported on 30th January 2020, with the cases crossing 6000 on the day paper was written.', 'Complete lockdown of the nation for 21 days and immediate isolation of infected cases are the proactive steps taken by the authorities.', 'For a better understanding of the evolution of COVID-19 in the country, Susceptible-Infectious-Quarantined-Recovered (SIQR) model is used in this paper.', 'It is predicted that actual infectious population is ten times the reported positive case (quarantined) in the country.', 'Also, a single case can infect 1.5 more individuals of the population.', 'Epidemic doubling time is estimated to be around 4.1 days.', 'All indicators are compared with Brazil and Italy as well.', 'SIQR model has also predicted that India will see the peak with 22,000 active cases during the last week of April followed by reduction in active cases.', 'It may take complete July for India to get over with COVID-19.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1241, 'end': 1249}, {'entity': 'indicators', 'type': 'Chemical', 'start': 980, 'end': 990}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 620, 'end': 628}, {'entity': 'nation', 'type': 'Organization', 'start': 462, 'end': 468}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'AIDS', 'type': 'Disease', 'start': 4, 'end': 8}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'RNA', 'type': 'Gene', 'start': 673, 'end': 676}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'MHC', 'type': 'Gene', 'start': 633, 'end': 636}\n",
            "['Socioeconomic differences in mortality in the antiretroviral therapy era in Agincourt, rural South Africa, 2001–13: a population surveillance analysis\\tThe poorest people in the population continue to bear a high burden of HIV/AIDS and tuberculosis mortality, despite free antiretroviral therapy being made available from public health facilities.', 'Associations between socioeconomic status and increasing burden of mortality from non-communicable diseases is likely to become prominent.', 'Integrated strategies are needed to improve access to and uptake of HIV testing, care, and treatment, and management of non-communicable diseases in the poorest populations.']\n",
            "unmatched tags:  [{'entity': 'non-communicable diseases', 'type': 'Disease', 'start': 606, 'end': 631}, {'entity': 'non-communicable diseases', 'type': 'Disease', 'start': 429, 'end': 454}, {'entity': 'era', 'type': 'Gene', 'start': 289, 'end': 292}, {'entity': 'tuberculosis', 'type': 'Disease', 'start': 235, 'end': 247}, {'entity': 'HIV/AIDS', 'type': 'Disease', 'start': 222, 'end': 230}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 135, 'end': 141}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'lupus erythematosus', 'type': 'Disease', 'start': 102, 'end': 121}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'zidovudine', 'type': 'Drug', 'start': 13, 'end': 23}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'pneumonia', 'type': 'Disease', 'start': 120, 'end': 129}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cardiovascular disease', 'type': 'Disease', 'start': 647, 'end': 669}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'protein', 'type': 'Gene', 'start': 215, 'end': 222}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'protein', 'type': 'Gene', 'start': 1184, 'end': 1191}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'kidney injury', 'type': 'Disease', 'start': 26, 'end': 39}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'protein', 'type': 'Gene', 'start': 282, 'end': 289}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'protein', 'type': 'Gene', 'start': 665, 'end': 672}\n",
            "['Significance of hydrophobic and charged sequence similarities in sodium-bile acid cotransporter and vitamin D-binding protein macrophage activating factor\\tSodium-bile acid cotransporter, also denominated sodium-taurocholate cotransporting polypeptide (NTCP) is an integral membrane protein with multiple hydrophobic transmembrane domains.', 'The third extracellular domain of NTCP presents a stretch of nine aminoacids (KGIVISLVL) that is characterized by pronounced hydrophobicity and serves as receptor for a protein, preS1, showing the hydrophobic epta-peptide sequence NPLGFFP.', 'Vitamin D-binding protein macrophage activating factor (DBP-MAF) is a multifunctional protein that is characterized by two hydrophobic regions able to bind fatty acids and vitamin D, respectively.', 'Here we demonstrate that NTCP and DBP-MAF show significant sequence similarities as far as hydrophobic stretches of aminoacids are concerned.', 'Alignment of the sequence of seven aminoacids preceding the 157-KGIVISLVL-165 stretch of NTCP shows four aminoacids that are identical to those of the corresponding sequence of DBP-MAF, and two that are conserved substitutions.', 'In addition, in the sequence of DBP-MAF that is aligned with the sequence YKGIVISLVL of NTCP, there are two contiguous negatively charged aminoacids (ED) and, in the preceding epta-peptide sequence, there are three negatively charged aminoacids (D-ED), whereas in the corresponding sequence of NTCP there are only two (D--D) that are not contiguous.', 'This concentration of negatively charged aminoacids may be involved in binding of protein inserts characterized by high density of positively charges residues.', 'The alternating hydrophobic and electrostatic interactions described in this paper may help elucidating the biological roles of these proteins as far as protein-protein interactions are concerned.']\n",
            "unmatched tags:  [{'entity': 'protein', 'type': 'Gene', 'start': 1817, 'end': 1824}, {'entity': 'proteins', 'type': 'Gene', 'start': 1790, 'end': 1798}, {'entity': 'high density', 'type': 'Gene', 'start': 1611, 'end': 1623}, {'entity': 'protein', 'type': 'Gene', 'start': 1578, 'end': 1585}, {'entity': 'charged aminoacids', 'type': 'Gene', 'start': 1529, 'end': 1547}, {'entity': 'NTCP', 'type': 'Gene', 'start': 1440, 'end': 1444}, {'entity': 'aminoacids', 'type': 'Gene', 'start': 1380, 'end': 1390}, {'entity': 'charged aminoacids', 'type': 'Gene', 'start': 1372, 'end': 1390}, {'entity': 'charged aminoacids', 'type': 'Gene', 'start': 1276, 'end': 1294}, {'entity': 'NTCP', 'type': 'Gene', 'start': 1234, 'end': 1238}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'pain', 'type': 'Phenotype', 'start': 176, 'end': 180}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 418, 'end': 426}\n",
            "['Decodingevolution and transmissions of novel pneumonia coronavirus using the whole genomic data\\tBackground.', 'The outbreak of COVID-19 started in mid-December 2019 in Wuhan, Central China.', 'Up toFebruary 18, 2020, SARS-CoV-2 has infected more than 70,000 people in China, and another 25countries across five continents.', 'In this study, we used 93 complete genomes of SARS-CoV-2 fromthe GISAID EpiFluTM database to decode the evolution and human-to-human transmissions ofSARS-CoV-2 in the recent two months.Methods.', 'Alignment of coding-regions was conducted haplotype analyses using DnaSP.', 'Substitutionsites were analyzed in codon.', 'Evolutionary analysis of haplotypes used NETWORK.', 'Population sizechanges were estimated using both DnaSP and Arlequin.', 'Expansion date of population size wascalculated based on the expansion parameter tau (τ) using the formula t=τ/2u.Findings.', 'Eight coding-regions have 120 substitution sites, including 79 non-synonymous and 40synonymous substitutions.', 'Forty-two non-synonymous substitutions changed the biochemicalproperty of amino acids.', 'No evident combination was found.', 'Fifty-eight haplotypes wereclassified as five groups, and 31 haplotypes were found in samples from both China and othercountries, respectively.', 'The rooted network suggested H13 and H35 to be ancestral haplotypes,and H1 (and its descendent haplotypes including all samples from the Hua Nan market) was derivedH3 haplotype.', 'Population size of SARS-CoV-2 were estimated to have a recent expansion on 6January 2020, and an early expansion on 8 December 2019.Interpretation.', 'Genomic variations of SARS-CoV-2 are still low in comparisons with publishedgenomes of SARS-CoV and MERS-CoV.', 'Phyloepidemiologic analyses indicated the SARS-CoV-2 source atthe Hua Nan market should be imported from other places.', 'The crowded market boosted SARS-CoV-2rapid circulations in the market and spread it to the whole city in early December 2019.Furthermore, phyloepidemiologic approaches have recovered specific direction of human-to-humantransmissions, and the import sources of international infectious cases.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1827, 'end': 1837}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1723, 'end': 1733}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1658, 'end': 1666}, {'entity': 'genomes', 'type': 'Gene', 'start': 1647, 'end': 1654}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1593, 'end': 1603}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1442, 'end': 1452}, {'entity': 'H1', 'type': 'Gene', 'start': 1317, 'end': 1319}, {'entity': 'H1', 'type': 'Gene', 'start': 1274, 'end': 1276}, {'entity': 'amino acids', 'type': 'Gene', 'start': 1054, 'end': 1065}, {'entity': 'coding-regions', 'type': 'Disease', 'start': 876, 'end': 890}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'protein', 'type': 'Gene', 'start': 826, 'end': 833}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'protein', 'type': 'Gene', 'start': 1119, 'end': 1126}\n",
            "['COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning\\tTo ultimately combat the emerging COVID-19 pandemic, it is desired to develop an effective and safe vaccine against this highly contagious disease caused by the SARS-CoV-2 coronavirus.', 'Our literature and clinical trial survey showed that the whole virus, as well as the spike (S) protein, nucleocapsid (N) protein, and membrane (M) protein, have been tested for vaccine development against SARS and MERS.', 'However, these vaccine candidates might lack the induction of complete protection and have safety concerns.', 'We then applied the Vaxign reverse vaccinology tool and the newly developed Vaxign-ML machine learning tool to predict COVID-19 vaccine candidates.', 'By investigating the entire proteome of SARS-CoV-2, six proteins, including the S protein and five non-structural proteins (nsp3, 3CL-pro, and nsp8-10), were predicted to be adhesins, which are crucial to the viral adhering and host invasion.', 'The S, nsp3, and nsp8 proteins were also predicted by Vaxign-ML to induce high protective antigenicity.', 'Besides the commonly used S protein, the nsp3 protein has not been tested in any coronavirus vaccine studies and was selected for further investigation.', 'The nsp3 was found to be more conserved among SARS-CoV-2, SARS-CoV, and MERS-CoV than among 15 coronaviruses infecting human and other animals.', 'The protein was also predicted to contain promiscuous MHC-I and MHC-II T-cell epitopes, and linear B-cell epitopes localized in specific locations and functional domains of the protein.', 'By applying reverse vaccinology and machine learning, we predicted potential vaccine targets for effective and safe COVID-19 vaccine development.', 'We then propose that an “Sp/Nsp cocktail vaccine” containing a structural protein(s) (Sp) and a non-structural protein(s) (Nsp) would stimulate effective complementary immune responses.']\n",
            "unmatched tags:  [{'entity': 'Nsp', 'type': 'Gene', 'start': 1843, 'end': 1846}, {'entity': 'protein', 'type': 'Gene', 'start': 1831, 'end': 1838}, {'entity': 'protein', 'type': 'Gene', 'start': 1794, 'end': 1801}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1761, 'end': 1768}, {'entity': 'Nsp', 'type': 'Gene', 'start': 1748, 'end': 1751}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1699, 'end': 1706}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1651, 'end': 1658}, {'entity': 'reverse vaccinology', 'type': 'Gene', 'start': 1586, 'end': 1605}, {'entity': 'protein', 'type': 'Gene', 'start': 1565, 'end': 1572}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronavirus', 'type': 'Virus', 'start': 165, 'end': 176}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronavirus', 'type': 'Virus', 'start': 1830, 'end': 1841}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tuberculosis', 'type': 'Disease', 'start': 239, 'end': 251}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'delusions', 'type': 'Disease', 'start': 259, 'end': 268}\n",
            "['Implementation of a Novel Remote Physician SBRT Coverage Process during the Coronavirus Pandemic\\tINTRODUCTION: During the COVID-19 pandemic, alternative methods of care are needed to reduce the relative risk of transmission in departments.', 'Also needed is the ability to provide vital radiation oncological care if radiation oncologists (RO) are reallocated to other departments.', 'We implemented a novel remote RO SBRT coverage practice, requiring it to be reliable, of high audio and visual quality, timely, and the same level of specialty care as our current in-person treatment coverage practice.', 'METHODS: All observed failure modes were recorded during implementation over the first 15 sequential fractions.', 'The time from CBCT to treatment was calculated before and after implementation to determine timeliness of remote coverage.', 'Image quality metrics were calculated between the imaging console screen and the RO′s shared screen.', 'Comfort levels with audio/visual communication as well as overall comfort in comparison to in-person RO coverage was evaluated using Likert scale surveys after treatment.', 'RESULTS: Remote RO SBRT coverage was successfully implemented in 14/15 fractions with 3 observed process failures that were all corrected before treatment.', 'Average times of pre-treatment coverage before and after implementation were 8.74 and 8.51min, respectively.', 'The cross correlation between the imaging console screen and RO′s shared screen was r=0.96 and lag was 0.05s.', 'The average value for all survey questions was above 4.5, approaching in-person RO coverage comfort levels.', 'CONCLUSIONS: Our novel method of remote RO SBRT coverage permits reduced personnel and patient interactions surrounding RT procedures.', 'This may help to reduce transmission of COVID-19 in our department and provides a means for SBRT coverage if ROs are reallocated to other areas of the hospital for COVID-19 support.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1888, 'end': 1896}, {'entity': 'ROs', 'type': 'Gene', 'start': 1833, 'end': 1836}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1764, 'end': 1772}, {'entity': 'RO', 'type': 'Gene', 'start': 1629, 'end': 1631}, {'entity': 'RO', 'type': 'Gene', 'start': 1561, 'end': 1563}, {'entity': 'RO', 'type': 'Gene', 'start': 1432, 'end': 1434}, {'entity': 'pre-treatment', 'type': 'Gene', 'start': 1279, 'end': 1292}, {'entity': 'RO', 'type': 'Gene', 'start': 1122, 'end': 1124}, {'entity': 'RO', 'type': 'Gene', 'start': 1036, 'end': 1038}, {'entity': 'RO', 'type': 'Gene', 'start': 915, 'end': 917}, {'entity': 'RO', 'type': 'Gene', 'start': 409, 'end': 411}, {'entity': 'departments', 'type': 'Organization', 'start': 366, 'end': 377}, {'entity': 'RO', 'type': 'Gene', 'start': 337, 'end': 339}]\n",
            "['A nematode-specific gene underlies bleomycin-response variation in\\tBleomycin is a powerful chemotherapeutic drug used to treat a variety of cancers.', 'However, individual patients vary in their responses to bleomycin.', 'The identification of genetic differences that underlie this response variation could improve treatment outcomes by tailoring bleomycin dosages to each patient.', 'We used the model organism Caenorhabditis elegans to identify genetic determinants of bleomycin-response differences by performing linkage mapping on recombinants derived from a cross between the laboratory strain (N2) and a wild strain (CB4856).', 'This approach identified a small genomic region on chromosome V that underlies bleomycin-response variation.', 'Using near-isogenic lines and strains with CRISPR-Cas9 mediated deletions and allele replacements, we discovered that a novel nematode-specific gene ( scb-1 ) is required for bleomycin resistance.', 'Although the mechanism by which this gene causes variation in bleomycin responses is unknown, we suggest that a rare variant present in the CB4856 strain might cause differences in the potential stress-response function of scb-1 between the N2 and CB4856 strains, thereby leading to differences in bleomycin resistance.', 'Article summary We performed linkage mapping on a panel of recombinant lines generated between two genetically divergent strains of Caenorhabditis elegans and identified a bleomycin-response QTL.', 'We generated CRISPR-Cas9 deletions and reciprocal allele-replacement strains for all six candidate genes across the QTL confidence interval.', 'Deletions of one gene, H19N07.3 , caused increased bleomycin sensitivity in both divergent genetic backgrounds.', 'This gene might act in stress responses and detoxification in nematodes.', 'We further compared our linkage mapping to a genome-wide association mapping and showed that a rare expression variant in the CB4856 strain likely underlies bleomycin-response differences.']\n",
            "unmatched tags:  [{'entity': 'CB4856', 'type': 'Chemical', 'start': 1898, 'end': 1904}, {'entity': 'gene', 'type': 'Gene', 'start': 1704, 'end': 1708}, {'entity': 'gene', 'type': 'Gene', 'start': 1678, 'end': 1682}, {'entity': 'bleomycin', 'type': 'Drug', 'start': 1638, 'end': 1647}, {'entity': 'gene', 'type': 'Gene', 'start': 1604, 'end': 1608}, {'entity': 'QTL', 'type': 'Gene', 'start': 1562, 'end': 1565}, {'entity': 'strains', 'type': 'Disease', 'start': 1515, 'end': 1522}, {'entity': 'CRISPR-Cas9', 'type': 'Chemical', 'start': 1459, 'end': 1470}, {'entity': 'gene', 'type': 'Gene', 'start': 1449, 'end': 1453}, {'entity': 'QTL', 'type': 'Gene', 'start': 1441, 'end': 1444}, {'entity': 'strains', 'type': 'Disease', 'start': 1371, 'end': 1378}, {'entity': 'genetically', 'type': 'Gene', 'start': 1349, 'end': 1360}, {'entity': 'gene', 'type': 'Gene', 'start': 1327, 'end': 1331}, {'entity': 'bleomycin', 'type': 'Drug', 'start': 1228, 'end': 1237}, {'entity': 'strains', 'type': 'Disease', 'start': 1185, 'end': 1192}, {'entity': 'CB4856', 'type': 'Chemical', 'start': 1178, 'end': 1184}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'angina', 'type': 'Phenotype', 'start': 158, 'end': 164}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancers', 'type': 'Disease', 'start': 261, 'end': 268}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tuberculosis', 'type': 'Disease', 'start': 38, 'end': 50}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'pulmonary tuberculosis', 'type': 'Disease', 'start': 233, 'end': 255}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'tuberculosis', 'type': 'Disease', 'start': 525, 'end': 537}\n",
            "[\"A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy\\tWe identified four prognostic factors that can be used to obtain an accurate prognostic index at diagnosis of AIDS-associated Kaposi's sarcoma.\", 'This index is widely applicable and can be used to guide therapeutic options.']\n",
            "unmatched tags:  [{'entity': 'era', 'type': 'Gene', 'start': 310, 'end': 313}, {'entity': \"AIDS-associated Kaposi's sarcoma\", 'type': 'Disease', 'start': 217, 'end': 249}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'asthma', 'type': 'Phenotype', 'start': 130, 'end': 136}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'asthma', 'type': 'Phenotype', 'start': 259, 'end': 265}\n",
            "['A governance framework for development and assessment of national action plans on antimicrobial resistance\\tStrengthening governance is an essential strategy to tackling antimicrobial resistance (AMR) at all levels: global, national, regional, and local.', 'To date, no systematic approach to governance of national action plans on AMR exists.', 'To address this issue, we aimed to develop the first governance framework to offer guidance for both the development and assessment of national action plans on AMR.', 'We reviewed health system governance framework reviews to inform the basic structure of our framework, international guidance documents from WHO, the Food and Agriculture Organization, the World Organisation for Animal Health, and the European Commission, and sought the input of 25 experts from international organisations, government ministries, policy institutes, and academic institutions to develop and refine our framework.']\n",
            "unmatched tags:  [{'entity': 'government ministries', 'type': 'Organization', 'start': 830, 'end': 851}, {'entity': 'national', 'type': 'Organization', 'start': 806, 'end': 814}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'thalassaemia', 'type': 'Disease', 'start': 58, 'end': 70}\n",
            "['Hypocretin (orexin) deficiency in human narcolepsy\\tAlterations in the hypocretin receptor 2 and preprohypocretin genes produce narcolepsy in animal models.', 'Hypocretin was undetectable in seven out of nine people with narcolepsy, indicating abnormal hypocretin transmission.']\n",
            "unmatched tags:  [{'entity': 'hypocretin', 'type': 'Gene', 'start': 249, 'end': 259}, {'entity': 'narcolepsy', 'type': 'Disease', 'start': 217, 'end': 227}, {'entity': 'Hypocretin', 'type': 'Gene', 'start': 156, 'end': 166}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'CoV', 'type': 'Virus', 'start': 253, 'end': 256}\n",
            "['A virus that has gone viral: Amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding and thus infectivity\\tSince 2002, beta coronaviruses (CoV) have caused three zoonotic outbreaks, SARS-CoV in 2002, MERS-CoV in 2012, and the recent outbreak of SARS-CoV-2 late in 2019 (also named as COVID-19 or novel coronavirus 2019 or nCoV2019.', 'Spike(S) protein, one of the structural proteins of this virus plays key role in receptor (ACE2) binding and thus virus entry.', 'Thus, this protein has attracted scientists for detailed study and therapeutic targeting.', 'As the 2019 novel coronavirus takes its course throughout the world, more and more sequence analyses are been done and genome sequences getting deposited in various databases.', 'From India two clinical isolates have been sequenced and the full genome deposited in GenBank.', 'We have performed sequence analyses of the spike protein of the Indian isolates and compared with that of the Wuhan, China (where the outbreak was first reported).', 'While all the sequences of Wuhan isolates are identical, we found point mutations in the Indian isolates.', 'Out of the two isolates one was found to harbour a mutation in its Receptor binding domain (RBD) at position 407.', 'At this site arginine (a positively charged amino acid) was replaced by isoleucine (a hydrophobic amino acid that is also a C-beta branched amino acid).', 'This mutation has been seen to change the secondary structure of the protein at that region and this can potentially alter receptor ding of the virus.', 'Although this finding needs further validation and more sequencing, the information might be useful in rational drug designing and vaccine engineering.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 1687, 'end': 1694}, {'entity': 'receptor ding', 'type': 'Gene', 'start': 1528, 'end': 1541}, {'entity': 'protein', 'type': 'Gene', 'start': 1474, 'end': 1481}, {'entity': 'hydrophobic amino acid', 'type': 'Chemical', 'start': 1338, 'end': 1360}, {'entity': 'isoleucine', 'type': 'Gene', 'start': 1324, 'end': 1334}, {'entity': 'site arginine', 'type': 'Gene', 'start': 1260, 'end': 1273}, {'entity': 'RBD', 'type': 'Gene', 'start': 1230, 'end': 1233}, {'entity': 'spike protein', 'type': 'Gene', 'start': 911, 'end': 924}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 615, 'end': 626}, {'entity': 'protein', 'type': 'Gene', 'start': 518, 'end': 525}, {'entity': 'ACE2', 'type': 'Gene', 'start': 471, 'end': 475}, {'entity': 'receptor', 'type': 'Gene', 'start': 461, 'end': 469}, {'entity': 'structural proteins', 'type': 'Gene', 'start': 409, 'end': 428}, {'entity': 'protein', 'type': 'Gene', 'start': 389, 'end': 396}]\n",
            "['Healthcare worker mask reuse in a global pandemic: Using idle resources to create an inexpensive, scalable, and accessible UV system for N95 sterilization\\tAs the current COVID-19 pandemic illustrates, not all hospitals and other facilities are equipped with enough personal protective equipment to meet the demand in a crisis.', 'Healthcare workers around the world utilize N95 masks to protect themselves and their patients, yet during this global pandemic they are forced to re-wear what is intended to be single-use masks.', 'This poses significant risk to these healthcare workers along with the populations they are trying to protect.', 'Ultraviolet germicidal irradiation (UVGI) has been validated previously as a way to effectively sterilize these masks between use, however, not all facilities have access to the high cost commercial UV-C lamp sterilization equipment.', 'However, UV-C bulbs are sitting idle in biosafety cabinets (BSCs) at universities and research facilities around the globe that have been shuttered to slow the spread of COVID-19.', 'These bulbs may also be available in existing medical centers where infectious diseases are commonly treated.', 'Therefore, we have developed a method to modify existing light fixtures, or create custom light fixtures compatible with new or existing common UV-C bulbs.', 'This system is scalable and can be created for less than 50 US dollars, on site, at the point of need, and leverages resources that are currently untapped and sitting unused in public and private research facilities.', 'The freely-accessible design can be easily modified for use around the world.', 'Hospitals can obtain this potentially life-saving UVGI resource with minimal funds, via collaboration between research facilities to obtain the UV-C meters and limited availability UVGI bulbs.', 'While mask reuse is not ideal, we must do what we can in emergency situations to protect our frontline healthcare workers and the communities they serve.']\n",
            "unmatched tags:  [{'entity': 'protect', 'type': 'Gene', 'start': 1883, 'end': 1890}, {'entity': 'infectious diseases', 'type': 'Disease', 'start': 1116, 'end': 1135}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1038, 'end': 1046}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'hypertension', 'type': 'Disease', 'start': 257, 'end': 269}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'coronavirus', 'type': 'Virus', 'start': 931, 'end': 942}\n",
            "['Cutaneous leishmaniasis\\tCutaneous leishmaniasis is endemic in the tropics and neotropics.', 'It is often referred to as a group of diseases because of the varied spectrum of clinical manifestations, which range from small cutaneous nodules to gross mucosal tissue destruction.', 'Cutaneous leishmaniasis can be caused by several']\n",
            "unmatched tags:  [{'entity': 'Cutaneous leishmaniasis', 'type': 'Disease', 'start': 274, 'end': 297}, {'entity': 'diseases', 'type': 'Disease', 'start': 128, 'end': 136}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'asthma', 'type': 'Phenotype', 'start': 195, 'end': 201}\n",
            "['Sexually transmissible infections other than HIV\\tSexually transmitted infections (STIs) are notable for their fastidious requirements for transmission and growth in the laboratory and for their high physical and psychosocial morbidity.', 'The combination of subtle or absent symptoms and stigma preventing the seeking of health care, leaves many infections undiagnosed.', 'The development of nucleic-acid amplification tests heralded a new era in sensitive and robust diagnostic procedures for STIs.', 'Unfortunately, many of these tests are not commercially available or are too expensive for the populations that need them most.']\n",
            "unmatched tags:  [{'entity': 'STIs', 'type': 'Disease', 'start': 488, 'end': 492}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'parkinsonism', 'type': 'Disease', 'start': 151, 'end': 163}\n",
            "['Immune Cell Profiling of COVID-19 Patients in the Recovery Stage by Single-Cell Sequencing\\tCOVID-19 caused by SARS-CoV-2 has recently affected over 200,000 people and killed more than 8000.', 'Immune system dysregulation such as lymphopenia and inflammatory cytokine storm has been observed in COVID-19 patients, but it remains unclear for the change of key immune cell subsets and their states during COVID-19.', 'Here, we applied single-cell technology to comprehensively characterize transcriptional changes of peripheral blood mononuclear cells in ten patients recovered from COVID-19.', 'Compared with healthy control, COVID-19 induced a unique signature of immune cells in humans, especially in the early recovery stage (ERS).', 'In ERS patients, T cells were decreased remarkably, while monocytes were increased.', 'A detailed analysis of monocytes showed that there was an increased ratio of classical CD14++ monocytes with highly inflammatory genes expression, as well as a greater abundance of CD14++IL1B+ monocytes.', 'For nature killer (NK) cells and T cells, CD4+ T cells were significantly decreased and expressed high level of inflammatory markers, while NK cells were increased.', 'In addition, T cells were highly expanded clone, especially in CD4+ T memory cells and CD8+ T cells.', 'Among B cells, plasma cells were increased remarkably, and naïve B cells were reduced.', 'Our study also identified several novel B cell receptor (BCR) changes (such as IGHV1-8 and IGHV3-7), and confirmed isotypes (IGKV3-11 and IGHV3-21) previously used for virus vaccine development.', 'The strongest pairing frequencies, IGHV3-23+IGHJ4, indicated a monoclonal state associated with SARS-CoV-2 specificity.', 'Furthermore, integrated analysis predicated that IL-1B and M-CSF may be novel candidate target gene for inflammatory storm, and TNFSF13, IL-18 and IL-4 may be benefit for the recovery of COVID-19 patients.', 'Our study provides the first evidence of inflammatory immune signature in early recovery stage, suggesting that the COVID-19 patients are still vulnerable after hospital discharge.', 'Our identification of novel BCR signaling may lead to the development of vaccine and antibodies for the treatment of COVID-19.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2184, 'end': 2192}, {'entity': 'vaccine', 'type': 'Drug', 'start': 2140, 'end': 2147}, {'entity': 'BCR', 'type': 'Gene', 'start': 2095, 'end': 2098}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2002, 'end': 2010}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1867, 'end': 1875}, {'entity': 'IL-4', 'type': 'Gene', 'start': 1827, 'end': 1831}, {'entity': 'IL-18', 'type': 'Gene', 'start': 1817, 'end': 1822}, {'entity': 'TNFSF13', 'type': 'Gene', 'start': 1808, 'end': 1815}, {'entity': 'gene', 'type': 'Gene', 'start': 1775, 'end': 1779}, {'entity': 'M-CSF', 'type': 'Gene', 'start': 1739, 'end': 1744}, {'entity': 'IL-1B', 'type': 'Gene', 'start': 1729, 'end': 1734}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1656, 'end': 1666}, {'entity': 'virus vaccine', 'type': 'Drug', 'start': 1533, 'end': 1546}, {'entity': 'isotypes', 'type': 'Gene', 'start': 1480, 'end': 1488}, {'entity': 'BCR', 'type': 'Gene', 'start': 1422, 'end': 1425}]\n",
            "['The host antiviral ribonuclease L protein supports Zika virus replication factory formation to enhance infectious virus production\\tThe flavivirus Zika virus (ZIKV) activates ribonuclease L (RNase L) catalytic antiviral function during infection, yet deletion of RNase L decreases ZIKV production, suggesting a proviral role of RNase L. In this study, we reveal that latent RNase L supports ZIKV replication factory (RF) assembly.', 'Deletion of RNase L induced broader cellular distribution of ZIKV dsRNA and NS3 compared with densely concentrated RFs detected in WT cells.', 'An inactive form of RNase L was sufficient to contain ZIKV genome and dsRNA within a smaller area, which increased levels of viral RNA within RFs as well as infectious ZIKV released from the cell.', 'We used a microtubule stabilization drug to demonstrate that RNase L deletion impaired the cytoskeleton rearrangements that are required for proper generation of RFs.', 'During infection with dengue or West Nile Kunjin viruses, RNase L decreased virus production, suggesting that RNase L proviral function is specific to ZIKV.']\n",
            "unmatched tags:  [{'entity': 'ZIKV', 'type': 'Virus', 'start': 1086, 'end': 1090}, {'entity': 'proviral', 'type': 'Virus', 'start': 1053, 'end': 1061}, {'entity': 'RNase L', 'type': 'Gene', 'start': 1045, 'end': 1052}, {'entity': 'RNase L', 'type': 'Gene', 'start': 993, 'end': 1000}, {'entity': 'West Nile Kunjin viruses', 'type': 'Virus', 'start': 967, 'end': 991}, {'entity': 'dengue', 'type': 'Disease', 'start': 957, 'end': 963}, {'entity': 'RFs', 'type': 'Disease', 'start': 930, 'end': 933}, {'entity': 'RNase L deletion', 'type': 'Gene', 'start': 829, 'end': 845}, {'entity': 'cell', 'type': 'Gene', 'start': 762, 'end': 766}, {'entity': 'ZIKV', 'type': 'Virus', 'start': 739, 'end': 743}, {'entity': 'RFs', 'type': 'Disease', 'start': 713, 'end': 716}, {'entity': 'viral RNA', 'type': 'Gene', 'start': 696, 'end': 705}, {'entity': 'dsRNA', 'type': 'Gene', 'start': 641, 'end': 646}, {'entity': 'ZIKV', 'type': 'Virus', 'start': 625, 'end': 629}, {'entity': 'RNase L', 'type': 'Gene', 'start': 591, 'end': 598}, {'entity': 'cell', 'type': 'Gene', 'start': 564, 'end': 568}, {'entity': 'RFs', 'type': 'Disease', 'start': 545, 'end': 548}, {'entity': 'NS3', 'type': 'Disease', 'start': 506, 'end': 509}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetic retinopathy', 'type': 'Disease', 'start': 338, 'end': 358}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'supranuclear palsy', 'type': 'Disease', 'start': 99, 'end': 117}\n",
            "['Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk\\tOur results show interactions between coding polymorphisms in fibrinogen and factor XIII and fibrinogen concentrations that modify fibrin and explain the apparent paradox between epidemiological studies of factor XIII 34Leu and reported in-vitro effects on fibrin structure and function.', 'We suggest a potential complexity of gene-gene and gene-environment interactions in determining cardiovascular risk.']\n",
            "unmatched tags:  [{'entity': 'fibrin', 'type': 'Gene', 'start': 375, 'end': 381}, {'entity': 'factor XIII', 'type': 'Gene', 'start': 324, 'end': 335}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'continence', 'type': 'Disease', 'start': 368, 'end': 378}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'seizures', 'type': 'Phenotype', 'start': 402, 'end': 410}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'diabetes', 'type': 'Disease', 'start': 126, 'end': 134}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'malaria', 'type': 'Disease', 'start': 634, 'end': 641}\n",
            "['The monoamine neurotransmitter disorders: an expanding range of neurological syndromes\\tThe monoamine neurotransmitter disorders consist of a rapidly expanding heterogeneous group of neurological syndromes characterised by primary and secondary defects in the biosynthesis degradation, or transport of dopamine, norepinephrine, epinephrine, and serotonin.', 'Disease onset can occur any time from infancy onwards.', 'Clinical presentation depends on the pattern and severity of neurotransmitter abnormalities, and is predominated by neurological features (encephalopathy, epilepsy, and pyramidal and extrapyramidal motor disorders) that are primarily attributed to deficiency of cerebral dopamine, serotonin, or both.']\n",
            "unmatched tags:  [{'entity': 'serotonin', 'type': 'Drug', 'start': 691, 'end': 700}, {'entity': 'cerebral dopamine', 'type': 'Drug', 'start': 672, 'end': 689}, {'entity': 'deficiency', 'type': 'Disease', 'start': 658, 'end': 668}, {'entity': 'epilepsy', 'type': 'Disease', 'start': 565, 'end': 573}, {'entity': 'serotonin', 'type': 'Drug', 'start': 344, 'end': 353}]\n",
            "['Loss of IKK subunits limits NF-κB signaling in reovirus infected cells\\tViruses commonly antagonize innate immune pathways that are primarily driven by Nuclear Factor-κB (NF-κB), Interferon Regulatory Factor (IRF) and Signal Transducer and Activator of Transcription (STAT) family of transcription factors.', 'Such a strategy allows viruses to evade immune surveillance and maximize their replication.', 'Using an unbiased RNA-seq based approach to measure gene expression induced by transfected viral genomic RNA (vgRNA) and reovirus infection, we discovered that mammalian reovirus inhibits host cell innate immune signaling.', 'We found that while vgRNA and reovirus infection both induce a similar IRF dependent gene expression program, gene expression driven by the NF-κB family of transcription factors is lower in infected cells.', 'Potent agonists of NF-κB, such as Tumor Necrosis Factor alpha (TNFα) and vgRNA, failed to induce NF-κB dependent gene expression in infected cells.', 'We demonstrate that NF-κB signaling is blocked due to loss of critical members of the Inhibitor of KappaB Kinase (IKK) complex, NF-κB Essential MOdifier (NEMO) and IKKβ.', 'The loss of the IKK complex components prevents nuclear translocation and phosphorylation of NF-κB, thereby preventing gene expression.', 'Our studies demonstrate that reovirus infection selectively blocks NF-κB, likely to counteract its antiviral effects and promote efficient viral replication.', 'IMPORTANCE Host cells mount a response to curb virus replication in infected cells and prevent infection of neighboring, as yet uninfected cells.', 'The NF-κB family of proteins is important for the cell to mediate this response.', 'In this study, we show that in cells infected with mammalian reovirus, NF-κB is inactive.', 'Further, we demonstrate that NF-κB is rendered inactive because virus infection results in reduced levels of upstream intermediaries (called IKKs) that are needed for NF-κB function.', 'Based on previous evidence that active NF-κB limits reovirus infection, we conclude that inactivating NF-κB is a viral strategy to produce a cellular environment that is favorable for virus replication.']\n",
            "unmatched tags:  [{'entity': 'cell', 'type': 'Gene', 'start': 2080, 'end': 2084}, {'entity': 'reovirus infection', 'type': 'Disease', 'start': 1991, 'end': 2009}, {'entity': 'virus infection', 'type': 'Disease', 'start': 1820, 'end': 1835}, {'entity': 'mammalian reovirus', 'type': 'Virus', 'start': 1717, 'end': 1735}, {'entity': 'cell', 'type': 'Gene', 'start': 1697, 'end': 1701}, {'entity': 'cell', 'type': 'Gene', 'start': 1635, 'end': 1639}, {'entity': 'proteins', 'type': 'Gene', 'start': 1605, 'end': 1613}, {'entity': 'cell', 'type': 'Gene', 'start': 1578, 'end': 1582}, {'entity': 'cell', 'type': 'Gene', 'start': 1516, 'end': 1520}, {'entity': 'cell', 'type': 'Gene', 'start': 1455, 'end': 1459}, {'entity': 'reovirus infection', 'type': 'Disease', 'start': 1310, 'end': 1328}, {'entity': 'IKKβ', 'type': 'Gene', 'start': 1139, 'end': 1143}, {'entity': 'NEMO', 'type': 'Gene', 'start': 1129, 'end': 1133}, {'entity': 'NF-κB Essential MOdifier', 'type': 'Gene', 'start': 1103, 'end': 1127}, {'entity': 'KappaB Kinase', 'type': 'Gene', 'start': 1074, 'end': 1087}, {'entity': 'cell', 'type': 'Gene', 'start': 968, 'end': 972}, {'entity': 'TNFα', 'type': 'Gene', 'start': 890, 'end': 894}, {'entity': 'Tumor Necrosis Factor alpha', 'type': 'Gene', 'start': 861, 'end': 888}, {'entity': 'agonists', 'type': 'Drug', 'start': 834, 'end': 842}, {'entity': 'cell', 'type': 'Gene', 'start': 820, 'end': 824}, {'entity': 'transcription factors', 'type': 'Gene', 'start': 777, 'end': 798}, {'entity': 'virus infection', 'type': 'Disease', 'start': 654, 'end': 669}, {'entity': 'reovirus infection', 'type': 'Disease', 'start': 651, 'end': 669}, {'entity': 'innate immune signaling', 'type': 'Chemical', 'start': 596, 'end': 619}, {'entity': 'cell', 'type': 'Gene', 'start': 591, 'end': 595}, {'entity': 'reovirus', 'type': 'Virus', 'start': 568, 'end': 576}, {'entity': 'mammalian reovirus', 'type': 'Virus', 'start': 558, 'end': 576}, {'entity': 'reovirus infection', 'type': 'Disease', 'start': 519, 'end': 537}, {'entity': 'transcription factors', 'type': 'Gene', 'start': 283, 'end': 304}, {'entity': 'Activator of Transcription', 'type': 'Gene', 'start': 239, 'end': 265}, {'entity': 'Interferon Regulatory Factor', 'type': 'Gene', 'start': 178, 'end': 206}, {'entity': 'Nuclear Factor-κB', 'type': 'Gene', 'start': 151, 'end': 168}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'strains', 'type': 'Disease', 'start': 239, 'end': 246}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'lupus', 'type': 'Disease', 'start': 78, 'end': 83}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'melanoma', 'type': 'Disease', 'start': 70, 'end': 78}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 239, 'end': 246}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'Zika virus', 'type': 'Virus', 'start': 152, 'end': 162}\n",
            "['Nucleotide Analogues as Inhibitors of SARS-CoV Polymerase\\tSARS-CoV-2, a member of the coronavirus family, has caused a global public health emergency.', '1 Based on our analysis of hepatitis C virus and coronavirus replication, and the molecular structures and activities of viral inhibitors, we previously reasoned that the FDA-approved heptatitis C drug EPCLUSA (Sofosbuvir/Velpatasvir) should inhibit coronaviruses, including SARS-CoV-2.', '2 Here, using model polymerase extension experiments, we demonstrate that the activated triphosphate form of Sofosbuvir is incorporated by low-fidelity polymerases and SARS-CoV RNA-dependent RNA polymerase (RdRp), and blocks further incorporation by these polymerases; the activated triphosphate form of Sofosbuvir is not incorporated by a host-like high-fidelity DNA polymerase.', 'Using the same molecular insight, we selected two other anti-viral agents, Alovudine and AZT (an FDA approved HIV/AIDS drug) for evaluation as inhibitors of SARS-CoV RdRp.', 'We demonstrate the ability of two HIV reverse transcriptase inhibitors, 3’-fluoro-3’-deoxythymidine triphosphate and 3’-azido-3’-deoxythymidine triphosphate (the active triphosphate forms of Alovudine and AZT), to be incorporated by SARS-CoV RdRp where they also terminate further polymerase extension.', 'Given the 98% amino acid similarity of the SARS-CoV and SARS-CoV-2 RdRps, we expect these nucleotide analogues would also inhibit the SARS-CoV-2 polymerase.', 'These results offer guidance to further modify these nucleotide analogues to generate more potent broad-spectrum anti-coronavirus agents.']\n",
            "unmatched tags:  [{'entity': 'nucleotide analogues', 'type': 'Gene', 'start': 1503, 'end': 1523}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1427, 'end': 1437}, {'entity': 'nucleotide analogues', 'type': 'Gene', 'start': 1383, 'end': 1403}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1349, 'end': 1359}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1336, 'end': 1344}, {'entity': 'amino acid', 'type': 'Gene', 'start': 1307, 'end': 1317}, {'entity': 'polymerase extension', 'type': 'Gene', 'start': 1271, 'end': 1291}, {'entity': 'SARS-CoV RdRp', 'type': 'Virus', 'start': 1223, 'end': 1236}, {'entity': 'AZT', 'type': 'Gene', 'start': 1195, 'end': 1198}, {'entity': 'Alovudine', 'type': 'Gene', 'start': 1181, 'end': 1190}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'glargine', 'type': 'Gene', 'start': 285, 'end': 293}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'leukaemia', 'type': 'Disease', 'start': 231, 'end': 240}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'vaccine', 'type': 'Drug', 'start': 333, 'end': 340}\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'lymphomas', 'type': 'Disease', 'start': 409, 'end': 418}\n",
            "['Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein\\tThe recent emergence of a novel coronavirus associated with an ongoing outbreak of pneumonia (Covid-2019) resulted in infections of more than 72,000 people and claimed over 1,800 lives.', 'Coronavirus spike (S) glycoprotein trimers promote entry into cells and are the main target of the humoral immune response.', 'We show here that SARS-CoV-2 S mediates entry in VeroE6 cells and in BHK cells transiently transfected with human ACE2, establishing ACE2 as a functional receptor for this novel coronavirus.', 'We further demonstrate that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S bind with similar affinities to human ACE2, which correlates with the efficient spread of SARS-CoV-2 among humans.', 'We found that the SARS-CoV-2 S glycoprotein harbors a furin cleavage site at the boundary between the S 1 /S 2 subunits, which is processed during biogenesis and sets this virus apart from SARS-CoV and other SARS-related CoVs.', 'We determined a cryo-electron microscopy structure of the SARS-CoV-2 S ectodomain trimer, demonstrating spontaneous opening of the receptor-binding domain, and providing a blueprint for the design of vaccines and inhibitors of viral entry.', 'Finally, we demonstrate that SARS-CoV S murine polyclonal sera potently inhibited SARS-CoV-2 S-mediated entry into target cells, thereby indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination.']\n",
            "unmatched tags:  [{'entity': 'cross-neutralizing antibodies', 'type': 'Gene', 'start': 1398, 'end': 1427}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1327, 'end': 1337}, {'entity': 'polyclonal sera', 'type': 'Gene', 'start': 1292, 'end': 1307}, {'entity': 'SARS-CoV S murine', 'type': 'Virus', 'start': 1274, 'end': 1291}, {'entity': 'vaccines', 'type': 'Drug', 'start': 1205, 'end': 1213}, {'entity': 'receptor-binding domain', 'type': 'Gene', 'start': 1136, 'end': 1159}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1063, 'end': 1073}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 967, 'end': 975}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 796, 'end': 806}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 753, 'end': 763}, {'entity': 'ACE2', 'type': 'Gene', 'start': 701, 'end': 705}]\n",
            "['Management of vertebral radiotherapy dose in paediatric patients with cancer: consensus recommendations from the SIOPE radiotherapy working group\\tInhomogeneities in radiotherapy dose distributions covering the vertebrae in children can produce long-term spinal problems, including kyphosis, lordosis, scoliosis, and hypoplasia.', 'In the published literature, many often interrelated variables have been reported to affect the extent of potential radiotherapy damage to the spine.', 'Articles published in the 2D and 3D radiotherapy era instructed radiation oncologists to avoid dose inhomogeneity over growing vertebrae.', 'However, in the present era of highly conformal radiotherapy, steep dose gradients over at-risk structures can be generated and thus less harm is caused to patients.']\n",
            "unmatched tags:  [{'entity': 'era', 'type': 'Gene', 'start': 733, 'end': 736}, {'entity': 'era', 'type': 'Gene', 'start': 671, 'end': 674}, {'entity': 'era', 'type': 'Gene', 'start': 640, 'end': 643}, {'entity': 'era', 'type': 'Gene', 'start': 527, 'end': 530}, {'entity': 'era', 'type': 'Gene', 'start': 521, 'end': 524}, {'entity': 'era', 'type': 'Gene', 'start': 451, 'end': 454}, {'entity': 'era', 'type': 'Gene', 'start': 348, 'end': 351}, {'entity': 'lordosis', 'type': 'Disease', 'start': 291, 'end': 299}, {'entity': 'spinal problems', 'type': 'Disease', 'start': 254, 'end': 269}, {'entity': 'era', 'type': 'Gene', 'start': 172, 'end': 175}, {'entity': 'era', 'type': 'Gene', 'start': 126, 'end': 129}]\n",
            "['SARS-CoV-2 might manipulate against its host the immunity RNAi/Dicer/Ago system\\tThe role of the RNAi/Dicer/Ago system to degrade RNA viruses has been elusive, which prompt authors to think that interferon (IFN) synthesis is essential, relegating the dsRNAs as accessory function.', 'We investigate SARS-CoV-2 genome responsible of the new deadly COVID-19 pandemic for the theoretical possibilities to engage intra pairing within the viral RNA and also hybrid pairing with human transcriptome.', 'Segmental pieces of RNAs that originate from SARS-CoV-2 were computationally searched as a potential source of one strand, the complementary strand being from the host transcriptome.', 'We therefore considered perfect complementarity of host RNA with any piece of SARS-CoV-2 RNA as a collection of theoretical siRNAs potentially Dicer substrates.', 'Few human genes seems targeted by SARS-CoV-2 RNA, among them mitochondrial deubiquitinase USP30 and a subunit of ubiquitin protein ligase complex FBXO21 could explain premature death of infected cell by the collapse of mitochondria.']\n",
            "unmatched tags:  [{'entity': 'cell', 'type': 'Gene', 'start': 1029, 'end': 1033}, {'entity': 'ubiquitin protein ligase complex FBXO21', 'type': 'Gene', 'start': 947, 'end': 986}, {'entity': 'USP30', 'type': 'Gene', 'start': 924, 'end': 929}, {'entity': 'RNA', 'type': 'Gene', 'start': 879, 'end': 882}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 868, 'end': 878}, {'entity': 'siRNAs', 'type': 'Gene', 'start': 797, 'end': 803}, {'entity': 'RNA', 'type': 'Gene', 'start': 762, 'end': 765}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 751, 'end': 761}, {'entity': 'RNA', 'type': 'Gene', 'start': 729, 'end': 732}, {'entity': 'complementarity', 'type': 'Gene', 'start': 705, 'end': 720}, {'entity': 'complementary strand', 'type': 'Gene', 'start': 617, 'end': 637}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 535, 'end': 545}]\n",
            "Current entity is inside the privious entity, skip it:  {'entity': 'cancer', 'type': 'Disease', 'start': 551, 'end': 557}\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "gef3ckFc0LkM",
        "colab_type": "code",
        "colab": {}
      },
      "source": [
        "train_inputs_embeds = prepare_embedding(datas)"
      ],
      "execution_count": null,
      "outputs": []
    }
  ]
}